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Abstract 
___________________________________________________________________________ 
Background 
Smoking cessation interventions play an important role in dental care, especially for patients 
with periodontitis. Novel nicotine products, such as electronic cigarettes (e-cigarettes), have 
recently become popular with smokers and can be used to quit or reduce tobacco smoking.   
Aims/objectives 
This research aimed to explore the behavioural and biological changes that occur when 
smokers with periodontitis are provided with an e-cigarette.  
Methods 
This research had three components. Firstly, a systematic review investigated the in vitro 
effects of nicotine on periodontal cells. Secondly, a 6-month pilot randomised controlled trial 
(RCT) was conducted of an e-cigarette smoking cessation intervention in smokers with 
periodontitis. Outcome measures were collected on both smoking status and oral health. The 
main focus was on feasibility, including recruitment and retention rates. Thirdly, theory-based 
qualitative interviews investigated patient perceptions about smoking, dental smoking 
cessation interventions and e-cigarettes.  
Results  
The systematic review concluded that nicotine, at physiological concentrations, was not 
cytotoxic to periodontal cells in vitro. Nicotine may have effects on other cell functions 
although evidence was contradictory. In the pilot RCT, 80 smokers with periodontitis were 
recruited in 15 months. Participant retention was 73% at 6 months. The e-cigarette 
intervention was well received with 90% using an e-cigarette  at the quit date. 20% of 
participants in the control group used an e-cigarette, against instructions. Outcome measures 
were successfully completed. A weekly smoking questionnaire had poor completion rates. 
Several factors were perceived to influence smoking behaviour in individuals with 
periodontitis. These patients perceived dentist-delivered smoking cessation advice positively. 
General perceptions of e-cigarettes were mixed and influenced by personal experience, other 
users, addiction concerns, health concerns and social acceptability.  
Conclusions 
Providing and studying an e-cigarette intervention within the dental setting was feasible and 
well accepted by patients. Insights were gained into perceived influences on smoking 
behaviour and how to best conduct future research.  
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Chapter 1. Literature Review 
___________________________________________________________________________ 
Prologue 
Dental professionals have an important role in supporting their patients to stop smoking by 
providing smoking cessation interventions. Many oral diseases are linked to tobacco smoking 
and dental treatments have improved outcomes if smokers quit. Electronic cigarettes (e-
cigarettes) have become common among smokers and ex-smokers and the implications for 
oral health need to be investigated, including their role as a smoking cessation aid as well as 
the potential effects on the oral tissues and treatment outcomes.     
This literature review opens with an overview of the historical and current situation of 
tobacco smoking and disease burden. Mechanisms of smoking-related oral diseases are then 
considered, with particular focus on periodontal diseases. Next, methods of smoking 
cessation, both generally and within the dental setting, are discussed. The development of e-
cigarettes is then explored, including the possible oral health implications.   
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1.1 Tobacco smoking  
1.1.1 Epidemiology and the smoking epidemic 
Tobacco smoking killed 100 million people worldwide in the 20th century and is still the 
single greatest preventable cause of death worldwide (World Health Organisation, 2008). The 
World Health Organisation (WHO) predicts that tobacco-related mortality could reach one 
billion (cumulatively) during the 21st century (World Health Organisation, 2008). Global 
smoking rates are around 15% with over 1.1 billion smokers in 2015 (World Health 
Organisation, 2015).   
Within the UK, tobacco smoking peaked around the middle of the 20th century. The first 
available data (industry figures) reports the peak of male smoking in 1948 at 81%, with 
female smoking peaking in 1966 (and 1969) at 44% (Royal College of Physicians, 2000). 
Independent data were collected from 1972 and demonstrated a progressive decline in both 
sexes, occurring at the fastest rate during the 1970s and 1980s (Royal College of Physicians, 
2000). Since then there has been a continued decline but at a slower rate, sometimes almost 
plateauing (Action on Smoking and Health, 2017c). The most recent data, from 2017, 
reported 15.1% of UK adults as current smokers (Office of National Statistics, 2018b). 
Lopez et al. (1994) proposed a 100-year, four-stage model for the smoking epidemic in 
developed countries, portrayed in Figure 1.1. Many developed countries, such as the UK and 
US, are now in stage IV of the model, where smoking prevalence rates are decreasing in both 
sexes and smoking-related deaths have peaked but are starting to decline. Global attention is 
now focusing on developing countries in the earlier stages of the smoking epidemic. The 
WHO predict that 80% of the 8 million annual smoking-related deaths will occur in 
developing countries by 2023 (World Health Organisation, 2008).     
Developed countries at stage IV of the tobacco epidemic are now discussing ‘smokefree’ 
goals. A number of countries have set ambitious targets to reduce smoking prevalence rates to 
five percent or below: New Zealand by 2025 (New Zealand Government, 2011), Scotland by 
2034 (The Scottish Government, 2013), and Canada by 2035 (Health Canada, 2017). 
England’s most recent policy is somewhat less ambitious, aiming to achieve smoking 
prevalence of 12% or less by 2022 (Department of Health, 2017). Often the ‘tobacco 
endgame’ concept is discussed; this is a chess analogy, whereby, with fewer pieces on the 
board, it is necessary to change tactics to win (McDaniel et al., 2016). This endgame vision 
goes beyond ‘business as usual’ and requires radical strategies, moving from controlling to 
ending the tobacco epidemic (McDaniel et al., 2016). Four broad target areas of potential 
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strategies have been proposed: products (make cigarettes less appealing or displace with less 
harmful alternatives), users (restrict access, introduce licences/prescriptions), market 
mechanisms (reduce availability or impose a ban), and structural (state takeover of tobacco 
companies) (McDaniel et al., 2016). Many countries are now ‘racing’ to be the first to achieve 
smokefree status. 
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Figure 1.1 Model of the smoking epidemic in developed countries. 
Reproduced from Lopez et al. (1994). Four stages of the smoking epidemic were proposed. 
Stage 1: both male and females have low smoking prevalence for 1-2 decades as smoking 
becomes socially acceptable. Stage 2: male smoking prevalence rises to a peak in the range 
50-80%; female smoking prevalence lags behind that of males by 1-2 decades; stage spans 2-
3 decades; male smoking-attributable deaths reach 10% by the end of this stage. Stage 3: male 
smoking prevalence rates decline; female smoking prevalence rates peak at 35-45%; male 
smoking-attributable deaths rise to 25-30%; female smoking-attributable deaths around 5%; 
stage lasts 3 decades. Stage 4: Both male and female smoking prevalence rates slowly decline; 
male smoking-attributable deaths peak at 30-35%, then decline; female smoking-attributable 
deaths rise rapidly.  
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1.1.2 Nicotine and tobacco addiction  
Nicotine biochemistry 
Nicotine is an alkaloid present naturally in tobacco leaves, acting as a botanical insecticide 
(Benowitz et al., 2009). During tobacco combustion, the nicotine is distilled and carried on tar 
droplets into the user’s body. Nicotine is absorbed across biological membranes, especially 
the small airways and alveoli, but sometimes in the mouth depending on the pH of the smoke 
and ratio of ionised:unionised nicotine (Benowitz et al., 2009). High levels of nicotine reach 
the brain in a matter of seconds, producing rapid behaviour reinforcement and contributing to 
the well-known addictiveness of tobacco smoking (Benowitz, 1990). Nicotinic cholinergic 
receptors are stimulated to release a variety of neurotransmitters, including dopamine, which 
signals a pleasurable experience (Benowitz, 2010). Chewing tobaccos, snuff and nicotine 
replacement therapies (NRT) have a buffered alkaline pH. This facilitates nicotine absorption 
through the membrane linings such as the buccal mucosa in the mouth, leading to much 
slower absorption (West et al., 2000), with any swallowed nicotine being subjected to first-
pass metabolism (Benowitz et al., 1987; Benowitz et al., 2009). Transdermal NRT patches 
rely on the knowledge that nicotine base is well absorbed through skin.   
Nicotine has sympathomimetic effects such as increasing the heart rate and transiently 
increasing blood pressure (Benowitz, 2003). However, nicotine has not been associated with 
any significant general health harms, is categorised as a non-carcinogen (World Health 
Organisation, 2014), and has been used in the form of NRT for several decades (Stead et al., 
2012). Preclinical studies have suggested potential therapeutic roles in psychiatric conditions 
such as Alzheimer’s disease and post-traumatic stress disorder (Moran, 2012).     
Nicotine has a relatively short half-life (2 hours) and is converted to six main metabolites 
(Benowitz et al., 2009). In humans, 70-80% is converted to cotinine, which has a much longer 
half-life (16 hours) than nicotine, making it a useful biomarker for nicotine intake (Benowitz 
et al., 2009). Cotinine has different biological effects to nicotine, being non-addictive and 
without cardiovascular effects (Barreto et al., 2015).  
Addiction 
Addiction can be defined as the compulsive use of a substance despite harmful consequences, 
characterised by the inability to stop using it (National Institute on Drug Abuse, 2018). 
Physical dependence refers to the body’s reliance on an external source of the substance to 
avoid withdrawal symptoms. Often addiction and physical dependence coexist and can be 
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hard to distinguish. The addictive potential of pure nicotine is weak (Scientific Committee on 
Emerging and Newly Identified Health Risks (SCENIHR), 2010), however, when delivered in 
a tobacco cigarette it is highly addictive (Royal College of Physicians, 2016). Many aspects of 
tobacco cigarette product design enhance nicotine delivery and uptake. For example, several 
substances are added including: monoamine oxidase inhibitors, which enhance the 
motivational properties of nicotine; sugar and polysaccharides, which form further addictive 
compounds that also act synergistically with nicotine; menthol, which increases the 
palatability of smoke, facilitating deeper inhalation and higher nicotine intake; cocoa and 
chocolate, which contain theobromine, a bronchodilator; levulinic acid, which is addictive in 
itself but also increases the palatability of smoke; and alkaline additives which optimise the 
pH of the smoke and again enhance nicotine absorption (Benowitz, 2010). Tobacco addiction 
occurs when users rely on smoking to modulate mood and arousal, relieve withdrawal 
symptoms, or both (Benowitz, 2010). Tobacco addiction is more complex than simply 
nicotine addiction and involves positive reinforcements, conditioning, neuroadaptation, 
genetic predisposition and vulnerability to addiction (Benowitz, 2010). In the context of 
traditional NRTs, there is a relatively low potential for physical dependence or addiction, 
mainly because of the route of administration and comparatively slow nicotine delivery to the 
brain (Le Houezec, 2003).  
1.1.3 Smoking-induced diseases 
The detrimental health effects of smoking have been extensively studied following the 
landmark ‘British Doctors Study’ initiated in 1951. This followed over forty thousand 
medical doctors and was the first prospective study to convincingly link tobacco smoking 
with risk of death from lung cancer, myocardial infarction and chronic obstructive pulmonary 
disease (COPD) (Doll and Hill, 1954; Doll and Hill, 1956). The study later went on to 
demonstrate the life-long effects of smoking with over 50 years of follow up (Doll et al., 
2004). A key finding was that lifelong smokers had a 50% chance of dying prematurely from 
a complication of smoking (Doll et al., 2004). Quitting at any age resulted in benefits e.g. a 
60-year-old smoker who quit would gain an additional three years of life (Doll et al., 2004). 
Subsequently, smoking has been linked to a wide range of diseases and conditions including: 
cancers, respiratory and circulatory diseases, stomach and duodenal ulcers, erectile 
dysfunction, infertility, osteoporosis, cataracts, periodontitis, pregnancy complications and 
birth defects (The National Institute for Health and Care Excellence, 2013a). Smokers have 
poorer quality of life as measured on several scales with significant improvement following 
cessation (Goldenberg et al., 2014).    
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There is significant health inequality with smoking being the primary reason for the gap in 
healthy life expectancy between the highest and lowest socioeconomic groups in western 
society (Jha et al., 2006). Within the lowest socioeconomic groups, smoking was responsible 
for almost half of the total male mortality during the 1990s (Jha et al., 2006). Smoking 
prevalence rates exist on a social gradient with higher smoking rates in lower socioeconomic 
groups (Amos et al., 2011). These so-called disadvantaged smokers have a higher level of 
cigarette consumption and although they are equally likely as those of higher socio-economic 
status to make a quit attempt, they are less likely to be successful (Amos et al., 2011). 
Tobacco control measures need to be designed to reduce socioeconomic inequalities; a recent 
review concluded that increasing tobacco price via tax had the greatest potential (Hill et al., 
2014).   
Tobacco smokers are at increased risk of poorer health, poorer quality of life and increased 
mortality. Oral health is an important aspect of this, with the mouth being the first contact 
point for tobacco smoke when it enters the body, when the smoke is at its hottest and most 
concentrated. Many oral diseases and conditions have been associated with tobacco smoking, 
such as: oral potentially malignant disorders, oral cancer, periodontitis, peri-implantitis, acute 
necrotising ulcerative gingivitis, oral mucosa diseases (candidosis, melanosis), dental caries, 
alveolar osteitis (dry sockets), staining and halitosis. The investigations presented in this 
thesis focus on periodontitis and hence the literature review will focus on this in subsequent 
sections.     
1.2 Periodontitis and tobacco smoking  
1.2.1 Definition and classification of periodontal diseases 
Periodontal diseases (gum diseases) are some of the most common inflammatory conditions 
in humans (Kassebaum et al., 2014). Periodontitis, an advanced form of periodontal disease, 
has a multifactorial aetiology but the principal process involves a dental plaque biofilm 
accumulating in the subgingival environment causing an immune and inflammatory response 
that leads to destruction of the tooth supporting structures. Consequences of periodontitis 
include tooth mobility and eventually tooth loss. Severe periodontitis, threatening tooth 
retention, affects approximately 10% of UK adults; while moderate periodontitis affects 40-
60% (Morris et al., 2011). A recent estimate calculated that 4.4 million adults in the UK were 
suffering from severe periodontitis (Griffiths and Preshaw, 2014). 
Periodontal diseases are currently classified into eight categories as detailed in  
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Figure 1.2. This classification system was developed at an international workshop in 1999 
(Armitage, 1999) and has been used extensively since. The two main categories relevant to 
this study are chronic and aggressive periodontitis. Chronic periodontitis has several principal 
clinical features or characteristics: most prevalent in adults; destruction consistent with 
presence of local factors; subgingival calculus is often present; variable microbiota; slow-
moderate rate of progression; it can be exacerbated by systemic diseases, cigarette smoking or 
emotional stress (Lindhe et al., 1999). Chronic periodontitis can be further characterised by  
extent and severity. Extent of disease is categorised as localised or generalised, depending on 
the percentage of sites affected (30% cut off). Severity is categorised according to clinical 
attachment loss (CAL): slight = 1-2 mm CAL, moderate = 3-4 mm CAL, severe = ≥5 mm 
CAL. These two descriptors are added to the diagnosis to give the final diagnosis e.g. Severe 
generalised chronic periodontitis. Aggressive periodontitis has three primary features: 
individuals are systemically healthy, there is rapid attachment loss and bone destruction, and 
familial aggregation (Lang et al., 1999). Secondary features comprise: microbial deposits 
being inconsistent with the severity of destruction, elevated proportions of Actinobacillus 
actinomycetemcomitans and Porphyromonas gingivalis, phagocyte abnormalities, hyper-
responsive macrophage phenotypes and progression that may be self-arresting (Lang et al., 
1999). In practice, there are often cases in which it can be challenging to differentiate between 
severe chronic periodontitis and aggressive periodontitis.  
Since the development of this classification system there has only been a minor update 
(American Academy of Periodontology, 2015). However, in 2017 an international workshop 
convened to develop a new classification system (Caton et al., 2018). The results of this 
workshop have only recently been published and are not yet in routine use.  
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I Gingival diseases 
II Chronic periodontitis 
III Aggressive periodontitis 
IV Periodontitis as a manifestation of systemic disease 
V Necrotising periodontal disease 
VI Abscesses of the periodontium 
VII Periodontitis associated with endodontic lesions 
VIII Developmental or acquired deformities and conditions 
 
Figure 1.2 Main disease categories in the 1999 periodontal disease classification system. 
 
 
1.2.2 Risk factors for periodontal diseases 
Periodontal disease is predominately related to the dental plaque biofilm. The individual’s 
response to this microbial challenge is the major factor in disease susceptibility, severity and 
progression. Several risk factors have been identified and confirmed as important through 
several decades of research (Genco and Borgnakke, 2013). A number of national databases 
made the study of risk factors possible. For example, the National Health and Nutrition 
Examination Survey (NHANES) has reported on risk profiles for periodontitis in US adults 
(Dye et al., 2007; Eke et al., 2016). Broadly, risk factors can be classified as systemic or 
local, depending on their mode of action. Furthermore, risk factors can be sub-divided into 
those which are modifiable or non-modifiable, a useful distinction for patients and dental 
professionals. Figure 1.3 details the known risk factors for periodontal disease using this 
categorisation.  
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 Risk Factors 
Modifiable factors Non-modifiable 
factors 
Local 
factors 
Acquired Anatomical  
Plaque & calculus 
Partial dentures 
Open contacts 
Overhanging & poorly 
contoured restorations 
 
Malpositioned teeth 
Furcations 
Root grooves & 
concavities 
Enamel pearls 
 
Systemic 
factors 
Smoking 
Diabetes 
Poor diet 
Certain medications 
Stress 
Socioeconomic status 
Genetics 
Adolescence 
Pregnancy 
Age 
Leukaemia Emerging evidence: Nutrition, Alcohol, 
Obesity/overweight 
 
Figure 1.3 Risk factors for periodontal diseases. 
 
Adapted from the Good Practitioner’s Guide to Periodontology (British Society of 
Periodontology, 2016) 
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Local risk factors 
Given the significance of the microbial biofilm in periodontal pathogenesis, local factors 
which influence the amount of biofilm present are important. This is usually mediated by 
factors which impede biofilm removal through natural (saliva flow) or artificial means (oral 
hygiene procedures). Several anatomical variations can lead to increased biofilm development 
e.g. malpositioned teeth, furcations or uneven tooth surfaces. Several acquired local factors 
can also lead to increased biofilm accumulation. For example, plaque/calculus deposits, 
overhanging and poorly contoured restorations can make oral hygiene procedures more 
challenging and less effective. Partial dentures increase plaque deposition in both the adjacent 
teeth and opposing arch (Addy and Bates, 1979). Open contacts between teeth lead to 
increased food packing and hygiene difficulties. The influence of most of these factors can be 
reduced by remedial dental treatment (e.g. corrections of deficient restorations or closing 
contact points) or by educating patients about oral hygiene measures. The management of 
local risk factors is an essential component of successful periodontal therapy.          
Tobacco smoking 
Tobacco smoking is arguably the most important known risk factor for periodontitis. The first 
study associating tobacco smoking with periodontal disease was in 1947 and this exposure-
risk relationship has subsequently been the subject of extensive investigation (Pindborg, 
1947). Initially, the association was attributed to the poorer oral hygiene seen in smokers 
compared to non-smokers. However, subsequent studies with adjustment for confounders 
(including oral hygiene) concluded that moderate tobacco smoking is of itself a risk factor for 
periodontitis with odds ratios of 4-5 presented and a clear dose-response relationship observed 
(Grossi et al., 1994; Grossi et al., 1995). Furthermore, reviews of the topic have reinforced 
the importance of tobacco smoking as an independent risk factor (Bergstrom and Preber, 
1994; Papapanou, 1996; Tonetti, 1998; Genco and Borgnakke, 2013; Leite et al., 2018). 
Genco and Borgnakke (2013) provided five supporting factors for this: 1) consistency of 
results across many studies; 2) strength of the association; 3) dose-response of the association; 
4) temporal sequence of smoking and periodontal disease; and 5) biological plausibility.  
Analysis of the NHANES data collected between 1988-1994 estimated that over 50% of all 
cases of chronic periodontitis were attributed to cigarette smoking (Tomar and Asma, 2000). 
Extrapolating this to the UK population would equate to approximately 2.2 million 
individuals. Increased tooth loss in smokers has been consistently observed in many 
populations around the world including the United States of America (USA) (Albandar et al., 
2000; Krall et al., 2006), Australia (Arora et al., 2010), Brazil (Haas et al., 2012) and 
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Thailand (Torrungruang et al., 2012). Tobacco smoking has impacts on initial treatment 
outcomes (see section 1.2.7) as well as during longer-term periodontal maintenance with 
smokers being five times more likely to suffer from tooth loss (Chambrone et al., 2010). 
Diabetes 
Diabetes is a metabolic disorder characterised by hyperglycaemia caused by defects in insulin 
action or production. Poorly controlled diabetes (type 1 or 2) is a risk factor for periodontal 
diseases with hyperglycaemia leading to adverse periodontal outcomes (Chapple and Genco, 
2013). A two-way relationship has been described with poorly controlled periodontal disease 
also leading to poorer glycaemic control (Preshaw et al., 2012; Chapple and Genco, 2013). 
Mechanical periodontal therapy has been shown to reduce HbA1c (a measure of 
hyperglycaemia) by 0.4% at 3 months post-treatment, which is equivalent to the addition of a 
second pharmacological drug (Preshaw et al., 2012; Chapple and Genco, 2013). The 
combined effects of tobacco smoking and diabetes (i.e. the diabetic smoker) have been shown 
to be synergistic with regards to microbiological outcomes (Ganesan et al., 2017b), although 
not confirmed by the limited clinical data available (Han et al., 2012). 
Other systemic factors 
A number of other systemic factors have been categorised as risk factors for periodontitis, 
comprising: stress, poor diet and certain medications, with emerging evidence for the 
implication of nutrition, alcohol consumption and obesity. Stress, including distress and 
coping skills, as a risk factor is likely to act through several possible mechanisms including 
immunosuppression and modified behaviours (Genco and Borgnakke, 2013). A two-year 
study found those with active coping modes had improved periodontal outcomes compared to 
those with passive coping strategies (Wimmer et al., 2005). Regarding obesity, several 
systematic reviews have shown a significant association with periodontal disease (Suvan et 
al., 2011; Keller et al., 2015; Gerber et al., 2016) with one reporting an odds ratio (OR) of 
2.13 for an association between overweight/obesity and periodontitis (Suvan et al., 2011).      
1.2.3 Clinical effects of tobacco smoking 
Smokers are at increased risk of a broad range of intra-oral effects. The most significant, at an 
individual level, is oral cancer; there is a strong synergistic relationship with alcohol 
consumption. At the most extreme, those who are heavy tobacco smokers (>40 cigarettes/day 
for >20 years) and heavy alcohol drinkers (>30 drinks/week) are at thirty-eight times 
increased risk of developing oral cancer (Blot, 1992). More recent data continues to show the 
importance of smoking and alcohol as risk factors, irrespective of human papillomavirus 
infection status, a relatively recently identified risk factor (Anantharaman et al., 2016). Once 
13 
 
diagnosed, smokers have poorer survival rates compared to never- and former-smokers 
(Abrahao et al., 2018).  
Oral cancer is associated with significant morbidity and mortality. Although periodontitis is 
not directly life threatening it is likely to be a more significant consequence of tobacco 
smoking at a public health level. Periodontitis has a high global burden, being responsible for 
3.5 million years lived with disability, $54 billion/year in lost productivity and a major 
portion of the $442 billion/year costs for oral diseases (Tonetti et al., 2017). As previously 
discussed (see section 1.2.2) there are multiple risk factors for periodontitis, but tobacco 
smoking is arguably the most important and certainly the most significant environmental risk 
factor. Tobacco smoking is thought to affect the periodontal tissues via multiple pathways, 
such as effects on the host immune and inflammatory response and on the oral microbiome 
(see sections 1.2.4 and 1.2.5) (Palmer et al., 2005).  
Tobacco smokers also experienced other effects of smoking on their soft tissues including 
increased prevalence of mucosal disease such as melanosis (Hedin, 1977) and candidosis 
(Soysa and Ellepola, 2005). Similarly, tobacco smokers have poorer wound healing and are 
more likely to suffer complications after surgery e.g. ‘dry sockets’ after tooth extractions. 
Dental implants are also affected by tobacco smoking, with both short- and long-term effects. 
In the short term, tobacco smokers are at increased risk of failure of osseointegration (Hinode 
et al., 2006). In the longer term, tobacco smokers are at increased risk of implant failure 
(Strietzel et al., 2007; Chambrone et al., 2014) and peri-implantitis (Heitz-Mayfield, 2008; 
Lindhe and Meyle, 2008; Sgolastra et al., 2015) although the evidence is not yet convincing.  
Finally, tobacco smokers have higher rates of dental staining and halitosis (bad breath). 
Although these may not be significant health impacts, they are often the most important to 
smokers in their impact on quality of life and can be useful prompts in cessation interventions.   
1.2.4 Microbiological effects of tobacco smoking 
Tobacco smoke has effects on the oral microbial ecology. It has been known for some time 
that tobacco smokers harbour greater numbers of potential periodontal pathogens than non-
smokers (Palmer et al., 2005). Recent profiling of microbial communities, using next 
generation sequencing, has demonstrated smokers to have significantly different periodontal 
microbiomes than non-smokers with a highly diverse, pathogen-rich, commensal-poor, 
anaerobic microbiome, suggesting that they are primed for future disease progression (Mason 
et al., 2015; Wu et al., 2016). Delima et al. (2010) demonstrated that, when smokers quit, 
they developed increased bacterial diversity and altered community composition with greater 
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numbers of health-associated species and significantly lower prevalence and abundance of 
periodontal pathogens. Conversely, Nociti et al. (2015) discuss that several studies have 
shown minor or no differences between smokers and non-smokers. These conflicting findings 
are perhaps due to the differences in microbiological techniques used in different studies.   
1.2.5 Vascular, immune and inflammatory effects of tobacco smoking 
Reaction to the plaque biofilm via immune and inflammatory responses are critical factors in 
individual susceptibility to periodontitis. Tobacco smokers experience impairment of the 
periodontal vasculature with lower oxygen tension (Hanioka et al., 2000) and suppression of 
the normal inflammatory response to subgingival biofilm (which presents clinically as 
reduced gingival redness), volume of gingival crevicular fluid (GCF) and bleeding (Preber 
and Bergstrom, 1986; Lie et al., 1998). When smokers quit, the local inflammatory response 
recovers quickly and they often experience a transient increase in gingival bleeding (Nair et 
al., 2003). Tobacco smoking additionally reduces the healing potential of the tissues, 
negatively impacting on fibroblast function and collagen synthesis (Palmer et al., 2005; 
Reuther and Brennan, 2014).  
Neutrophils are critical cells in the maintenance of periodontal health and it is clear that 
tobacco smoke affects multiple functions of neutrophils that collectively contribute towards 
the tissue destruction seen in periodontitis (Palmer et al., 2005). Tobacco smokers have 
increased numbers of T-cells and elevated T-cell responsiveness leading to greater potential 
for periodontal breakdown (Loos Bruno et al., 2004). Additionally, it has been suggested that 
an imbalance in cytokine production seen in smokers affects periodontal pathogenesis (Genco 
and Borgnakke, 2013).  
1.2.6 Nicotine effects on the oral tissues 
Whole tobacco smoke contains a complex mixture of an estimated 10,000-100,000 chemicals 
(Rodgman and Perfetti, 2009), including over 70 known human carcinogens (Smith et al., 
1997; Smith et al., 2000; Smith et al., 2001) and several other notable compounds including: 
nicotine, hydrogen cyanide, formaldehyde, lead, arsenic, ammonia, benzene, carbon 
monoxide, nitrosamines and polycyclic aromatic hydrocarbons (Talhout et al., 2011).  
As previously discussed (see section 1.2.3) whole tobacco smoke has detrimental effects on 
oral and periodontal tissues and in vitro studies have shown it to be highly toxic to oral cells 
(Zhang et al., 2009) with significant disruption to cellular functions (Semlali et al., 2011). 
However, it is largely unknown which compounds in tobacco smoke are responsible for the 
observed effects, as most studies evaluate the impact of whole cigarette smoke rather than a 
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particular component. Often studies and review papers confuse nicotine and whole tobacco 
smoke, using the terms interchangeably. For example, within their review, Genco and 
Borgnakke (2013) postulate that the smoking effects seen on periodontal health are ‘mainly 
through the effects of nicotine’ and that nicotine enhances the degranulation of neutrophils, 
making them more sensitive to bacterial challenge. In support of this argument, they cite a 
clinical study (Söder et al., 1999) which investigated smokers but did not include nicotine as a 
variable (whole tobacco smoking was compared to not smoking). Nicotine and whole tobacco 
smoke have been confused in this instance (although not by Söder et al. (1999), who do not 
mention nicotine once within their paper). Javed et al. (2017b) made similar errors in their 
review which we highlighted in journal correspondence (Holliday et al., 2017b).  
The specific pathogenic role of nicotine has been of increasing relevance with the introduction 
and widespread use of NRT and recent development of novel nicotine products such as e-
cigarettes. A review concluded that nicotine has likely been ‘unfairly blamed’ for the 
detrimental oral effects of tobacco smoke (Palmer et al., 2005). There have been a large 
number of in vitro studies investigating the effect of nicotine in isolation on oral and 
periodontal cells. These have often reported contradictory results. For example Wu et al. 
(2013), stated that ‘nicotine, the main toxic component in tobacco, was confirmed as the main 
effect of smoking on periodontal tissue destruction’ whereas Checchi et al. (1999), concluded 
‘nicotine by itself is toxic only at concentrations higher than that found in plasma and 
crevicular fluid of heavy smokers’. Wyganowska-Swiatkowska and Nohawica (2015) 
published a ‘systematic review’ on the topic and concluded that exposing periodontal 
fibroblasts to nicotine resulted in detrimental effects on viability and cellular functions. 
However, the review methodology and reporting fell significantly below conventional 
standards (e.g. the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
[PRISMA]) and the paper would be best described as a narrative non-systematic review. 
Hence, a robust systematic review has not yet been published on this important topic and 
researchers and dental professionals are left with an unclear message about the oral health 
harms from nicotine. Undoubtedly, this has contributed to some of the perceptions around 
nicotine as discussed later (see section 1.4.7). One of the objectives of this thesis is therefore 
to conduct a systematic review on this topic.     
A number of animal studies have reported detrimental periodontal and healing effects of 
nicotine administration (Nociti et al., 2000; Nociti et al., 2001; Pinto et al., 2002; Cesar-Neto 
et al., 2005; Francisco et al., 2007; de Almeida et al., 2011). They used rat models with 
ligatures around teeth to stimulate periodontal disease and once daily intraperitoneal 
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injections of various nicotine concentrations. They generally concluded that administration of 
nicotine did not produce periodontal bone loss by itself but did seem to enhance existing 
inflammation (Nociti et al., 2015). The clinical relevance of these studies to humans is 
challenging to interpret, particularly given the difference in the mode of nicotine 
administration and dosing compared to smoking. Further studies, using passive smoking 
models, reported that rats exposed to cigarette smoke had higher ligature-induced bone loss 
and other detrimental effects but nicotine itself was not a variable (César et al., 2004; Braga et 
al., 2005; Cesar-Neto et al., 2005; Batista et al., 2006).   
It is well known that tobacco smokers have significant impairment of the periodontal 
vasculature, although the specific role of nicotine in this is unclear. On one hand, nicotine 
activates the sympathetic nervous system to cause generalised vasoconstriction (Toshiya et 
al., 2004). Conversely, nicotine applied topically can have angiogenic effects and has been 
shown to increase blood flow and oxygen tension in the gingival tissues (Johnson et al., 1991; 
Sorensen, 2012). Nicotine administered via transdermal patches has even been suggested to 
have a therapeutic effect with reduced myocardial ischaemia (Mahmarian et al., 1997) and 
facilitation of wound healing after surgery (Jacobi et al., 2002; Reuther and Brennan, 2014). 
The oral health effects of nicotine have been investigated to some extent through clinical 
studies of NRT. Christen et al. (1985) compared nicotine-containing and placebo chewing 
gum, concluding there was no significant influence on oral health parameters. Another study 
investigated nicotine chewing gum compared to a nicotine sublingual tablet, comparing tooth 
staining (Whelton et al., 2012). They concluded that using nicotine chewing gum for 6 weeks 
in a smoking cessation programme resulted in reduced stain and shade lightening, with no 
adverse events in either group. Conversely, a meta-analysis of hundreds of studies cited oral 
soreness or ulcers as adverse events of orally-administered NRT (Mills et al., 2010; Stead et 
al., 2012). Analysis is complicated because these effects are often seen in smoking cessation 
with mouth ulcers reported in about 40% of individuals who successfully quit, usually within 
the first two weeks (McRobbie et al., 2004). However, Mills et al. (2010) accounted for this 
by comparing to inert controls (e.g. placebo) and reported that orally-administered NRT was 
associated with mouth and throat soreness (5.4% prevalence, OR 1.87, 95% CI: 1.36-2.57) 
and mouth ulcers (OR 1.49, 95% CI 1.05-2.20) (Mills et al., 2010). They advise that users 
who develop oral symptoms should switch to an alternative form of delivery e.g. skin patch or 
nasal spray.    
Finally, nicotine metabolites, particularly cotinine, could be of importance, given its extended 
half-life. No clinical studies exist but in vitro studies have found that cotinine exposure did 
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not result in statistically significant effects on the periodontal ligament (PDL) fibroblasts 
(James et al., 1999). This corroborates the results of other studies which showed cotinine to 
have lower toxicity than nicotine (Babich and Borenfreund, 1992). However, the relatively 
long half-life of cotinine will expose cells to its effects for an extended period, potentially 
escalating any impacts.   
In summary, nicotine appears not to be a major pathological agent in tobacco smoke, although 
it may have some effects. There are numerous in vitro studies on oral cells, which would 
benefit from being collated in a systematic review, one of the objectives of this thesis.    
1.2.7 Impact on periodontal treatment outcomes 
A common scenario that presents to dental professionals is that of an individual who has 
periodontitis and who has smoked tobacco for many years. In this case, the focus moves away 
from the impact of tobacco smoking on aetiology and pathogenesis, towards treatment 
outcomes. Given the known damaging effect of smoke on periodontal tissues, the logical 
corollary is that periodontal treatment outcomes will be worse in smokers and better in non-
smokers with former smokers having intermediate responses (Heasman et al., 2006).  
Studies have shown that tobacco smokers have poorer responses to both non-surgical and 
surgical periodontal therapies (Papantonopoulos, 2004; Heasman et al., 2006; Johnson and 
Guthmiller, 2007; Brurberg et al., 2008; Chambrone et al., 2009; Preshaw et al., 2013; Nociti 
et al., 2015; Leite et al., 2018). A review (Brurberg et al., 2008) found that 34 of 38 studies 
showed poorer responses to periodontal therapies in smokers compared to non-smokers with a 
mean difference in post-therapeutic pocket probing depths (PPDs) being 0.33 mm (95% CI 
0.22-0.42 mm) (Brurberg et al., 2008) which is of questionable clinical significance. More 
clinically significant PPD reductions (around 1 mm) have been reported in individual studies 
(Jin et al., 2000). Not all studies, however, demonstrated improved clinical outcomes in non-
smokers (Pucher et al., 1997; Zuabi et al., 1999). For example, Pucher et al. (1997) reported 
that smokers and non-smokers responded similarly to non-surgical periodontal therapy after 
nine months.  
Two prospective studies (Preshaw et al., 2005; Rosa et al., 2011) have investigated the impact 
of quitting smoking during periodontal therapy. A systematic review and meta-analysis 
(Chambrone et al., 2013) concluded that there was a statistically significant beneficial impact 
of quitting smoking on the number of sites demonstrating PPD reductions ≥ 2 mm (incident 
rate ratio: 1.30, 95% CI: 1.17-1.44). A 2 mm or greater reduction in PPD is generally regarded 
as clinically meaningful at an individual site (Greenstein, 2003). Indeed, it has been suggested 
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that for smokers with periodontitis, dentists should focus on smoking cessation as a primary 
treatment strategy for the periodontitis, rather than conventional therapies (Preshaw et al., 
2018).    
Following an active course of periodontal therapy, individuals should be entered into a 
supportive periodontal therapy (SPT) phase of treatment, sometimes also known as 
periodontal maintenance (Cohen, 2003; British Society of Periodontology, 2016). Maintaining 
smoking abstinence or encouraging smoking cessation are critical aspects of this phase of 
treatment. Studies (McGuire and Nunn, 1996a; McGuire and Nunn, 1996b; Preshaw and 
Heasman, 2005; Dannewitz et al., 2016) have repeatedly demonstrated that smokers have 
poorer outcomes during this phase with one study (Chambrone et al., 2010) calculating that 
smokers were five times more likely to suffer from tooth loss. Risk assessment tools are often 
used during SPT to customise the frequency and content of SPT visits (Lang et al., 2015). The 
Periodontal Risk Assessment (PRA) developed by Lang and Tonetti (2003) assesses risk in 
six domains and is available for online use from the University of Bern (Ramseier, 2009). 
One of these domains is tobacco smoking and the PRA places individuals into five categories: 
non-smoker, former smoker (those who quit more than five years ago), occasional smoker (< 
10 cigarettes/day), smoker (10-19 cigarettes/day) and heavy smoker (≥20 cigarettes/day). 
Non-smokers and former smokers are deemed to have a low risk of recurrence of 
periodontitis, while occasional smokers and smokers are deemed to have moderate risk, and 
heavy smokers high risk. This categorisation is now outdated and can be difficult to use. For 
example, an individual who quit smoking 0-5 years ago does not easily fit into any category 
and the category name of ‘occasional smoker’ is misleading given this category includes those 
who smoke up to 10 cigarettes/day. Another risk assessment tool is the Periodontal Risk 
Calculator (PRC) which has a more detailed categorisation of smoking habits, detailing what 
is smoked and how often (Oral Health Innovations Ltd, 2008). However, the algorithm for 
how this relates to the risk score is not available as this is a commercial product.            
In summary, tobacco smoking is a risk factor for both periodontal disease development and 
treatment outcomes. Hence, supporting patients to quit smoking is an important aspect of 
disease prevention and an essential component of successful periodontal therapies. The next 
section (1.3) will discuss smoking cessation generally and within the dental context.   
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1.3 Smoking cessation 
1.3.1 The development of smoking cessation  
The twentieth century’s smoking epidemic peaked in the middle of the century with over 80% 
of males smoking in 1948 (Royal College of Physicians, 2000). Since the 1960s there has 
been a steady decline in smoking prevalence rates. Landmark reports (The Royal College of 
Physicians, 1962; Surgeon General, 1964) linking smoking to diseases such as lung cancer 
were fundamental in helping this decline. Likewise, the World Health Organisation (WHO) 
Framework Convention on Tobacco Control (FCTC) developed during the first few years of 
the 21st century, have contributed to the continued decline seen worldwide (World Health 
Organisation, 2008; Ng et al., 2014; Bilano et al., 2015). The FCTC was accompanied by the 
MPOWER framework to identify key elements for implementation of the treaty alongside the 
Articles contained within the FCTC. The MPOWER framework comprises: monitoring 
tobacco use and prevention policies, protecting people from tobacco, offering help to quit 
tobacco use, enforcing bans on tobacco advertising, promotion and sponsorship, and raising 
taxes on tobacco (World Health Organisation, 2008).  
A key component of tobacco control policies is the offer of smoking cessation support to 
smokers, included in Article 14 of the FCTC. During the 1990s within the UK, government 
policies and guidelines were developed for smoking cessation support, including by 
healthcare professionals (Department of Health, 1998; Raw et al., 1998; Raw et al., 1999). 
Dedicated stop smoking services were developed nationwide by 2000 with subsequent 
evaluations and reviews showing the success of the service (Bauld et al., 2010; Dobbie et al., 
2015). The key features of these services included access to behavioural support (either one-
to-one or group sessions) and pharmacotherapy (such as NRT, varenicline, bupropion) 
(Dobbie et al., 2015). Evaluations of the services found that those attending the stop smoking 
services are 3-4 times more likely to quit than those attempting to do so by willpower alone 
(Dobbie et al., 2015). Historically, however, relatively few smokers access these services: 
around 6-10% but with a recent decline to 4% in May 2016 (West and Brown, 2016). Many 
barriers have been reported to smokers accessing these services including: fear of failure; fear 
of being judged; lack of knowledge; access barriers e.g. childcare issues; and perceptions 
about pharmacotherapy cost and ineffectiveness (Roddy et al., 2006a; Murray et al., 2009). 
Recent declines in client numbers have been attributed to: funding cuts; service reorganisation 
(particularly in England where services moved from the National Health Service [NHS] to 
local authorities); lack of mass media campaigns to promote the services; and smokers 
preferring to use e-cigarettes (Smith et al., 2018).  
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Current national guidelines continue to require that all smokers attending healthcare services 
are advised and encouraged to stop and given the support they need (The National Institute for 
Health and Care Excellence, 2018). Unfortunately, the current austerity programme has 
limited access to services with a recent survey reporting successive budget cuts during 2015 – 
2017, with only 61% of the English local authorities providing a specialist stop smoking 
service to all smokers in 2017 (Cancer Research UK and Action on Smoking and Health, 
2018). In our local area (North East England), although there have been recent changes, 
Newcastle upon Tyne still has a specialist stop smoking service operated by Change Grow 
Live (Change Grow Live, 2018). Surrounding areas have a mixture of services available.  
Not all experts agree on the need for services to help smokers quit, with a recent paper 
arguing that unassisted quit attempts were undervalued (Chapman and Wakefield, 2013). The 
authors specifically challenged the need for nicotine products, referring to the successes in the 
era prior to their availability. They cited the American Cancer Society who estimated that 
90% of the 37 million Americans who stopped smoking since the 1964 Surgeon General’s 
report had done so unaided (American Cancer Society, 1986). However, for countries at the 
end of the tobacco epidemic (i.e. stage IV) (Lopez et al., 1994), many feel there is an 
important role for the specialist stop smoking services in supporting those remaining smokers 
to quit. The ‘hardening’ hypothesis states that remaining smokers are ‘hard-core’ smokers and 
find it more difficult to quit. This hypothesis has an intuitive and common-sense appeal; 
nonetheless, although it is supported by some evidence (Shiffman et al., 2008), it is not 
strongly supported in the literature (Hughes, 2011; Cohen et al., 2012; Docherty and McNeill, 
2012).   
Finally, in some nations, harm reduction approaches have been used alongside other tobacco 
control measures consistent with the MPOWER framework and the FCTC. In the UK, 
national guidance recommends harm reduction approaches for those not able or wanting to 
fully quit, those not wanting to quit nicotine, or those who aren’t ready to quit but want to 
reduce the amount they smoke (The National Institute for Health and Care Excellence, 
2013b). The rationale for this approach is two-fold. Firstly, reduction may eventually lead to 
complete cessation with smokers who cut down being more likely to attempt and be 
successful in quitting (‘cutting down to quit’). Secondly, there are some benefits to reducing 
smoking, although these are limited; complete cessation should be the ultimate objective of 
gradual reduction, as the National Institute of Clinical Excellence (NICE) harm reduction 
guidance explains (The National Institute for Health and Care Excellence, 2013b). All three 
major fatal smoking-related diseases (coronary heart disease, lung cancer and COPD) have a 
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clear dose-response relationship between tobacco consumption and risk of developing or 
dying from the disease (Forey et al., 2011; Lee et al., 2012). Reducing the exposure to 
tobacco toxins is likely to lead to a reduction in disease burden, especially for diseases such as 
COPD with a steep dose-response relationship (Begh et al., 2015). However, it must be 
emphasised that the evidence is mixed and a recent meta-analysis of coronary heart disease 
and stroke concluded that smoking only one cigarette per day carried a large risk, about half 
that of a twenty per day smoker (Hackshaw et al., 2018). There are four main harm reduction 
approaches: stopping smoking but using a nicotine-containing product to prevent relapse, 
cutting down prior to stopping smoking, smoking reduction (with or without a nicotine-
containing product) and temporary abstinence from smoking (with or without a nicotine-
containing product)(The National Institute for Health and Care Excellence, 2013b). Within 
the context of this thesis harm reduction relates to smoking reduction i.e. reduction in 
cigarettes per day.  
1.3.2 Smoking cessation delivery by healthcare professionals   
Within the UK, national guidance recommends that all patients should be asked if they smoke 
by their healthcare professionals (HCPs). If they are smokers, they should be offered advice 
on how to stop and a referral made to an evidence-based smoking cessation service (The 
National Institute for Health and Care Excellence, 2013a). HCPs such as medical doctors and 
dentists, can provide smoking cessation advice in many different formats. The most 
frequently recommended format is that of a ‘Very Brief Advice’ (VBA) intervention which is 
designed to last 30 seconds and usually follows a Three A’s format: Ask, Advise, Act. The 
patient should be asked about smoking and have their smoking status recorded in their 
records. They should be advised that the best way to quit is though using behavioural support 
plus medication. The HCP should then act on the patient’s response by: referring to a 
specialist stop smoking service and/or prescribing pharmacotherapy or agreeing to review at 
subsequent visits if the patient is not interested at the present time (National Centre for 
Smoking Cessation and Training, 2012c). There are conflicting instructions between different 
guidance documents regarding the ‘Advise’ step. Some guidance recommends that if the 
intervention is designed to have a 30 second duration, it should not mention any harms of 
smoking/personal benefits of quitting in order to avoid entering into a prolonged discussion 
and for fear of producing a defensive reaction and anxiety in the patient (Aveyard et al., 2012; 
National Centre for Smoking Cessation and Training, 2012c). Other guidance suggests that 
the personal benefits of quitting should be discussed with patients during the brief 
intervention; in these circumstances, it is likely that the duration of the intervention will need 
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to be several minutes to allow sufficient dialogue around this aspect  (National Centre for 
Smoking Cessation and Training; Public Health England, 2014b; The National Institute for 
Health and Care Excellence, 2018). Occasionally a Five A’s technique is recommended: Ask 
the patient about their tobacco usage, Advise them to quit, Assess their willingness to quit, 
Assist them in quitting, and Arrange follow-ups (Action on Smoking and Health, 2012; 
British Dental Association, 2015).  
A Cochrane systematic review (Stead et al., 2013a) looked at the effect of a brief advice 
intervention delivered by physicians. Data from 17 studies were pooled and brief intervention 
was shown to be effective compared to no advice (Relative Risk [RR]: 1.66, 95% CI: 1.42-
1.94). More intensive interventions gave a higher estimated effect (RR 1.84, 95% CI:1.60-
2.13) but, statistically, there was no difference between minimum and intensive interventions 
(Stead et al., 2013a).  Assuming an unassisted 6-month success rate of 3%, a brief advice 
intervention can increase the quit rates (6-month) to 5% (Stead et al., 2013a).  
Despite brief interventions being designed to be quick and simple to deliver, the rates of 
delivery to patients appear suboptimal. Self-reported data for medical primary care settings 
(general medical practitioners [GMPs]) suggest that almost all new patients are asked about 
their smoking status, but with far fewer regular patients being asked or routinely being 
advised to quit (Stead et al., 2009). English data reported 98% of new patients had smoking 
status recorded while only 63% of returning smokers had their status checked and updated 
(McEwen et al., 2005). A recent audit completed in secondary care reported that, for hospital 
patients, fewer than a quarter of patients were asked if they smoked and only a quarter of  
smokers were asked if they would like to quit smoking (British Thoracic Society, 2016). 
Barriers to and facilitators of physicians’ engagement with smoking cessation have been 
extensively studied. For example, Stead et al. (2009) conducted a large European review of 
general practitioners that identified several factors: patient characteristics (smoking-related 
symptoms, pregnancy, heavy smokers), physician characteristics (own smoking status, 
attitude and cessation-specific knowledge and skills), and structural factors (reimbursement 
and time required).  
1.3.3 Behavioural support for smoking cessation 
Behavioural methods of support form an important component of stop smoking services and 
take several formats. A series of Cochrane systematic reviews have evaluated many of these 
interventions (Stead et al., 2013a; Stead et al., 2013b; Whittaker et al., 2016; Lancaster and 
Stead, 2017; Stead et al., 2017; Taylor et al., 2017).  
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Individual behavioural support 
Individual behavioural support involves face-to-face meetings with a trained smoking 
cessation counsellor. It typically involves weekly sessions over a period of four to eight 
weeks. There is high quality evidence that individual counselling is more effective than a 
minimal behavioural intervention (e.g. brief advice), when pharmacotherapy (NRT) is not 
offered to participants (RR 1.57, 95% CI: 1.40-1.77) (Lancaster and Stead, 2017). However, 
individual behavioural support is often combined with pharmacotherapy and there is moderate 
quality (downgraded due to imprecision) evidence that it is also effective in this circumstance 
(RR 1.24, 95% CI: 1.09-1.53) (Lancaster and Stead, 2017).   
Group behavioural support 
Group behavioural support involves meetings in which smokers receive information, advice 
and encouragement and some form of behavioural intervention. Sessions are typically weekly 
over a period of four weeks. There is moderate quality evidence (most studies at risk of bias) 
that group programmes are more effective than a self-help programme (RR 1.88, 95% CI: 
1.52-2.33) (Stead et al., 2017). There is low quality evidence (low grading due to 
inconsistency and risk of bias) for effectiveness compared to a brief intervention from a health 
care provider (RR 1.22, 95% CI: 1.03-1.43) and compared to no-intervention controls (RR 
2.60, 95% CI 1.80-3.76) (Stead et al., 2017). There is no evidence for effectiveness of a group 
programme plus pharmacotherapy compared with pharmacotherapy alone (RR 1.11, 95% CI: 
0.93-1.33) (Stead et al., 2017).  
Internet-based interventions 
The internet is a potentially powerful platform to provide cessation support with over 3.5 
billion users (smokers and non-smokers) worldwide in 2016. Studies suggest interactive and 
tailored internet-based interventions are effective compared to a non-active control (RR 1.15, 
95% CI: 1.01-1.30, low quality evidence) or moderately effective when combined with 
behavioural support (RR 1.69, 95% CI: 1.30-2.18, moderate quality evidence) (Taylor et al., 
2017). These results should be interpreted with caution as the evidence was often at high risk 
of bias with substantial statistical heterogeneity (Taylor et al., 2017).  
Telephone counselling and mobile phone-based interventions  
Telephone counselling can supplement or be a substitute for face-to-face contact and can be 
used alongside pharmacotherapy. There are financial and logistical advantages to providing 
support by telephone. The counselling can be proactive (counsellor initiates the calls) or 
reactive (on demand service for users to initiate). These helplines or quitlines are extensively 
used in countries without free-at-the-point-of-service, face-to-face cessation services as in the 
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UK. This is highlighted by the location of research studies, with sixty being completed in 
North America compared to three in the UK (Stead et al., 2013b). Both proactive and reactive 
forms of counselling have been shown to be effective (Stead et al., 2013b). For proactive 
forms there is a dose-response relationship with three or more calls being superior to fewer 
(Stead et al., 2013b). Mobile phone-based interventions, such as text messaging services, 
have also been shown to be effective (Whittaker et al., 2016).   
1.3.4 Pharmacotherapy for smoking cessation 
A number of pharmacological methods are available for smoking cessation. They can be used 
alone or alongside behavioural support. Often they are available over-the-counter or on 
prescription from a healthcare provider (or both) depending on local arrangements. A broad 
range of medications have been used as cessation aids, with most evidence for NRT, 
bupropion (Zyban), varenicline (Champix) and, to a lesser extent, cytisine.  
NRT is available in many different forms (patches, chewing gum, lozenges, sublingual 
tablets, sprays and inhalers) and aims to reduce motivation to smoke and the physiological 
and psychological withdrawal symptoms experienced during a quit attempt. Within the UK, 
over-the-counter NRT was, by far, the most popular quitting aid prior to 2013, after which e-
cigarettes became the most used (West et al., 2018). Varenicline is a selective nicotinic 
receptor partial agonist and is a prescription-only treatment. The use of varenicline peaked in 
2012 with 11% of smokers using it during quit attempts, with a steady decline since to around 
2-4% in 2017/2018 (West et al., 2018). Buproprion is now scarcely used, with the number of 
courses dispensed in the England seeing a 15-fold decrease between 2001 and 2014 
(Department of Health, 2015). Cytisine is not available in the UK but is commonly used in 
Poland and other parts of Eastern Europe (Walker et al., 2016).  
A Cochrane overview of reviews and network meta-analysis included 267 studies involving 
over 100,000 participants (Cahill et al., 2013). It concluded that NRT, bupropion, varenicline 
and cytisine increased the chances of quitting with odd ratios in the 2-4 region (Cahill et al., 
2013). Combination NRT (i.e. two NRT products, a slow and fast release) and varenicline 
were equally effective quitting aids (Cahill et al., 2013). None of the treatments had adverse 
events that would militate against their use (Cahill et al., 2013). The authors of this review 
also concluded that no further research was warranted into the efficacy or safety of NRT due 
to the large number of studies already conducted, with future trials unlikely to modify what 
was known about benefits and risks of the treatment (Cahill et al., 2013).        
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1.3.5 Smoking cessation interventions by dental professionals 
Guidance documents 
Dental professionals, in a similar fashion to other HCPs, are advised to provide brief advice 
interventions to their patients who smoke. A range of national guidance documents are 
available for dental professionals as detailed in Table 1.1. 
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Guidance document Publisher and year Content 
Smoking: brief interventions 
and referrals (PH1) 
The National Institute 
for Health and Care 
Excellence (2018) 
Advises that everyone who smokes should be advised to quit. If an individual presents 
with a smoking-related disease, the cessation advice should be linked to their medical 
condition. Dentists should refer people who smoke to specialist services.  
 
Stop smoking interventions 
and services (NG92) 
The National Institute 
for Health and Care 
Excellence (2018) 
At every opportunity, people should be asked if they smoke and advised to stop in a way 
that is sensitive to their preferences. VBA interventions should be delivered according to 
the National Centre for Smoking Cessation Training (NCSCT) training module (National 
Centre for Smoking Cessation and Training, 2012c). Smokers interested in quitting should 
be referred to a stop smoking service.  
 
The Clinical Case for 
providing stop smoking 
support to Dental Patients 
 
National Centre for 
Smoking Cessation and 
Training (2012a) 
VBA intervention suggested:  
ASK and record smoking status 
ADVISE - on personal health benefits of stopping smoking 
ACT - prescribe, monitor, refer.  
 
Very Brief Advice training 
module 
National Centre for 
Smoking Cessation and 
Training (2012c) 
This is an online training module for healthcare professionals. Describes a technique that 
allows an intervention to be delivered in <30 seconds. The ‘advise’ step deliberately 
leaves out the health benefits of stopping smoking/ harms of smoking in order to minimise 
the duration of the intervention and avoid a defensive reaction. 
 
Tobacco and Oral Health Action on Smoking 
and Health (2016) 
Suggests dentists provide smoking cessation advice using the 3 A’s technique as 
described by the NCSCT (National Centre for Smoking Cessation and Training, 2012c). 
The previous versions of this guidance recommended the 5 A’s technique: Ask, Assess, 
Advice, Assist, Arrange (Action on Smoking and Health, 2012).  
  
Smokefree and Smiling. 
Second edition.  
Public Health England 
(2014b) 
Tobacco users should receive a VBA intervention using the 3 A’s technique. There is 
confusion within the document regarding the ‘advise’ step. It states ‘advise on the 
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Guidance document Publisher and year Content 
personal benefits of quitting’ but contradicts this later when recommending the NCSCT 
VBA approach.   
 
Delivering better oral health: 
an evidence-based toolkit for 
prevention. Third Edition.  
Public Health England 
(2014a) 
VBA advised using 3 A’s technique.  
Specifically recommends the NCSCT VBA training module (National Centre for 
Smoking Cessation and Training, 2012c).  
 
Smoking cessation in NHS 
dentistry. BDA evidence 
summary.  
British Dental 
Association (2015) 
Concludes that behavioural interventions by health care professionals are effective in 
reducing tobacco use in smokers and smokeless tobacco users.  
 
Table 1.1 Guidance documents for dental professionals providing smoking cessation interventions. 
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Evidence 
A Cochrane systematic review (Carr and Ebbert, 2012) looked specifically at tobacco 
cessation within the dental setting and found it to significantly increase the odds of tobacco 
abstinence at 6 to 24 months (OR: 1.71, 95% CI: 1.44-2.03). However, there was high 
heterogeneity between studies (I2 = 61%), likely to be partially explained by the settings 
investigated. These varied from private specialist dental practices to federally funded general 
dental practices. Some studies targeted school children while others focused on adults, also 
contributing to the heterogeneity. A post hoc subgroup analysis of adult smokers in dental 
practice settings (5 studies) demonstrated no evidence of heterogeneity (I2 = 3%) and a 
significant benefit of the intervention (OR 2.38, 95% CI: 1.70 -3.35) as presented in Figure 
1.4. As previously, assuming an unassisted 6-month success rate of 3%, an intervention in the 
dental setting could increase the quit rates (6-month) to 7%. 
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Figure 1.4 Smoking cessation following behavioural interventions by general dental 
practitioners.  
Comparison: Behavioural interventions verses control. Outcome: Abstinence at the longest 
follow-up. Subgroup of trials in adult smokers seen by general dental practitioners. 
Reproduced from Carr and Ebbert (2012).  
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For patients suffering from periodontal disease, smoking cessation is especially important (see 
section 1.2.7), as highlighted in a number of European workshop consensus reports (Ramseier 
et al., 2006; Ramseier et al., 2010). Dental professionals are in a unique position to provide 
smoking cessation advice (SCA) as they often see patients over a sustained period of time for 
periodontal therapy, which has better outcomes when smokers quit (Chambrone et al., 2013). 
Additionally, patients with periodontitis are likely to have several visible signs of the disease 
process (staining, recession, drifting, mobility, tooth loss) which can be useful prompts for 
quit attempts.  
Both of the European workshop consensus reports identified that education in dental schools 
lacked both a knowledge-based curriculum and practical skills training of behaviourally-based 
interventions (Ramseier et al., 2006; Ramseier et al., 2010). A lack of training has often been 
identified as a barrier to providing SCA by dental professionals of all professional groups 
(Stacey et al., 2006; Ahmed et al., 2018). A European survey in 2009 reported that overall 
67% (UK data: 100%) of dental schools included tobacco education in their curricula for 
dentists, but only 18% (UK data: 67%) included any practical aspect of education e.g. 
delivering smoking cessation interventions. Assessment rates were low, with only 27% (UK 
data: 89%) of dental schools assessing theoretical knowledge and 4% (UK data: 11%) 
assessing practical skills. An update of UK dental schools in 2016 reported an improved 
situation with practical assessment rates increasing to 72% (Holliday et al., 2017a). All UK 
programmes expected their graduates to be clinically competent at discussing the health 
consequences of smoking, delivering a brief smoking cessation intervention and referring 
patients to stop smoking services (Holliday et al., 2017a).    
Harm reduction approaches 
As previously discussed (see section 1.3.1), harm reduction approaches are advised for those 
not able or wanting to quit in one step (abruptly), in order to increase the likelihood of later 
quit attempts and reduce health harms (The National Institute for Health and Care Excellence, 
2013b). From a periodontal disease perspective, harm reduction is also an important 
consideration with patients often asking if there is benefit for their gum health in cutting 
down. The damage caused by tobacco smoke does appear to be dose-dependent with disease 
severity increasing with a greater number of cigarettes smoked per day or increasing pack-
years (Martinez-Canut et al., 1995; Tomar and Asma, 2000; Dietrich et al., 2015). Few 
studies have demonstrated a dose-response for treatment outcomes. A dose-response has been 
shown in one study for surgical outcomes (Cortellini and Tonetti Maurizio, 2015) and two 
studies for tooth loss during supportive periodontal therapy (Rieder et al., 2004; Matuliene et 
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al., 2008). Chaffee et al. (2016) warned about compensatory smoking (e.g. deeper breaths to 
obtain as much nicotine as possible from each cigarette), with reduced smoking not 
necessarily leading to reduced exposure to harmful tobacco products. Therefore, the use of 
NRT while cutting down is critical for the harm reduction concept (The National Institute for 
Health and Care Excellence, 2013b) as it reduces the extent of compensatory smoking by 
providing an alternative nicotine source. In patients who continue to smoke, there has been 
some consideration of approaches that control the damage, slowing the disease process 
(Chaffee et al., 2016). Host modulation therapies may reduce the damage caused by tobacco 
smoke. Such therapies include agents that reduce inflammatory response or promote healing 
after resolution of inflammation. There is some evidence that the use of tetracycline family 
antibiotics has positive effects for smokers when combined with periodontal debridement 
(Chaffee et al., 2016), although not all studies agree (Needleman et al., 2007).    
In summary, dental professionals are in an influential position to provide effective SCA to 
their patients who smoke. Dental professionals are advised to deliver SCA using VBA 
interventions such as the 3 A’s technique. Ideally, this will result in a referral to a specialist 
stop smoking service where high success rates can be achieved utilising combined 
pharmaceutical and behavioural interventions. However, with recent declines in the 
availability of this service, there may be a growing role for the dental team to deliver more 
intensive interventions.    
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1.4 Electronic cigarettes  
1.4.1 The rise of the e-cigarette 
Although e-cigarettes have become popular recently, the concept goes back over half a 
century. The first record of an e-cigarette was in 1963 when a US patent was filed for a 
‘smokeless non-tobacco cigarette’ (Herbert A Gilbert, 1963). The patent describes a device 
not dissimilar to the modern day e-cigarette with the objective of providing a ‘safe and 
harmless means for, and method of, smoking by replacing burning tobacco and paper with 
heated, moist, flavored air’ and that it maintained ‘the satisfaction of smoking without any of 
its disadvantages’. It also proposed that the device could be used therapeutically by ‘inhaling 
warm medication into the lungs in case of a respiratory ailment under direction of a 
physician’. The invention did not gain popularity, probably due to limitations with the 
technology at the time. In the 1970s, development slowly continued with Dr Jacobson being 
one of the first to use the term ‘vaping’ (smokeless cigs: 'they satisfy', 1980).  
The rise in e-cigarette popularity seen during the first years of the twenty-first century is often 
linked to Hon Lik, a Chinese pharmacist and heavy smoker. He filed a US patent in 2005 for 
an ‘electronic atomization cigarette’ that contained ‘nicotine without tar’, to reduce the ‘risk 
of suffering cancer’ (Hon, 2005). Early manufacture of e-cigarettes was limited to China with 
exports to the US and Europe. As the popularity of e-cigarettes grew, manufacturing 
developed outside of China. The tobacco industry’s interest in the market was relatively slow 
but eventually became established in 2012 with the purchase of Chinese based company 
Dragonite International Ltd. by Imperial Tobacco Group PLC for $75 million (Gustafsson, 
2013). Commentators liken the tobacco industry’s sudden interest to an attempt to avoid the 
‘Kodak moment’, when the world’s leading maker of camera film realised the world had gone 
digital and it was too late to catch up (Kodak moment, 2013).  
E-cigarette use in early years (2006-2010) was negligible, although this is hard to quantify as 
epidemiological surveys did not regularly include questions about e-cigarettes prior to that 
date e.g. the UK based Smoking Toolkit Study introduced e-cigarette questions in 2011 (West 
et al., 2018). Over recent years, e-cigarette use has grown considerably with ‘ever-use’ being 
estimated at 12.6%, 19.4% and 15% in US (2014), UK (2017) and European (2017) adults 
respectively  (Schoenborn and Gindi, 2015; European Commission, 2017; Office of National 
Statistics, 2018b). Current (every day or some days) e-cigarette usage rates vary between 2-
5.6% in US, UK and European populations (Schoenborn and Gindi, 2015; Coleman et al., 
2017; European Commission, 2017; Office of National Statistics, 2018b). UK data report that 
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men (aged ≥16 years old) are more likely than women to be current e-cigarette users (6.3% 
compared to 4.9% for women) or ever users (detailed data not provided) of e-cigarettes 
(Office of National Statistics, 2017). Young adults (16-24 years) were most likely to have 
tried an e-cigarette and those aged 35-49 years were most likely to be current e-cigarette users 
(Office of National Statistics, 2017). There are notable gender variations by age groups with 
more men being current e-cigarette users in the youngest age group (16-24 years, 8.9% versus 
2.6%) whilst there were more women e-cigarette users in older age groups (50-59 years, 7.5% 
versus 5.5%) (Office of National Statistics, 2017).  
Prior to e-cigarettes, the most popular quit aid used by smokers was over-the-counter NRT, 
with e-cigarettes accounting for less than 1% in 2011 (West et al., 2018). During 2011-2013 
there was considerable growth, with almost 30% reporting use of e-cigarettes in their most 
recent quit attempt, by the end of 2013 (West et al., 2018). Since 2013, the rate of growth has 
plateaued, being 33% in the second quarter of 2018, as demonstrated in Figure 1.5 (West et 
al., 2018).  
 
 
Figure 1.5 Aid used in the most recent quit attempt. 
 
Reproduced from the Smoking Toolkit Study (West et al., 2018). Based on 14050 adults who 
smoke and tried to stop or who stopped in the past year.  
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E-cigarette users report a variety of reasons for e-cigarette use with the most common 
including: as an aid to stopping smoking, because they perceived it be less harmful than 
tobacco cigarettes or because they could use it at a time or place where tobacco cigarettes 
were not allowed (Coleman et al., 2017; Office of National Statistics, 2018b).  
In adults, e-cigarette users are almost exclusively current and ex-smokers. Very few adult 
never-smokers report being current e-cigarette users (every day or some days) with 
prevalence rates of 0.2-0.6% being reported in the US and UK (Schoenborn and Gindi, 2015; 
Action on Smoking and Health, 2017a; Office of National Statistics, 2018b; West et al., 
2018). The smoking status of e-cigarette users is made up of an increasing proportion of ex-
smokers and decreasing proportion of current smokers, with approximately 45% using e-
cigarettes alongside tobacco (so called dual use) in 2017 (Action on Smoking and Health, 
2017a; McNeill et al., 2018; West et al., 2018). It has been noted that the dual usage rates for 
e-cigarettes are similar to those for NRT alongside burnt tobacco (McNeill et al., 2018; West 
et al., 2018).      
E-cigarette use by young people has been the topic of much concern and debate. 
Experimentation with e-cigarettes is common in young people with rates of ‘ever’ e-cigarette 
use in US high school students being 37.7% (U.S. Surgeon General, 2016), slightly higher 
than rates seen in the UK which are in the range 7-32% (McNeill et al., 2018). Rates of 
regular use (defined as weekly use [UK] or ‘using e-cigarette on 20 or more days in the last 
30 days’ [US]) are in the range 1-3% for US teenage populations (U.S. Surgeon General, 
2016) and 0.1-0.5% for UK populations (Bauld et al., 2017). Vastly different public health 
analyses and approaches are taken on this topic. A recent report by the U.S. Surgeon General 
(U.S. Surgeon General, 2016) concluded that:  
 e-cigarette use by youth was a public health concern;  
 e-cigarette use by youth was strongly associated with use of combustible tobacco 
products;  
 any form of nicotine was unsafe and could harm the development of the adolescent 
brain;  
 education should be provided (to parents, teachers, coaches and health professionals) 
on the risks of e-cigarette use among young people.  
On the contrary, a recent report from Public Health England (PHE) (McNeill et al., 2018) 
concluded that:  
 despite some experimentation, regular use was rarely seen in never-smokers;  
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 e-cigarettes did not appear to be undermining the long-term decline in cigarette 
smoking;  
 the ‘common liability’ hypothesis seems a plausible explanation for the relationship 
between e-cigarette and smoking initiation;  
 harms from long-term nicotine use such as ‘snus’ and NRT in pregnancy did not lead 
to health harms;  
 widespread misperceptions about the relative risks of nicotine and tobacco need to be 
addressed and corrected.  
A recent UK House of Commons Science and Technology Select Committee reported similar 
conclusions to the PHE report (House of Commons, 2018). Additionally they called for a 
medically licensed e-cigarette to be encouraged, by streamlining regulatory processes, in 
order to make it easier for medical professionals to assist smoking cessation efforts.  
This variance in approach has been partly attributed to usage profiles and marketing 
differences (U.S. Surgeon General, 2016) but is likely to be much wider reaching and 
complex e.g. cultural differences (Thirlway, 2018).  
Although an important topic, the youth debate is not directly relevant to this research project. 
This project focuses on adults (the age-profile of periodontitis is middle to older aged) who 
are existing smokers. The issues of youth uptake, use by never-smokers and the gateway 
effect are not explored in detail within this thesis.   
1.4.2 The technology of the e-cigarette 
E-cigarettes are battery-operated devices that delivers the users with a aerosol(commonly 
referred to as ‘vapour’) and are commonly categorised into three generations (McEwan and 
McRobbie, 2016). First generation e-cigarettes (‘cig-a-likes’ or ‘minis’) typically resemble 
traditional tobacco cigarettes. They are often classed as starter devices, have a low cost and 
are disposable. Nicotine delivery in these first generation devices is often poor and the battery 
life is limited. Only 4% of users reported using a disposable e-cigarette in 2017, reducing 
from 8% in 2014 (Action on Smoking and Health, 2017a).  
Second generation e-cigarettes (‘tanks’) do not resemble cigarettes and often look like pens. 
They usually contain a tank that is re-fillable by the user. They have larger batteries and are 
re-chargeable. In 2017, the majority of e-cigarette users (69%) reported using a rechargeable 
device with a tank or reservoir that is filled with liquids, increasing from 41% in 2014 (Action 
on Smoking and Health, 2017a).  
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Third generation e-cigarettes are modifiable (‘mods’) and have more advanced features such 
as variable voltage systems and digital readouts, allowing ‘vapers’ to customise their 
experience. The technology of this field is constantly changing, often at a rapid pace. A recent 
example of an innovative design is the ‘JUUL’ e-cigarette which has a unique presentation 
(similar to an USB stick) and alternative chemistry, using nicotine salts rather than free-base 
nicotine (JUUL, 2018).  JUUL was the most popular e-cigarette brand in the USA in 2017, 
and became available for sale in the UK in July 2018 (Bauld, 2018).  
The vast majority of e-cigarettes contain e-cigarette liquid (hereafter e-liquid), either in the 
form of pre-loaded capsules, pre-loaded bottles with which the users top up their device, or 
do-it-yourself (DIY) kits in which the users mix their own solutions at home. The majority 
(around 90%) of the solution is made up of a carrier or diluent, usually propylene glycol (PG), 
vegetable glycerine (VG) or a mixture of the two. It is this diluent that accounts for most of 
the vapour production. Nicotine is included at varying concentrations, limited to 20mg/ml in 
the EU but available above 50mg/ml in some other locations. Since both the diluent and 
nicotine are largely tasteless, flavourings are often added to enhance the user experience. The 
most popular flavours are fruit, tobacco and menthol/mint (McNeill et al., 2018) but the array 
of options are extensive with over 7,000 flavours identified in 2014 (Zhu et al., 2014).  
1.4.3 The legal and regulatory framework for e-cigarettes 
The rapid emergence of e-cigarettes onto the market meant that initially there were no specific 
regulations. In the UK, e-cigarettes were initially regulated as consumer products and were 
subject to existing product safety regulations (Rough and Barber, 2017). The UK’s Medicines 
and Healthcare products Regulatory Agency (MHRA) subsequently set out plans to regulate 
e-cigarettes as medicines but the European Union Tobacco Products Directive (TPD) 
superseded these (European Commission, 2014). The TPD entered into force in May 2014 
and was transposed into UK law in May 2016 (UK Government, 2016). The TPD covers 
product standards and nicotine strength, safety, labelling and packaging, notification and 
vigilance, advertising and annual reporting. Manufacturers are still able to apply for medical 
licences for their products but only one has been awarded to date and this product has never 
been brought to market (Medicines and Healthcare products Regulatory Agency, 2015). 
During the transposition of the TPD into UK law, additional domestic regulations were added. 
These included an almost complete marketing ban (print, online, broadcast), age of sale laws 
and a ban on proxy sales (where an adult would buy an e-cigarette for a young person). All 
areas of the UK have introduced age restrictions on e-cigarettes that prohibit their sale to, and 
purchase on behalf of, those aged under 18 years old (Rough and Barber, 2017). 
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Internationally there are a broad range of approaches to e-cigarette regulation with outright 
bans on the sale, distribution and importation of e-cigarettes present in some countries e.g. 
Brazil and Singapore (Rough and Barber, 2017). Others have imposed a de facto ban with 
devices being legal but the sale and possession of nicotine within them being illegal e.g. 
Australia (Rough and Barber, 2017).     
1.4.4 Efficacy and effectiveness of e-cigarettes for smoking cessation and reduction  
As previously discussed, the most commonly cited reason for e-cigarette use is as an aid to 
quitting tobacco smoking. There has been a considerable amount of research interest in this 
field, using several different research designs. Randomised controlled trials (RCTs) randomly 
allocate smokers to receive different methods of smoking cessation support which include an 
e-cigarette study arm (Bullen et al., 2013; Caponnetto et al., 2013; Adriaens et al., 2014). 
Cohort studies include those with a prospective interventional design (i.e. all smokers are 
provided with an e-cigarette and followed for a period of time), those with a retrospective 
cohort design (i.e. describes abstinence in smokers who have used an e-cigarette within a 
specific period), and those which report adverse events only. Systematic reviews with or 
without meta-analyses have attempted to summarise the research findings and, intriguingly, 
produced conflicting conclusions. There have been six meta-analyses published to date.   
A Cochrane systematic review (Hartmann-Boyce et al., 2016) identified 24 completed studies 
but included only two RCTs in the meta-analysis (Bullen et al., 2013; Caponnetto et al., 
2013). A third study (Adriaens et al., 2014) was included narratively but not in the meta-
analysis because of the study design, with all participants receiving an e-cigarette by six 
months. The authors of the review identified a considerable amount of ongoing research 
activity with 27 ongoing studies, including 15 potentially eligible RCTs. They concluded that 
there was evidence that nicotine e-cigarettes helped smokers to quit (RR 2.29, 95% 1.05-
4.96), that there were no reported serious side effects (up to 2 years) and that further research 
was needed. The quality of the evidence was rated as low on the GRADE scale (Guyatt et al., 
2008), not because of how the studies were conducted but because of the small number of 
studies and indirectness (the devices used in these studies were no longer available on the 
market) (Hartmann-Boyce et al., 2016). Four other meta-analyses (Rahman et al., 2015; 
Khoudigian et al., 2016; Vanderkam et al., 2016; El Dib et al., 2017) used similar 
methodology, included the same two studies (Bullen et al., 2013; Caponnetto et al., 2013), 
and reported comparable findings as detailed in Table 1.2. Conflicting findings were 
presented in one meta-analysis which concluded that e-cigarettes were associated with 
significantly less quitting in smokers (Kalkhoran and Glantz, 2016). The difference in these 
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findings and conclusions seems to be due to methodological issues, particularly regarding the 
study inclusion criteria. Kalkhoran and Glantz (2016) proposed to conduct a real-world 
assessment and included 20 studies in their analysis, unlike all the other meta-analyses which 
included only two RCTs, undoubtedly leading to the different findings. Nineteen of the 
included studies in the Kalkhoran and Glantz (2016) review were of a non-randomised design, 
meaning there was no controlling for unexplored confounders. Additionally many of the 
included longitudinal surveys were at high risk of selection bias. They assessed smoking 
cessation in e-cigarette users compared with non-users. In the e-cigarettes users group they 
only included those who were continuing smokers at baseline, meaning those who had already 
successfully quit using e-cigarettes were excluded from the study population. The resulting 
sample was potentially biased towards more dependent smokers who may have found it 
harder to quit. Although many of the systematic reviews included these longitudinal studies, 
discussing them narratively, only Kalkhoran and Glantz (2016) included them in their meta-
analysis and their findings therefore need to be interpreted cautiously. Historically, similar 
issues have occurred with NRT evaluations when poorly designed observational studies 
showed negative correlations in contrast to the vast majority of RCTs which demonstrated a 
strong positive cessation effect, as presented in a Cochrane review including 117 RCTs and 
over 50,000 participants (Stead et al., 2012). As the number of published RCTs on e-
cigarettes increase, it is likely that the meta-analysis results will have improved clarity and 
strength.  
All clinical trials exist on an efficacy (explanatory) – effectiveness (pragmatic) continuum 
(Thorpe et al., 2009). The majority of the e-cigarettes for smoking cessation clinical trials 
focus on intervention efficacy (i.e. whether they deliver the expected result under ideal 
circumstances), although many are moderately pragmatic given the nature of tobacco smoking 
as a complex behaviour. E-cigarettes present a particular evaluative opportunity, due to their 
use widely within whole populations, almost as a natural experiment, potentially meaning true 
effectiveness can be assessed. McNeill et al. (2018) suggested that the smoking quitting 
success rate in England is at its highest level ever observed, with parity across different 
socioeconomic groups. They concluded that it is plausible that e-cigarettes were contributing 
to this.  
There have been several attempts to estimate the population-level effect of the introduction of 
e-cigarettes on smoking rates. West et al. (2016) completed analysis on English data (2014) 
and estimated that e-cigarette use within the population had created between 16,000 and 
22,000 additional long-term quitters. Beard et al. (2016) conducted similar analyses and 
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found that there was no clear evidence for an association between the prevalence of e-
cigarette use by smokers and attempts to quit smoking. However, increased e-cigarette 
prevalence was positively associated with the success rates of quit attempts (after adjusting 
for confounding variables) (Beard et al., 2016). They estimated that in 2015 there were an 
additional 54,288 short- to medium-term (<1 year) and 18,000 long-term quitters (Beard et 
al., 2016). Analysis of US data has shown similar patterns with Zhu et al. (2017) reporting a 
statistically significant increase in the smoking cessation rate at a population level with 
increasing e-cigarette use. At a European level, the Eurobarometer survey collected relevant 
data in 2014 from 28 countries. In a similar fashion to the previously discussed situation with 
the meta-analysis, conflicting results have been presented from different analyses of the data. 
Farsalinos et al. (2016) reported that 35.1% of current e-cigarette users reported smoking 
cessation with the help of e-cigarettes. Intensity of e-cigarette use was positively associated 
with smoking cessation (past experimentation versus current or past use) but there was no 
comparison to non-users of e-cigarettes. Contrastingly, Kulik et al. (2018) reported that e-
cigarettes were inhibiting smoking cessation within the European population (OR 0.25, 95% 
CI 0.18 to 0.35). They (Kulik et al., 2018) discuss as a limitation of their study that the survey 
data did not include timing of smoking cessation, meaning the sample included people who 
quit before e-cigarettes were available. They propose that this effect will bias the results 
towards the null, making the results even more reliable.    
In summary, we need further high-quality, well-designed studies to determine the efficacy and 
effectiveness of e-cigarettes for smoking cessation. At a population level, we need to continue 
to monitor smoking behaviour in different populations but due to the nature of the evidence 
produced by such an observational design (it is impossible to conduct a population level RCT) 
it can only provide evidence of associations and not of causation and will be open to different 
interpretations.    
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Study Studies included 
in the analysis 
Follow up period Management of loss 
to follow-up  
Cessation effect 
estimate:   
Notes 
Hartmann-
Boyce et al. 
(2016) 
2 RCTs Results at longest 
follow-up point 
Treated as continuing 
smokers 
RR 2.29  
(95% CI 1.05 to 4.96) 
Update of previous 
Cochrane review but 
with same meta-analysis 
results (McRobbie et al., 
2014). 
Rahman et al. 
(2015) 
2 RCTs Results at longest 
follow-up point 
Treated as continuing 
smokers 
RR 2.29  
(95% CI 1.05 to 4.96) 
 
El Dib et al. 
(2017) 
2 RCTs Results at 6 months  Treated as continuing 
smokers 
RR 2.03  
(95% CI 0.94 to 4.38) 
 
Khoudigian et 
al. (2016) 
2 RCTs Results at 6 months and 
9 months 
Treated as continuing 
smokers 
RR 2.02  
(95% CI 0.97 to 4.22) 
 
Vanderkam et 
al. (2016) 
2 RCTs Results at 6 months Treated as continuing 
smokers 
RR 1.93 
(95% CI 0.92 to 4.01) 
 
Kalkhoran and 
Glantz (2016) 
15 cohort studies, 
3 cross-sectional 
studies,  
2 clinical trials.  
Not specified in review 
methodology. Included 
studies ranged from 3 
months to 6 years.    
As managed in the 
original paper 
OR 0.72 
(95% CI 0.57 to 0.91) 
 
Table 1.2 Comparison of meta-analyses of e-cigarettes for smoking cessation. 
Adapted from Hartmann-Boyce (2017) conference presentation. RR: relative risk; CI: confidence interval; RCT: randomised controlled trial.  
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1.4.5 Safety 
The safety of e-cigarettes covers the device itself, e-liquid constituents, vapour constituents, 
and encompasses potential harms to the users themselves and to bystanders. With regards to 
the devices, there have been a number of reports of exploding e-cigarettes resulting in severe 
injuries, usually burns to the hands and face. McNeill et al. (2018) identified 25 published 
case reports or case series, three from the UK. Overall, the number of incidents is very small 
and appears to be related to malfunctioning lithium-ion batteries.   
The toxic and carcinogenic mixture of tobacco smoke is the biggest cause of cancer 
worldwide and the most significant source of toxic chemical exposure and chemically 
mediated disease in humans. The risk of using e-cigarettes, relative to tobacco smoke, is 
reported to be much lower. For example, several authorities have concluded that e-cigarettes 
were ‘unlikely to exceed 5% of the harms from smoking tobacco’ and using the phrase 
‘vaping is at least 95% less harmful than smoking’ is a good way to communicate the large 
difference in relative risk (McNeill et al., 2015; Royal College of Physicians, 2016; McNeill 
et al., 2018). Cancer potencies of e-cigarettes were reported to be largely under 0.5% of the 
risk of tobacco smoking (McNeill et al., 2018).      
The potential health risk to users is complex to estimate accurately given the large number of 
variables: devices, e-liquids, puffing topography and device settings. Cell culture and animal 
studies are challenging to interpret and to relate to human risk. They provide only weak 
evidence but can help direct future research. Additionally, the lack of long term clinical data 
further complicates safety assessments. More robust evidence will eventually come from 
health outcomes in cohorts of e-cigarette users but these data will take many years to accrue  
and will also be subject to complex confounding factors i.e. the vast majority of e-cigarette 
users are previous or current tobacco smokers. A Cochrane systematic review concluded that 
there were no observed health risks, up to two years, of e-cigarette use within the clinical 
trials they reviewed (Hartmann-Boyce et al., 2016). Biomarker studies have demonstrated that 
toxin and carcinogen exposure for e-cigarette users are comparable to those for NRT users, 
supporting the relative risk estimates previously mentioned (Goniewicz et al., 2017; Shahab et 
al., 2017). It should be noted that these biomarker studies focus on known carcinogens and 
toxicants of tobacco smoke and it is plausible that there are unknown carcinogens/toxicants 
produced by e-cigarettes that have not been assessed in these studies.         
Second-hand vapour studies have shown that bystanders can be exposed to low levels of 
nicotine vapour with levels of other compounds at very low or trace levels (Glasser et al., 
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2017). McNeill et al. (2018) concluded that there have been no identified health risks to 
bystanders of passive vaping.   
E-cigarette flavours have been a particular focus of attention. The flavours used in e-liquids 
are generally recognised as safe (GRAS) but this is in relation to eating or drinking, rather 
than inhalation following heating (Royal College of Physicians, 2016). An example of a 
flavour that has caused concerns is diacetyl, producing a buttery flavouring, and potentially 
causing bronchiolitis obliterans (‘popcorn lung’). This has been the topic of many media 
stories in the UK and internationally (Macrae, 2015; Sifferlin, 2015). Diacetyl is present in 
tobacco smoke at levels hundreds of times higher than that observed in e-liquids and since 
tobacco smoking is not a risk factor for this rare disease, it seems unlikely that diacetyl in e-
liquid will pose a significant risk. The MHRA chose to ban diacetyl in e-liquids within the 
UK (Medicines and Healthcare products Regulatory Agency, 2016b), highlighting how a 
synthetic product such as e-liquid can be easily modified when potentially undesirable 
components are identified.        
Conflicting views of the evidence exist with heavy criticism of the first PHE report (McNeill 
et al., 2015) by several prominent individuals (Gornall, 2015; Lancet, 2015; McKee and 
Capewell, 2015). Glantz and Bareham (2018) criticise the ‘95% safer’ statement in their 
review paper. They question the credibility of the authors, implying financial conflicts of 
interest, which were previously refuted (Ann McNeill, 2015). They (Glantz and Bareham, 
2018) accept that e-cigarettes deliver lower levels of carcinogens than tobacco cigarettes but 
highlight that cardiovascular and non-cancer lung disease kill more smokers than cancer, 
discussing the limited evidence for these risks with e-cigarettes. They conclude that, in their 
opinion, ‘it would not be surprising if e-cigarettes impose half (or more) of the overall long-
term risks as those from conventional cigarettes’.       
In summary, the relative health harms from e-cigarettes compared to tobacco cigarettes appear 
relatively small at present. As with any drug delivery device, there will be absolute health 
risks and research should focus on identifying these, allowing products to be modified to the 
safest possible forms. Finally, it is notable that oral health harms have scarcely been 
mentioned in the health harms debate; this is surprising given the established relationship of 
many oral diseases with tobacco smoking and the mouth being the first contact point for e-
cigarette vapour.     
43 
 
1.4.6 Effect on oral health 
The harmful effects of tobacco smoke on oral health are extensive and well documented (see 
section 1.2.3). The potential effects of e-cigarette vapour on oral tissues and disease pathology 
are currently unknown. From our understanding of the constituents, the hypothesis is that e-
cigarette vapour is significantly less damaging than tobacco smoke. For example, nicotine at 
the levels found in e-cigarettes is non-toxic to oral cells in vitro (see chapter 2) and has been 
used clinically in the form of NRT for several decades. Adverse effects (e.g. soreness and 
ulcers) from orally administered NRT are well documented and it would be expected that e-
cigarettes would have a similar risk profile (Mills et al., 2010). Nonetheless, the current 
evidence base for e-cigarette effects on oral health is limited and consists of laboratory studies 
of cell cultures, small ‘pilot’ clinical studies and adverse reactions data.  
In vitro studies on oral cells 
There are a number of laboratory-based studies on the exposure of oral cells to different 
conditions i.e. e-cigarette vapours. One of the first of these studies investigated DNA damage 
in cells exposed to e-cigarette vapour and concluded that e-cigarette vapour was cytotoxic to 
epithelial cell lines (Yu et al., 2016); press releases from this study reported that e-cigarettes 
were no better than smoking regular cigarettes (EurekAlert!, 2015). This study was 
subsequently heavily critiqued in the mass media (Bauld, 2015) and also in a commentary we 
published (Holliday et al., 2016) because of several methodological and reporting 
deficiencies. A critical factor omitted from the results, discussions and conclusions (as well as 
from the majority of the resulting press attention) was that the authors were unable to 
complete the tests on the cells exposed to cigarette smoke due to its high toxicity. Reference 
was only made to this briefly within the methods section where the authors describe only 
being able to expose cells to cigarette smoke for 24 hours, due to the level of toxicity. In 
contrast, the cells exposed to e-cigarette vapour were cultured for up to 8 weeks, with the cell 
culture solution (containing the relevant e-cigarette vapour extract) refreshed every three 
days. Somewhat misleadingly, three of the six figures within the results section display the 
results of the cigarette smoke alongside the results of the e-cigarette vapour. Figure 1.6 is a 
bar chart taken from the study presenting DNA double strand breaks as measured by γ-H2Ax 
immunofluorescence. When reading these graphs the reader would likely draw the conclusion 
that the e-cigarette vapour caused similar levels of damage to cigarette smoke. In fact what 
these graphs are showing is a comparison between cells exposed to cigarette smoke for 24 
hours against cells exposed to e-cigarette vapour for much longer periods (168 hours in the 
example given in Figure 1.6). The figure legend partially acknowledges this, stating that 
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cigarette smoke results ‘are shown for comparison’ but what is meant by this could have been 
made clearer to the reader. A simple alternative conclusion from the results of this study is 
that epithelial cells can survive in e-cigarette vapour extract (refreshed every three days) for 8 
weeks but only 24 hours when exposed to cigarette smoke. However, the study does show 
that in in vitro conditions e-cigarette vapour is not inert and exposure can lead to cytotoxic 
and DNA damaging effects, although the clinical relevance is challenging to interpret.  
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Figure 1.6 DNA double strand breaks in epithelial cells. 
 
Figure adapted from Yu et al. (2016) and presents DNA double strand breaks as measured by 
γ-H2Ax immunofluorescence in an epithelial cell line exposed to different conditions. V2 and 
VaporFi conditions are different e-cigarette devices either with or without nicotine. 
Supplementary annotations are added in red to highlight the different exposure times, crucial 
to the interpretation of the graph, but omitted from the original publication. **P<0.05, 
***P<0.001, ****P<0.0001  
24-hour exposure 
168-hour exposure 
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A number of comparable laboratory studies have investigated a range of parameters, often 
with similar limitations. A few studies exposed periodontal fibroblast cell cultures directly to 
e-liquid and reported the e-liquids to be cytotoxic (Sancilio et al., 2016; Sancilio et al., 2017) 
with menthol flavour being the most harmful (Willershausen et al., 2014). Other studies have 
tried a more realistic approach by exposing cell cultures to smoke or vapour (Sundar et al., 
2016; Yu et al., 2016; Rouabhia et al., 2017). Sundar et al. (2016) exposed oral epithelial and 
periodontal fibroblast cell cultures to e-cigarette vapour and reported increased oxidative and 
carbonyl stress and inflammatory cytokine release. Unfortunately, they had similar 
methodological issues to Yu et al. (2016) with a lack of detail about the exposure conditions, 
the absence of a tobacco smoke control and poor choice of exposure conditions. They (Sundar 
et al., 2016) varied both flavour and nicotine concentration simultaneously meaning that no 
useful comparisons could be drawn as illustrated in Figure 1.7. Rouabhia et al. (2017) 
reported e-cigarette vapour to cause cell shape modification and increased L-lactate 
dehydrogenase activity in gingival epithelial cell cultures (no tobacco smoke control).    
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Figure 1.7 Inflammatory response to e-cigarette vapour in periodontal ligament 
fibroblasts. 
Figure adapted from Sundar et al. (2016) and presents interleukin-8 (IL-8) production by 
periodontal ligament fibroblasts exposed to air, tobacco flavour e-cigarette vapour and 
menthol flavour e-cigarette vapour. Supplementary annotations are added in red to highlight 
the difference in the nicotine concentrations of the two conditions, important to the 
interpretation of this graph. * P < 0.05  
  
16 mg/ml nicotine  
0 mg/ml nicotine  
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Plaque biofilm studies 
As previously discussed, tobacco smoking has significant effects on the oral biofilm leading 
to an environment primed towards periodontitis. Only one published study to date has 
investigated the effect of e-cigarette aerosol on the oral biofilm (Stewart et al., 2018). They 
(Stewart et al., 2018) investigated the buccal oral biofilm in tobacco smokers, e-cigarette 
users and controls (non-users). They found the oral (buccal) biofilm was comparable in e-
cigarette users and the controls, unlike in tobacco smokers who had increased proportions of 
pathogens. However, this was a small study with only ten participants in each group and the 
authors called for validation in larger cohorts. No published studies have investigated 
subgingival plaque biofilm as relevant to periodontitis. In the absence of published studies, 
there are a number of conference abstracts that have reported on this topic (Ganesan et al., 
2016; Ganesan et al., 2017a; Vieth et al., 2017). Ganesan et al. (2016) examined the 
subgingival plaque biofilm in periodontally healthy subjects and concluded that the 
microbiome of e-cigarette users was virulence rich. They also conducted in vitro experiments 
which reportedly demonstrated that nicotine exposure of health-compatible biofilms lead to 
upregulation of virulence factors. In a later abstract (seemingly from the same study) they 
concluded that ‘risk-for-harm with e-cigs may be similar to or greater than smoking’ 
(Ganesan et al., 2017b). In another abstract, the same research group reported that those using 
e-cigarettes as a cessation tool had distinct bacterial community shifts in their subgingival 
plaque biofilm (Vieth et al., 2017). In-depth analysis of these studies is not possible due to 
their format as conference abstracts, and they should be interpreted cautiously. However, the 
findings suggest that e-cigarette vapour may have effects on the subgingival plaque biofilm 
and this needs to be further investigated in larger-scale clinical studies.        
Clinical studies on oral health 
There are a growing number of ‘pilot’ level non-randomised clinical studies investigating oral 
health outcomes (Franco et al., 2016; Reuther et al., 2016; Tatullo et al., 2016; Wadia et al., 
2016; Javed et al., 2017a; Al‐Aali et al., 2018). Methodological issues with these pilot studies 
are discussed in detail later (see section 3.2). Although none of these studies were designed or 
appropriately powered to demonstrate clinical outcomes, they indicated improvement in oral 
health when tobacco smokers switched to vaping e-cigarettes (Franco et al., 2016; Tatullo et 
al., 2016; Wadia et al., 2016; Javed et al., 2017a).   
A cross-sectional survey of over sixty-five thousand Korean school students examined three 
unconventional self-reported outcomes: ‘gingival pain and/or bleeding’, ‘cracked/broken 
teeth’ and ‘tongue/inside-cheek pain’ (Cho, 2017). They reported no association between e-
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cigarette use and ‘gingival pain and/or bleeding’. They reported an association between ever 
and current e-cigarette use and ‘cracked/broken teeth’ and between current e-cigarette use and 
‘tongue/inside-cheek pain’. As acknowledged by the author, there are several limitations in 
the study design with likely unknown confounders. They also proposed several unusual 
mechanisms for the effects reported which are outwith conventional understanding. For 
example, they suggest nicotine has effects on dental pulp cells and increases pulpal 
inflammation leading to ‘cracked/broken teeth’. Pulpal inflammation would not be considered 
a common cause of cracked teeth.  
Adverse reactions data 
No population-based studies exist for adverse reactions. A recent review of the Yellow Card 
Scheme in the UK found very few reports (McNeill et al., 2018), although this may be a 
under-representation given the MHRA classification of e-cigarettes (Medicines and 
Healthcare products Regulatory Agency, 2016a). Research studies record adverse events and 
the most frequently reported have been mouth and throat irritation, most commonly 
dissipating over time (Hartmann-Boyce et al., 2016). Survey data report similar findings 
including a dry mouth (Etter and Bullen, 2011a; Dawkins et al., 2013). Hartmann-Boyce et al. 
(2016) suggest that the common oral adverse effects are likely caused by PG (a humectant) 
and nicotine (which has a hot/peppery taste).    
1.4.7 Views of the public and profession 
There are a wide range of potential influences on public opinion, including: traditional media, 
social media, government approaches, regulations and healthcare professionals’ advice. Given 
the novel nature of e-cigarettes there has been much media attention, often with conflicting 
and confusing messages. McNeill et al. (2018) provide examples of circumstances when front 
page headlines have been based on suboptimal studies and often misreported. Conflicting 
messages have also been provided by public health agencies with Figure 1.8 demonstrating 
contrasting public health campaigns in England and California.  
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Figure 1.8 Contrasting public health approaches to e-cigarettes as shown through 
promotion campaigns. 
Contrasting public health approaches to e-cigarettes as shown through promotion campaigns. 
Both left images are from the “Wake Up” campaign by California Department of Public 
Health in 2015. These adverts tell users to ‘wake up’ to the risks from e-cigarette use and 
states that they are producing the next generation of addicts. The upper right image is from the 
“Stoptober” campaign by Public Health England in 2017. This campaign promoted the e-
cigarette as a method of stopping smoking in posters and also a television advert. The lower 
right image is from a Cancer Research UK awareness pilot campaign in Greater Manchester 
in 2018 aiming to improve the public’s knowledge and harm perception of e-cigarettes.   
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These factors have undoubtedly contributed to the observed trend of increasing perceived 
relative harm of e-cigarettes compared to tobacco cigarettes. There has been an increase from 
7% (2013) to 26% (2017) of those perceiving e-cigarettes to be more or equally harmful 
(Action on Smoking and Health, 2017a). The data suggest that concerns about the health 
harms of nicotine are contributory to this and common across tobacco cigarettes, NRT and e-
cigarettes. Although it is well established in the evidence base that none or a very small part 
of the risk of smoking comes from nicotine, only a small proportion (7.5%-12.9%) of adults 
correctly select this answer in surveys (Action on Smoking and Health, 2017a; McNeill et al., 
2018). Similarly, public perceptions of the cancer risk of nicotine are at odds with the 
scientific data i.e. nicotine is considered non-carcinogenic (World Health Organisation, 2014) 
and NRT is on the World Health Organisation list of essential medicines (World Health 
Organisation, 2017). An international study tracked public perception over 12 years, across 
four countries (US, UK, Canada and Australia) and reported that only approximately 40-50% 
of respondents correctly answered that nicotine in cigarettes does not cause cancer, with the 
UK having slightly lower misperceptions more recently (McNeill et al., 2018).   
Healthcare professionals will be exposed to the same influences as the general public but are 
also likely to have specific professional influences such as journals (peer reviewed and non-
peer reviewed) and outputs from professional organisations. We conducted a recent survey of 
dental professionals with similar findings to those from the general public. Approximately a 
third (31%) of respondents were of the opinion that e-cigarettes were more or equally harmful 
than cigarettes and half reported becoming less positive about their use over the previous 12 
months (Ahmed et al., 2018). This is in keeping with a recent survey that reported rates of 
43% and 36% for dental students in one American and one Spanish dental school, 
respectively, who held the opinion that e-cigarettes were more or equally harmful than 
cigarettes (Martín Carreras-Presas et al., 2018). The authors of this paper take a negative 
stance on e-cigarettes, perhaps reflective of their geographical location (mainly California). 
For example, they allude to a ‘misperception’ that e-cigarettes are a potential smoking 
cessation tool. They criticise the close-to-half of the students who agreed that e-cigarettes 
could be a smoking cessation aid, calling for further education, particularly of the ‘proven 
toxicity to multiple tissues including pulmonary and oral mucosa’. They cite no evidence on 
the effectiveness or otherwise of e-cigarettes within their paper. They also incorrectly talk 
about the ‘largely unsupervised marketing and manufacturing of e-cigarettes’ but confusingly 
later discuss in detail the regulations that do exist in the United States (US) and European 
Union (EU) around marketing and manufacturing.  
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A number of professional dental organisations have provided opinions or guidance regarding 
e-cigarettes which present a range of opinions (Table 1.3). It is unclear to what extent these 
have influenced dental professionals but the lack of consensus clearly demonstrates the need 
for further research and dissemination.     
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Organisation Output Summary of key messages regarding e-cigarettes 
British Society of 
Periodontology 
(2016) 
The Good 
Practitioner’s 
Guide to 
Periodontology 
 Relative effect not yet investigated 
 Likely to be less harmful to periodontal tissues than conventional cigarettes but not as good 
as stopping both. 
 Patients should be made aware of the ‘knowledge and evidence gap’ 
British Dental 
Association (2016) 
Position 
statement  
 E-cigarettes may provide a valuable cessation aid or means of harm reducing for some 
tobacco users.  
 Caution that evidence of long-term health effects not yet available 
 Efforts to minimise uptake by non-users of tobacco 
 Support current regulatory regime (TPD) 
 Concerned about adolescents who use e-cigarettes progressing to tobacco smoking. Will 
continue to monitor ‘gateway effect’ evidence.  
European 
Association of 
Dental Public 
Health (2014) 
Conference 
resolution on 
the control of e-
cigarettes 
 Uncertainties around manufacture, safety, marketing, advertising, regulation and long term 
general and oral health outcomes.  
 Calls to regulate e-cigarettes as tobacco products to support current tobacco restrictions and 
to maintain and improve oral health.  
The Canadian 
Dental Hygienists 
Association (2015) 
Position 
statement 
Four recommendations:  
 Ban on e-cigarettes containing nicotine 
 Ban on sale to minors 
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Organisation Output Summary of key messages regarding e-cigarettes 
 Ban on flavourings 
 Ban on use in public places and workplaces 
Canadian Dental 
Assistants 
Association (2017) 
Position 
statement 
Seven recommendations:  
 Develop new framework for regulating e-cigarettes (+/- nicotine) 
 Conduct longitudinal studies on health effects 
 Consider e-cigarettes as posing a significant health risk, unless scientific data proves 
otherwise 
 Child-resistant packaging 
 Distinct packaging from nicotine cigarettes 
 Strict marketing restrictions, especially for youth 
 Prohibit flavours that appeal to youth 
 Ban on flavourings 
 Ban on use in public places and workplaces 
Australian Dental 
Association (2017) 
Letter to  
government 
committee 
 Much more research is needed to confirm whether the use of e-cigarettes assists quit 
attempts and does not cause health impacts.  
 E-cigarettes pose oral health (and general health) dangers as they contain harmful 
chemicals, including carcinogens.  
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Organisation Output Summary of key messages regarding e-cigarettes 
 Nicotine is a highly addictive substance, has a myriad of short and long-term side effects 
and is a schedule 7 dangerous poison.  
 E-cigarettes have not been rigorously assessed and quality and safety is unknown.  
 Supporting e-cigarettes risks re-normalisation of smoking.  
 Cite Sundar et al. (2016) regarding periodontal health (previously discussed in section 
1.4.6 and Figure 1.7).   
 Patients should only use e-cigarettes after all other options attempted, be urged not to use 
them indefinitely and refrain from using in the presence of children.  
 Urges the government to take a ‘precautionary principle’, adopting tobacco regulations for 
e-cigarettes.  
 
Table 1.3 Professional dental organisations’ outputs on e-cigarettes. 
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1.4.8 Other novel nicotine products/ heated tobacco devices 
The alternative nicotine product market is rapidly evolving, involving products beyond e-
cigarettes. These include nicotine gels and heated tobacco products. Heated tobacco products 
(also known as heat-not-burn) are devices that heat tobacco to a lower temperature than 
combustion, aiming to avoid the harmful products produced by burning. Heated tobacco 
products have been recently launched by several tobacco companies, starting in Japan and 
slowly increasing distribution worldwide. As of 2018, in the UK these products were mainly 
available online, with only a handful of shops selling products.   
The evidence base for heated tobacco products is in its infancy. McNeill et al. (2018) 
reviewed the evidence, finding the majority (12 out of 19) of studies were funded by the 
tobacco industry. Given that combustion is avoided, it is likely that these products expose 
users and bystanders to less harm than regular tobacco smoke, although the extent is 
unknown. Only one study (funded by a tobacco company) has been published to date on oral 
health, investigating staining of resin composite (Zhao et al., 2017). Additionally there are 
two conference abstracts (also both funded by tobacco companies) investigating dental 
staining potential (Xiaoyi Zhao et al., 2017; Dalrymple et al., 2018). All these studies 
conclude that heated tobacco products lead to reduced dental staining compared to tobacco 
smoke. This is a useful outcome for the manufacturers who can use this in marketing material 
because it is a cosmetic and not a health claim (health claims would require medical 
authorisation by the MHRA).      
1.5 Summary 
Tobacco smoking remains one of the main public health issues of our age. Smoking is 
responsible for increased prevalence and severity of oral diseases, especially periodontitis. 
Dental professionals have an important role to play in providing SCA to their patients who 
smoke in order to improve their general health, oral health and treatment outcomes. E-
cigarettes are increasingly being used by smokers to cut down or quit tobacco smoking. They 
potentially offer a vital tool in the tobacco endgame towards a smoke-free future. However, 
due to their recent introduction the evidence base is still under-developed, particularly in the 
field of oral health. Well-designed investigations need to be conducted to establish the role of 
the e-cigarette in smoking cessation or harm reduction within the dental setting and to 
ascertain any undesirable effects on oral health.      
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1.6 Aims and objectives of the thesis 
This mixed methods PhD research aimed to explore the behavioural and biological changes 
when smokers with periodontitis were provided with an e-cigarette. To achieve this aim the 
research had four objectives:  
1. To systematically review the literature with regards to the in vitro effects of nicotine 
on periodontal cells.  
2. To conduct a feasibility randomised controlled trial (external pilot trial) of an e-
cigarette intervention within the dental setting in order to address uncertainties 
regarding eligibility, recruitment and retention rates, to explore the feasibility and 
acceptability of trial procedures, and to collect data to inform power calculations for 
definitive trials. 
3. To explore perceptions about theory-based factors influencing dentist-delivered SCA.  
4. To explore the broad perceptions of dental patients towards e-cigarettes and 
specifically towards being provided an e-cigarette as part of a smoking cessation 
intervention within the dental setting.      
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1.7 Overview of the thesis 
This chapter has described the background, scientific evidence and public health policy for 
this area of study. It has provided the rationale for the studies subsequently completed and 
outlined the aims and objectives of the research.  
Chapter 2 presents a systematic review of studies that evaluated effects of nicotine on human 
gingival and periodontal cells in vitro, specifically: cell viability, cell attachment, cell 
proliferation and inflammatory mediator production. 
Chapter 3 describes the methods and findings of a pilot randomised controlled trial providing 
smokers with periodontitis an e-cigarette as part of a smoking cessation intervention. A range 
of outcome measures were assessed over a 6-month period.  
Theory-based semi-structured interviews were conducted on a purposeful sample of study 
participants. Chapter 4 describes the interview methods and findings with regards 
perceptions about smoking and dentist-delivered SCA. Chapter 5 presents the findings 
regarding perceptions towards e-cigarettes and the e-cigarette intervention delivered in the 
study.  
Finally, Chapter 6 collates the findings from the research conducted, setting them within the 
context of the existing, albeit limited, evidence base, proposing directions for practice and 
future research (i.e. definitive studies) and acknowledging the strengths and weaknesses of the 
research methodologies.    
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Chapter 2  Effect of nicotine on human gingival and periodontal cells. A 
systematic review of the literature. 
___________________________________________________________________________ 
2.1 Abstract 
Introduction 
Tobacco smoking is a major risk factor for periodontitis and compromises success of 
treatment. The specific role of nicotine on periodontitis risk is unclear despite a large number 
of in vitro studies. This study aimed to conduct a systematic review of studies that evaluated 
effects of nicotine on human gingival and periodontal cells in vitro.  
Methods 
Primary research studies on human gingival or periodontal cells, using nicotine exposure as a 
variable, with appropriate controls, and published in English were identified up to May 2017. 
Study data were tabulated and analysed narratively.  
Results 
Of 317 potentially eligible studies, 39 were included. The median quality assessment score 
was 8/15. Study designs were highly heterogeneous. IC50 values for nicotine (the exposure 
concentration causing 50% cell death or inhibition of cell growth or other utilised toxicity 
metric) derived from nine studies ranged from 6 μM to 15.6 mM. Studies investigating cell 
attachment, proliferation and inflammatory mediator production suggested that effects can be 
seen at a wide range of nicotine concentrations, but results were often contradictory.  
Conclusions  
According to findings from in vitro studies, nicotine, at levels found in tobacco smokers, 
nicotine replacement therapy users and e-cigarette users, is unlikely to be cytotoxic to human 
gingival and periodontal cells, though saliva levels in smokeless tobacco users may be high 
enough to achieve cytotoxicity. There was limited and contradictory evidence for nicotine 
effects on cell attachment, proliferation and inflammatory mediator production. 
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2.2 Introduction 
Smoking is highly prevalent in many populations worldwide. The harmful effects of smoking 
on general health have been well documented (Clareboets et al., 2010). Smoking also has 
significant adverse effects on oral health, with an extensive literature documenting the 
relationship of smoking to periodontal disease (Tomar and Asma, 2000), wound healing and 
oral cancers (Vineis et al., 2004).  
In 2000, it was estimated that over 50% of all cases of periodontitis could be attributed to 
cigarette smoking (Tomar and Asma, 2000). Smokers are 2-8 times more susceptible to 
periodontitis than non-smokers (Palmer et al., 2005; Johnson and Guthmiller, 2007) and five 
times more likely to suffer from tooth loss as a result of periodontitis during long-term 
periodontal maintenance (Chambrone et al., 2010). Smokers have poorer responses to both 
non-surgical and surgical periodontal therapies compared to non-smokers (Papantonopoulos, 
2004; Johnson and Guthmiller, 2007; Chambrone et al., 2009). Similarly, it has been shown 
that smokers who quit smoking during periodontal therapy achieve improved clinical 
outcomes compared with those who continue to smoke (Preshaw et al., 2005; Rosa et al., 
2011).  
The mechanisms linking smoking and periodontitis have been the focus of numerous in vitro 
studies that have investigated tobacco smoke and its constituents. Whole tobacco smoke has 
been shown to be highly toxic to oral cells (Zhang et al., 2009) with significant disruption to 
cellular functions (Semlali et al., 2011).  
There have been previous attempts at reviewing the in vitro literature in this field (Palmer et 
al., 2005; Wyganowska-Swiatkowska and Nohawica, 2015). Palmer et al. (2005) reviewed 
the potential biological mechanisms underlying the effects of tobacco smoking on 
periodontitis. With regards to nicotine specifically, they concluded that ‘nicotine may be 
unfairly blamed for most of these properties’. In previous decades, this was of little 
consequence and classifying nicotine as harmful was useful in presenting a simple tobacco 
control public health message. However, in the modern environment with the availability of 
NRT and new nicotine delivery technologies (such as e-cigarettes) the effect of nicotine in 
isolation is of much more relevance.  
The in vitro studies that have investigated the effect of nicotine in isolation on periodontal 
cells have often reported contradictory results. Authors have sometimes selectively identified 
studies, presenting widely differing viewpoints. For example Wu et al. (2013) stated 
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‘nicotine, the main toxic component in tobacco, was confirmed as the main effect of smoking 
on periodontal tissue destruction’ whereas Checchi et al. (1999) concluded ‘nicotine by itself 
is toxic only at concentrations higher than that found in plasma and crevicular fluid of heavy 
smokers’. To the best of our knowledge there has not been a systematic review conducted on 
the in vitro effects of nicotine on periodontal cells despite the large number of studies 
published.     
The aim of this systematic review, therefore, was to evaluate the in vitro effects of nicotine on 
human gingival, periodontal and oral epithelial cells, specifically: cell viability, cell 
attachment, cell proliferation and inflammatory mediator production.  
2.3 Materials and methods 
The PRISMA statement, checklist (Appendix A- Supplementary Figure S1) and flow diagram 
(Figure 2.1) were utilised in this review. A search protocol was developed a priori following 
discussion between all members of the research team (Richard Holliday, Philip Preshaw and 
James Campbell). The focussed question for the review was: In in vitro conditions, does 
nicotine exposure, compared to no nicotine exposure, lead to changes in cell viability, 
attachment, proliferation or inflammatory mediator production in human gingival and 
periodontal fibroblasts and epithelial cells?  
This question was constructed according to the PICOS framework (Table 2.1).  
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Figure 2.1 Flow chart of included and excluded studies (PRISMA). 
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PICOS 
Population/patient Human gingival and 
periodontal fibroblasts and 
epithelial cells 
Intervention/indicator Nicotine exposure 
Comparator/control No nicotine exposure 
Outcomes Cell viability 
Cell attachment/adhesion 
Cell proliferation 
Inflammatory mediator 
production  
 
Study design In vitro, experimental 
 
Table 2.1 Focused research question presented using the PICOS framework. 
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2.3.1 Criteria for considering studies for review  
Inclusion criteria for studies were: (i) primary studies on human gingival fibroblasts (HGFs) 
or human periodontal ligament cells (HPDLCs) or human gingival/oral epithelial cells 
(HGECs/HOECs); (ii) nicotine exposure as a variable; (iii) inclusion of an appropriate control 
(no nicotine); and (iv) published in the English language. Animal studies and abstracts 
without full papers were excluded.  
2.3.2 Search methods for identification of studies 
Electronic searching 
The search terms employed in this study were: ((perio$ [All fields] OR gingiva$ [All fields]) 
AND (fibroblast$ [All fields] OR epithelia$ [All Fields]) AND nicotine). MEDLINE, 
EMBASE and Web of Science were searched without language restriction up to, and 
including 31st May 2017.  
Unpublished data and hand-searching 
Unpublished data were sought by searching a database listing unpublished studies 
(www.opengray.eu). Additionally, reference lists of any potential studies were examined (i.e. 
hand searching) in an attempt to identify any further studies that could be considered for 
inclusion. Bibliographies of review articles, relevant texts, World and European 
Periodontology Workshops were also screened.  A manual search was performed of the 
Journal of Clinical Periodontology (1974-2017), Journal of Periodontology (1944-2017) and 
Journal of Periodontal Research (1966-2017).   
2.3.3 Data collection, extraction and management 
Titles and abstracts from the electronic searches were imported into EndNote X8 (Thomson 
Reuters, New York City, NY, US).  Duplicates were eliminated. Titles were screened 
independently by two reviewers (RH and JC) and those indicating no relevance to this study 
were excluded. Abstracts were then screened independently by two reviewers (RH and JC). 
The full texts of potentially eligible studies were then reviewed against the 
inclusion/exclusion criteria independently by the two reviewers and disagreement resolved by 
discussion and consultation with a third author if necessary. Data were extracted 
independently from the full text articles by two reviewers using a piloted data extraction form. 
Data collected comprised: year of publication, location of first author, funding source(s), cell 
types studied, 15-item Consolidated Standards of Reporting Trials (CONSORT) quality 
assessment, cell viability data (assay used, nicotine exposure conditions and results), cell 
attachment data (assay used, nicotine exposure conditions and results), cell proliferation data 
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(assay used, nicotine exposure conditions and results) and inflammatory mediator production 
data (assay used, nicotine exposure conditions and results).  
2.3.4 Assessment of quality in included studies 
A quality assessment was completed on each included study. A 15-item modified CONSORT 
checklist was used (Faggion, 2012). Developed by Faggion (2012), this checklist is designed 
for assessing the quality of in vitro pre-clinical research and gives a score out of 15 (with a 
higher score indicating higher quality).  
2.3.5 Data synthesis 
Data were collated into evidence tables, with study characteristics, details of the exposure 
conditions, details of the assays conducted and quality assessment included. For data analysis, 
a narrative approach was utilised.   
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2.4 Results 
2.4.1 Search results and characteristics of included studies  
The flow chart of manuscripts screened is shown in Figure 2.1. A total of 317 potentially 
eligible studies were identified by the search strategies. Following de-duplication, title 
screening was completed on 271 studies with 183 studies being excluded at this stage. 
Abstract screening was completed on 88 studies with 63 progressing to full-text review. An 
additional three studies were identified from the references of the screened studies. Finally, 39 
studies were included in the full data analysis (Appendix B Supplementary Table S1 provides 
reasons for exclusion of reviewed full-text studies).  
The characteristics of the included studies are presented in Supplementary Table S2 
(Appendix C). The included studies were published over a 20 year period from 1995 (Tipton 
and Dabbous, 1995) to 2015 (Dinos et al., 2015; Esfahrood et al., 2015). Studies were 
conducted in 13 different countries (based on first author location) with researchers in the 
USA (Tipton and Dabbous, 1995; Johnson and Organ, 1997; Tanur et al., 2000; Wendell and 
Stein, 2001; Fang and Svoboda, 2005; Olson et al., 2005; Zhou et al., 2007; Johnson et al., 
2010; San Miguel et al., 2010; San Miguel et al., 2012; Gao et al., 2013; Dinos et al., 2015), 
South Korea (Lee et al., 2005; Lee et al., 2008; Lee et al., 2009; Kang et al., 2011; Kim et al., 
2012; Lee et al., 2013; Park et al., 2013) and Japan (Nakao et al., 2009; Takeuchi et al., 2010; 
Kashiwagi et al., 2012; Nakata et al., 2013; Takeuchi-Igarashi et al., 2014) publishing the 
greatest numbers of studies per country.   
2.4.2 Quality assessment 
The median (interquartile range [IQR]) quality assessment score of the 39 assessed papers 
was 8.0 [1.0], with a theoretical range of scores between zero and 15. The lowest score was 
six (Alpar et al., 1998; Giannopoulou et al., 1999) and the highest score was nine (Tipton and 
Dabbous, 1995; Johnson and Organ, 1997; Checchi et al., 1999; Fang and Svoboda, 2005; 
Mahanonda et al., 2009; Nakao et al., 2009; San Miguel et al., 2010; Takeuchi et al., 2010; 
Kashiwagi et al., 2012; San Miguel et al., 2012; Silva et al., 2012; Nakata et al., 2013; Park et 
al., 2013; Wu et al., 2013; Takeuchi-Igarashi et al., 2014; Wu et al., 2014; Esfahrood et al., 
2015). Regarding the key methodological domains assessed by the modified CONSORT 
checklist, all of the studies failed to achieve: sample size determination, random sequence 
generation, allocation concealment, implementation details, blinding and publication of the 
full study protocol. Supplementary Table S3 (Appendix D) provides detailed breakdowns of 
the quality assessment for each study.   
67 
 
Regarding funding sources for published studies, six studies did not provide any details about 
funding (Alpar et al., 1998; Ciapetti et al., 1999; Olson et al., 2005; Ho and Chang, 2006; 
Zhou et al., 2007; Dinos et al., 2015), two stated that they had received no funding (Kang et 
al., 2011; Esfahrood et al., 2015), one detailed an individual providing equipment 
(Giannopoulou et al., 1999), one was funded by a tobacco manufacturer (Gao et al., 2013), 
one was funded by a tobacco endowment fund (Fang and Svoboda, 2005), and the remainder 
received funding from various educational, governmental and charitable sources (Appendix C 
Supplementary Table S2). 
2.4.3 Cell types investigated 
The most studied cell type were HGFs, being investigated in 21 studies (Tipton and Dabbous, 
1995; Alpar et al., 1998; Checchi et al., 1999; Ciapetti et al., 1999; Tanur et al., 2000; 
Wendell and Stein, 2001; Argentin and Cicchetti, 2004; Fang and Svoboda, 2005; Ho and 
Chang, 2006; Zhou et al., 2007; Nakao et al., 2009; San Miguel et al., 2010; Takeuchi et al., 
2010; Kang et al., 2011; Desjardins and Grenier, 2012; San Miguel et al., 2012; Silva et al., 
2012; Park et al., 2013; Takeuchi-Igarashi et al., 2014; Dinos et al., 2015; Esfahrood et al., 
2015). Fifteen studies investigated HPDLCs (Alpar et al., 1998; Giannopoulou et al., 1999; 
James et al., 1999; Chang et al., 2001a; Chang et al., 2002; Olson et al., 2005; Lee et al., 
2009; San Miguel et al., 2010; Takeuchi et al., 2010; Kim et al., 2012; San Miguel et al., 
2012; Lee et al., 2013; Wu et al., 2013; Takeuchi-Igarashi et al., 2014; Wu et al., 2014). 
HGECs were investigated by eight studies (Johnson and Organ, 1997; Lee et al., 2005; Lee et 
al., 2008; Mahanonda et al., 2009; Johnson et al., 2010; Kashiwagi et al., 2012; Gao et al., 
2013; Nakata et al., 2013), with one study using HOECs (Desjardins and Grenier, 2012). 
Supplementary Table S2 (Appendix C) provides details of the origin of the cells.  
2.4.4 Nicotine exposure 
Exposure conditions varied among the studies with respect to nicotine concentrations used 
and the duration of exposure.  The nicotine concentrations used varied from 1 nM (Wendell 
and Stein, 2001; Esfahrood et al., 2015) to 62 mM (Alpar et al., 1998), with a mean (SD) of 
4.16 mM (7.92) (median and mode: 1 mM). The exposure time varied from 30 minutes (San 
Miguel et al., 2012) to 4 weeks (Tanur et al., 2000) with a mean (SD) of 31.2 hours (54.9) 
(median and mode: 24 hours). Typically, a single dose was administered as diluted pure 
nicotine added to culture medium. One study administered nicotine hemisulphate (Fang and 
Svoboda, 2005). Four studies reported subsequent repeat doses of nicotine, all at 24 hour 
intervals (Alpar et al., 1998; Checchi et al., 1999; Ciapetti et al., 1999; Dinos et al., 2015) but 
only one of these ran a single-dose control (Alpar et al., 1998).  
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2.4.5 Cell viability 
Thirty-one studies investigated cell viability using a range of assays (Tipton and Dabbous, 
1995; Johnson and Organ, 1997; Alpar et al., 1998; Checchi et al., 1999; Ciapetti et al., 1999; 
Chang et al., 2001b; Wendell and Stein, 2001; Chang et al., 2002; Argentin and Cicchetti, 
2004; Lee et al., 2005; Ho and Chang, 2006; Zhou et al., 2007; Lee et al., 2008; Lee et al., 
2009; Mahanonda et al., 2009; Nakao et al., 2009; Johnson et al., 2010; San Miguel et al., 
2010; Takeuchi et al., 2010; Kang et al., 2011; Desjardins and Grenier, 2012; Kashiwagi et 
al., 2012; Kim et al., 2012; San Miguel et al., 2012; Silva et al., 2012; Gao et al., 2013; Lee et 
al., 2013; Nakata et al., 2013; Park et al., 2013; Dinos et al., 2015; Esfahrood et al., 2015). 
Fourteen studies used the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) assay (Chang et al., 2001a; Chang et al., 2002; Lee et al., 2005; Zhou et al., 2007; 
Lee et al., 2008; Lee et al., 2009; Mahanonda et al., 2009; Kang et al., 2011; Desjardins and 
Grenier, 2012; Kim et al., 2012; Lee et al., 2013; Nakata et al., 2013; Park et al., 2013; 
Esfahrood et al., 2015), five studies used the MTS (3-(4,5-Dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay (Johnson and Organ, 1997; 
Johnson et al., 2010; San Miguel et al., 2010; San Miguel et al., 2012; Silva et al., 2012), five 
studies used the trypan blue assay (Alpar et al., 1998; Wendell and Stein, 2001; Argentin and 
Cicchetti, 2004; Mahanonda et al., 2009; Takeuchi et al., 2010), two studies used the neutral 
red assay (Checchi et al., 1999; Ciapetti et al., 1999), two studies used microscopic 
observation (Tipton and Dabbous, 1995; Dinos et al., 2015), one study used the 
sulforhodamine B assay (Gao et al., 2013), one study used the lactate dehydrogenase leakage 
assay (Ho and Chang, 2006), one study used fluorescent dye assessment (Alpar et al., 1998), 
and three studies investigated cell viability in preliminary experiments (but methodological 
details were not provided) (Tipton and Dabbous, 1995; Nakao et al., 2009; Kashiwagi et al., 
2012). Supplementary Table S4 (Appendix E) details the principal results.  
There was significant heterogeneity between studies with respect to nicotine exposure 
conditions. However, 17 studies investigated the effect of a 24-hour exposure of nicotine on 
HGFs (Tipton and Dabbous, 1995; Alpar et al., 1998; Checchi et al., 1999; Ciapetti et al., 
1999; Wendell and Stein, 2001; Argentin and Cicchetti, 2004; Takeuchi et al., 2010; Kang et 
al., 2011; Desjardins and Grenier, 2012; Silva et al., 2012; Park et al., 2013; Esfahrood et al., 
2015) or HPDLCs (Alpar et al., 1998; Chang et al., 2001a; Chang et al., 2002; Lee et al., 
2009; Takeuchi et al., 2010; Kim et al., 2012; Lee et al., 2013) (studies explicitly on cells 
from smokers were excluded in this analysis). Data were derived from these studies and all 
data points combined in Figure 2.2.   
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Figure 2.2 Results of cell viability assays carried out on fibroblast cultures.   
Results of cell viability assays carried out on fibroblast cultures (not reported to be from smokers) after a 24-hour nicotine exposure; expressed as 
percentage (of viable cells relative to nicotine-free control) on a logarithmic scale of nicotine concentration. Triangles represent data points 
derived from the studies; dotted line represents line of best-fit (Y = -3.5518 x 10-6 X + 85.497). Normal reported plasma, saliva and gingival 
crevicular fluid nicotine concentrations are shown for comparison with each marker identifying a study. The corresponding references are: 1= 
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Bullen et al., 2010; Ebert et al., 1984; Gourlay et al., 1997; Herning et al., 1983; Jarvis et al., 1984; Russell et al., 1981; Vansickel et al., 2010; 
Benowitz et al., 1997; Farsalinos et al., 2014. 2= Russell et al., 1981. 3= Benowitz et al., 1997; Bullen et al., 2010; Evans et al., 2006; Gourlay et 
al., 1997. 4= Bullen et al., 2013; Bullen et al., 2010; Vansickel et al., 2010; Farsalinos et al., 2014; Vansickel & Eissenberg, 2013; Dawkins et 
al., 2016. 5= Picavet et al., 2016. 6= Jarvis et al., 1984. 7= Feyerabend et al., 1982; Jarvis et al., 1984; Robson et al., 2010; Ryder et al., 1998. 
8= Hoffmann & Adams, 1981. 9= Jarvis et al., 1984; Feyerabend et al., 1982. 10= Ryder et al., 1998. 
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IC50 
IC50 (defined as the exposure concentration at which there is 50% cell death or inhibition of 
cell growth or other utilised toxicity metric) values were identified from 16 studies reporting 
toxicity data over a range of concentrations for HGFs or HPDLCs (Alpar et al., 1998; 
Checchi et al., 1999; Ciapetti et al., 1999; Chang et al., 2001a; Wendell and Stein, 2001; 
Chang et al., 2002; Argentin and Cicchetti, 2004; Lee et al., 2009; Takeuchi et al., 2010; 
Kang et al., 2011; Desjardins and Grenier, 2012; Kim et al., 2012; Silva et al., 2012; Lee et 
al., 2013; Park et al., 2013; Esfahrood et al., 2015)  (studies explicitly on cells from smokers 
were excluded in this analysis). One study explicitly reported an ED50 value (Alpar et al., 
1998), defining this as ‘effective dose50, concentration of a substance which damages 50% of 
cells irreversibly’. A further eight studies (Chang et al., 2001a; Chang et al., 2002; Argentin 
and Cicchetti, 2004; Lee et al., 2009; Takeuchi et al., 2010; Kang et al., 2011; Desjardins and 
Grenier, 2012; Esfahrood et al., 2015) investigated a sufficient exposure concentration range 
to allow an IC50 value to be derived from the data (Figure 2.3). Seven studies (Checchi et al., 
1999; Ciapetti et al., 1999; Wendell and Stein, 2001; Kim et al., 2012; Silva et al., 2012; Lee 
et al., 2013; Park et al., 2013) did not investigate a sufficient exposure concentration range to 
allow IC50,  determination (Figure 2.3). The IC50 ranged from 6 µM to 15.6 mM with a mean 
(SD) of 7.6 mM (7.0 mM). Two studies reported values in this range for HGECs; Lee et al. 
(2005) reported an IC50 value of 300 µM (24 hours) while Gao et al. (2013) reported that an 
EC50 (‘effective concentration for 50% cytotoxicity’) was not reached with 2.8 mM (24 
hours).   
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Figure 2.3 IC50 of fibroblasts exposed to nicotine.   
IC50 of fibroblasts (not reported to be from smokers) after a 24 hour nicotine exposure (nicotine concentrations at which a 24-hour exposure causes 
fibroblast viability to diminish to below 50% relative to nicotine-free control); expressed in milimolar on a linear scale. Squares represents IC50 values 
and the line represents the range of nicotine concentrations used in each study. 
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2.4.6 Cell attachment/adhesion 
Four studies investigated cell attachment/adhesion using a range of assays (Giannopoulou et 
al., 1999; James et al., 1999; Tanur et al., 2000; Esfahrood et al., 2015). Two studied HGFs 
(Tanur et al., 2000; Esfahrood et al., 2015) and two studied HPDLCs (Giannopoulou et al., 
1999; James et al., 1999) (Appendix E Supplementary Table S4). Three different attachment 
surfaces were used in the studies: plastic (culture plates) (Giannopoulou et al., 1999; James et 
al., 1999), root surfaces (from extracted teeth) (Tanur et al., 2000; Esfahrood et al., 2015) and 
glass (Tanur et al., 2000). Two studies used similar nicotine concentrations (620 nM) and 
reported similar reductions in attachment (approximately 60%) although they had very 
different exposure durations: 6 hours (Giannopoulou et al., 1999) and 4 weeks (Tanur et al., 
2000).  
Esfahrood et al. (2015) reported reduced attachment at a wide range of nicotine 
concentrations (1 nM, 1 µM, 1 mM, 5 mM at 24 h) while James et al. (1999) reported an 
approximately 60% reduction in attachment using high nicotine concentrations (31 mM for 24 
hours). Both of these studies (James et al., 1999; Esfahrood et al., 2015) used a viability assay 
to quantify cells remaining attached to a plate under various levels of stress, and it is therefore 
not readily apparent whether viability, proliferation or attachment is being measured. In 
summary, although there were conflicting results (widely different results at similar exposure 
conditions), there was an indication that in vitro cell attachment to a variety of surfaces, 
including tooth roots, can be affected by nicotine concentrations at the nanomolar level. 
2.4.7 Cell proliferation 
Eleven studies investigated the effect of nicotine concentration on cell proliferation. Six 
studies investigated the effects on proliferation of HGFs (Tipton and Dabbous, 1995; Alpar et 
al., 1998; Checchi et al., 1999; Ciapetti et al., 1999; Argentin and Cicchetti, 2004; San 
Miguel et al., 2012), five on HPDLCs (Alpar et al., 1998; Giannopoulou et al., 1999; Chang 
et al., 2002; Olson et al., 2005; San Miguel et al., 2012), and two on HGECs (Johnson and 
Organ, 1997; Lee et al., 2005) (Appendix E Supplementary Table S4). 
Nine studies reported reductions in cell proliferation (Tipton and Dabbous, 1995; Alpar et al., 
1998; Checchi et al., 1999; Ciapetti et al., 1999; Giannopoulou et al., 1999; Chang et al., 
2002; Lee et al., 2005; Olson et al., 2005; San Miguel et al., 2012), one of which also 
observed increased cell proliferation at a lower nicotine concentration (2.3 mM, 24 hours) 
(Olson et al., 2005). Two studies reported inhibition of proliferation at 3.7 mM over 24 hours 
(Checchi et al., 1999) and 48 hours (Ciapetti et al., 1999) respectively, but no statistically 
significant inhibition at lower concentrations of 37 μM and 370 µM. Ciapetti et al. (1999) 
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observed inhibition only after 48 hours exposure, and not at 24 hours. Checchi et al. (1999) 
observed inhibition with 3.7 mM over 24 hours; this did not apply to the cells sourced from 
smoking subjects over 40 years of age. Two studies reported no statistically significant effect 
of nicotine exposure on cell proliferation, at respective exposures of 100 nM, 10 μM and 1 
mM over 4 and 48 hours (Johnson and Organ, 1997) and 1 μM over 24 to 72 hours (Argentin 
and Cicchetti, 2004). 
Of  five studies (Alpar et al., 1998; Giannopoulou et al., 1999; Chang et al., 2002; Olson et 
al., 2005; San Miguel et al., 2012) which investigated the effect of nicotine on HPDLC  
proliferation, four studies noted inhibitory effects (Alpar et al., 1998; Giannopoulou et al., 
1999; Chang et al., 2002; Olson et al., 2005), with one study (San Miguel et al., 2012) 
reporting that proliferation was not significantly affected (6, 8 mM; 30 minutes). Chang et al. 
(2002) observed dose-dependent inhibition between 25 μM and 200 μM after 96 hours of 
exposure to nicotine; all proliferation ceased at concentrations above 400 μM. Alpar et al. 
(1998) also found dose-dependent inhibition at concentrations above 3.9 mM after 24 hours 
(all proliferation ceased above 31 mM). Only one study reported an increase in cell 
proliferation (Olson et al., 2005) at 2.3 mM after 24 hours, with inhibition of cell proliferation 
observed at the higher nicotine concentration of 9.2 mM. 
Two studies also investigated cell proliferation indirectly using wound repopulation, or rate of 
artificial wound closure (Fang and Svoboda, 2005; Dinos et al., 2015). Both studies used 
gingival fibroblasts on culture plates (Appendix E Supplementary Table S4). Dinos et al. 
(2015) reported significant reduction in wound repopulation after 4 days of exposure to 4 mM 
nicotine, and at 6 days with as little as 1 mM nicotine. Fang and Svoboda (2005) reported 
approximately 50% reduction in wound closure rate after 12, 24 and 36 hours of exposure to 
0.5 μM nicotine.  
2.4.8 Inflammatory mediator production 
Fourteen studies investigated the effect of nicotine on production of cytokines and other 
inflammatory mediators relevant in the pathogenesis of periodontitis. Six studies investigated 
the effects on HGFs (Tipton and Dabbous, 1995; Wendell and Stein, 2001; Zhou et al., 2007; 
Nakao et al., 2009; Desjardins and Grenier, 2012; Takeuchi-Igarashi et al., 2014), five on 
HPDLCs (Olson et al., 2005; Kim et al., 2012; Wu et al., 2013; Takeuchi-Igarashi et al., 
2014; Wu et al., 2014), four on HGECs (Johnson and Organ, 1997; Mahanonda et al., 2009; 
Johnson et al., 2010; Kashiwagi et al., 2012), and one on HOECs (Desjardins and Grenier, 
2012). The included studies investigated between six (Zhou et al., 2007) and one (Tipton and 
Dabbous, 1995; Olson et al., 2005; Mahanonda et al., 2009; Nakao et al., 2009; Kashiwagi et 
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al., 2012; Wu et al., 2013) inflammatory mediator(s). The most common mediator 
investigated was interleukin-8 (IL-8) (Johnson and Organ, 1997; Wendell and Stein, 2001; 
Mahanonda et al., 2009; Desjardins and Grenier, 2012; Kashiwagi et al., 2012; Wu et al., 
2014) followed by interleukin-6 (IL-6) (Wendell and Stein, 2001; Olson et al., 2005; 
Desjardins and Grenier, 2012), interleukin-1β (IL-1β) (Johnson and Organ, 1997; Wu et al., 
2013; Wu et al., 2014), Prostaglandin E2 (PGE2) (Johnson and Organ, 1997; Nakao et al., 
2009; Kim et al., 2012) and interleukin-1α (IL-1α) (Johnson and Organ, 1997; Johnson et al., 
2010) (Appendix F Supplementary Table S5).  
With respect to IL-8, two studies (Johnson et al., 2010; Desjardins and Grenier, 2012) showed 
no effect on IL-8 production in HOECs, HGECs and HGFs cultures with exposure to a 
relatively wide range of nicotine concentrations (100 nM - 1 mM; 24 hours).  Conversely, 
four studies (Wendell and Stein, 2001; Mahanonda et al., 2009; Kashiwagi et al., 2012; Wu et 
al., 2014) showed increased IL-8 production in HGFs, HPDLCs and HGECs and ‘stimulated 
HGECs’ cultures with exposure to similar nicotine concentrations (1 nM – 1mM; 24 hours).  
Almasri et al. (2007) investigated the expression of 23 inflammatory mediators on the HGF 
cell membrane (rather than production/secretion) and reported that nicotine exposure (1.5 
mM, 48 hours) resulted in the greatest increased expression of growth-regulating oncogene-α 
(GRO-α), interleukin-7 (IL-7) and interleukin-15 (IL-15).  
Several studies investigated matrix metalloproteinase (MMP) activity following exposure to 
nicotine. Tipton and Dabbous (1995) reported that collagenase activity in HGFs was 
statistically significantly increased by nicotine concentrations ≥ 1.5 mM with a 6-day 
exposure. Both Zhou et al. (2007) and Takeuchi-Igarashi et al. (2014) reported that nicotine 
exposures (both nM and mM ranges) had no statistically significant effect on MMP-1 and 
MMP-2 at time frames up to 48 hours. Kim et al. (2012) demonstrated an increase in MMP-2 
and MMP-9 (1, 5, 10 mM nicotine for 24 hours) but no statistical tests were performed.    
Takeuchi-Igarashi et al. (2014)  reported significantly increased tissue inhibitors of 
metalloproteinases- 1 (TIMP-1) levels (in cell culture supernatants) when cells were exposed 
to nicotine (6.2 nM for 12, 24, and 48 hours) whereas Zhou et al. (2007) reported reduced 
levels of TIMP-1 in nicotine-treated cells (1.5 mM, 48 hours, no statistical tests performed).   
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2.5 Discussion 
This systematic review identified a large number of studies that have investigated the in vitro 
effects of nicotine on human gingival, periodontal and oral epithelial cells. We observed high 
heterogeneity between studies particularly regarding the assays performed, the cells studied 
and the exposure conditions that were applied. The exposure conditions were particularly 
varied with nicotine concentrations ranging from 1 nM (Wendell and Stein, 2001; Esfahrood 
et al., 2015) to 62 mM (Alpar et al., 1998) and exposure time varying from 30 minutes (San 
Miguel et al., 2012) to 4 weeks (Tanur et al., 2000).  
The plasma nicotine concentration of tobacco smokers is well established in the literature with 
reported concentrations usually being in the range of 70 nM to 200 nM (Russell et al., 1981; 
Herning et al., 1983; Ebert et al., 1984; Jarvis et al., 1984; Benowitz et al., 1997; Gourlay et 
al., 1997; Bullen et al., 2010; Vansickel et al., 2010; Farsalinos et al., 2014). Salivary nicotine 
concentrations of tobacco smokers have been reported from 4 µM to 10 µM (Feyerabend et 
al., 1982; Jarvis et al., 1984; Ryder et al., 1998; Robson et al., 2010) with much higher levels 
being reported in smokeless tobacco users (0.43- 9.62 mM) (Hoffmann and Adams, 1981). 
GCF was found to have a nicotine concentration of 37µM in an analysis of seven smokers 
(Ryder et al., 1998). Plasma nicotine concentrations in those using NRT have been shown to 
be similar to or lower than those found in cigarette smokers (Benowitz et al., 1997; Gourlay et 
al., 1997; Evans et al., 2006; Bullen et al., 2010). With regards to e-cigarettes, several studies 
reported little effect on plasma nicotine levels (Bullen et al., 2010; Eissenberg, 2010; 
Vansickel et al., 2010; Bullen et al., 2013) most likely because they used early products and 
novice users. More recent studies have reported plasma nicotine concentrations that are more 
similar to those of tobacco smokers: 100 nM (Vansickel and Eissenberg, 2013; Farsalinos et 
al., 2014) and 300 nM (Dawkins et al., 2016). We are not aware of any published salivary 
nicotine concentrations in e-cigarette users, although salivary cotinine levels in e-cigarette 
users have been reported to be similar to those of tobacco smokers (Etter and Bullen, 2011b). 
A heated tobacco product (heat-not-burn) has been reported to deliver a plasma nicotine 
concentration of 50 nM (Picavet et al., 2016) (although this paper was published by a tobacco 
manufacturer). Non-smokers have very low salivary nicotine concentrations (30 nM) (Jarvis 
et al., 1984).  
It is noteworthy that many of the studies used nicotine concentrations in the mM range and 
these concentrations are only observed in vivo saliva of smokeless tobacco users (Hoffmann 
and Adams, 1981).  
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The challenge with any in vitro research is to interpret the findings in an appropriate way, 
considering the clinical relevance. For example, when considering cell viability experiments, 
with nicotine concentrations in the regions observed in smokers, NRT users and e-cigarette 
users, no effect on cell viability was observed. This suggests that nicotine is not the cytotoxic 
component of tobacco smoke. Consistent with the findings of an earlier review 
(Wyganowska-Swiatkowska and Nohawica, 2015), the identified studies in our review only 
reported a substantial effect on cell viability at nicotine concentrations above approximately 5 
mM, and such concentrations would only be seen in vivo in the saliva of smokeless tobacco 
users.  From the identified studies, we derived the IC50 of nicotine, in HGFs and HPDLCs, 
and with 24-hour exposure, to range from 6 µM to 15.6 mM (mean [SD]: 7.6 mM [6.8]). The 
results of our review therefore indicate that the high salivary nicotine concentrations reported 
in smokeless tobacco users can be cytotoxic to periodontal cells in vitro. A previous review 
also discussed the concerns around smokeless tobacco, periodontal disease and gingival 
recession (Warnakulasuriya et al., 2010).  
It should be remembered that pathological processes are more complicated than simple cell 
viability assays and in this review we also looked at studies that reported on cell attachment, 
cell proliferation and inflammatory mediator production. We found that studies reported 
inhibition of cell attachment with exposure to nM concentrations of nicotine whereas cell 
proliferation seemed only to be inhibited by higher concentrations of nicotine (in the µM and 
mM range). Production of inflammatory mediators, including cytokines, appeared to be 
stimulated by exposure to nicotine at a wide range of concentrations (in the nM to mM range). 
However, the identified studies often reported contradictory results, which make it hard to 
draw any definitive conclusions. For example, when considering cell proliferation, for an 
exposure range between 1-5 mM (24 hours), some studies reported inhibitory effects (Tipton 
and Dabbous, 1995; Alpar et al., 1998; Checchi et al., 1999), whilst other reported no effects 
(Johnson and Organ, 1997; Ciapetti et al., 1999) or even increased proliferation (Olson et al., 
2005).   
It has been postulated by Checchi et al. (1999) that some of the differences between studies 
may be accounted for by varied culture or nicotine exposure conditions. They also proposed 
that contradictory findings could result from differences in the cell types studied (for example, 
whether cells were obtained from smokers or non-smokers, or from younger or older 
individuals, with or without periodontitis, or were commercially-available cell lines, and 
whether the cells were exposed to nicotine after a variable number of passages). It has also 
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been suggested than nicotine may have a synergistic action with other substances, for example 
bacterial toxins (Sayer et al., 1997).   
Our quality assessment demonstrated several common deficiencies among the included 
studies. All lacked any randomisation, allocation concealment and blinding meaning that there 
was a high risk of potential bias. When considering human studies, the RCT is considered to 
have the most robust study design for answering research questions. Similar designs can be 
utilised for in vitro studies to reduce the risk of bias (Faggion, 2012). We also noted that 
many studies failed to mention any limitations of their work. Finally, funding details were 
absent from a number of the studies, which is particularly important given this field of 
research potentially involving funding from the tobacco industry. Only one study openly 
reported being funded directly by the tobacco industry, with another funded by a tobacco 
endowment fund.   
There are some limitations of our systematic review. We limited the scope to nicotine and did 
not include cotinine. In vivo, nicotine is metabolised to cotinine which has a longer half-life 
than that of nicotine (11-24 hour compared to 30-150 minutes) meaning that in vivo, cells 
could be exposed to cotinine for longer periods with potentially more detrimental effects. 
Including cotinine was beyond the scope of this review but would be an important 
consideration for future research. We did not attempt to analyse the effect of study 
heterogeneity (e.g. by comparing cells from smokers/non-smokers or from patients with 
periodontitis versus healthy patients), though the scope for doing this was limited given the 
variable design of the studies that were identified. We limited our review to concentrating on 
four domains (cell viability, attachment, proliferation and inflammatory mediator production) 
and there may be other domains that are important, e.g. bacterial susceptibility. We included 
additional information on wound repopulation and cytokine expression. Although these were 
not part of our original inclusion criteria, after evaluating the included studies we felt they 
offered additional important information and included the data in the relevant sections. There 
is also potential for publication bias e.g. studies which demonstrated no effect of nicotine on 
the outcome of interest may have been less likely to be published.    
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2.6 Conclusions 
From the studies identified in this review, it appears that nicotine at concentrations found in 
the plasma, saliva and GCF of tobacco smokers, NRT users and e-cigarette users is unlikely 
to be cytotoxic to human gingival and periodontal cells in in vitro conditions. However, the 
nicotine concentrations seen in smokeless tobacco users can be cytotoxic in these conditions. 
Evidence of effects on cell attachment, cell proliferation and inflammatory mediator 
production suggested that effects could be seen at a wide range of nicotine concentrations but 
evidence was limited and often contradictory.  
2.7 Protocol and registration 
There is no registration system for non-clinical systematic reviews. The review protocol can 
be obtained by emailing the lead author.  
2.8 Funding 
RH is funded by a National Institute for Health Research (NIHR) Doctoral Research 
Fellowship (DRF-2015-08-077). This paper presents independent research funded by the 
NIHR. The views expressed are those of the authors and not necessarily those of the NHS, the 
NIHR or the Department of Health. 
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Chapter 3 A pilot randomised controlled trial of e-cigarettes for smoking 
cessation or harm reduction in patients with periodontitis.   
___________________________________________________________________________ 
3.1 Abstract 
Background 
Tobacco smoking is a major risk factor for several oral diseases, including periodontitis. 
Smoking cessation is an important component of periodontal therapy and e-cigarettes are a 
novel method of smoking cessation that has recently become popular. This pilot trial aimed to 
assess the viability of delivering and evaluating an e-cigarette intervention for smoking 
cessation or harm reduction within the dental setting, prior to a definitive study.  
Methods 
An external pilot 2-armed parallel group, individually randomised controlled trial, with a 1:1 
allocation ratio, was conducted over 22 months in the Newcastle Dental Clinical Research 
Facility. Eligibility criteria included being a tobacco smoker, having periodontitis (≥8 sites 
with pocket probing depths ≥5 mm) and not currently using an e-cigarette. All participants 
were provided with non-surgical periodontal therapies and smoking cessation advice. The 
intervention consisted of an e-cigarette starter kit with brief training. Participants were 
followed up at 4 weeks, 3 months and 6 months. Proposed outcomes for a future definitive 
trial, in terms of smoking behaviour and periodontal/oral health were collected. Analysis was 
descriptive, with 95% confidence intervals presented where appropriate.  
Results 
Eighty participants were successfully recruited from a range of primary and secondary care 
dental settings. Participant retention was 73% [95% CI: 62%-81%] at 6 months. The e-
cigarette intervention was well received, with usage rates of 90% [95% CI: 77%-96%] at quit 
date, 78% [95% CI: 63%-88%] at 4 weeks and 53% [95% CI: 38%-67%] at 6 months. 20% 
[95% CI: 11%-35%] of participants in the control group used an e-cigarette at some point 
during the study (against instructions). The majority of the outcome measures were 
successfully collected, apart from a weekly smoking questionnaire which had poor 
completion rates. Harm reduction (reduction from baseline to 6 months of expired air carbon 
monoxide) of 6 ppm [95% CI: 1-10] and 12 ppm [95% CI: 8-16] were observed in the control 
and intervention groups respectively; rates of abstinence (carbon monoxide verified 
continuous abstinence for 6 months) for the two groups were 5% [95% CI: 1%-17%; control 
group] and 15% [95% CI: 7%-29%; intervention group].    
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Conclusions 
Data suggest that a definitive trial is feasible and that the intervention may improve smoking 
quit rates and may have minimal positive effects on periodontal health at 6 months. Insights 
were gained into how best to conduct the definitive trial.    
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3.2 Background 
Periodontal diseases are amongst the most common inflammatory conditions in humans 
(Tonetti et al., 2017). Periodontitis, an advanced form of periodontal disease, has a 
multifactorial aetiology but the principal process involves a dental plaque biofilm 
accumulating in the subgingival environment causing an immune and inflammatory response 
that leads to destruction of the supporting structures. Consequences of periodontal disease 
progression include tooth mobility and eventually tooth loss. Severe periodontitis, threatening 
tooth retention, affects approximately 10% of UK adults; with moderate periodontitis 
affecting 40-60% (Morris et al., 2011). A recent estimate is that 4.4 million adults in the UK 
have severe disease (Griffiths and Preshaw, 2014).  
There are multiple risk factors for periodontal diseases but tobacco smoking is the most 
important environmental risk factor. Smoking is thought to affect the periodontal tissues via 
multiple pathways, including effects on the host immune and inflammatory response, 
impaired blood flow and microbiological changes. Of particular relevance in the management 
of periodontitis is the knowledge that smokers who quit are 30% more likely to see clinically 
significant improvements than individuals who continue to smoke (Chambrone et al., 2013). 
Dental professionals are advised to provide SCA to all patients who smoke and a range of 
brief interventions are available as detailed in Table 1.1.  
The development of e-cigarettes has added a new option for smokers. Although still limited, 
there is a growing body of evidence to suggest that e-cigarettes are a useful smoking cessation 
aid, with effectiveness similar to traditional NRT (Hartmann-Boyce et al., 2016). Likewise, 
the health risks of e-cigarettes appear to be a fraction of those of tobacco cigarettes with 
sources stating the risk to be less than 5% (Royal College of Physicians, 2016; McNeill et al., 
2018). At a population level, e-cigarettes have been hugely popular with 2.8 million users in 
the UK as of 2017 (Office of National Statistics, 2018b).  
Feasibility studies are an important research design and ensure that future definitive studies 
are well designed, appropriately powered and deliverable. Feasibility studies can include pilot 
studies, a miniature test of components of the proposed main study. In some cases this can 
resemble the proposed main trial very closely as an internal or external pilot trial (see Figure 
3.1)  
The purpose of pilot studies or trials is to assess feasibility, which is fundamentally different 
to definitive trials which seek to address efficacy, effectiveness and/or cost-effectiveness. 
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Pilot studies or trials should focus on descriptive statistics (with confidence intervals) rather 
than formal hypothesis testing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Relationship between feasibility studies, pilot studies and pilot trials. 
  
Feasibility studies 
Pilot trials 
Pilot studies 
84 
 
The e-cigarette research field is a good example of how pilot studies can be extremely useful. 
With e-cigarettes only being available for small number of years, there are many uncertainties 
regarding the feasibility and acceptability of the intervention and trial processes (e.g. 
willingness to be randomised). For instance, there were no existing data (at the time of 
designing the study in 2014/2015) to inform a sample size calculation; pilot studies can be 
used to estimate the variability of potential primary outcome measures to inform power 
calculations for future definitive trials.    
Within the medical literature, it has been identified that pilot studies, and more particularly 
pilot trials, are often poorly conducted and inadequately reported. Lancaster et al. (2004) 
summarised these concerns: ‘pilot studies play an important role in health research, but they 
can be misused, mistreated and misrepresented’. Subsequently, the CONSORT group 
developed an extension to the CONSORT 2010 statement (Moher et al., 2010) to cover pilot 
and feasibility trials (Eldridge et al., 2016). Although this is primarily directed at RCT 
designs, the principles are transferrable to other research designs.  
Five pilot studies on e-cigarettes and oral health were published from 2016 to 2018 (Reuther 
et al., 2016; Tatullo et al., 2016; Wadia et al., 2016; Javed et al., 2017a; Al‐Aali et al., 2018). 
Table 3.1 evaluates the reporting quality of these studies against the CONSORT checklist for 
pilot and feasibility trials, which includes 40 items in 26 sections (Eldridge et al., 2016). 
Some of the checklist items were not applicable, as the majority of the studies did not 
randomly allocate participants to groups, so the relevant totals were 28 or 29 items. Overall, 
these pilot studies performed poorly, only reporting between 5 (out of 28) and 12 (out of 29) 
checklist items. There were several areas of common weakness. None of the studies had 
appropriate research questions or objectives. Some of the studies discussed the need for pilot 
work prior to a definitive study but none clearly outlined how the pilot study would inform 
the design of that definitive study (other than it being larger). Methods of sample size 
determination for the pilot study were inadequate in all cases. Estimating the variability of 
potential primary outcome measures, to inform a definitive study’s sample size calculation, is 
often one of the major reasons for conducting a pilot study.  Recommendations suggest that to 
obtain a robust estimate, outcome data for approximately 30-35 participants per arm are 
required (Lancaster et al., 2004; Teare et al., 2014). However, none of the pilot studies 
followed this guidance and instead used a range of invalid methods for determining their 
sample sizes. For example, Wadia et al. (2016) based their sample size calculation on data 
from a study not using e-cigarettes, proposing it as a method of estimating the effects of e-
cigarettes. Javed et al. (2017a) also conducted inappropriate sample size determination as 
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discussed in a letter to the editor (Holliday et al., 2018). All of the studies inappropriately 
included change in a clinical outcome measures as their primary objective. Most conducted 
formal hypothesis testing and reported conclusions based upon these, against 
recommendations by Eldridge and colleagues (Eldridge et al., 2016).   
In summary, the pilot studies so far published investigating e-cigarettes and oral health fall far 
short of the required standard. As Lancaster et al. (2004) found in the medical literature, in 
this field the term ‘pilot study’ is often being used as an excuse for poor design and 
inadequate sample sizes. Pilot studies play an important role in health research and tools such 
as the CONSORT pilot and feasibility trial checklist (Eldridge et al., 2016) should be utilised 
by researchers and journal editors to ensure the highest levels of research rigour.    
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Checklist item Pilot study 
Al‐Aali et 
al. (2018) 
Javed 
et al. 
(2017a) 
Wadia et al. 
(2016) 
Tatullo 
et al. 
(2016) 
Reuther et al. 
(2016) 
1a: title identification X   X  
1b: structured summary X partly partly partly X 
2a: background, rationale for future definitive trial, reasons for pilot study X X partly X X 
2b: objectives/ research questions X X X X X 
3a: trial design description      
3b: amendments N/A N/A N/A N/A N/A 
4a: eligibility criteria     partly 
4b: settings & locations partly partly   partly 
4c: participant identification & consent X X  X X 
5: intervention details N/A N/A  N/A N/A 
6a: outcome details and how linked to 2b X X X X X 
6b: amendments to outcome measures N/A N/A N/A N/A N/A 
6c: criteria for judging whether to proceed to future definitive trial (if 
applicable)  
X X X X X 
7a: sample size rationale X X X X X 
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Checklist item Pilot study 
Al‐Aali et 
al. (2018) 
Javed 
et al. 
(2017a) 
Wadia et al. 
(2016) 
Tatullo 
et al. 
(2016) 
Reuther et al. 
(2016) 
7b: interim analysis or stopping guidelines (if applicable) X X X X X 
8a: sequence generation N/A N/A N/A N/A N/A 
8b: type of randomisation N/A N/A N/A N/A N/A 
9: allocation concealment mechanism N/A N/A N/A N/A N/A 
10: implementation N/A N/A N/A N/A N/A 
11a: blinding  partly partly N/A N/A N/A 
11b: description of similarity of interventions (if blinding) N/A N/A N/A N/A N/A 
12: statistical methods X X X X X 
13a: participant flow X X    
13b: losses & exclusions after randomisation X X    
14a: recruitment dates     X 
14b: reason trial ended or stopped N/A N/A N/A N/A N/A 
15: baseline data N/A N/A N/A  N/A 
16: numbers analysed      
17: outcomes and estimation X X X X X 
18: ancillary analysis X X X X X 
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Checklist item Pilot study 
Al‐Aali et 
al. (2018) 
Javed 
et al. 
(2017a) 
Wadia et al. 
(2016) 
Tatullo 
et al. 
(2016) 
Reuther et al. 
(2016) 
19: harms     X 
19a: other important unintended consequences (if relevant) N/A N/A N/A N/A N/A 
20: limitations     X 
21: generalisability X partly partly X X 
22: interpretation consistent with pilot objectives and findings X X X X X 
22a: proposed amendments for definitive trial X partly X X X 
23: registration X X X X X 
24: protocol X X X X X 
25: funding   partly  X 
26: ethical approval partly partly partly  X 
Overall score 7/29  8/29 12/29 12/29 5/28 
 
Table 3.1 CONSORT 2010 checklist of information to include when reporting a pilot or feasibility trial.
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Future rigorous research is required to determine the effectiveness of e-cigarettes as a 
smoking cessation or harm reduction tool within the dental setting and any subsequent 
impacts on oral health, specifically with regard to the periodontal tissues and periodontal 
treatment outcomes. An essential pre-requisite to a definitive trial of the effectiveness and 
cost-effectiveness of e-cigarettes in this context is a well-designed pilot trial, to address 
uncertainties regarding eligibility, recruitment and retention rates, to explore the feasibility 
and acceptability of the intervention and of trial procedures, and to collect data to inform 
power calculations for the definitive trial.  
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3.3 Aim and Objectives 
3.3.1 Aim 
The aim of this study was, to assess the viability of delivering and evaluating an e-
cigarette intervention for smoking cessation or harm reduction within the dental setting, 
using a randomised controlled design. The focus of this study was the deliverability, 
feasibility and acceptability of the e-cigarette intervention and of trial procedures (e.g. 
randomisation and data collection), rather than the clinical efficacy or effectiveness of the 
intervention (Eldridge et al., 2016). It did not seek to produce any definitive results 
relating to the proposed interventions. If the current study indicates that the intervention 
and trial procedures are feasible and acceptable, a future RCT will be conducted to 
investigate the clinical effectiveness (in terms of smoking cessation, reduction in 
cigarettes per day, or periodontal treatment outcome) and cost-effectiveness of e-cigarettes 
in patients with periodontitis.  
3.3.2 Trial Objectives 
The objectives relate to assessing the feasibility of the future definitive RCT.  In particular: 
• To estimate trial eligibility rates among our patient population.  
• To assess patients’ willingness to enter the trial. 
• To estimate the recruitment rate; can 80 eligible patients be recruited in a 12-
month period?   
• To ascertain the retention rate of the participants for 6-month follow-up data. 
• To ascertain the randomised group contamination rates (i.e. the extent of cross-
over between the two arms of the trial).  
• To test a weekly smoking status data collection method.  
• To compare, descriptively, novel and traditional periodontal outcome measures. 
(Novel: Periodontal Inflamed Surface Area [PISA], Periodontal Epithelial Surface 
Area [PESA]; Traditional: PPDs and Bleeding on Probing [BOP]).  
• To compare, descriptively, smoking behaviour and reduction in cigarettes per day. 
• To estimate the standard deviation of smoking behaviour and periodontal outcome 
measures to inform sample size calculation for future definitive trials. 
• To test the collection of subgingival plaque for microbiome analysis.   
• To test the collection of GCF for inflammatory biomarker analysis.  
• To ascertain participant compliance when provided with an e-cigarette.  
• To describe tobacco smoking and e-cigarette usage in this patient population.  
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• To ascertain participant behaviour regarding the use of the e-cigarette: straight 
nicotine replacement or nicotine cessation device? 
• To complete a qualitative process evaluation to establish the views of participants 
on the provision of e-cigarettes and to finalise the exact characteristics of an e-
cigarette intervention for the future definitive study in this patient group.  
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3.4 Methods 
3.4.1 Design 
This study was a mixed methods feasibility study, comprising a pilot RCT with embedded 
qualitative process evaluation (presented in chapters 4 and 5). The participants were smokers 
who had a diagnosis of periodontitis (severe chronic, see section 1.2.1) and who were 
provided with a smoking cessation intervention alongside their standard periodontal therapy. 
This feasibility study provided essential information on the practicality of running a full scale 
trial and provided data on study design, the distributional properties of the proposed outcome 
measures, e-cigarette acceptability, recruitment and retention. The pilot RCT was an 
individually randomised, 2-armed parallel group trial with a 1:1 allocation ratio. Outcome 
assessors (for periodontal outcome measures) were blinded to participant allocation and 
smoking status. Participants in the control group received usual care (SCA) and those in the 
intervention group received usual care plus the e-cigarette intervention.  
This study adhered to the CONSORT guidance for pilot and feasibility trials (Eldridge et al., 
2016) and a completed CONSORT checklist is included (Appendix G). 
3.4.2 Participants 
This study was conducted within the DCRF of the NDH, a secondary and tertiary care 
provider.  
Study inclusion was limited to those:  
 aged over 18 years old;  
 smoker of burnt tobacco ( ≥10 factory-made cigarettes/day or 7 g [0.25 oz]) loose 
tobacco/day or 14 hand-rolled cigarettes/day);  
 not currently using an e-cigarette, or not used one for more than two days in the last 30 
days; 
 willing and able to come to the DCRF in the NDH for the required study visits; 
 having a minimum of 16 natural teeth (excluding third molars);  
 being diagnosed with periodontal disease,  having interproximal pocket probing depths 
(PPDs) of ≥ 5 mm at ≥ 8 sites.  
Study exclusions were:  
 having used an e-cigarette for more than two days in the last 30 days;  
 infectious or systemic diseases (myocardial infarction, cerebrovascular accident; 
phaeochromocytoma; uncontrolled hyperthyroidism; liver or kidney problems; chronic 
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obstructive pulmonary disease) that may be unduly affected by participation in this 
study;  
 haemodynamically unstable patients hospitalised with severe arrhythmias;  
 patients taking the medication adenosine (due to drug interaction);  
 lack of capacity to be able to consent to the research project and/or inability to follow 
study instructions;  
 participation in a dental research study within the previous 20 days;  
 pregnant by medical history, or nursing;  
 received any non-surgical periodontal therapy other than a routine scale and polish in 
the last 6 months;  
 currently undergoing or requiring extensive dental, orthodontic or implant treatment, 
or treatment for peri-implantitis.  
A number of clinical characteristics required further discussions with potential participants 
before inclusion:  
 asthma (severity needed to be assessed, patient made aware that NRT is better than 
smoking but best to use NRT as a short term stop smoking treatment);  
 long term throat disease (severity needs to be assessed, NRT use may exacerbate 
symptoms); 
 stomach ulcer, duodenal ulcer, irritation or inflammation of the stomach or throat 
(NRT may exacerbate symptoms);  
 diabetes mellitus (advised to monitor their blood glucose more closely when initiating 
treatment, advised to discuss this with their doctor or diabetic nurse specialist);  
 those taking theophylline, clozapine and ropinirole medications (metabolised by CYP 
1A2 and with a narrow therapeutic window, can be affected by stopping smoking, 
advised to see their doctor to discuss changing the dose prior to starting the quit 
attempt). 
 
3.4.3 Recruitment 
Potential participants were identified through two routes: at new patient and treatment clinics 
of the NDH or by primary care practitioners. New patient clinics comprised periodontal 
specific clinics and general restorative dentistry clinics. Treatment clinics comprised mainly 
the dental emergency clinic but also the student clinics and specialty registrar (StR) clinics. 
Within the NDH, potential participants were identified by a member of the existing clinical 
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care team (comprising dentists, hygienists, therapists, dental nurses). The clinical team 
member contacted the research team (research dentist or research dental nurse) who attended 
the clinic (if available) to discuss the study with the patient, provide the participant 
information sheet (PIS, see Appendix H) and arrange appointments. If required, a screening 
visit was arranged in the DCRF to check for participant eligibility and answer any further 
questions. Primary care practitioners (general dental practitioners, therapists, hygienists) who 
identified potentially eligible patients were asked to provide the patient with a PIS and refer 
them directly to the DCRF (using a dedicated proforma, see Appendix I) for a screening visit.  
3.4.4 Sample size 
No formal sample size calculation was performed for this pilot RCT. Recommendations for 
good practice in feasibility trials (Lancaster et al., 2004) suggest 30 patients or more are 
retained in each arm of the trial for provision of data on the proposed primary outcome for the 
future trial, to provide a robust estimate of the distribution of key study parameters to input to 
sample size calculations for future definitive trial applications. However, because the attrition 
rate for randomised patients in this study was not known at the outset (because it was part of 
the feasibility assessment), 80 patients in total were randomised, 40 to each arm of the trial, to 
allow for up to 25% attrition while achieving 30 patients per intervention arm with complete 
study follow-up. 
3.4.5 Intervention: smoking cessation advice 
All participants in this study received SCA delivered by a single treating dentist (myself) 
alongside the dental care, as part of usual care. This SCA followed the ‘3 A’s’: Ask, Advise, 
Act technique (National Centre for Smoking Cessation and Training, 2012c). A referral to 
Newcastle stop smoking services was available. This intervention was audio-recorded to 
allow tests for fidelity. The SCA intervention is fully described in Table 3.3 according to the 
template for intervention description and replication (TiDieR) checklist (Hoffmann et al., 
2014).  
3.4.6 Intervention: e-cigarette intervention 
Participants within the intervention group received the same usual care (SCA) as the control 
group but also had the offer of an e-cigarette starter kit (as detailed in Table 3.2). The 
participants were provided with an approximately two-week supply of e-liquid and 
information on where to buy more themselves. Participants were instructed to use only the 
Vype brand of e-liquids for the duration of the study, if possible, to match the e-cigarette 
device provided. At every contact, we monitored what e-cigarette product was being used as 
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well as the frequency and length of use. The e-cigarette intervention is fully described in 
Table 3.4 according to the TiDieR checklist (Hoffmann et al., 2014). 
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Item Quantity Details 
Vype eTank clearomizer (tank) 2  
650mAh battery  2  
USB charging cable 1  
UK plug 1  
Manufacturer’s users’ guide 1  
10ml e-liquid 2 Flavour options: Blended Tobacco, 
Crisp Mint, Dark Cherry and Vpure 
(flavourless)*.  
Nicotine strength concentrations: 
0mg/ml, 6mg/ml, 12mg/ml, 
18mg/ml. 
 
Table 3.2 E-cigarette starter kit contents. 
Manufacturer details: The Vype product was produced by Nicoventure Trading Limited 
(Blackburn, UK) who are a subsidiary of British American Tobacco PLC (BAT, London, 
UK). The products for this study were procured through our NHS hospital pharmacy either 
through a NHS wholesaler (AAH Pharmaceuticals, Alliance Healthcare) or directly from the 
manufacturer (plugs).  
*The e-liquid flavours will be referred to as tobacco, mint, cherry and flavourless respectively 
throughout the rest of this thesis. 
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3.4.7 Intervention: periodontal therapy 
All participants, regardless of arm, received identical routine non-surgical periodontal 
therapy. This followed established and routine clinical management protocols that are already 
in use in the NDH. Thus, clinical care was not altered in any way by participation in the study. 
Patients initially underwent a period of patient education and motivation (oral hygiene 
instruction [OHI]) which followed a structured approach as described by Jönsson et al, 2009. 
This OHI intervention is fully described in Table 3.5 according to the TiDieR checklist 
(Hoffmann et al., 2014).  The OHI was followed by debridement of the root surfaces of teeth 
under local anaesthetic. A full mouth debridement (FMD) technique was used in which all the 
root surface debridement was completed within a short time frame (ideally 24 hours) in line 
with local (Holliday, 2017) and international (Sanz and Teughels, 2008) guidance. 
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No.  Item Definition 
1 Brief Name Smoking Cessation Advice (SCA) 
2 Why A Very Brief Advice intervention, within a medical setting, has been shown to have a significant increase in the 
rate of quitting (RR 1.66) (Stead et al., 2013a). Oral health care professionals are in an opportunistic position to 
deliver a smoking cessation intervention. They can provide advice to quit on medical grounds with very powerful 
patient specific prompts (e.g. radiographs). Specifically for patients with periodontitis, stopping smoking prior to 
the delivery of their periodontal intervention will lead to significant, visually obvious and relatively rapid 
improvements.  
3 What 
(materials) 
If the patient had a panoramic radiograph this was used as a prompt to demonstrate any periodontal disease 
diagnosis, bone loss and likely impact of smoking on the mouth. If no radiographs were available then other 
prompts such as tooth staining and bad breath were used as personal prompts.  
4 What 
(procedure) 
The SCA is a short behavioural based intervention based around three domains:  
• ASK: Ask and record the smoking status (current smokers, ex-smoker, non-smoker)? 
• ADVISE: Advise on the likely impact of smoking on the mouth, specifically periodontitis (using patient 
specific prompts where appropriate e.g. panoramic radiograph).  Advise on the best way to quitting (the 
best way of stopping smoking is with a combination of medication and specialist support).  
• ACT: Act on patient’s response. Build confidence, give information and refer. Patients are up to four 
times more likely to quit successfully with support.  
A referral was available to the local stop smoking services. A suggested quit date of visit 2 (initial visit of 
periodontal therapy) was suggested.   
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No.  Item Definition 
5 Who provided A dentist provided the SCA. All those providing SCA had completed the NCSCT e-learning module ‘Very Brief 
Advice on Smoking’ (National Centre for Smoking Cessation and Training, 2012c).  
6 How The SCA was delivered at an individual level, by the dentist, integrated as part of a dental visit.  
7 Where Dental Surgery, Dental Clinical Research Facility, Newcastle Dental Hospital. 
8 When and 
how much 
The SCA was specifically delivered during study visit 1 (the dental visit prior to the commencement of the 
periodontal therapy). During this visit the periodontal diagnosis was discussed with the patient, oral hygiene 
instruction given and the SCA provided. The duration of the SCA was meant to be between 2-5 minutes depending 
on the response of the participant. The SCA was reinforced at each subsequent dental visit, dependent on the 
individual participant.  
9 Tailoring The duration of the SCA was dependent on the engagement of the individual participant. 
Participants received supportive advice, at follow up visits, tailored to their level of engagement. As a minimum a 
30 second SCA was delivered at each dental visit. As indicated above, prompts were tailored to patient 
circumstances. 
10 Modifications NA 
11 How well 
(Planned) 
The SCA training was delivered by a national organisation. Dentists also received training on discussing the effects 
of smoking on oral health as part of their undergraduate degrees.  
The SCA delivered during the first study visit was audio-recorded and a sample checked for implementation 
fidelity against the SCA flow diagram.  
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No.  Item Definition 
12 How well 
(Actual) 
A sample of 10 random audio-recordings were checked by a research dental nurse. The average duration was 3 
minutes and 12 seconds (ranging from 1 minutes and 10 seconds to 4 minutes and 53 seconds). All the sample 
contained the three elements of the SCA intervention (Ask, Advise, Act).    
 
Table 3.3 TiDieR checklist: smoking cessation advice.  
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No.  Item Definition 
1 Brief Name E-cigarette intervention 
2 Why E-cigarettes have seen a significant rise in popularity in recent years and there is a growing body of 
evidence that they are an attractive and effective smoking cessation/ harm reduction tool. E-cigarettes are 
easy for dentists to recommend and/or provide.  
3 What (materials) The participants were provided with a second generation (tank) e-cigarette. A starter kit was provided as 
detailed in Table 3.2. Participants had a choice of four flavour and nicotine concentrations. An information 
sheet was provided which provided information on setting up the e-cigarette, and where to purchase 
further e-liquids and tanks (see Appendix J).   
4 What (procedure) The dentist provided the e-cigarette starter kit and e-liquid to each participant in the intervention arm of 
the study. They practically demonstrated the e-cigarette set up with each participant. They talked through 
the information sheets and answered any questions.  
5 Who provided A dentist provided the e-cigarette and training.  
6 How The e-cigarette training was delivered as a conversation with the e-cigarette as a prompt.   
7 Where Dental Surgery, Dental Clinical Research Facility (DCRF), Newcastle Dental Hospital (NDH). 
8 When and how much The e-cigarette intervention was delivered directly following the SCA intervention and was expected to be 
10-15 minutes in duration.   
9 Tailoring The e-cigarette intervention was the same for all participants, with patient choice in respect of flavour and 
concentration of e-liquid respected. Participants were able to request further support at subsequent 
appointments as required.   
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No.  Item Definition 
10 Modifications NA 
11 How well (Planned) The dentist providing the e-cigarette intervention followed the information sheet as a prompt and had a 
discussion guide (see Appendix K). The e-cigarette intervention was audio-recorded and a sample checked 
for implementation fidelity.  
12 How well (Actual) A sample of 10 random audio-recordings were checked against the 22 items in the discussion guide 
(Appendix K) by a research dental nurse. The average duration was 9 minutes and 29 seconds. Nineteen 
items were present 100% of the time. Item 3 (‘You are still free to use any of the other ways to stop 
smoking on top of this’) was absent on one occasion, although this was likely to have been delivered at 
another non-recorded time point. Items 15 (introducing the users guide) was absent on three occasions, 
although this was implied by the subsequent use of the users guide. Item 16 (highlighting the 
manufacturer’s users’ guide at the back of the box) was absent on three occasions.   
 
Table 3.4 TiDieR checklist: e-cigarette intervention. 
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No.  Item Definition 
1 Brief Name Oral Hygiene Instruction (OHI) 
2 Why Obtaining a satisfactory level of oral hygiene is an important factor in the success of periodontal 
interventions.   
3 What (materials) As appropriate:  
 Inter-dental cleaning aids: dental floss, inter-dental brushes 
 Single tufted brush 
 Manual toothbrush (demo only) 
 Powered toothbrush (demo only) 
 Dental demonstration model  
4 What (procedure) The dentist/hygienist presented information on caries and/or gingivitis/periodontitis; oral hygiene 
instruction was given based on plaque scores. The individual’s oral status was reviewed at subsequent 
visits.  
5 Who provided A dentist or hygienist. 
6 How The OHI was delivered as a face-to-face conversation at an individual level.    
7 Where Dental Surgery, Dental Clinical Research Facility, Newcastle Dental Hospital. 
8 When and how 
much 
The OHI was delivered during one of the initial visits. The OHI duration was 5-10 minutes.   
At subsequent visits further OHI was provided as appropriate, often integrated as part of the periodontal 
therapy.  
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No.  Item Definition 
9 Tailoring The OHI followed the same structure for all participants and was tailored according to the participant’s 
existing level of oral hygiene, level of oral hygiene knowledge and level of engagement.  
10 Modifications NA 
11 How well (Planned) The dentist/hygienist who provided the OHI were experienced practitioners.  
12 How well (Actual) NA 
 
Table 3.5 TiDieR checkist: oral hygiene instruction.
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3.4.8 Overview of study visits 
Participants were asked to attend for six study visits over six months (Figure 3.2 Study design 
overview). There were no additional visits for research purposes with all visits being in line 
with normal periodontal therapy and follow-up.  
Pre-study visit - screening 
As previously detailed (see section 3.4.3), potential participants were identified 
opportunistically by existing clinical care teams within either the NDH or primary dental 
services. Potential participants were screened against the study eligibility criteria. Information 
was provided about the research study and potential participants had the opportunity to ask 
questions. A research ethics committee (REC) approved participant information sheet was 
discussed with the participants and a copy provided to take away. Participants had at least 24 
hours to consider their willingness to enter the study before signing the informed consent 
form, with further time available if required.    
Baseline (visit 1)- consent, demographics, baseline measurements/samples, randomisation 
and smoking interventions    
If potential participants agreed to participate in the research study, informed consent was 
taken by an appropriately trained (non-blinded) member of the research team. An informed 
consent form (see Appendix L) was signed and the participant was provided with a copy for 
their own records. Demographic information were collected and recorded in a case report 
form (CRF) by a non-blinded researcher. These data comprised: date of birth, age, gender, 
ethnicity, occupation, entitlement to free prescriptions, body mass index (BMI), previous 
smoking habits, previous quit attempts and previous use of stop smoking support or 
medications (including e-cigarettes). Baseline smoking-related outcome data were collected, 
comprising: self-reported smoking status, expired air carbon monoxide (eCO), Fagerstrom 
Test for Nicotine Dependence (FTND) (Heatherton et al., 1991) and the Mood and Physical 
Symptoms Scale (MPSS) (West and Hajek, 2004). Saliva was collected for salivary cotinine 
(SC) and salivary anabasine (SA) determination. Baseline oral health related outcome data 
were collected by a single blinded research dental hygienist and comprised: PPD, modified 
gingival index (MGI), plaque index (PI), BOP, Clinical Oral Dryness Score (CODS) and the 
UK Oral Health-related Quality of Life Measure (OHQoL-UK) (McGrath and Bedi, 2002). 
GCF and subgingival plaque were collected for inflammatory biomarker and microbiological 
analysis (details of this methodology is detailed in section 3.4.14). Table 3.6 provides a 
detailed breakdown of the schedule of events throughout the study.  
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Participants were randomised to either the control or intervention group (see section 3.4.9 for 
details of the randomisation process). All participants were provided with SCA with those in 
the intervention group also receiving the e-cigarette intervention.      
Quit date (visit 2)- periodontal intervention (part 1) 
The non-surgical periodontal intervention was provided using a FMD technique where 
appropriate. This was delivered over two visits, usually using a split mouth technique (right 
then left). OHI was provided. This visit was the suggested smoking quit date.  
Second treatment visit (visit 3)- periodontal intervention (part 2) 
The second part of the FMD periodontal intervention.  
4 weeks (visit 4)- SPT, smoking-related outcome measurements and samples 
SPT provided as required. Smoking-related outcome data were collected, comprising: self-
reported smoking status, eCO, FTND and MPSS. Saliva was collected for SC and SA 
determination.  
3 months (visit 5)- SPT, smoking and oral health related outcome measurements and samples 
SPT provided as required. Smoking-related outcome data were collected, comprising: self-
reported smoking status, eCO, FTND and MPSS. Saliva was collected for SC and SA 
determination. Oral health related outcome data were collected by a blinded research dental 
hygienist, comprising: PPD, MGI, PI, BOP, CODS. GCF and subgingival plaque samples 
were collected for inflammatory biomarker and microbiological analysis. 
6 months (visit 6)- SPT, smoking and oral health related outcome measurements and samples 
SPT provided as required. Smoking-related outcome data were collected, comprising: self-
reported smoking status, eCO, FTND and MPSS. Saliva was collected for SC and SA 
determination. Oral health related outcome data were collected by a blinded research dental 
hygienist and comprised: PPD, GI, PI, BOP, CODS and OHQoL-UK. GCF and subgingival 
plaque samples were collected for inflammatory biomarker and microbiological analysis. 
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Event Visit 1 
(baseline) 
Visit 2 
(quit date) 
Visit 3 
 
Visit 4 
(4 weeks) 
Visit 5 
(3 months) 
Visit 6 
(6 months) 
Periodontal outcome measures     
No. teeth X    X X 
PPD X    X X 
MGI X    X X 
PI X    X X 
CAL X    X X 
BOP X    X X 
Microbiological X    X X 
Inflammatory biomakers X    X X 
OHQoL-UK X     X 
CODS X    X X 
       
Smoking outcome measures      
FTND  X X  X  X 
MPSS X X  X  X 
eCO X X  X  X 
SC X X  X  X 
SA X X  X  X 
Self-reported smoking status X X  X X X 
Table 3.6 Schedule of events.
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Figure 3.2 Study design overview. 
Please note that the participant numbers presented in this figure are estimated numbers and 
not the actual participant numbers observed in the RCT. The actual participant numbers are 
presented in Figure 3.5 CONSORT flow diagram.  
Abbreviations: eCO- Expired air Carbon Monoxide, FTND- Fagerstom Test for Nicotine 
Dependence, MPSS- Mood and Physical Symptoms Scale, PPD- Pocket Probing Depths, 
MGI- Modified Gingival Index, PI- Plaque Index, CAL- Clinical Attachment Loss, BOP- 
Bleeding on Probing, CODS- Clinical Oral Dryness Score, SC- Salivary Cotinine, SA- 
Salivary Anabasine, Micro- Microbiological outcome measure, IB- Inflammatory biomarkers, 
OHQoL-UK- Oral Health Quality of Life Assessment, TDF- Theoretical Domains 
Framework.  
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3.4.9 Assignment of interventions 
Following the assessment of eligibility and completion of informed consent, participants were 
randomised to the control or intervention group, in a 1:1 ratio using random permuted blocks 
of variable length. The randomisation allocation schedule was generated by a statistician with 
no other involvement in the study, to achieve concealment of allocation. Randomisation was 
performed using a secure password-protected web-based system administered by Newcastle 
CTU. Randomisation generated a unique 4-digit “Study ID number” for each participant. 
There were no stratification factors.  
3.4.10 Concomitant care 
Participants in the control group were asked not to use an e-cigarette for the duration of the 
study, especially during the first 4 weeks. They were asked to sign a commitment form 
demonstrating that they agreed to this (see Appendix M). It was impractical to completely 
prohibit e-cigarette use, since they are freely available on general sale. The use of all stop 
smoking services and cessation aids (including e-cigarettes) was recorded in detail at each 
study visit for all participants. 
Participants in the intervention group were advised to use only the recommended brand of e-
liquids for the duration of the study. At each study visit, we monitored which e-cigarette 
product was being used as well as the frequency and length of use. The participants were free 
to use other NRT products, either purchased over the counter or provided through the 
specialist stop smoking services. 
3.4.11 Blinding 
Due to the nature of this study, the participants and care providers could not be blinded to 
assigned intervention. At each study visit, participants saw the dentist, for any study 
interventions, and if applicable, the research hygienist, for clinical study measurements. 
The outcome assessor, measuring the range of oral health indices, was blind to participants’ 
smoking status and intervention allocation. These study measurements were collected by a 
trained, blinded, calibrated research hygienist, not otherwise involved in the study. 
Participants were asked not to disclose their smoking status or methods of smoking cessation 
to the blinded assessor and were reminded of this prior to every visit by the unblinded 
research nurse.  
3.4.12 Outcomes and data collection methods 
A range of outcome measures were used to assess both smoking behaviour and oral health; 
these were selected in anticipation of their inclusion as primary or secondary outcomes in a 
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future definitive trial. For smoking behaviour, they comprised: self-reported tobacco and e-
cigarette use, eCO, SC, SA, FTND and MPSS. For oral health, they comprised: PPD, MGI, 
PI, CAL, BOP, CODS, PESA, PISA and OHQoL-UK. The data collection method for each 
outcome is described below.  
Self-reported tobacco and e-cigarettes use  
Participants were asked to verbally report (to the research dentist [Richard Holliday]) their 
tobacco and e-cigarette use at visits 1, 2, 4, 5 and 6. For tobacco, details on the quantity 
(number of cigarettes or weight of loose tobacco per day) and type of tobacco (factory-made, 
hand-rolled) were recorded. For e-cigarettes, the number of days on which e-cigarettes were 
used, as well as product details, were recorded.  
Cumulative tobacco and e-cigarette use 
Participants were asked to complete a weekly questionnaire which asked them to report their 
average cigarettes/day over the last 7 days. The questionnaire was made available in several 
mediums to accommodate the participant’s preference: short message service (SMS) text 
message with an embedded link to a mobile web page, email with embedded link, telephone 
call or a paper version.   
Expired air carbon monoxide 
A calibrated carbon monoxide monitor (piCO SMOKERLYZER, Bedfont Scientific Ltd, 
Maidstone, UK) was used to measure eCO at visits 1, 2, 4, 5 and 6. A single reading was 
taken by a non-blinded member of the research team. A reading of 10 parts per million (ppm) 
or above signified that the participant had smoked tobacco in the preceding 24 hours (West et 
al., 2005b). 
Salivary cotinine and salivary anabasine 
Cotinine is a metabolite of nicotine and SC is a biomarker of nicotine exposure which gives 
high readings in those using tobacco, e-cigarettes or other nicotine replacement products. A 
SC reading below 15ng/ml signified a non-user of tobacco or nicotine products (West et al., 
2005b). SA is an alkaloid with a very similar chemical structure to nicotine; SA is found in 
tobacco but not NRT or e-cigarettes. Anabasine was used to confirm if a participant using 
NRT/e-cigarettes had also obtained nicotine from tobacco. A SA reading below 0.1ng/ml 
signified that they had not used tobacco (M Doig [ABS Laboratories], personal 
communication, 3 August 2018) (Jacob et al., 2002; Brown et al., 2014a). This allowed the 
bio-chemical verification of the self-reported smoking statuses of those who abstained from 
all nicotine, those using only NRT/e-cigarettes and those still smoking. Saliva samples were 
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collected at visits 1, 2, 4, 5 and 6 (see section 3.4.14 for complete details of saliva collection 
methods).  
Fagerstrom test for nicotine dependence 
This six-item questionnaire is designed to assess the degree of dependence among smokers 
coming to a smoking cessation clinic (Heatherton et al., 1991). It produces a score between 0-
10 with higher scores representing more dependence (see Appendix N). The FTND was 
completed at visits 1, 2, 4, 5 and 6.   
Mood and physical symptoms scale 
This 12-item questionnaire assesses cigarette withdrawal symptoms (West and Hajek, 2004). 
The ratings can be analysed individually or totalled together to give composite scores. Scores 
were combined to give four scores: MPSS(Mood [M]) [items 1-7], MPSS(Cravings [C]) 
[items 8 and 9], MPSS(Physical [P]) [items 10-12] and MPSS(total) [items 1-12] (National 
Centre for Smoking Cessation and Training, 2012b) (see Appendix O).  
Smoking abstinence measures 
Smoking abstinence was reported in six different categories. In increasing strictness these 
comprised: self-reported quitter, eCO-verified self-reported quitter, SC/SA-verified self-
reported quitter, eCO- and SC/SA-verified self-reported quitter, Russell Standard 6-month 
quitter based upon eCO (RS6-eCO) and the Russell Standard 6-month quitter based upon 
eCO and salivary analysis (RS6-S). The RS6 includes six criteria as detailed in Table 3.7. 
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Russell Standard criteria Compliance of this study 
Six-month follow-up from quit date Complied fully 
  
Self-reported smoking abstinence 
over whole follow-up period 
allowing up to five cigarettes in total 
Complied by recording self-reported smoking status 
at each visit. A two week grace period from the quit 
date was applied as recommended.    
 
Biochemical validation of abstinence Complied by using eCO and/or SC/SA validation. 
 
Intention-to-treat analysis with 
participants counted as smokers if 
smoking status can’t be determined 
[unless died or moved to an 
untraceable address] 
 
Complied by using intention-to-treat analysis.  
Following up ‘protocol violators’ 
and using true smoking status in 
analysis. 
Complied by following up all participants in their 
original groups.  
 
 
Blind follow-up Oral health data were collected by a blinded 
assessor. Due to the limitations of a doctoral 
research project it was not possible to collect 
smoking outcome data blinded. Follow-up rates 
were reported for each group as recommended.   
 
Table 3.7 Russell Standard outcome criteria in smoking cessation. 
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Pocket probing depths 
A single trained and calibrated hygienist, blinded to group allocation, collected the PPDs 
using a manual University of North Carolina (UNC)-15 periodontal probe to record the 
probing depths to the nearest millimetre. Probing depth was defined as the distance from the 
probe tip (assumed to be at the base of the pocket) to the free gingival margin. This was 
recorded at six sites per tooth at visits 1, 5 and 6.  
Modified gingival index 
A gingival index based on the Lobene Modified Gingival Index (Lobene et al., 1986) was 
used to rate the gingival inflammation on a scale of zero to four. This index was assessed by 
the blinded research hygienist. Table 3.8 detail the parameters of the scale. This index was 
recorded at six sites per tooth at visit 1, 5 and 6.   
Plaque index 
The plaque index of Silness and Loe (1964) was employed to measure plaque (without 
disclosing), rating it on a scale of zero to three. This index was assessed by the blinded 
research hygienist. This was recorded at six sites per tooth at visit 1, 5 and 6. Table 3.9 details 
the parameters of the scale.  
Clinical attachment loss 
Gingival recession was defined as the distance from the free gingival margin to the cemento-
enamel junction. It was recorded to the nearest mm using a manual UNC-15 periodontal 
probe. Gingival recession was indicated as a positive number and gingival overgrowth was 
recorded as zero. CAL was calculated by adding the gingival recession and PPD 
measurements. This measurement was collected by the blinded research hygienist, at visit 1, 5 
and 6.    
Bleeding on probing 
Following probing, each site was assessed for bleeding on probing. If bleeding occurred 
within 30 seconds of probing, a score of one was assigned for the site, otherwise, a score of 
zero was assigned. This measurement was collected by the blinded research hygienist, 
recorded at six sites per tooth at visit 1, 5 and 6. 
Clinical oral dryness score 
Oral dryness (xerostomia) was measured using a ten-item scale as described by Osailan et al. 
(2012), giving scores from zero to ten. This index was collected by the blinded research 
hygienist, at visit 1, 5 and 6. Table 3.10 details the ten items on the scale (each item is 
assigned a score of one if present).   
114 
 
Oral health quality of life assessment 
The OHQoL-UK questionnaire (McGrath and Bedi, 2002) was used to measure oral health-
related quality of life at visit 1 and 6. The 16 items allow responses in either a positive or 
negative (bidirectional) manner to a series of statements about the effect of oral health on 
specific aspects of respondents’ daily lives (see Appendix P). The responses range from “very 
bad” (score 1) to “very good” (score 5). Responses are then summed to give a total score, or 
can also be summed within three sub-domains (physical [items 1-4, 15-16], social [items 6-8, 
12-13] and psychological [items 5, 9-11, 14]) as described in the literature (McGrath and 
Bedi, 2002; Durham et al., 2013). The lower the score the poorer the OHQoL. McGrath and 
Bedi (2001) reported this questionnaire to have good validity and reliability for assessing the 
impact of oral health on life quality. 
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Score  Description 
0 Absence of inflammation 
1 Mild inflammation; slight change in colour, little change in texture of any 
portion of but not the entire margin or papillary gingival unit 
2 Mild inflammation; but involving entire margin or papillary unit 
3 Moderate inflammation; glazing, redness, oedema and/or hypertrophy of 
margin or papillary unit 
4 Severe inflammation; marked redness, oedema and/or hypertrophy of 
marginal or papillary gingival unit, spontaneous bleeding, congestion, or 
ulceration 
 
Table 3.8 Modified gingival index (Lobene et al., 1986). 
 
 
 
Score  Description 
0 No plaque 
1 A thin film of plaque at the gingival margin which may be seen only after 
running the probe along the tooth surface 
2 Moderate accumulation of plaque deposits which can be seen with the naked 
eye 
3 Extensive accumulation of plaque deposits 
 
Table 3.9 Plaque index (Silness and Loe, 1964). 
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Item  Description 
1 Mirror sticks to buccal mucosa 
2 Mirror sticks to tongue 
3 Frothy saliva 
4 No saliva pooling in floor of mouth 
5 Tongue shows loss of papillae 
6 Altered/smooth gingival architecture 
7 Glassy appearance of other oral mucosa, especially palate 
8 Tongue lobulated/fissured 
9 Active or recently restored (last 6 months) cervical caries (>2 teeth) 
10 Debris on palate (excluding under dentures) 
 
Table 3.10 Clinical oral dryness score (Osailan et al., 2012). 
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3.4.13 Examiner alignment and assessment 
A single examiner recorded all of the oral health measurements throughout the study. The 
examiner was an experienced research dental hygienist, blinded to treatment arm. In order to 
reduce examiner bias and increase the validity of the study results, an intra-examiner clinical 
reproducibility assessment exercise was conducted on two oral health measurements: PPD 
and gingival recession. Repeat measurements were taken in pre-specified quadrants on six 
participants and the percentage agreement of duplicated measurements were calculated (Hefti 
and Preshaw, 2012). Results demonstrated good agreement with over 98% of measurements 
within 2 mm for both parameters (Table 3.11). Bland-Altman plots were generated (Figure 
3.3 and Figure 3.4) and there was no indication of proportional bias (Bland and Altman, 
1986).       
 
 
 
 
Oral health 
measurement 
Exact agreement 
(%) 
Agreement +/-
1mm (%) 
Agreement +/-
2mm (%) 
PPD 66.7 92.8 98.1 
Gingival recession 82.4 92.0 98.1 
 
Table 3.11 Intra-examiner clinical reproducibility assessment. 
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Figure 3.3 Bland-Altman plots for PPD. 
 
 
 
Figure 3.4 Bland-Altman plots for gingival recession measurement.  
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3.4.14 Collection and analysis of biological samples 
Saliva was collected at each study visit (excluding visit 3) to allow determination of SC and 
SA. GCF and subgingival plaque were collected alongside the periodontal indices at visits 1, 
5 and 6. GCF was used for biomarker analysis whilst the subgingival plaque was used for the 
microbiological analysis.   
Saliva collection 
Saliva samples were obtained at least one hour following the last consumption of food, drink 
or medication by the participant and at least one hour following the last episode of oral 
hygiene (toothbrushing, flossing, mouthrinses etc). Samples were collected at any time during 
the working day. Participants were seated in the dental chair, without distraction, noise, or 
conversation. A Salivette® (Sarstedt, Nümbrecht, Germany) was labelled with a sample 
identifier number and date. Participants were advised to remove the stopper, whilst holding 
the suspended insert and to place the swab under the tongue by tipping the Salivette® close to 
the mouth. Participants were not allowed to touch the swab. The swab was left in place until 
‘soggy’ before transferring directly from the mouth to the suspended insert. The stopper was 
replaced and the Salivette® immediately placed on ice, transferred to the laboratory and 
placed in a -80oC freezer.   
Saliva analysis 
The saliva was analysed for concentrations of cotinine and anabasine. This analysis was 
conducted at an external commercial laboratory (ABS Laboratories,Welwyn Garden City, 
UK). Samples were stored in -80oC freezer within the Cell and Molecular Biosciences 
Laboratory (Newcastle University) until transfer. Samples were transferred to ABS 
Laboratories in one shipment at the end of the study using a courier service. The samples were 
classified as ‘Category B’ samples and transported accordingly (Health and Safety Executive, 
2009).   
GCF collection 
Two periodontal pockets (5≤ PPD≤8 mm) were identified and recorded in the CRF. The sites 
were isolated using cotton rolls and any supragingival plaque was removed with curettes and 
cotton pellets. Prior to collecting the GCF, two pre-labelled cryovials were prepared chairside. 
A Periopaper strip (Oraflow Inc., New York, USA) was placed carefully into the sulcus of the 
identified site until mild resistance was felt. The strip was left in place, holding the cheek 
retracted for 30 seconds. The strips was immediately transferred to separate sterile, dry 
labelled microcentrifuge tubes. Any excessively blood-soaked strips were discarded and new 
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samples taken. The samples were stored on ice before prompt transfer to the -80oC freezer in 
the laboratory.  
Subgingival plaque collection 
Ten periodontal pockets (PPD ≥ 5 mm) were identified and recorded in the CRF. Any 
supragingival plaque was removed with curettes and cotton pellets. Sterile endodontic paper 
points (up to three, parallel, size 60) were inserted into each periodontal pockets for 10 
seconds. The points were immediately transferred to sterile, dry microcentrifuge tubes. Any 
excessively blood-soaked points were discarded and new samples taken. The samples were 
placed on ice immediately before prompt transfer to storage at -80oC.  
3.4.15 Follow-up 
Participants were scheduled to return for their study assessments at three time points: visit 4 
(4 weeks post-randomisation, minus 3 days or plus 14 days), visit 5 (3 months post 
randomisation, minus 15 days or plus 28 days), visit 6 (6 months post-randomisation, minus 
15 days or plus 28 days). The 4-week and 6-month time points and associated visit windows 
were based upon the Russell Standards for smoking cessation studies (West et al., 2005b). 
Participants could withdraw from the study for any reason, at any time; for those who 
withdrew, no further data or tissue were collected post-withdrawal and no other research 
procedures were carried out on or in relation to the participant. Participants who failed to 
attend a scheduled visit and were unreachable were deemed lost to follow-up. Since the 
interventions were delivered at the start of the study it was almost impossible to withdraw 
from just the intervention and continue follow-up. 
3.4.16 Safety/adverse events 
Participant safety was monitored from the time each participant signed an informed consent 
form until conclusion of the study. The sponsor’s standard operating procedure (SOP) on 
managing adverse events was followed (Newcastle Joint Research Office, 2015; Newcastle 
Joint Research Office, 2017).  
Adverse Events (AE): At the time of enrolment, a medical history was recorded. At all 
subsequent time points, AEs were detailed in the CRF. The chief investigator made an 
assessment of the relationship of the event to the study (i.e. ‘definitely not related’, ‘probably 
not related’, ‘possibly related’, ‘probably related’, ‘definitely related’) and of expectedness as 
per available reference safety information for e-cigarettes.   
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Serious Adverse Events (SAE): Any serious adverse event (SAE) as defined by the 
International Council for Harmonisation (ICH) Guideline for Good Clinical Practice E6, were 
reported to the REC by the chief investigator. 
3.4.17 Approvals and monitoring 
Newcastle upon Tyne Foundation Hospital Trust (NuTH) acted as the sponsor for this study. 
A favourable opinion was obtained from the North East- Tyne & Wear South NHS Research 
Ethics Committee on 03/08/2016 with the reference number 16/NE/0219. The Health 
Research Authority (HRA) approved the project and subsequent amendments (Integrated 
Research Approval System [IRAS] project ID: 199724). Details of the amendments are 
provided in Table 3.12. 
A Trial Oversight Committee (TOC) was responsible for data and patient safety monitoring. 
The TOC combined the roles of a Trial Steering Committee and Data Monitoring Committee. 
The TOC was an independent group of experts consisting of a periodontal research expert, 
statistician and two lay members. A TOC charter was created at the first meeting (see 
Appendix Q) with subsequent meetings at 4, 7, 10, 13, 18 and 24 months. 
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Protocol version Amendment Details Approved Date 
1.0, dated 30/07/2016 Original submission  REC: 03/08/2016  
 
1.1, dated 24/08/2016 Protocol changes Non-substantial changes were made to the protocol following REC 
approval. This was to confirm who would have access to data and 
update the sponsor contact details. 
HRA: 02/09/2016 
Notified REC: 
06/09/2016 
1.2, dated 13/10/2016 Protocol changes  Non-substantial changes were made to the protocol. Change in the way 
periodontitis was classified and several minor administrative changes. 
The classification changes comprised the removal of the BOP criterion 
as it was proving to be an unreliable index to use in smokers (smoke 
affects the periodontal vasculature making this hard to interpret). 
Additionally the term ‘sites’ was used instead of ‘teeth’ in order to aid 
recruitment to this feasibility study.   
HRA: 4/11/16 
1.2, dated 13/10/2016 Addition of PICs Submitted as a ‘substantial amendment’ but downgraded by the HRA 
to a non-substantial amendment (Category B).  
HRA: 4/11/16 
Sponsor sign off: 
9/11/2016 
1.3, dated 06/04/2017 Protocol changes and 
use of promotional 
materials 
Non-substantial changes were made to the protocol. The minimum 
number of teeth required was reduced from 20 to 16 (16 teeth 
represents 50% of the dentition of a normal adult).  
Promotional materials were developed to enhance recruitment as 
existing recruitment centres.  
HRA: 09/05/2017 
1.3, dated 06/04/2017 Extension of study 
end date 
Non-substantial amendment to extend the recruitment period and study 
end date by 4 months.  
Sponsor sign off: 
21/07/2017 
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Protocol version Amendment Details Approved Date 
Original recruitment end date: 20/09/2017.  
Amended recruitment end date: 20/01/2018 
Original study end date: 31/03/2018 
Amended study end date: 31/07/2018 
 
HRA approval: 
27/07/2017  
 
Table 3.12 Protocol approval and amendment dates.
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3.4.18 Registration and funding 
This study was accepted for adoption to the NIHR portfolio on 12th September 2016 and 
registered on the International Standard Randomised Controlled Trial Number (ISRCTN) 
registry (ISRCTN17731903) on 19th September 2016.  
A full version of the protocol is provided in Appendix R.  
This study was funded by a NIHR Doctoral Research Fellowship (DRF-2015-08-077). 
3.4.19 Data management and confidentiality    
All study-related information was stored securely at the DCRF. All identifiable participant 
information, including signed consent forms, was stored in locked filing cabinets in the 
restricted access DCRF office. Paper-based CRFs were used for the collection of clinical data, 
with blinded and un-blinded versions of the CRF for each participant. The CRFs were 
identified by a coded ID number and participant initials. All records that contained names or 
other personal identifiers, such as informed consent forms, were stored separately from those 
study records which were identified by code number only. Only investigators had access to 
information linking the participants to the ID numbers.  
During data collection any modification to a written form or source document was amended 
with a single line through the erroneous data, with the correction legibly entered, as well as 
the initials and date of the person making the correction. Data were entered into secured 
databases (IBM SPSS Statistics, Version 24, Chicago, SPSS Inc.), password protected on the 
Newcastle University server. Source documents used to originally record participant data 
were maintained as part of standard case notes in the NDH.    
3.4.20 Missing data 
Smoking outcome data 
Those who did not attend for review visits when smoking outcome data were collected (visits 
4, 5 and 6) were considered as continuing smokers or to have relapsed, in line with standard 
research practice (West et al., 2005b; Hartmann-Boyce et al., 2016). Therefore, missing data 
were recorded as non-quitters for the outcomes: self-reported quitters, RS6-eCO, RS6-S. For 
continuous data (eCO, SC, SA), missing data were not imputed.  
Periodontal data 
Missing periodontal data due to participant loss to follow-up were not imputed. 
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Teeth lost during the study 
Several of the oral health outcome measures for this study were ‘summary’ measures 
calculated on all teeth present. Teeth that were planned to be removed as part of the initial 
treatment plan were not included in any analysis and periodontal indices were not collected on 
such teeth. For teeth that were lost during the study period (i.e. their loss was not in the initial 
treatment plan) a ‘last observation carried forwards’ approach was used for the periodontal 
indices where possible i.e. if a tooth was lost between visit 5 and 6 then the data were carried 
forwards from visit 5. If a tooth was lost before visit 5 then no data were imputed.   
Questionnaires 
For missing questionnaire (OHQoL-UK, FTND, MPSS) data, published guidelines were 
followed for validated questionnaires.  If no such guidelines were available, the ‘rule of 
halves’ was employed (Fairclough and Cella, 1996; Fayers et al., 1998; Peyre et al., 2011). 
For the OHQoL-UK questionnaire, patients who had not responded to ≥10% of the items in 
OHQoL-UK questionnaire were excluded from analyses, with their responses being treated as 
missing data. For patients who had <10% missing responses, the answers to the missing items 
were derived using group mean score imputation for each item in order to calculate the 
individual domain scores and the summary scores as reported in the literature (Steele et al., 
2004; Durham et al., 2013; Irani et al., 2015). For the FTND and MPSS questionnaires no 
published guidelines exist on how to manage incomplete data and the ‘rule of halves’ was 
used (missing item replaced with the mean of the answered items in the subscale, if at least 
half of the subscale has been answered).  
3.4.21 Statistics 
In accordance with recommendations for the analysis of feasibility studies, the data analyses 
were descriptive and statistical comparisons between the randomised groups were not 
undertaken. For the feasibility outcome measures all proportions/rates were calculated as 
defined and reported with 95% confidence intervals (CIs). Summaries of the change from 
baseline to 3 months and baseline to 6 months for the study assessment outcome measures 
were reported as: minimum value, median (lower quartile [LQ]- upper quartile [UQ]), mean 
(standard deviation, SD), maximum value and 95% CI.    
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3.5 Results 
The following section describes the results for the quantitative aspects of the feasibility study. 
Chapters 4 and 5 cover the qualitative findings (derived from participant interviews) as well 
as the feasibility aspects of the e-cigarette intervention.   
3.5.1 Study set-up 
The primary objective of this pilot RCT was to assess the viability of delivering and 
evaluating an e-cigarette intervention within a research study. Given the unusual situation of 
e-cigarettes and their regulatory status, the study set-up was complicated and formed an 
important feasibility component of the study.  
A research study which provides a medicinal product to a participant to investigate a medical 
claim is categorised as a Clinical Trial of Investigational Medical Product (CTIMP). CTIMPs 
require clinical trial authorisation (CTA) which is granted by the MHRA. The authorisation 
requirements vary depending on the risk of the study. Prior to April 2015 there were 13 UK e-
cigarette clinical studies registered on clinical research trial databases (Clinicaltrials.gov, 
EudraCT database and the UK Clinical Trials Gateway), which were all classed as non-
CTIMPs (to the best of our knowledge). Subsequently, there was an 18-month period in 
which no new trials were registered (until this pilot RCT in September 2016). Although e-
cigarette regulations were established following the implementation of the EU TPD, there was 
still uncertainty about research regulations. In the case of our study, the MHRA initially 
categorised it as a CTIMP requiring CTA (a change from the previous studies), before 
downgrading the study to a non-CTIMP due to its feasibility outcomes. However, I continued 
to investigate the regulatory challenges as they could potentially impede a future definitive 
trial.  
As previously mentioned, authorisation requirements vary depending on the risk of the study. 
There are different levels of CTIMPs: 
• Type A- Comparable to the risk of standard medical care 
• Type B- Somewhat higher than the risk of standard medical care 
• Type C- Markedly higher than the risk of standard medical care 
Type A studies are much less burdensome in terms of obtaining authorisation and conducting 
the trial, as they are considered to be low-risk. An example of a type A study would be a study 
using a product that already has a medicinal licence for the indication in question. These 
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products will have ‘Summary of Product Characteristics’ documents in the public domain, 
which could be submitted to the MHRA, without any interaction with the manufacturer.  
However, as no medically licenced e-cigarette product is yet available, it is likely that studies 
will classed as type B or C CTIMPs (this stance changed in 2017, which is discussed at the 
end of this section). These higher risk studies require more detailed information as part of the 
authorisation process. This includes the production of an Investigational Medicinal Product 
Dossier (IMPD) and Investigator Brochure which are substantial documents that require 
significant input from the Investigational Medicinal Product (IMP) manufacturer. They set out 
details of the manufacture of the product and contain important safety information. 
Within the e-cigarette market, the only manufacturers with large enough research & 
development departments to be able to provide the level of information required are likely to 
be those larger brands owned by tobacco companies. This poses a barrier for any university-
based researcher as non-disclosure agreements (NDAs) would need to be put in place and 
many universities would not allow this. Within Newcastle University I explored the feasibility 
of setting up these NDAs with the business development team (with input from the university 
faculty steering group) and it was concluded that the university would be unlikely to sign such 
a NDA, or at the very least, it would require significant amounts of legal input. Therefore, at 
the time, conducting a clinical trial on e-cigarettes in the UK would be almost impossible for a 
university-based researcher.  
I was subsequently invited to join colleagues, led by ASH, to work with the MHRA in 
establishing a suitable solution. They have subsequently agreed that a clinical trial using a 
TPD regulated e-cigarette (all those available for general sale in the UK) would not be 
categorised as a CTIMP and hence not need CTA, avoiding the aforementioned barriers 
(Medicines and Healthcare products Regulatory Agency, 2017). If the trial included medicinal 
products (such as nicotine patches) then the study would be classed as a CTIMP and require 
CTA.      
3.5.2 Participant recruitment 
This study aimed to recruit 80 participants over a 12-month period (7 participants/month). By 
12 months, 66 participants had been recruited and the recruitment period was extended by 
three months. Recruitment opened on 20th September 2016 and closed on 7th December 2017 
when the eightieth participant was recruited. Data collection was completed on 7th June 2018, 
when the last patient visit occurred. The majority of the patients were recruited from the 
clinics of the NDH, mainly through periodontal new patient clinics or the DEC.  
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Table 3.13 shows the detailed breakdown of the recruitment source. PICs identified a large 
number of potentially eligible participants but less than half of these progressed into the 
study, contributing 15 in total. The overall consent rate was 67% [95% CI: 58%-75%] of 
those eligible, but this masked differences between NDH clinics and PICs of 77% [95% CI: 
28%-59%] and 43% [95% CI: 67%-85%] respectively. Figure 3.5 shows the CONSORT flow 
diagram.  
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Recruitment source Potentially eligible 
participants [n (%)] 
Consented and 
randomised [n (%)] 
Periodontal new patient clinic 29 (24%) 24 (30%) 
Other new patient clinics 9 (8%) 9 (11%) 
Dental Emergency Clinic (DEC) 43 (36%) 29 (36%) 
Participant Identification Centres (PICs) 35 (29%) 15 (19%) 
Other e.g. Undergraduate student clinic 3 (3%) 3 (4%) 
Total 119 (100%) 80 (100%) 
 
Table 3.13 Recruitment source of study participants. 
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Figure 3.5 CONSORT flow diagram.  
PC= Periodontal new patient clinic, DEC= Dental emergency clinic, PIC= Participant 
Identifying Centre, FTA= Failed to attend. 
 
Attended visit (n=35) 
Reasons for non-attendance: 
- Personal reasons (n=1) 
- FTA (n=4) 
Attended visit (n= 32) 
Reasons for non-attendance: 
- Work commitments (n=1) 
- FTA (n=7) 
 
 
4-week follow-up (visit 4) 
Assessed for eligibility (n=119) 
Allocated to control group (n=40) 
 Received allocated intervention (n=40) 
 
Allocated to intervention group (n=40) 
 Received allocated intervention (n=40) 
Allocation 
Randomized 
(n=80) 
Enrolment 
Eligible/potentially eligible, but did not 
take part in the study (n= 34)  
Reason:  
- Childcare commitments (PC): 
n=1 
- FTA (PC): n=4 
- Unable to contact (DEC): n=7 
- FTA (DEC): n=1 
- Not interested (DEC): n=4 
- Can’t commit (DEC): n=1 
- Work commitments (DEC): n=1 
- Can’t commit- family issues 
(PIC): n=1 
- Can’t commit (PIC): n=1 
- FTA (PIC): n=5 
- Unable to contact (PIC): n=3 
- Work commitments (PIC): n=4 
- Too far to travel (PIC): n=1 
 
Ineligible (n=5) 
 
Reasons:  
- Started vaping (PIC): n=2 
- Stopped smoking (PIC): n=3 
 
Remaining in the study (n=31) 
Reasons for non-attendance: 
- Personal reasons (n=1) 
- Participant withdrew (n=1) 
- FTA (n=7) 
 
Remaining in the study (n= 33) 
Reasons for non-attendance: 
- Work commitments (n=1) 
- Work and family commitments (n=1) 
- FTA (n=5) 
 
 
3-month follow-up (visit 5) 
Remaining in the study (n=29) 
Reasons for non-attendance: 
- Personal reasons (n=1) 
- Participant withdrew (n=1) 
- FTA (n=9) 
 
Remaining in the study (n=29) 
Reasons for non-attendance: 
- Work commitments (n=1) 
- Work and family commitments (n=1) 
- FTA (n=9) 
 
6-month follow-up (visit 6) 
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3.5.3 Eligibility rates 
One of the trial objectives was to estimate eligibility rates among the patient population. 
Due to the wide range of recruitment sources, it was not possible to collect the relevant 
data (i.e. the magnitude of the denominator) to estimate the eligibility rate from the whole 
patient population. However, it was possible to estimate the eligibility rate from the 
periodontal new patient clinic. Twenty-nine eligible participants were identified from 391 
patients giving a 7.4% eligibility rate [95% CI: 5.2%-10.5%]. Reasons for ineligibility 
from the periodontal new patient clinic are provided in Table 3.14. 
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Eligibility outcome No. of patients  
  
Eligible 29 (7.4%) 
Ineligible 362 (92.6%) 
  
Reason for ineligibility:  
Non-smoker 334 (85.4%) 
Smoker but smokes <10 factory-made cigarettes/day 8 (2.0%) 
Using an e-cigarette (3 or more days use in the last 30) 8 (2.0%) 
<16 natural teeth# 4 (1.0%) 
Declined participation in research study* 4 (1.0%) 
Periodontitis does not meet criteria  2 (0.5%) 
Significant medical history 1 (0.3%) 
Currently undergoing extensive dental, orthodontic, implant or peri-
implant treatment 
1 (0.3%) 
Pregnant/nursing 0 
Periodontal treatment (other than scale and polish) in last 6 months 0 
 
Table 3.14 Eligibility outcomes from the periodontal new patient clinic. 
# This was 20 teeth for the first part of the study until the protocol change after seven months. 
*Declined to take part in research study at the initial contact by the usual care team.  
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3.5.4 Participant follow-up   
Participants were scheduled to return for their study assessments at the following time points:  
 Visit 4: 4 weeks post-randomisation (minus 3 days or plus 14 days) 
 Visit 5: 3 months post-randomisation (minus 15 days or plus 28 days)  
 Visit 6: 6 months post randomisation (minus 15 days or plus 28 days)  
The study window periods for visits 4 and 6 were based on the Russell Standards for smoking 
cessation studies (West et al., 2005b). Four participants withdrew from the study and 18 
participants were lost to follow up. The most frequent time point for withdrawal/lost to 
follow-up was after visit 3; Table 3.15 provides a detailed breakdown. Fifty eight (73%) 
participants attended visit 4 within the designated study window, two (3%) attended early, 
seven (9%) attended late and 13 (16%) did not attend. Fifty nine (74%) participants attended 
visit 5 within the designated study window, five (6%) attended early, three (4%) attended late 
and 16 (20%) did not attend. Fifty one (64%) participants attended visit 6 within the 
designated study window, two (3%) attended early, five (6%) attended late and 22 (28%) did 
not attend. A detailed breakdown of participant follow-up, by randomisation group, is 
provided in Table 3.16 and Figure 3.6. There were no differences in the numbers of 
participants attending each visit by randomisation group and only minor differences in the 
proportion attending within the designated visit window. At the final data collection point (6 
months), 11 participants in each randomisation group did not attend, giving 58 participants for 
the final analysis. The baseline readings of key parameters are presented in Table 3.20. Those 
participants lost to follow-up appeared to have higher eCO and FTND readings and more 
severe periodontal diseases.  
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Participant 
No. 
Study Arm Study visits 
completed?  
Reason 
1004 Intervention 1,2 (3 not required) Work commitments 
1014 Control 1,2,3,4,5 FTA/unreachable 
1019 Control 1,2,3,4 FTA/unreachable 
1020 Intervention 1,2,3,4 Work and family commitments 
1021 Control 1,2,3 Personal reasons 
1022 Control 1,2,3,4 FTA/unreachable 
1030 Intervention 1,2,3 FTA/unreachable 
1031 Control 1 FTA/unreachable 
1032 Intervention 1,2,3,4,5 FTA/unreachable 
1033 Intervention 1 FTA/unreachable 
1037 Control 1,2,3,4 Subject decision 
1038 Control 1 FTA/unreachable 
1039 Intervention 1 FTA/unreachable 
1046 Control 1,2,3 FTA/unreachable 
1056 Intervention 1,2,3 FTA/unreachable 
1057 Intervention 1,2,3 FTA/unreachable 
1058 Intervention 1,2,5 FTA/unreachable 
1060 Control 1,2,3,4 FTA/unreachable 
1064 Control 1,2,3 FTA/unreachable 
1068 Intervention 1,2,3,4,5 FTA/unreachable 
1073 Control 1,2,3,4,5 FTA/unreachable 
1079 Intervention 1,2,3,4,5 FTA/unreachable 
1048 Intervention 1,2,5,6 FTA/unreachable for visit 3&4 
but attended visit 5 & 6.   
 
Table 3.15 Details of withdrawals and loss to follow-up. 
FTA= Failed to attend 
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Control 
n=40 
Intervention 
n=40 
Total 
n=80 
Visit 1 (Baseline) 40 
(100%) 
40 (100%) 80 (100%) 
Visit 4  
(4 weeks [minus 
3 days or plus 
14 days]) 
Complied with study window 29 (73%) 29 (73%) 58 (73%) 
Outwith study window  
6 (15%) 3 (8%) 9 (11%) 
 Did not attend 5 (13%) 8 (20%)    13 (16%) 
Visit 5  
(3 months 
[minus 15 days 
or plus 28 days]) 
Complied with study window 28 (70%) 31 (78%) 59 (74%) 
Outwith study window  
3 (8%) 2 (5%) 5 (6%) 
 Did not attend 9 (23%) 7 (18%) 16 (20%) 
Visit 6  
(6 months 
[minus 15 days 
or plus 28 days]) 
Complied with study window 27 (68%) 24 (60%) 51 (64%) 
Outwith study window  
2 (5%) 5 (13%) 7 (9%) 
 Did not attend 11 (28%) 11 (28%) 22 28%) 
 
Table 3.16 Participant follow-up by randomisation group. 
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Figure 3.6 Compliance with study windows at visit 4, 5, and 6.  
Green bars show those who attended within visit window.  
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3.5.5 Baseline participant characteristics 
The study sample comprised 38 (47.5%) males and 42 (52.5%) females. Ethnicity was 
primarily white (n=75, 94%) (British, Irish or other white) with five (6%) Asian or Asian 
British, reflective of the North East’s population (Office of National Statistics, 2018a). The 
majority of the participants were in employment (n=60, 75%) mainly working in routine or 
manual (n=20, 25%) or in intermediate (n=22, 27.5%) occupations. There was a good balance 
with respect to all demographic characteristics which are presented by randomisation group in 
Table 3.17.  
The age of the participants ranged from 19 to 71 years at the time of randomisation. The mean 
age of the participants was 44 years. Fifty eight (73%) reported smoking factory cigarettes, 21 
(13%) reported smoking hand-rolled cigarettes and one (1%) reported smoking both. The 
mean number of cigarettes smoked per day was 17, 16 and 21, respectively for all, factory and 
hard-rolled cigarettes. The majority of participants reported started smoking in their teenage 
years, with a mean age of 16 years. The mean baseline eCO reading was 21 ppm with all but 
one participants scoring a reading >10 ppm, indicating they were current tobacco smokers 
(one participant had refrained from smoking prior to the baseline visit and hence provided a 
eCO reading of 1 ppm). The participants had a moderate nicotine dependence with a mean 
FTND score at baseline of 5.0. There was a good balance with respect to all age and smoking 
behaviour demographics which are presented by randomisation group in Table 3.18. 
The number of teeth (excluding third molars) that participants had at baseline ranged from 16 
to 28, with a mean of 24 and a median of 25. The participants demonstrated a severe level of 
periodontal disease, in keeping with the study inclusion criteria. The mean PPD was 4.0 mm 
with the mean percentage of sites with PPDs ≥5 mm being 40%. The mean percentage BOP 
was 20%. A low-moderate amount of xerostomia was observed with a mean CODS of 4.0, 
indicating some reduced mucosal wetness. The descriptive statistics of the baseline oral health 
outcome measures are presented in Table 3.19. Many of the measures demonstrated good 
balance across randomisation group (No. teeth, MGI, PPD, CAL, PESA, CODS, OHQoL-
UK) but overall there was a tendency for the severity of the periodontal disease to be worse in 
the control group, specifically: PPD, percentage sites with PPD ≥5 mm, percentage sites with 
PPD ≥6 mm, PI, BOP, PISA.  
For those participants who were lost to follow-up, key parameters are presented in Table 3.20.  
Those participants lost to follow-up appeared to have higher eCO and FTND readings and 
more severe periodontal diseases.
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Categorical Baseline Characteristic 
[n (%)] 
Control group 
n=40 
Intervention group 
n=40 
Total 
n=80 
Sex    
Female 20 (50%) 22 (55%) 42 (52.5%) 
Male 20 (50%) 18 (45%) 38 (47.5%) 
Ethnicity     
White (British, Irish, other White) 
Mixed (White & Black Caribbean, White & Black African,      
White  & Asian, other Mixed)  
Asian or Asian British (Indian, Pakistani, Bangladeshi, other Asian)  
Black or Black British (Caribbean, African, other Black)  
Chinese or other ethnic group  
Not Stated  
36 (90%) 
0 
 
4 (10%) 
0 
0 
0 
39 (97.5%) 
0 
 
1 (2.5%) 
0 
0 
0 
75 (93.8%) 
0 
 
5 (6.3%) 
0 
0 
0 
Occupation    
Working in a routine or manual occupation 
Working in an intermediate occupation   
Working in a managerial or professional occupation   
Unemployed/not working for a year or more  
Full time student  
Retired 
9 (22.5%) 
9 (22.5%) 
9 (22.5%) 
6 (15%) 
0 
1 (2.5%) 
11 (27.5%) 
13 (32.5%) 
9 (22.5%) 
2 (5%) 
1 (2.5%) 
4 (10%) 
20 (25%) 
22 (27.5%) 
18 (22.5%) 
8 (10%) 
1 (1.3%) 
5 (6.3%) 
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Categorical Baseline Characteristic 
[n (%)] 
Control group 
n=40 
Intervention group 
n=40 
Total 
n=80 
Sick/Disabled/Unable to return to work  
Home carer (unpaid) 
None of these  
4 (10%) 
2 (5%) 
0 
0 
0 
0 
4 (5.0%) 
2 (2.5%) 
0 
 
Table 3.17 Baseline categorical demographic characteristics. 
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Continuous Baseline Characteristic 
Min  
Median (LQ-UQ) 
Mean (SD) 
Max 
Control group 
n=40 
Intervention group 
n=40 
Total 
n=80 
Age [years]  
 
25 
44 (38-52) 
45 (9.5) 
61 
19 
43 (35-52) 
45 (11.8) 
71 
19 
43 (37-52) 
44.3 (10.7) 
71 
 
Number of cigarettes/day [any] 
 
10 
15 (11-20) 
17 (7.0) 
30 
10 
15 (15-20) 
17 (6.4) 
40 
10 
15 (13-20) 
17.4 (6.6) 
40 
 
Number of factory cigarettes/day  
 
n=33 5 
15 (10-20) 
16.6 (7.2) 
30 
n=26 10 
15 (10-20) 
14.8 (4.4) 
25 
5 
15 (10-20) 
15.8 (6.1) 
30 
 
Number of hand-rolled cigarettes/day  
 
n=8 12 
15 (15-28) 
19 (7.1) 
30 
n=14 15 
20 (19-26) 
22 (7.0) 
40 
12 
20 (15-26) 
21 (7.0) 
40 
 
Age started smoking 
 
 
10 
16 (15-18) 
16 (2.8) 
24 
10 
15 (14-16) 
15 (3.2) 
29 
10 
15 (14-17) 
15.7 (3.0) 
29 
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Continuous Baseline Characteristic 
Min  
Median (LQ-UQ) 
Mean (SD) 
Max 
Control group 
n=40 
Intervention group 
n=40 
Total 
n=80 
 
eCO [ppm] 
 
1 
18 (10-26) 
18 (10.0) 
49 
6 
22 (12-32) 
23 (12.2) 
55 
1 
19.5 (12-28) 
20.6 (11.3) 
55 
 
FTND 
 
1 
5 (3-7) 
5 (2.4) 
9 
1 
5 (4-6) 
5 (1.8) 
9 
1 
5 (3-7) 
5 (2.1) 
9 
 
MPSS 
   
14 
21 (18-27) 
23 (7.0) 
44 
 
13 
22 (19-26) 
23 (5.9) 
40 
13 
21 (18-27) 
23 (6.4) 
44 
SC (ng/ml) 0 
322 (203-382) 
303 (128.3) 
541 
 
133 
310 (265-433) 
343 (138.1) 
754 
0 
314 (249-409) 
323 (134.0) 
754 
SA (ng/ml) 0 
0.7 (0.2-1.7) 
1.1 (1.4) 
0.1 
0.9 (0.5-1.3) 
1.2 (1.2) 
0 
0.7 (0.4-1.4) 
1.2 (1.3) 
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Continuous Baseline Characteristic 
Min  
Median (LQ-UQ) 
Mean (SD) 
Max 
Control group 
n=40 
Intervention group 
n=40 
Total 
n=80 
7.3 
 
5.4 7.3 
 
 
Table 3.18 Descriptive statistics of age and smoking demographics at baseline by randomisation group. 
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Clinical Examination 
Min  
Median (LQ-UQ) 
Mean (SD) 
Max 
Control group 
n=40 
Intervention group 
n=40 
Total 
n=80 
Number of teeth (excluding 3rd molars)  16 
25 (21-27) 
24 (3.6) 
28 
16 
25 (20-27) 
24 (4.0) 
28 
16 
25 (21-27) 
24 (3.8) 
28 
 
Mean PI 0.1 
1.1 (0.5-1.6) 
1.1(0.7) 
2.4 
0.0 
0.6 (0.3-1.3) 
0.8 (0.6) 
2.4 
0.0 
0.9 (0.4-1.5) 
1.0 (0.7) 
2.4 
 
% BOP score  
 
1 
19 (7-37) 
24 (18.3) 
68 
0 
13 (5-25) 
16 (13.4) 
54 
0 
16 (6-31) 
20 (16.4) 
68 
 
 Mean MGI  
 
1 
2.6 (2.3-2.8) 
2.5 (0.5) 
3.4 
1.6 
2.4 (2.1-2.8) 
2.5 (0.4) 
3.3 
1.0 
2.5 (2.2-2.8) 
2.5 (0.5) 
3.4 
 
Mean PPD [mm]  
 
2.6 
4.1 (3.7-4.5) 
4.1 (0.8) 
6.4 
2.5 
3.9 (3.4-4.3) 
3.9 (0.7) 
6.0 
2.5 
3.9 (3.5-4.4) 
4.0 (0.7) 
6.4 
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Clinical Examination 
Min  
Median (LQ-UQ) 
Mean (SD) 
Max 
Control group 
n=40 
Intervention group 
n=40 
Total 
n=80 
 
Mean CAL [mm]  
 
  
2.7 
4.9 (4.3-6.1) 
5.2 (1.4) 
8.5 
 
3.0 
5.0 (4.1- 6.0) 
5.1 (1.3) 
7.7 
2.7 
5.0 (4.2-6.0) 
5.1 (1.3) 
8.5 
PESA [mm2]  
 
1241 
1971 (1582-2837) 
2134 (667) 
3648 
929 
1944 (1512-2383) 
2014 (644) 
4008 
 
929 
1959 (1568-2484) 
2074 (654) 
4009 
PISA [mm2]  
 
10 
378 (140-1159) 
635 (630) 
2141 
0 
266 (104-589) 
387 (346) 
1333 
 
0 
351 (128-731) 
511 (520) 
2141 
No. of sites with PPD ≥5 mm  11 
62 (38-81) 
61 (30.9) 
136 
11 
49 (34-79) 
54 (27.5) 
123 
 
11 
57 (37-80) 
57 (29) 
136 
% of sites with PPD ≥5 mm  7 
44 (29-55) 
42 (19.6) 
7 
39 (25-53) 
38 (18.1) 
7 
40 (27-53) 
40 (18.8) 
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Clinical Examination 
Min  
Median (LQ-UQ) 
Mean (SD) 
Max 
Control group 
n=40 
Intervention group 
n=40 
Total 
n=80 
91 74 
 
91 
No. of sites with PPD ≤4 mm  
 
20 
79 (60-100) 
83 (32.1) 
157 
28 
86 (65-107) 
87 (30.3) 
151 
 
20 
81 (62-105) 
85 (31) 
157 
% of sites with PPD ≤4 mm  
 
13 
56 (45-71) 
58 (19.4) 
94 
20 
62 (47-75) 
61 (19.1) 
93 
 
13 
60 (47-74) 
59 (19) 
94 
CODS 
 
0 
4 (3-5) 
4 (1.3) 
6 
2 
4 (3-5) 
4 (1.0) 
7 
 
0 
4 (3-5) 
4 (1.2) 
7 
OHQoL-UK 32 
42 (40-45) 
43 (6.6) 
66 
25 
44 (40-47) 
44 (8.7) 
65 
25 
43 (40-47) 
43 (7.7) 
66 
 
Table 3.19 Descriptive statistics of baseline oral health outcome measures by randomisation group.  
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Baseline variable All participants Participant lost to 
follow-up 
Remaining participants 
Control 
group 
n=40 
Intervention 
group 
n=40 
Control 
group 
n=11 
Intervention 
group 
n=11 
Control 
group 
n=29 
Intervention 
group 
n=29 
Mean age (SD) 45 (9.5) 45 (11.8) 48 (6.4) 37 (12.8) 43 (10.3) 47 (10.5) 
Mean eCO (SD) 18 (9.9) 23 (12.2) 21 (8.1) 26 (10.7) 17 (10.4) 22 (12.8) 
Mean self-reported cigarettes/day (SD) 17 (6.9) 17 (6.4) 18 (4.8) 16 (4.4) 17 (7.6) 21 (9.0) 
Mean FTND (SD) 5 (2.4) 5 (1.8) 6 (2.1) 6 (2.1) 5 (2.4) 5 (1.6) 
Mean PPD (SD) 4.1 (0.7) 3.9 (0.7) 4.4 (0.4) 4.1 (0.6) 4.0 (0.8) 3.8 (0.7) 
Mean No. teeth (SD) 24 (3.6) 24 (4.0) 21 (3.6) 24 (3.9) 25 (3.0) 24 (4.1) 
Mean % sites with PPD ≥5 mm (SD) 42 (19.6) 38 (18.1) 50 (13.3) 47 (20.5) 39 (20.8) 35 (16.2) 
 
Table 3.20 Baseline characteristics by lost to follow-up.
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3.5.6 Safety data            
There were no SAEs in this study but 56 AEs were observed across 35 patients. The most 
frequently reported AEs were: toothache (15 events in 13 participants), dentine 
hypersensitivity (6 events), tooth/teeth loss (5 events), dental/periodontal abscess (5 events), 
and fractured/carious filling or tooth (5 events). Seven participants had unplanned tooth 
extractions during the study period, losing a total of 15 teeth. Two participants reported mouth 
ulceration and three separate participants reported soreness of the intra-oral soft tissues. All 
five of these were in the intervention group; these symptoms are well recognised side effects 
of smoking cessation and NRT use. A summary of the AEs reported in this study is presented 
in Table 3.21.     
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Adverse events Control group Intervention group 
No. AEs No. of 
participants 
affected 
No. AEs No. of 
participants 
affects 
Toothache 4 4 11 9 
Dentine hypersensitivity  3 3 3 3 
Tooth/teeth loss  5  
(6 teeth) 
4 5  
(9 teeth) 
3 
Dental/periodontal abscess 2 2 3 3 
Mouth ulceration 0 0 2 2 
Soreness of intra-oral soft tissues 0 0 3 3 
Fractured/carious filling or tooth 3 3 2 2 
Other 3 2 6 5 
 
Table 3.21 Summary of adverse events. 
AEs= Adverse Events 
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3.5.7 Participant compliance 
Participant compliance was determined by attendance at the review visits (visit 4, 5 and 6). 
Fifty seven (71%, 95% CI: 61%-80%) participants attended all of the review visits and were 
retained for 6-month follow-up data collection, whilst 62 (78%, 95% CI: 67%-85%) attended 
at least two review visits. Forty one (51%, 95% CI: 40%-62%) participants attended all of the 
review visits within the specified visit windows. Sixty-seven (84%, 95% CI: 74%-90%) 
participants were retained at the 4-week review, 64 (80%, 95% CI: 70%-87%) at the 3-month 
review and 58 (73%, 95% CI: 62%-81%) at the 6-month review. A summary of participant 
compliance with attending review visits is presented in Table 3.22. Little difference was seen 
between the randomisation groups but there were differences depending on recruitment source 
(Table 3.23).   
Participants were required to complete a weekly smoking status questionnaire for the duration 
of the study. The majority of the participants chose to receive the weekly questionnaire by 
SMS text message or email (see Table 3.25). Overall, the mean number of weekly responses 
to the survey was 14 (95% CI: 11-17), ranging from 0 to 32 entries. For the 58 participants 
who completed the study, mean study duration was 29 weeks, meaning the number of 
questionnaire entries (per participant) should have been 29. The number of questionnaire 
entries, from the 58 participants who completed the study, varied from 0 to 32 with a mean of 
18 (95% CI: 15-21). This was sometimes more than the 26 weeks of the study because 
participants started completing the questionnaire at visit 1 but week zero was designated to be 
at visit 2 (quit date). There was a variable amount of time between visit 1 and 2; ranging from 
0 to 9 weeks, with a mean (SD) of 2.6 (2.0) weeks. Participants in the intervention group 
returned slightly more questionnaires than the control group. Overall, 46% of participants 
completed the questionnaire at least half of the time (>14 entries) and 30% completed it at 
least 80% of the time (>23 entries), increasing to 64% and 41% respectively, for those 59 
participants who completed the study. The descriptive statistics for the completion of the 
weekly questionnaire are presented in Table 3.24 and Figure 3.7.   
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Compliance level Randomisation group [n (%)] 
Control group 
n=40 
Intervention 
group 
n=40 
Total 
n=80 
All reviews 29 (73%) 28 (70%) 57 (71%) 
2/3 reviews 2 (5%) 3 (8%) 5 (6%) 
1/3 reviews 4 (10%) 3 (8%) 7 (9%) 
0/3 reviews 5 (13%) 6 (15%) 11 (14%) 
 
Table 3.22 Summary of participant compliance with attending follow-up visits. 
 
 
 
Recruitment source No. of 
participants 
attending the 6-
month visit  
Percentage of 
participants 
attending the 6-
month visit from 
those recruited 
from source 
Periodontal new patient clinic 20 83% 
General restorative dentistry new patient clinic 8 89% 
Dental emergency clinic  19 66% 
Participant identification centre  8 53% 
Other 3  100% 
All 58  73% 
 
Table 3.23 Participants attending 6-month visit by recruitment source. 
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Min  
Median (LQ-UQ) 
Mean (SD) 
Max 
95% CI 
Control group 
 
Intervention 
group 
 
Total 
 
All participants 
(n=80) 
0 
12 (3-24) 
13 (10.8) 
31 
10-16 
 
0 
12 (2-27) 
15 (12.6) 
32 
11-19 
0 
12 (3-26) 
14 (11.7) 
32 
11-17 
Participants who 
completed the study 
(n=58) 
0 
18 (7-26) 
16 (10.6) 
31 
12-20 
0 
26 (7-29) 
19 (12.0) 
32 
15-24 
0 
21 (7-27) 
18 (11.3) 
32 
15-21 
 
Table 3.24 Descriptive statistics for the completion of the weekly smoking questionnaire 
(number of responses). 
 
 
 
Contact method No. of participants [n (%)] 
SMS text message with link  66 (83) 
Email with link 11 (14) 
Paper version 3 (4) 
 
Table 3.25 Preferred method of weekly smoking questionnaire. 
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Figure 3.7 Completion of weekly smoking questionnaire by study week.  
Quit date and follow-up visits illustrated on figure. Note that week zero is the quit date (visit 2). Participants were provided with the weekly 
questionnaire at visit 1 and there was a variable duration between visits 1 and 2, although it was recommended this was not more than 4 weeks.  
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3.5.8 Intervention compliance  
The forty participants in the randomisation group were offered an e-cigarette starter kit. One 
participant declined the starter kit on the grounds that he did not intend to change his smoking 
behaviour (intention to quit was not an inclusion criteria for this study). Acceptability of the 
e-cigarette intervention was high with 90% of participants using the device at the quit date 
(visit 2). The proportion of participants still using the device remained high (>70%) at the 4-
week and 3-month reviews. By the end of the study approximately half of participants were 
still using the e-cigarette device. Table 3.26 presents the detailed breakdown of the 
intervention compliance at key visits.  
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 Participants using e-cigarette  
[n (%, 95% CI)] 
Participants not using e-cigarette  
[n (%, 95% CI)] 
Participants who did not attend the visit  
[n (%, 95% CI)] 
Visit 2 (Quit date) 36 (90%, 95% CI: 77%-96%) 2 (5%, 95% CI: 1%-17%) 2 (5%, 95% CI: 1%-17%) 
Visit 4 (4 weeks) 31 (78%, 95% CI: 63%-88%) 1 (3%, 95% CI: 0%-13%) 8 (20%, 95% CI: 11%-35%) 
Visit 5 (3 months) 28 (70%, 95% CI: 55%-82%) 5 (13%, 95% CI: 5%-25%) 7 (18%, 95% CI: 9%-32%) 
Visit 6 (6 months) 21 (53%, 95% CI: 38%-67%) 8 (20%, 95% CI: 11%-35%) 11 (28%, 95% CI: 16%-43%) 
 
Table 3.26 Compliance with e-cigarette usage (intervention group). 
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Participants were recommended to use the same brand of e-liquid as supplied in the e-
cigarette starter kit. Four (10%, 95% CI: 4%-23%), six (15%, 95% CI: 7%-29%), nine (23%, 
95% CI: 12%-38%) and five (13%, 95% CI: 5%-26%) participants were using another brand 
of e-liquid at quit date, 4 weeks, 3 months and 6 months, respectively. These other brands 
were: Cirro, Edge, Totally wicked, Vape 88, Vaporized, TECC and unknown non-
recommended brands. Five of the six participants (83%) who achieved RS6-eCO and three of 
the four participants (75%) who achieved RS6-S were participants who chose to use non-
recommended e-liquid brands. These 11 participants who used a non-recommended e-liquid 
brands on at least one time point were not obviously different with regards to age, gender and 
smoking behaviour. Table 3.27 provides details of those participants who chose to use non-
recommended e-liquids. No information is available on the reasons why some participants 
chose to switch to a non-recommended brand.    
Six participants reported using a different e-cigarette device (i.e. not the one supplied in the 
starter kit) during the study. Figure 3.8 presents the details of the devices and the time points 
at which they were used. Two of these participants were RS6-eCO quitters and none were 
RS6-S quitters. 
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Participant E-liquid brand   Smoking quit status  
Quit date 4 weeks 3 months 6 months  RS6-eCO RS6-S 
1001 Recommended Unknown Unknown #  Smoker Smoker 
1003 Recommended TECC Totally wicked Totally wicked  Smoker Smoker 
1013 Recommended Recommended Recommended Unknown  Quitter Quitter 
1018 Recommended Recommended Cirro Cirro  Quitter Quitter 
1030 VIP * * *  Smoker Smoker 
1035 Recommended Recommended Unknown Vaporized  Smoker Smoker 
1051 Recommended Vaporized Vaporized Recommended  Quitter Smoker 
1054 Unknown Vape 888 Vape 888 Vape 888  Quitter Smoker 
1061 Nicocig Nicocig Nicocig #  Smoker Smoker 
1068 Recommended Recommended Unknown *  Smoker Smoker 
1075 Edge Edge Edge Recommended  Quitter Quitter 
Total using non-
recommended 
brands (n) 
4 6 9 5    
 
Table 3.27 Use of non-recommended e-liquids (intervention group). 
Data only presented for those participants in the intervention group who reported use of non-recommended e-liquids on at least one time point.  *Did 
not attend visit. #Stopped using a e-cigarette.  
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Participant E-liquid brand   Smoking quit status  
Quit date 4 weeks  3 months 6 months  RS6-eCO RS6-S 
1003 Recommended TECC arc mini TECC arc mini TECC arc mini  Smoker Smoker 
1035 Recommended Recommended Unknown 3rd generation Unknown 3rd generation  Smoker Smoker 
1051 Recommended Recommended PRISM T18E PRISM T18E  Quitter Smoker 
1054 Recommended Vype- other** Vype-other** Vype-other**  Quitter Smoker 
1061 Nicocig Nicocig Nicocig #  Smoker Smoker 
1068 SMOCK SMOCK SMOCK *  Smoker Smoker 
Total using different 
device (n) 
2 4 6 4    
 
Figure 3.8 Use of different e-cigarette device (intervention group). 
*Did not attend visit. #Stopped using a e-cigarette. **Participant lost their e-cigarette and tried to purchase an exact replacement of that provided in the 
study. The model used was no longer available and the participant purchase a newer model.   
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3.5.9 E-liquid flavour and strength selection 
Those participants in the intervention group who accepted the e-cigarette starter kit had a 
choice of two e-liquids from four flavour options (tobacco, mint, cherry and flavourless) and 
four nicotine strengths (0, 6, 12, 18 mg/ml). There were ten possible e-liquid flavour 
selections as demonstrated in Table 3.28. The most frequent selection was tobacco and mint 
followed by mint only. Over half of participants (52%) did not include a tobacco flavour in 
their selection, while 62% included mint flavour. There were ten possible nicotine strength 
selections as demonstrated in Table 3.29. The most frequent nicotine strength selection was 
12 mg/ml and 18 mg/ml, selected by over half of participants, while none opted for the lowest 
concentration options. The modal nicotine concentration was 18 mg/ml.  
E-liquid selections at follow-up are presented in Table 3.30 and Table 3.31. 
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Flavour choice Percentage of participants in 
intervention group (n=39) [% (n)] 
Tobacco only 13% (5) 
Cherry only 10% (4) 
Mint only 21% (8) 
Mint & Cherry 15% (6) 
Tobacco & Cherry 5% (2) 
Tobacco & Mint 23% (9) 
Flavourless only 0 
Flavourless & Tobacco 8% (3) 
Flavourless & Mint 3% (1) 
Flavourless & Cherry 3% (1) 
 
Table 3.28 E-liquid flavour participant selection. 
 
 
 
Nicotine choices (mg/ml) 
 
Percentage of participants in 
intervention group (n=39) [% (n)] 
Choice 1 Choice 2  
0 0 0 
0 6 0 
0 12 0 
0 18 0 
6 6 0 
6 12 5% (2) 
6 18 0 
12 12 18% (7) 
12 18 54% (21) 
18 18 23% (9) 
 
Table 3.29 E-liquid strength (nicotine) participant selection. 
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Flavour choice Percentage of participants in intervention group  [% (n)] 
Quit date 
n=37 
4 weeks 
n=30 
3 months 
n=27 
6 months 
n=21 
Tobacco* 41% (15) 30% (9) 33% (9) 33% (7) 
Mint# 38% (14) 37% (11) 30% (8) 29% (6) 
Cherry 16% (6) 23% (7) 15% (4) 14% (3) 
Unflavoured 3% (1) 3% (1) 4% (1) 5% (1) 
Strawberry & Lime 3% (1) 3% (1) 4% (1)  
Blackcurrant  3% (1)   
Apple & Cherry   4% (1)  
Blackberry   4% (1) 5% (1) 
Grape and Blackcurrant   4% (1)  
Shluuurrp   4% (1)  
Infused Vanilla    5% (1) 
Strawberry Cheesecake    5% (1) 
Strawberry Dream    5% (1) 
 
Table 3.30 E-liquid flavour usage at follow-up visits. 
*All tobacco flavours combined in this category. Includes ‘tobacco’, ‘blended tobacco’ and 
‘rolling tobacco’.  
# All mint flavours combined in this category. Includes: ‘crisp mint’, ‘mint’ and ‘menthol’.  
 
 
 Percentage of participants in intervention group   
[% (n)] 
 Quit date 
n=37 
4 weeks 
n=30 
3 months 
n=27 
6 months 
n=21 
Nicotine strength (mg/ml)  
18 51% (19) 40% (12) 33% (9) 29% (6) 
16 5% (2)    
14  3% (1)   
12 38% (14) 43% (13) 37% (10) 38% (8) 
11   7% (2) 10% (2) 
10  3% (1) 4% (1)  
6 3% (1) 6% (2) 4% (1) 5% (1) 
3  3% (1) 8% (2) 10% (2) 
0   8% (2) 10% (2) 
Can’t recall 3% (1)    
     
Mean (SD) 15 (3.3) 14 (4.2) 12 (5.6) 11 (5.9) 
 
Table 3.31 E-liquid strength usage at follow-up visits.  
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3.5.10 E-cigarette use in the control group 
Participants in the control group were asked to use one of the traditional methods of smoking 
cessation in their quit attempt e.g. NRT or varenicline. They were asked to refrain from using 
an e-cigarette, specifically for the first four weeks but ideally over the full duration of the 
study. The participants in the control group were asked to sign a commitment form. Two 
participants declined to sign the form and one of these went on to use an e-cigarette during the 
study. In total, eight participants in the control group (20%, 95% CI: 11%-35%) reported 
using an e-cigarette at some point in the study, with one reporting usage at all post-
randomisation visits. At the quit date four participants were using an e-cigarette, peaking at 
five participants at the 4-week and 3-month visits, and decreasing to three at the 6-month 
visit. Complete details are shown in Table 3.32.    
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Participant Using an e-cigarette?   Smoking quit status 
Quit date 4 weeks 3 months 6 months  RS6-eCO RS6-S 
1006 Yes Yes No No  Quitter Quitter 
1008 Yes Yes No No  Smoker Smoker 
1041 No No Yes No  Smoker Smoker 
1063 Yes Yes Yes Yes  Quitter Smoker 
1065 No No No Yes  Smoker Smoker 
1067 Yes Yes Yes No  Smoker Smoker 
1071 No No Yes Yes  Smoker Smoker 
1078 No  Yes Yes No  Smoker Smoker 
Total (n) 4 5 5 3    
 
Table 3.32 E-cigarette use in the control group. 
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3.5.11 Methods of smoking cessation (non-e-cigarette) 
A variety of smoking cessation techniques were used by our participants. Forty percent of the 
control group reporting making contact with the NHS stop smoking service, compared to 
none in the intervention group. Four of the eight participants (50%) who used an e-cigarette in 
the control group (see section 3.5.10) also reported making contact with the stop smoking 
service. Table 3.33 provides details of the smoking cessation methods reportedly used by the 
participants by randomisation group.  
 
 
Smoking cessation method Randomisation group [n (%)] 
Control 
group 
n=40 
Intervention 
group 
n=40 
Total 
n=80 
NHS stop smoking services 16 (40%) 0  16 (20%) 
General Medical Practitioner 
(GMP) support 
2 (5%) 0  2 (3%) 
NRT (non-e-cigarette) 8 (20%) 4 (10%) 12 (15%) 
Varenicline (Champix) 5 (13%) 0  5 (6%) 
 
Table 3.33 Methods of smoking cessation used by randomisation group. 
Some participants used multiple methods e.g. NHS stop smoking service and NRT.  
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3.5.12 Oral health outcome measures 
Outcome  
 
Min  
Median (LQ-UQ) 
Mean (SD) 
Max 
95% CI 
 
Unless otherwise 
detailed 
Control Group, n=40 Intervention Group, n=40 
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Number of teeth 
(excluding 3rd 
molars) 
16 
25 (21-27) 
24 (3.6) 
28 
23-25 
17 
26 (23-27) 
25 (2.9) 
28 
24-26 
 
 
17 
26(23-27) 
25 (3.0) 
28 
24-26 
17 
26 (23-27) 
25 (2.9) 
28 
24-26 
17 
26 (23-27) 
25 (3.0) 
28 
24-26 
16 
25 (20-27) 
24 (4.0) 
28 
23-25 
16 
26 (21-27) 
 24 (4.0) 
28 
23-25 
      16 
26 (21-27) 
24 (4.1) 
28 
22-25 
15 
25 (20-27) 
23 (4.4) 
28 
22-25 
14 
25 (21-27) 
23 (4.5) 
28 
22-25 
Mean PPD [mm] 
  
2.6 
4.1 (3.7-4.5) 
4.1 (0.8) 
6.4 
3.8-4.3 
 
2.6 
4.0 (3.6-4.6) 
4.0 (0.8) 
6.4 
3.7-4.3 
2.6 
3.9 (3.3-4.5) 
4.0 (0.8) 
6.4 
3.6-4.3 
2.1 
3.3 (2.7-3.8) 
3.3 (0.7) 
4.8 
3.0-3.6 
2.1 
3.1 (2.7-3.6) 
3.3 (0.7) 
4.9 
3.0-3.6 
2.5 
3.9 (3.4-4.3) 
3.9 (0.7) 
6.0 
3.7-4.1 
2.5 
3.8 (3.4-4.3) 
3.9 (0.7) 
6.0 
3.7-4.2 
2.5 
3.8 (3.3-4.1) 
3.8 (0.7) 
6.0 
3.6-4.1 
2.2 
3.0 (2.8-3.3) 
3.1 (0.4) 
4.5 
2.9-3.3 
2.4 
 3.0 (2.8-3.2) 
3.0 (0.4) 
4.1 
2.9-3.2 
Mean PPD [mm] 
of those sites 
with a baseline 
probing depth of  
≥ 5 mm     
 
5.0 
5.6 (5.3-5.9) 
5.7 (0.5) 
7.3 
5.5-5.8 
5.0 
5.5 (5.3-6.2) 
5.7 (0.6) 
7.3 
5.5-5.9 
5.0 
5.5 (5.2-6.2) 
5.7 (0.6) 
7.3 
5.5-5.9 
2.6 
4.2(3.2-5.0) 
4.1 (1.0) 
5.8 
3.8-4.5 
2.4 
4.0 (3.2-5.0) 
4.0 (1.0) 
5.9 
3.6-4.4 
5.1 
5.5 (5.2-5.9) 
5.6 (0.5) 
7.1 
5.4-5.8 
5.1 
5.6 (5.2-6.0) 
5.7 (0.5) 
7.1 
5.5-5.8 
5.1 
5.5 (5.2-6.0) 
5.6 (0.5) 
7.1 
5.4-5.8 
2.7 
3.9 (3.6-4.3) 
4.0 (0.6) 
5.3 
3.7-4.2 
2.9 
3.8 (3.4-4.3) 
3.9 (0.6) 
5.1 
3.6-4.1 
Mean PPD [mm] 
of those sites 
with a baseline 
probing depth of  
≥ 6 mm   
   
6.0 
6.5 (6.3-7.0) 
6.6 (0.4) 
7.7 
6.4-6.7 
3.0 
4.9 (4.2-5.8) 
4.9 (1.0) 
7.1 
4.5-5.3 
2.8 
4.7 (3.8-5.6) 
4.6 (1.1) 
6.3 
4.2-5.1 
3.0 
4.9 (4.2-6.0) 
4.9 (1.0) 
7.1 
4.5-5.3 
2.8 
4.7 (4.0-6.0) 
4.6 (1.1) 
6.3 
4.2-5.1 
6.0 
6.6 (6.3-7.0) 
6.6 (0.5) 
8.2 
6.5-6.8 
2.0 
4.6 (4.1-5.3) 
4.6 (1.0) 
6.5 
4.2-5.0 
3.0 
4.6 (3.8-5.2) 
4.6 (0.9) 
6.6 
4.2-5.0 
2.0 
4.6 (4.1-5.3) 
4.6 (1.0) 
6.5 
4.2-5.0 
3.0 
4.6(3.8-5.2) 
4.6 (0.9) 
6.6 
4.2-5.0 
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Outcome  
 
Min  
Median (LQ-UQ) 
Mean (SD) 
Max 
95% CI 
 
Unless otherwise 
detailed 
Control Group, n=40 Intervention Group, n=40 
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Mean PPD [mm] 
of those sites 
with a baseline 
probing depth of  
≥ 7 mm     
 
7.0 
7.3 (7.0-7.6) 
7.5 (0.7) 
11.0 
7.2-7.7 
7.0 
7.3 (7.0-7.6) 
7.5 (0.8) 
11 
7.2-7.8 
 
7.0 
7.3 (7.0-7.6) 
7.5 (0.9) 
11.0 
7.1-7.9 
3.5 
5.8 (5.0-6.2) 
5.6 (1.3) 
10.0 
5.1-6.1 
2.0 
5.6 (4.0-6.1) 
5.1 (1.7) 
10.0 
4.4-5.9 
7.0 
7.2 (7.0-7.6) 
7.4 (0.5) 
8.9 
7.3-7.6 
7.0 
7.3 (7.2-7.7) 
7.5 (0.6) 
8.9 
7.3-7.8 
7.0 
7.3 (7.2-7.7) 
7.5 (0.5) 
8.9 
7.3-7.8 
0.0 
4.7 (4.0-5.6) 
4.8 (1.5) 
8.5 
4.1-5.4 
0.0 
4.6 (3.7-5.3) 
4.4 (1.5) 
6.7 
3.7-5.0 
Mean PPD [mm] 
of those sites 
with a baseline 
probing depth of  
≤ 4 mm 
 
2.4 
2.8 (2.7-3.1) 
2.8 (0.3) 
3.5 
2.8-2.9 
2.4 
2.8 (2.6-3.1) 
2.8 (0.3) 
3.5 
2.7-2.9 
 
2.4 
2.8 (2.6-3.1) 
2.8(0.3) 
3.5 
2.7-2.9 
2.0 
2.6 (2.4-3.0) 
2.7 (0.3) 
3.2 
2.5-2.8 
2.0 
2.6 (2.4-3.0) 
2.7 (0.3) 
3.3 
2.5-2.8 
2.2 
2.9 (2.7-3.0) 
2.9 (0.2) 
3.3 
2.8-2.9 
2.2 
2.9 (2.7-3.0) 
2.9 (0.2) 
3.3 
2.8-2.9 
2.2 
2.9 (2.7-3.0) 
2.8 (0.2) 
3.3 
2.7-2.9 
2.1 
2.6 (2.4-2.8) 
2.6 (0.3) 
3.2 
2.5-2.7 
2.2 
2.6 (2.4-2.8) 
2.6 (2.2) 
3.1 
2.5-2.7 
Percentage of 
sites with PPD ≥ 
5 mm  
7 
44 (29-55) 
42 (19.6) 
91 
36-48 
7 
41 (26-56) 
41 (21) 
91 
33-48 
 
7 
40 (21-52) 
39 (20.8) 
91 
31-47 
0 
26 (4-36) 
23 (18.1) 
59 
16-30 
0 
16 (5-28) 
20 (17.2) 
58 
13-26 
7 
38 (25-53) 
38 (18.1) 
74 
33-44 
7 
36 (25-49) 
38 (17.6) 
74 
32-44 
7 
34 (24-42) 
35 (16.2) 
73 
29-41 
2 
14 (11-19) 
17 (11) 
52 
13-21 
3 
13 (7-18) 
14 (9.8) 
46 
10-17 
Percentage of 
sites with PPD 
>6 mm 
0 
7 (1-14) 
10 
(11.3) 
51 
6-14 
 
0 
6 (1-19) 
11 (12.6) 
51 
6-15 
 
0 
5 (1-13) 
10 (12.7) 
51 
5-15 
0 
3 (0-9) 
5 (6.9) 
21 
3-8 
0 
1 (0-8) 
5(7.4) 
28 
2-8 
0 
6 (1-11) 
8 (8.2) 
37 
5-10 
0 
6 (1-11) 
8 (8.4) 
37 
5-11 
0 
5 (0-11) 
7 (8.5) 
37 
4-10 
0 
1 (0-3) 
2 (3.0) 
15 
1-3 
 
0 
1 (0-3) 
2 (2.1) 
8 
1-3 
Percentage of 
sites improving 
by  ≥2 mm 
 
- - - - 2 
25 (13-36) 
25 (14.1) 
53 
19-30 
- - - - 7 
27 (17-32) 
27 (13.4) 
70 
21-32 
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Outcome  
 
Min  
Median (LQ-UQ) 
Mean (SD) 
Max 
95% CI 
 
Unless otherwise 
detailed 
Control Group, n=40 Intervention Group, n=40 
B
a
se
li
n
e 
(a
ll
)   
 
B
a
se
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n
e 
fo
r 
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o
se
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a
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g
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v
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it
    
B
a
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o
se
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in
g
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-m
o
n
th
 
v
is
it
   
3
 m
o
n
th
s 
6
 m
o
n
th
s 
B
a
se
li
n
e 
(a
ll
)    
B
a
se
li
n
e 
fo
r 
th
o
se
 
re
a
ch
in
g
 3
-m
o
n
th
 
v
is
it
    
B
a
se
li
n
e 
fo
r 
th
o
se
 
re
a
ch
in
g
 6
-m
o
n
th
 
v
is
it
   
3
 m
o
n
th
s 
6
 m
o
n
th
s 
Percentage of 
sites improving 
by ≥3 mm 
- - - - 2 
8 (4-17) 
11 (8.8) 
37 
8-14 
- - - - 0 
10 (4-15) 
11 (9.7) 
47 
7-15 
Percentage of 
sites with 
baseline PPD ≥4 
mm improving 
by ≥2 mm 
 
- - - - 20 
48 (37-59) 
50 (17.2) 
87 
43-56 
- - - - 22 
54 (38-62) 
52 (16.3) 
90 
46-58 
Percentage of 
sites with 
baseline PPD ≥5 
mm improving 
by ≥2 mm 
 
- - - - 22 
59 (44-74) 
59 (20.7) 
100 
51-67 
- - - - 11 
57 (44-68) 
57 (18.6) 
96 
50-64 
Percentage of 
sites with 
baseline PPD ≥6 
mm improving 
by ≥2 mm 
 
 
 
 
- - - - 0 
55 (42-75) 
54 (26.0) 
100 
44-64 
- - - - 0 
58 (44-75) 
58 (28.1) 
100 
47-68 
167 
 
Outcome  
 
Min  
Median (LQ-UQ) 
Mean (SD) 
Max 
95% CI 
 
Unless otherwise 
detailed 
Control Group, n=40 Intervention Group, n=40 
B
a
se
li
n
e 
(a
ll
)   
 
B
a
se
li
n
e 
fo
r 
th
o
se
 
re
a
ch
in
g
 3
-m
o
n
th
 
v
is
it
    
B
a
se
li
n
e 
fo
r 
th
o
se
 
re
a
ch
in
g
 6
-m
o
n
th
 
v
is
it
   
3
 m
o
n
th
s 
6
 m
o
n
th
s 
B
a
se
li
n
e 
(a
ll
)    
B
a
se
li
n
e 
fo
r 
th
o
se
 
re
a
ch
in
g
 3
-m
o
n
th
 
v
is
it
    
B
a
se
li
n
e 
fo
r 
th
o
se
 
re
a
ch
in
g
 6
-m
o
n
th
 
v
is
it
   
3
 m
o
n
th
s 
6
 m
o
n
th
s 
Mean MGI  
 
1.0 
2.6 (2.3-2.8) 
2.5(0.5) 
3.4 
2.4-2.7 
 
1.0 
2.6 (2.1-2.9) 
2.5(0.5) 
3.4 
2.3-2.7 
1.0 
2.6 (2.1-2.9) 
2.5 (0.5) 
3.4 
2.3-2.7 
1.1 
2.2 (1.7-2.4) 
2.0 (0.4) 
2.6 
1.9-2.2 
0.7 
2.1 (1.7-2.3) 
1.9 (0.5) 
2.6 
1.7-2.1 
1.6 
2.4 (2.2-2.8) 
2.5 (0.4) 
3.3 
2.3-2.6 
1.6 
2.4 (2.1-2.8) 
2.4 (0.4) 
3.2 
2.3-2.6 
1.6 
2.3 (2.1-2.6) 
 2.3(0.4) 
3.1 
2.2-2.5 
0.8 
1.8 (1.5-2.1) 
1.8 (0.5) 
2.8 
1.7-2.0 
0.7 
1.7 (1.3-2.0) 
1.6 (0.5) 
2.6 
1.4-1.8 
Mean PI  0.1 
1.1 (0.5-1.6) 
1.1 (0.7) 
2.4 
0.9-1.3 
0.1 
1.0 (0.4-1.5) 
1.0 (0.6) 
2.3 
0.8-1.2 
0.1 
1.0 (0.4-1.5) 
1.0 (0.6) 
2.3 
0.7-1.2 
0.0 
3.4 (0.1-0.5) 
0.4 (0.4) 
1.9 
0.3-0.6 
0.0 
3.3 (0.1-0.6) 
0.4 (0.4) 
1.5 
0.3-0.6 
0.0 
0.6 (0.3-1.3) 
0.8 (0.6) 
2.4 
0.6-1.0 
0.0 
0.6 (0.2-1.4) 
0.8 (0.7) 
2.4 
0.6-1.0 
0.0 
0.5 (0.2-1.1) 
0.7 (0.7) 
2.4 
0.5-1.0 
0.0 
0.0 
0.2 (0.9-0.3) 
0.3 (0.4) 
1.5 
0.2-0.4 
 
0.0 
0.1 (0.1-0.4) 
0.4 (0.5) 
1.8 
0.2-0.5 
Mean CAL 
[mm] 
 
2.7 
4.9 (4.3-6.1) 
5.2 (1.4) 
8.5 
4.8-5.6 
2.7 
4.7 (4.2-5.3) 
5.0 (1.4) 
8.5 
4.4-5.5 
 
2.7 
4.7 (4.2-5.2) 
4.8 (1.2) 
8.5 
4.3-5.3 
2.4 
4.2 (3.4-5.1) 
4.6 (1.6) 
8.5 
4.0-5.2 
2.2 
4.0(3.3-5.0) 
4.3 (1.5) 
8.2 
3.8-4.9 
3.0 
5.0 (4.1-6.0) 
5.1 (1.3) 
7.7 
4.7-5.5 
3.3 
5.1 (4.0-6.0) 
5.1 (1.2) 
7.7 
4.7-5.6 
3.3 
5.0 (3.9-6.0) 
5.1 (1.3) 
7.7 
4.6-5.6 
2.8 
4.9 (3.3-5.6) 
4.6 (1.2) 
6.6 
4.1-5.0 
2.8 
4.4 (3.2-5.5) 
4.4 (1.3) 
6.7 
3.9-4.9 
% BOP score 
 
1 
19 (7-37) 
24 (18.3) 
68 
18-30 
 
2 
23 (7-44) 
26 (19.4) 
68 
19-34 
2 
23 (6-42) 
25 (18.5) 
61 
18-32 
1 
8 (3-19) 
13 (13.4) 
53 
8-18 
0 
10 (4-20) 
14 (13.9) 
52 
9-19 
0 
13 (5-25) 
16 (13.4) 
54 
12-21 
0 
14 (6-26) 
17 (12.3) 
42 
12-21 
0 
14 (6 -29) 
17(12.6) 
42 
12-22 
0 
6 (2-11) 
8 (10.2) 
54 
5-12 
0 
7 (2-13) 
10 (12.9) 
63 
5-15 
CODS 0.0 
4.0 (3.0-5.0) 
4.0 (1.3) 
6.0 
3.6-4.4 
 
0.0 
4.0 (3-5) 
3.8 (1.3) 
6.0 
3.3-4.3 
0.0 
4.0 (3.0-5.0) 
3.7(1.3) 
6.0 
3.2-4.2 
1.0 
3.0 (2.0-5.0) 
3.5 (1.4) 
6.0 
3.0-4.0 
1.0 
3.0 (2.0-4.0) 
3.0 (1.4) 
6.0 
2.5-3.6 
2.0 
4.0 (3.0-5.0) 
4.1 (1.0) 
7.0 
3.7-4.4 
2 
4.0 (3-4) 
3.9 (0.9) 
6.0 
3.6-4.2 
2.0 
4.0 (3.0-4.0) 
3.8 (0.9) 
6.0 
3.4-4.2 
1.0 
4.0 (2.0-5.0) 
3.6 (1.7) 
7.0 
3.0-4.2 
1.0 
4.0 (2.0-4.0) 
3.5 (1.5) 
7.0 
2.9-4.1 
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Outcome  
 
Min  
Median (LQ-UQ) 
Mean (SD) 
Max 
95% CI 
 
Unless otherwise 
detailed 
Control Group, n=40 Intervention Group, n=40 
B
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e 
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)   
 
B
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li
n
e 
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g
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g
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3
 m
o
n
th
s 
6
 m
o
n
th
s 
B
a
se
li
n
e 
(a
ll
)    
B
a
se
li
n
e 
fo
r 
th
o
se
 
re
a
ch
in
g
 3
-m
o
n
th
 
v
is
it
    
B
a
se
li
n
e 
fo
r 
th
o
se
 
re
a
ch
in
g
 6
-m
o
n
th
 
v
is
it
   
3
 m
o
n
th
s 
6
 m
o
n
th
s 
PESA [mm2]  
 
1241 
1971 (1582-2837) 
2134 (667) 
3648 
1921-2347 
1277 
2145 (1596-2958) 
2241 (701) 
3648 
1984-2498 
1277 
1979 (1589-2919) 
2200 (704) 
3648 
1932-2468 
935 
1781 (1300-2349) 
1769 (589) 
2904 
1553-1985 
874 
1568 (1268-2103) 
1730 (599) 
2903 
1503-1958 
 
929 
1944 (1512-2383) 
2014 (644) 
4009 
1808-2220 
929 
1956 (1552-2433) 
2046 (680) 
4009 
1805-2287 
929 
1932 (1479-2380) 
1992 (696) 
4009 
1728-2257 
809 
1487 (1158-1687) 
1455 (393) 
2612 
1309-1602 
701 
1432 (1164-1641) 
1423 (376) 
2256 
1280-1566 
PISA [mm2] 
 
10 
378 (140-1159) 
635 (630) 
2141 
433-836 
23 
474 (140-1453) 
735 (677) 
2141 
487-983 
1277 
1979 (133-1447) 
687 (646) 
1786 
441-932 
 
7 
178 (41-410) 
317 (396) 
1517 
172-462 
0 
133 (62-424) 
321 (391) 
1407 
172-470 
0 
266 (104-588) 
387 (346) 
1333 
276-497 
0 
346 (134-655) 
396 (322) 
1114 
281-510 
0 
346 (120-655) 
391 (324) 
1114 
268-514 
0 
86 (45-216) 
162 (257) 
1411 
66-258 
0 
87 (21-230) 
177 (265) 
1332 
76-278 
OHQoL-UK  32 
42 (40-45) 
43 (6.6) 
66 
41-45 
- 32 
42 (40-45) 
43 (6.7) 
66 
41-46 
- 30 
46 (42-62) 
53 (13.5) 
80 
47-57 
25 
44 (40-47) 
44 (8.7) 
65 
41-46 
- 25 
43 (41-47) 
43 (7.7) 
64 
40-46 
- 39 
48 (46-60) 
53 (10.3) 
79 
49-57 
 
Table 3.34 Oral health outcome measures. 
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Outcome  
 
Min  
Median (LQ-UQ) 
Mean (SD) 
Max 
95% CI 
Control Group, n=40 Intervention Group, n=40 
Change from 
baseline to 3 
months 
Change from 
baseline to 6 
months 
 
Change from 
baseline to 3 
months 
Change from 
baseline to 6 
months 
 
Mean PPD [mm] -1.7 
-0.5 (-1.1 to -0.3) 
-0.7 (0.4) 
0.0 
-0.9 to -0.5 
-1.7 
-0.5 (-1.1 to -0.3) 
-0.7 (0.5) 
0.0 
-0.9 to -0.5 
-2.8 
-0.7 (-1.0 to -0.5) 
-0.8 (0.6) 
0.3 
-1 to -0.6 
-2.7 
-0.8 (-1.1 to -0.4) 
-0.8 (0.6) 
0.0 
-1.0 to -0.6 
 
Mean PPD [mm] of those 
sites with a baseline probing 
depth of  ≥5 mm     
 
-2.4 
-1.7 (-2.1 to -1.1) 
-1.6 (0.6) 
-0.6  
-1.8 to -1.4  
-2.6 
-1.7 (-2.1 to -1.1) 
-1.7 (0.6) 
-0.4 
-1.9 to -1.4 
-3.6 
-1.6 (-2.0 to -1.3) 
-1.7 (0.7) 
0.1 
-2.0 to -1.4 
-3.8 
-1.7 (-2.0 to -1.3) 
-1.8 (0.7) 
-0.9 
-2.0 to -1.5 
 
Mean PPD [mm] of those 
sites with a baseline probing 
depth of  ≥6 mm     
 
-3.4  
-1.9 (-2.3 to -1.2) 
-1.7 (0.9) 
1.1 
-2.1 to -1.4 
-3.5 
-1.9 (-2.5 to -1.4) 
-1.9 (0.8) 
-0.2 
-2.3 to -1.6 
-4.4 
-2.0 (-2.6 to -1.4) 
-2.1(1.1) 
0.3 
-2.5 to -1.7 
-4.7 
-2.0 (-2.5 to -1.7) 
-2.1 (1.1) 
0.6 
-2.5 to -1.7 
 
Mean PPD [mm] of those 
sites with a baseline probing 
depth of  ≥7 mm     
 
-3.5 
-1.9 (-2.5 to -1.1) 
-1.9 (0.8) 
-0.7 
-2.2 to -1.6 
-5.0 
-2.2 (-3.0 to -1.4) 
-2.4 (1.2) 
-0.8 
-2.9 to -1.9 
-7.2 
-2.7 (-3.2 to -1.9) 
-2.8 (1.5) 
0.2 
-3.4 to -2.1 
-7.2 
-2.6 (-4.2 to -2.0) 
-3.1 (1.5) 
-1.5 
-3.8 to -2.5 
 
Mean PPD [mm] of those 
sites with a baseline probing 
depth of  ≤4 mm 
 
-0.9 
-0.1 (-0.4 to 0.1) 
-0.2 (0.3) 
0.4 
-0.3 to -0.1  
-0.9 
-0.1 (-0.4 to 0.2) 
-0.2 (0.4) 
0.5 
-0.3 to 0 
-0.7 
-0.2 (-0.3 to 0.0) 
-0.2 (0.3) 
0.4 
-0.3 to -0.1 
-0.6 
-0.3 (-0.5 to -0.1) 
-0.3 (0.3) 
0.4 
-0.4 to -0.2 
 
Percentage of sites with PPD 
≥5 mm     
-46 
-13 (-32 to -8) 
-17 (13.1) 
1 
-22 to -13 
-51 
-15 (-31 to -9) 
-19 (13) 
0.5 
-24 to -14 
-57 
-21 (-25 to -12) 
-21 (14.8) 
10 
-26 to -15 
-58 
-21 (-29 to -9) 
-22 (14) 
-3 
-27 to -16 
 
Percentage of sites with PPD 
>6 mm     
-34 
-3 (-7 to 0) 
-5 (7.6) 
2 
-8 to -2 
-32 
-3 (-8 to 0) 
-5 (7.0) 
3 
-7 to -2 
-36 
-4 (-7 to 0) 
-6 (7.8) 
4 
-9 to -3 
-35 
-3 (-7 to 0) 
-6 (7.9) 
2 
-9 to -3 
 
Mean MGI  
 
-1.2 
-0.5 (-0.7 to -0.2) 
-0.5 (0.4) 
0.2 
-0.6 to -0.3 
-1.6 
-0.5 (-0.8 to -0.3) 
-0.5 (0.5) 
0.8 
-0.7 to -0.3 
-1.1 
-0.5 (-0.8 to -0.2) 
-0.5 (0.3) 
0.2 
-0.7 to -0.4 
-1.9 
-0.7 (-1.0 to -0.3) 
-0.7 (0.5) 
1.2 
-0.9 to -0.5 
 
Mean PI  
 
-1.4 
-0.6 (-0.9 to -0.1) 
-0.6 (0.5) 
0.3 
-0.7 to -0.4 
-1.5 
-0.5 (-1.0 to -0.2) 
-0.6 (0.5) 
0.4 
-0.7 to -0.4 
-1.6 
-0.3 (-0.8 to -0.1) 
-0.4 (0.4) 
0.1 
-0.6 to -0.3 
-1.6 
-0.3 (-0.4 to -0.1) 
-0.4 (0.4) 
0.2 
-0.5 to -0.2 
 
Mean CAL [mm] 
 
-1.4 
-0.4 (-1.0 to -0.1) 
-0.4 (0.7) 
1.4 
-0.6 to -0.1 
-1.7 
-0.4 (-1.2 to -0.2) 
-0.5 (0.9) 
1.6 
-0.8 to -0.1 
-2.1 
-0.6 (-0.8 to -0.3 
-0.5 (0.7) 
1.5 
-0.8 to -0.3 
-1.9 
-0.7 (-1.1 to -0.2 
-0.6 (0.7) 
0.9 
-0.9 to -0.4 
 
% BOP score 
 
-47 
-10 (-20 to -2) 
-14 (14.1) 
11 
-19 to -8 
-35 
-10 (-24 to -1) 
-11 (13.5) 
23 
-16 to -6 
-28 
-5 (-13 to -1) 
-7 (11.0) 
28 
-11 to -3 
-38 
-4 (-18 to 0) 
-7 (13.6) 
36 
-12 to -2 
 
CODS -3 
0 (-2 to 1) 
0 (1.8) 
-4 
0 (-2 to 1) 
-1 (1.6) 
-3 
0 (-2 to 1) 
0 (1.8) 
-3 
0 (-1 to 1) 
0 (1.3) 
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Outcome  
 
Min  
Median (LQ-UQ) 
Mean (SD) 
Max 
95% CI 
Control Group, n=40 Intervention Group, n=40 
Change from 
baseline to 3 
months 
Change from 
baseline to 6 
months 
 
Change from 
baseline to 3 
months 
Change from 
baseline to 6 
months 
 
3 
-0.9 to 0.4 
2 
-1.3 to -0.1 
3 
-0.9 to 0.4 
2 
0.8 to 0.2 
 
PESA [mm2]  
 
-1240 
-380 (-713 to -220) 
-472 (325) 
1 
-591 to -353 
-1210 
-404 (-692 to -241) 
-469 (320) 
4 
-591 to -348 
-2104 
-474 (-660 to -244) 
-541 (435) 
158 
-704 to -379 
-2080 
-457 (-786 to -237) 
-569 (460) 
20 
-744 to -394 
 
PISA [mm2] 
 
-1701 
-297 (-674 to -49) 
-418 (498) 
193 
-601 to -235 
-1293 
-238 (-712 to -48) 
-366 (462) 
581 
-541 to -190 
 
-1032 
-132 (-323 to -20) 
-190 (298) 
626 
-301 to -79 
-1084 
-137 (-330 to -13 
-214 (332) 
547 
-340 to -88 
 
OHQoL-UK  - -24 
5 (0 to 16) 
9 (15.3) 
47 
3 to 15 
- -11 
6 (0 to 16) 
9 (13.2) 
48 
4 to 14 
 
Table 3.35 Change in oral health outcome measures between visits.
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Number of teeth 
The number of teeth present at baseline ranged from 16 to 28. The distribution of the number 
of teeth present at baseline is presented in Figure 3.9. Fifteen teeth were lost from seven 
participants throughout the study, who lost between one and five teeth each. Figure 3.10 
presents the number of teeth present by randomisation group at three time points.  
 
 
Figure 3.9 Number of teeth present at baseline. 
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Figure 3.10 Number of teeth present by randomisation group at baseline, 3 months and 
6 months. 
Boxplot representing five-number summary: minimum value that is no greater than 1.5 times 
the IQR (lower whisker), 25th percentile (bottom of box), median (dark line in middle), 75th 
percentile (top of box) and maximum value that is no greater than 1.5 times IQR (upper 
whisker). Mild outliers (open circles) are values between 1.5 and 3 times the IQR. Extreme 
outliers (asterisks) are values more than 3 times the IQR.   
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Mean pocket probing depth  
The mean PPD was similar for both groups at baseline, 4.1 mm and 3.9 mm for the control 
and intervention group respectively. The mean PPD of both groups decreased over the six 
months of the study, denoting an improvement in periodontal health. The control group 
reduced by 0.7 mm, whilst the intervention group reduced by 0.8 mm, over the 6 month 
duration of the study. Figure 3.11 presents the mean PPD by randomisation group at three 
time points.   
 
 
 
Figure 3.11 Mean PPD (mm) by randomisation group at baseline, 3 months and 6 
months.   
Boxplot representing five-number summary: minimum value that is no greater than 1.5 times 
the IQR (lower whisker), 25th percentile (bottom of box), median (dark line in middle), 75th 
percentile (top of box) and maximum value that is no greater than 1.5 times IQR (upper 
whisker). Mild outliers (open circles) are values between 1.5 and 3 times the IQR. Extreme 
outliers (asterisks) are values more than 3 times the IQR.   
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Percentage of sites with a PPD ≥5 mm 
The percentage of sites with a PPD ≥5 mm, an indication of more severe disease, reduced for 
both groups over the duration of the study. Both groups had approximately 40% of sites in 
this category at baseline, indicating the severe nature of their periodontal disease. The control 
and intervention groups demonstrated an absolute reduction in this measure over the study of 
19% and 22%, respectively. Figure 3.12 presents the percentage of sites with a PPD ≥5 mm 
by randomisation group at three time points.   
  
 
 
Figure 3.12 Percentage of sites with a PPD ≥5 mm by randomisation groups at baseline, 
3 months and 6 months.   
Boxplot representing five-number summary: minimum value that is no greater than 1.5 times 
the IQR (lower whisker), 25th percentile (bottom of box), median (dark line in middle), 75th 
percentile (top of box) and maximum value that is no greater than 1.5 times IQR (upper 
whisker). Mild outliers (open circles) are values between 1.5 and 3 times the IQR. Extreme 
outliers (asterisks) are values more than 3 times the IQR.   
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Percentage of sites with a PPD >6 mm 
The percentage of sites with a PPD >6 mm reduced for both groups over the duration of the 
study. Both groups had approximately 10% of sites in this category at baseline. The control 
group reduced by a mean of 5% while the intervention group reduced by 6%. Figure 3.13 
presents the percentage of sites with a PPD >6 mm by randomisation group at three time 
points.   
 
 
 
Figure 3.13 Percentage of sites with PPD >6 mm by randomisation group at visit 
baseline, 3 months and 6 months. 
Boxplot representing five-number summary: minimum value that is no greater than 1.5 times 
the IQR (lower whisker), 25th percentile (bottom of box), median (dark line in middle), 75th 
percentile (top of box) and maximum value that is no greater than 1.5 times IQR (upper 
whisker). Mild outliers (open circles) are values between 1.5 and 3 times the IQR. Extreme 
outliers (asterisks) are values more than 3 times the IQR.   
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Percentage of sites with a PPD improving by ≥2 mm 
The percentage of sites with a PPD improving by ≥2 mm indicates those sites that have had a 
clinically meaningful improvement (Greenstein, 2003; Addy and Newcombe, 2005). A mean 
of 25% of sites in the control group improved by ≥2 mm compared to 27% in the intervention 
group.  Figure 3.14 presents the percentage of sites with a PPD improving by ≥2 mm by 
randomisation group.  
 
 
 
 
Figure 3.14 Percentage of sites with a PPD improving by ≥2 mm between baseline and 6 
months. 
Boxplot representing five-number summary: minimum value that is no greater than 1.5 times 
the IQR (lower whisker), 25th percentile (bottom of box), median (dark line in middle), 75th 
percentile (top of box) and maximum value that is no greater than 1.5 times IQR (upper 
whisker). Mild outliers (open circles) are values between 1.5 and 3 times the IQR. Extreme 
outliers (asterisks) are values more than 3 times the IQR.   
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Percentage of sites with a PPD improving by ≥3 mm 
Similar to the previous measure, the percentage of sites with a PPD improving by ≥3 mm 
indicates those sites that have had a clinically meaningful improvement. The same percentage 
of sites (mean = 11%) in both the control and intervention group improved by ≥3 mm 
between baseline and 6 months. Figure 3.15 presents the percentage of sites with a PPD 
improving by ≥ 3 mm by randomisation group.  
 
 
 
 
Figure 3.15 Percentage of sites with a PPD improving by ≥3 mm between baseline and 6 
months. 
Boxplot representing five-number summary: minimum value that is no greater than 1.5 times 
the IQR (lower whisker), 25th percentile (bottom of box), median (dark line in middle), 75th 
percentile (top of box) and maximum value that is no greater than 1.5 times IQR (upper 
whisker). Mild outliers (open circles) are values between 1.5 and 3 times the IQR. Extreme 
outliers (asterisks) are values more than 3 times the IQR.   
  
178 
 
Percentage of deep sites improving by ≥2 mm  
 
This measure indicates those deep sites that showed clinically meaningful improvement. 
Three definitions of deep sites were used: PPD ≥ 4 mm, PPD ≥ 5 mm and PPD ≥ 6 mm.   
Figure 3.16 presents the percentage of deep sites, using the three definitions that demonstrated 
clinically meaningful improvement in PPD (≥2 mm).   
 
 
 
Figure 3.16 Percentage of deep sites improving by ≥2 mm between baseline and 6 
months. 
Boxplot representing five-number summary: minimum value that is no greater than 1.5 times 
the IQR (lower whisker), 25th percentile (bottom of box), median (dark line in middle), 75th 
percentile (top of box) and maximum value that is no greater than 1.5 times IQR (upper 
whisker). Mild outliers (open circles) are values between 1.5 and 3 times the IQR. Extreme 
outliers (asterisks) are values more than 3 times the IQR.   
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Mean modified gingival index 
 
The mean MGI for both groups was similar at baseline (mean of 2.5) and reduced in both 
groups throughout the study, denoting an improvement in gingival health. The largest 
reduction was seen during the first three months, with little change thereafter. Over the six 
month duration of the study the control group had a reduction of 0.5, and the intervention 
group had a reduction of 0.7. Figure 3.17 presented the MGI by randomisation group at three 
time points.   
 
 
 
Figure 3.17 Mean MGI by randomisation group at baseline, 3 months and 6 months. 
Boxplot representing five-number summary: minimum value that is no greater than 1.5 times 
the IQR (lower whisker), 25th percentile (bottom of box), median (dark line in middle), 75th 
percentile (top of box) and maximum value that is no greater than 1.5 times IQR (upper 
whisker). Mild outliers (open circles) are values between 1.5 and 3 times the IQR. Extreme 
outliers (asterisks) are values more than 3 times the IQR.   
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Mean plaque index 
 
The control group had larger baseline scores compared to the intervention group (1.1 versus 
0.8). The mean PI reduced in both groups throughout the study. Over the six months of the 
study the control group had a reduction of 0.6 and the intervention group had a reduction of 
0.4. Figure 3.18 presents the mean PI by randomisation group at three time points.    
 
 
 
Figure 3.18 Mean PI by randomisation group at baseline, 3 months and 6 months. 
Boxplot representing five-number summary: minimum value that is no greater than 1.5 times 
the IQR (lower whisker), 25th percentile (bottom of box), median (dark line in middle), 75th 
percentile (top of box) and maximum value that is no greater than 1.5 times IQR (upper 
whisker). Mild outliers (open circles) are values between 1.5 and 3 times the IQR. Extreme 
outliers (asterisks) are values more than 3 times the IQR.   
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Mean clinical attachment level  
 
The mean CAL was similar for the two groups at baseline, 5.2 mm in the control group and 
5.1 mm in the intervention group. The mean CAL reduced in both groups throughout the 
study, denoting improvement in periodontal health. The control and intervention groups had 
similar mean changes over 6 months with 0.5 mm and 0.6 mm, respectively.  Figure 3.19 
presents the mean CAL by randomisation group at three time points.    
 
 
 
Figure 3.19 Mean CAL by randomisation group at baseline, 3 months and 6 months. 
Boxplot representing five-number summary: minimum value that is no greater than 1.5 times 
the IQR (lower whisker), 25th percentile (bottom of box), median (dark line in middle), 75th 
percentile (top of box) and maximum value that is no greater than 1.5 times IQR (upper 
whisker). Mild outliers (open circles) are values between 1.5 and 3 times the IQR. Extreme 
outliers (asterisks) are values more than 3 times the IQR.   
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Percentage bleeding on probing  
 
At baseline the control group had a higher percentage BOP compared to the intervention 
group (24% versus 16%). Over the six months of the study, both groups had absolute 
reductions in the percentage BOP, by a mean of 11% in the control group and 7% in the 
intervention group. Figure 3.20 presents the percentage BOP by randomisation group at three 
time points.    
 
 
 
Figure 3.20 Percentage BOP by randomisation group at baseline, 3 months and 6 
months. 
Boxplot representing five-number summary: minimum value that is no greater than 1.5 times 
the IQR (lower whisker), 25th percentile (bottom of box), median (dark line in middle), 75th 
percentile (top of box) and maximum value that is no greater than 1.5 times IQR (upper 
whisker). Mild outliers (open circles) are values between 1.5 and 3 times the IQR. Extreme 
outliers (asterisks) are values more than 3 times the IQR.   
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Clinical oral dryness score  
 
The CODS was similar in both groups at baseline, 4.0 in the control group and 4.1 in the 
intervention group. The CODS reduced by 1 unit in control group (indicating a reduction in 
oral dryness) and remained unchanged in the intervention group. Figure 3.21 presents the 
CODS by randomisation group at three time points 
 
 
 
Figure 3.21 CODS by randomisation group at baseline, 3 months and 6 months. 
Boxplot representing five-number summary: minimum value that is no greater than 1.5 times 
the IQR (lower whisker), 25th percentile (bottom of box), median (dark line in middle), 75th 
percentile (top of box) and maximum value that is no greater than 1.5 times IQR (upper 
whisker). Mild outliers (open circles) are values between 1.5 and 3 times the IQR. Extreme 
outliers (asterisks) are values more than 3 times the IQR.   
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Periodontal epithelial surface area  
 
The PESA was similar in both groups at baseline, although marginally higher in the control 
group (2134 mm2 in the control group and 2014 mm2 in the intervention group). The PESA 
reduced in both groups during the study, denoting improvement in periodontal health. The 
control group had a 469 mm2 PESA reduction and the intervention group had a 569 mm2 
PESA reduction. Figure 3.22 presents the PESA by randomisation group at three time points. 
 
 
 
Figure 3.22 PESA by randomisation group at baseline, 3 months and 6 months. 
Boxplot representing five-number summary: minimum value that is no greater than 1.5 times 
the IQR (lower whisker), 25th percentile (bottom of box), median (dark line in middle), 75th 
percentile (top of box) and maximum value that is no greater than 1.5 times IQR (upper 
whisker). Mild outliers (open circles) are values between 1.5 and 3 times the IQR. Extreme 
outliers (asterisks) are values more than 3 times the IQR.   
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Periodontal inflammed surface area  
 
The PISA was higher in the control group at baseline (635 mm2 versus 387 mm2). The PISA 
reduced in both groups during the study, denoting an improvement in periodontal health. The 
control group had a 366 mm2 reduction and the intervention group had a 214 mm2 reduction. 
The percentage reductions were similar for both groups (58% versus 55%). Figure 3.23 
presents the PISA by randomisation group at three time points.  
 
 
 
Figure 3.23 PISA by randomisation group at baseline, 3 months and 6 months. 
Boxplot representing five-number summary: minimum value that is no greater than 1.5 times 
the IQR (lower whisker), 25th percentile (bottom of box), median (dark line in middle), 75th 
percentile (top of box) and maximum value that is no greater than 1.5 times IQR (upper 
whisker). Mild outliers (open circles) are values between 1.5 and 3 times the IQR. Extreme 
outliers (asterisks) are values more than 3 times the IQR.   
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OHQoL-UK 
 
The OHQoL-UK scores were similar for both groups at baseline, 43 in the control group and 
44 in the intervention group. This is comparable to a previous study, which reported a mean 
score of 47 for patients with periodontitis and 53 for periodontally health patients (Durham et 
al., 2013). The slightly lower scores in the current study, denoting poorer oral health related 
quality of life, is likely to reflect the more severe disease observed in our sample (e.g. the 
mean number of sites with PPD ≥5 mm was 33 [Durham et al. (2013)] and 57 [current 
study]). The OHQoL-UK increased in both groups during the study (mean of 9 units in both 
groups), denoting an improvement in oral health related quality of life. Figure 3.24 presents 
the OHQoL-UK by randomisation group at two time points. 
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Figure 3.24 OHQoL-UK by randomisation group at baseline and 6 months. 
Boxplot representing five-number summary: minimum value that is no greater than 1.5 times 
the IQR (lower whisker), 25th percentile (bottom of box), median (dark line in middle), 75th 
percentile (top of box) and maximum value that is no greater than 1.5 times IQR (upper 
whisker). Mild outliers (open circles) are values between 1.5 and 3 times the IQR. Extreme 
outliers (asterisks) are values more than 3 times the IQR.   
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3.5.13 Comparing novel and traditional periodontal outcome measures 
This study collected a range of traditional periodontal outcome measures such as PPD, CAL, 
BOP, PI, and MGI. We also calculated the novel outcome measures PESA and PISA. One of 
the objectives of the pilot RCT was to compare the traditional and novel outcome measures. 
Figure 3.25 and Figure 3.26 present scatter plots of the novel outcome measures against the 
key traditional outcome measures. The scatter plots suggest good correlation. This is not 
surprising since PESA and PISA are derived from PPDs, gingival recession and BOP.     
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Figure 3.25 Comparison of PESA with PPD, BOP and % of sites with a PPD ≥5 mm.   
 
Data points combined from baseline, 3-month, 6-month visits (n=199).  
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Figure 3.26 Comparison of PISA with PPD, BOP and % of sites with a PPD ≥5 mm. 
 
Data points combined from baseline, 3-month, 6-month visits (n=199).
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3.5.14 Smoking outcome measures 
Outcome  
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FTND  1 
5 (3-7) 
5 (2.4) 
9 
4-6 
 
1 
5 (3-7) 
5 (2.4) 
9 
4-6 
1 
5(3-6) 
5 (2.4) 
9 
4-6 
1 
5 (3-6) 
5 (2.5) 
9 
4-6 
0 
4 (3-5) 
4 (2.4) 
9 
3-5 
0 
3 (1-4) 
3 (2.1) 
8 
2-4 
0 
3 (1-4) 
3 (2.3) 
8 
2-4 
0 
3 (1-4) 
3 (2.4) 
8 
2-4 
1 
5 (4-6) 
5 (1.8) 
9 
4-6 
1 
5 (4-6) 
5 (1.8) 
9 
4-6 
1 
5 (4-6) 
5 (1.8) 
9 
4-6 
1 
5 (4-5) 
5 (1.6) 
8 
4-5 
0 
3 (0-5) 
3 (2.2) 
7 
3-5 
0 
3 (0-4) 
2 (2.2) 
6 
2-3 
0 
3 (0-4) 
2 (1.8) 
6 
2-3 
0 
3 (0-4) 
3 (2.1) 
7 
2-4 
MPSS  14 
21 (18-27) 
23 (7.0) 
44 
21-25 
 
14 
20 (17-27) 
22 (7.2) 
44 
20-25 
14 
20 (17-27) 
23 (7.3) 
44 
20-25 
14 
21 (18-27) 
23 (7.5) 
44 
20-26 
12 
21 (18-26) 
23 (6.9) 
41 
20-25 
11 
19 (15-23) 
20 (6.3) 
36 
18-22 
10 
20 (14-22) 
19 (5.2) 
29 
17-21 
10 
17 (14-27) 
20 (7.2) 
36 
17-23 
13 
22 (19-26) 
23 (5.9) 
40 
21-25 
14 
21 (19-26) 
22 (4.8) 
34 
20-24 
13 
20 (19-26) 
22 (5.0) 
34 
20-24 
13 
20 (19-26) 
22 (4.9) 
34 
20-24 
12 
21 (17-24) 
21 (5.5) 
33 
20-23 
10 
20 (17-24) 
20 (5.0) 
29 
18-22 
10 
19 (15-21) 
19 (4.8) 
29 
17-21 
10 
17 (15-21) 
19 (7.7) 
52 
16-22 
MPSS (M)  7 
12 (9-15) 
13 (4.8) 
25 
11-14 
 
7 
11 (9-15) 
13 (4.9) 
25 
11-15 
7 
11 (9-15) 
13 (4.8) 
25 
11-15 
7 
12 (10-15) 
13 (4.9) 
25 
11-15 
7 
13 (10-17) 
13 (4.9) 
25 
12-15 
7 
10 (9-15) 
12 (5.0) 
23 
11-14 
7 
11 (8-13) 
11 (3.7) 
20 
10-13 
7 
11 (9-17) 
13 (5.3) 
23 
11-15 
7 
12 (10-16) 
13 (5.0) 
26 
12-15 
7 
12 (10-15) 
13 (3.9) 
22 
11-14 
7 
12 (10-15) 
13 (3.9) 
22 
11-14 
8 
11 (10-15) 
12 (3.9) 
22 
11-14 
7 
13 (9-15) 
13 (4.2) 
23 
11-14 
7 
13 (10-15) 
13 (4.0) 
22 
11-14 
7 
11 (9-15) 
12 (3.6) 
20 
10-13 
7 
10 (9-13) 
12 (5.2) 
35 
10-14 
MPSS (C)  2 
5 (4-7) 
5 (1.7) 
9 
5-6 
 
2 
5 (4-6) 
5 (1.7) 
9 
5-6 
3 
5 (4-6) 
5 (1.6) 
9 
5-6 
3 
5 (6-7) 
5 (1.6) 
9 
5-6 
0 
5 (4-6) 
5 (2.1) 
10 
4-5 
0 
4 (3-5) 
4 (1.6) 
7 
3-4 
0 
4 (3-5) 
4 (2.1) 
9 
3-5 
0 
3 (2-6) 
4 (2.4) 
10 
3-4 
2 
5 (4-6) 
5 (1.7) 
10 
5-6 
2 
5 (4-6) 
5 (1.5) 
10 
4-5 
2 
5 (4-6) 
5 (1.5) 
9 
4-5 
2 
5 (4-6) 
5 (1.3) 
8 
4-5 
0 
4 (3-5) 
4 (2.0) 
10 
4-5 
0 
4 (2-4) 
3 (1.9) 
10 
3-4 
0 
4 (2-4) 
3 (1.8) 
7 
3-4 
0 
4 (2-5) 
3 (2.3) 
10 
2-4 
MPSS (P)  
 
 
 
3 
4 (3-5) 
5 (2.1) 
13 
4-5 
 
3 
4 (3-5) 
5 (2.1) 
13 
4-5 
3 
4 (3-5) 
4 (2.2) 
13 
4-5 
3 
4 (3-5) 
4 (2.3) 
13 
4-5 
3 
4 (3-4) 
4 (2.1) 
14 
4-5 
3 
3 (3-4) 
4 (1.4) 
9 
3-4 
3 
3 (3-4) 
4 (1.2) 
8 
3-4 
3 
3 (3-4) 
4 (1.2) 
8 
3-4 
3 
4 (3-6) 
5 (1.9) 
10 
4-5 
3 
4 (3-6) 
5 (1.7) 
9 
4-5 
3 
4 (3-6) 
5 (1.7) 
9 
4-5 
3 
4 (3-6) 
5 (1.8) 
9 
4-5 
3 
4 (3-5) 
5 (1.4) 
8 
4-5 
3 
4 (3-4) 
4 (1.1) 
8 
3-4 
3 
4 (3-5) 
4 (1.7) 
10 
4-5 
3 
4 (3-5) 
4 (1.2) 
7 
4-5 
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Outcome  
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eCO (ppm) 1 
18 (10-26) 
18 (10.0) 
49 
15-21 
 
1 
14 (10-25) 
17 (10.2) 
49 
14-21 
1 
14 (10-25) 
17 (10.1) 
49 
13-21 
1 
14 (10-25) 
17 (10.4) 
49 
13-21 
0 
20 (12-27) 
20 (12.1) 
52 
16-24 
0 
15 (10-25) 
17 (12.5) 
64 
13-21 
0 
11 (2-17) 
11 (8.6) 
30 
8-14 
0 
10 (2-21) 
11 (9.8) 
32 
8-15 
6 
22 (12-32) 
23 (12.2) 
55 
19-27 
7 
25 (12-33) 
23 (12.4) 
55 
19-28 
6 
24 (12-33) 
23 (13.2) 
55 
19-28 
6 
20 (11-31) 
22 (12.8) 
55 
17-27 
0 
12 (3-20) 
15 (14.0) 
53 
10-19 
0 
8 (2-19) 
12 (12.1) 
46 
7-16 
0 
8 (3-16) 
10 (9.5) 
44 
7-14 
0 
7 (2-17) 
10 (8.3) 
29 
7-13 
SC (ng/ml) 0 
322  (203-
382) 
303 (128.3) 
541 
261-346 
0 
297(182-
366) 
284 (124.0) 
522 
240-328 
0 
292 (182-
367) 
281 (127.6) 
522 
233-330 
0 
287 
(163-371) 
277 
(131.5) 
522 
225-329 
0 
314 (185-
385) 
296 (136.4) 
552 
251-341 
0 
297 (167-
372) 
282 (141.1) 
522 
233-330 
- 0 
221 (87-
347) 
230 (169.1) 
560 
165-294 
133 
310 (265-
433) 
343 (138.1) 
754 
298-387 
161 
307 
(265-423) 
342 
(143.0) 
754 
290-393 
133 
308 
(261-436) 
342 
(146.5) 
754 
290-394 
133 
298 
(220-381) 
326 
(145.5) 
754 
271-382 
 
6 
282 (221-
366) 
308 (173.5) 
850 
251-366 
3 
270 (167-
372) 
278 (191.5) 
984 
209-347 
- 0 
241 (172-
352) 
264 (164.2) 
683 
202-327 
SA (ng/ml) 0 
0.7 (0.2-1.7) 
1.1 (1.4) 
7.3 
0.7-1.6 
0 
0.6 (0.2-1.2) 
0.8 (0.8) 
3.0 
0.5-1.1 
0 
0.6 (0.2-1.1) 
0.8 (0.8) 
3.0 
0.5-1.1 
0 
0.6 (0.2-1.1) 
0.8 (0.8) 
3.0 
0.5-1.1 
0 
0.7 (0.4-1.3) 
1.1 (1.3) 
7.5 
0.7-1.5 
0 
0.5 (0.2-1.1) 
0.8 (0.8) 
3.4 
0.5-1.0 
- 0 
0.4 (0.1-1.1) 
1.2 (2.4) 
12.6 
0.3-2.1 
0.1 
0.9 (0.5-1.3) 
1.2 (1.2) 
5.4 
0.8-1.5 
0.1 
0.9 
(0.4-1.3) 
1.2 
(1.3) 
5.4 
0.7-1.7 
0.1 
1.1 
(0.5-1.4) 
1.2 
(1.3) 
5.4 
0.8-1.7 
 
 
 
 
 
 
 
 
0.1 
1.0 
(0.4-1.4) 
1.2 
(1.3) 
5.4 
0.7-1.7 
0 
0.4 (0.2-1.0) 
0.8 (1.6) 
10.0 
0.3-1.4 
0 
0.4 (0.1-0.8) 
0.8 (2.1) 
12.0 
0.1-1.6 
- 0 
0.4 (0.1-1.4) 
0.8 (1.0) 
4.4 
0.4-1.2 
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Outcome  
 
Min  
Median 
(LQ-UQ) 
Mean (SD) 
Max 
95% CI 
Unless 
otherwise 
detailed 
Control Group, n= 40 Intervention Group, n= 40 
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6
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SA: 
Proportion 
of 
participants 
with 
readings 
below 
0.1ng/ml. 
 
7.5% [n=3] - - - 13% [n=5] 15% [n=6] - 15% [n=6] 0% [n=0] - - - 18% [n=7] 25% [n=10] - 18% [n=7] 
Self-reported 
daily 
smoking 
amount for 
all 
participants 
(cigarettes/ 
day) 
 
 
 
 
 
 
 
10 
15 (11-20) 
17 (7.0) 
30 
15-20 
10 
15 (10-20) 
17 (7.0) 
30 
15-20 
10 
15 (10-20) 
17 (7.4) 
30 
14-20 
10 
15 (10-23) 
17 (7.6) 
30 
15-20 
0 
11 (5-18) 
13 (9.0) 
30 
10-16 
0 
10 (4-15) 
10 (7.8) 
30 
8-13 
0 
9 (3-15) 
9.5 (7.8) 
30 
7-12 
0 
5 (1-15) 
9 (8.1) 
25 
5-12 
 
10 
15 (15-20) 
17 (6.4) 
40 
15-19 
10 
15 (15-20) 
18 (6.4) 
40 
15-20 
10 
15 (15-20) 
18 (6.7) 
40 
15-20 
10 
15 (13-20) 
16 (4.4) 
25 
14-18 
0 
5 (0-11) 
8 (8.6) 
30 
5-11 
0 
5 (0-14) 
7 (9.1) 
30 
4-11 
0 
5 (0-11) 
7 (7.1) 
25 
4-9 
0 
8 (0-12) 
8 (7.2) 
25 
5-11 
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Outcome  
 
Min  
Median 
(LQ-UQ) 
Mean (SD) 
Max 
95% CI 
Unless 
otherwise 
detailed 
Control Group, n= 40 Intervention Group, n= 40 
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s 
3
 m
o
n
th
s 
6
 m
o
n
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Self-reported 
daily 
smoking 
amount for 
only those 
smoking 
(cigarettes/ 
day) 
 
10 
15 (11-20) 
17 (6.9) 
30 
15-20 
10 
15 (10-20) 
17 (6.9) 
30 
15-20 
10 
15 (10-20) 
17 (7.4) 
30 
14-20 
10 
15 (10-23) 
17 (7.6) 
30 
14-20 
1 
12 (5-19) 
14 (8.7) 
30 
11-17 
2 
10 (5-15) 
11 (7.4) 
30 
9-14 
1 
10 (5-15) 
11 (7.5) 
30 
8-13 
1 
10 (5-20) 
11 (7.7) 
25 
8-14 
10 
15 (13-20) 
17 (6.4) 
40 
15-19 
10 
15 (15-20) 
18 (6.4) 
40 
15-20 
10 
15 (15-20) 
18 (6.7) 
40 
15-20 
10 
15 (15-20) 
16 (4.4) 
25 
14-18 
1 
9 (5-15) 
11 (8.4) 
30 
7-14 
2 
7 (5-19) 
12 (9.1) 
30 
7-16 
1 
9 (5-15) 
9 (6.7) 
25 
7-12 
2 
10 (6-15) 
11 (6.1) 
25 
8-14 
Cumulative 
self-reported 
burnt 
tobacco use 
 
 
Not able to be calculated due to incomplete weekly questionnaires data 
Cumulative 
self-reported 
e-cigarette 
use (No. of 
days using e-
cigarette) of 
those 
attending all 
visits (n=20)  
- - - - - - - - - - - - - - - 100 
198 (181-
217) 
196 (40.2) 
291 
177-215 
Table 3.36 Smoking outcome measures- continuous.  
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Outcome  
 
n 
% 
95% CI 
 
Control Group, n= 40 Intervention Group, n=40 
Q
u
it
 d
a
te
 
4
 w
ee
k
s 
3
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o
n
th
s 
6
 m
o
n
th
s 
Q
u
it
 d
a
te
 
4
 w
ee
k
s 
3
 m
o
n
th
s 
6
 m
o
n
th
s 
Self-reported quitters of burnt tobacco  
 
2 
5%  
1%-17% 
 
2 
5%  
1%-17% 
3 
8% 
3%-20% 
4 
10%  
4%-23% 
9 
23%  
12%-38% 
11 
28%  
16%-43% 
9 
23%  
12%-38% 
8 
20%  
11%-35% 
eCO verified self-reported quitter 
 
1 
3%  
0%-13% 
 
1 
3%  
0%-13% 
1 
3%  
0%-13% 
3 
8% 
3%-20% 
9 
23%  
12%-38% 
11 
28%  
16%-43% 
9 
23%  
12%-38% 
8 
20%  
11%-35% 
SC/SA verified self-reported quitter 
 
1 
3%  
0%-13% 
 
1 
3%  
0%-13% 
- 4 
10%  
4%-23% 
7 
18%  
9%-32% 
8 
20%  
11%-35% 
- 6 
15%  
7%-29% 
eCO and SC/SA verified self-reported quitter 
 
1 
3%  
0%-13% 
0 
0% 
0%-9% 
- 4 
10%  
4%-23% 
 
7 
18%  
9%-32% 
8 
20%  
11%-35% 
- 6 
15%  
7%-29% 
RS6-eCO - - - 2 
5%  
1%-17% 
 
- - - 6 
15%  
7%-29% 
RS6-S - - - 1 
3%  
0%-13% 
- - - 4 
10%  
4%-23%) 
Table 3.37 Smoking outcome measures- binary. 
  
196 
 
Outcome  
Min  
Median (LQ-UQ) 
Mean (SD) 
Max 
95% CI 
Control Group, n=40 
 
 
Intervention Group, n=40 
Change from 
baseline to 4 weeks 
Change from 
baseline to 3 
months 
Change from 
baseline to 6 
months 
Change from 
baseline to 4 weeks 
Change from 
baseline to 3 
months 
Change from 
baseline to 6 
months 
FTND  -9 
-1 (-3 to 0) 
-2 (2.5) 
2 
-2.7 to -1.0 
-9 
-1 (-3 to 0) 
-2 (2.4) 
3 
-2.7 to -0.9 
-8 
-1 (-2 to 0) 
-2 (2.1) 
1 
-2.4 to -0.8 
-8 
-2 (-4 to -1) 
-2 (2.3) 
2 
-3.2 to -1.6 
-8 
-3 (-4 to -1) 
-3 (2.1) 
1 
-3.5 to -2.0 
-7 
-2 (-3 to 0) 
-2 (2.0) 
1 
-2.7 to -1.2 
 
MPSS  -29 
-2 (-4 to 1) 
-3 (6.2) 
7 
-5 to -0.5 
-24 
-3 (-6 to 0) 
-4 (7.4) 
7 
-6.4 to -1.0 
-26 
-3 (-7 to 2) 
-3 (8.3) 
12 
-6.0 to 0.3 
-17 
-0.5 (-5 to 2) 
-2 (5.5) 
9 
-4.0 to 0.0 
-17 
-3 (-7 to 2) 
-3 (6.3) 
9 
-5.3 to -0.8 
-18 
-3 (-8 to 0) 
-3 (8.8) 
34 
-6.1 to 0.6 
 
eCO  -49 
2 (-6 to 7) 
-1 (13) 
35 
-6 to 4 
-49 
-3 (-11 to 0) 
-6 (11.9) 
14 
-10 to -2 
-47 
-4 (-11 to 2) 
-6 (12.3) 
16 
-10 to -1 
-33 
-12 (-20 to -4) 
-12 (10.3) 
8 
-15 to -8 
-33 
-12 (-23 to -3) 
-13 (11.0) 
6 
-17 to -9 
-34 
-12 (-20 to -5) 
-12 (11.0) 
8 
-16 to -8 
 
SC  -224 
10 (-27 to 57) 
12 (80.2) 
283 
-17 to 40 
- -457 
-15 (-66 to 33) 
-37 (133) 
147 
-90 to 16 
-297 
-70 (-124 to 2) 
-64 (113) 
230 
-104 to -23 
- -500 
-66 (-111 to 27) 
-62 (132) 
164 
-112 to -12 
 
SA -1.8 
0 (-0.3 to 0.2) 
0 (0.8) 
2.4 
-0.3 to 0.3 
- -1.8 
0.1 (-0.1 to 0.4) 
0.5 (2.3) 
11.6 
-0.5 to 1.4 
-4.5 
-0.4 (-0.8 to 0) 
-0.4 (1.9) 
8.0 
-1.1 to 0.3 
- -5.0 
-0.2 (-0.9 to 0.2) 
-0.4 (1.2) 
1.7 
-0.9 to 0 
Table 3.38 Change in smoking outcome measures between visits.
197 
 
Fagerstroms test of nicotine dependence 
The mean FTND score at baseline for both groups was five, indicating moderate nicotine 
dependence. The FTND reduced by two units in both groups during the six months of the 
study, denoting a reduction in nicotine dependence. Figure 3.27 presents the FTND by 
randomisation group at five time points. 
 
 
 
Figure 3.27 FTND by randomisation at baseline, quit date, 4 weeks, 3 months and 6 
month. 
Boxplot representing five-number summary: minimum value that is no greater than 1.5 times 
the IQR (lower whisker), 25th percentile (bottom of box), median (dark line in middle), 75th 
percentile (top of box) and maximum value that is no greater than 1.5 times IQR (upper 
whisker). Mild outliers (open circles) are values between 1.5 and 3 times the IQR. Extreme 
outliers (asterisks) are values more than 3 times the IQR.   
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Mood and physical symptoms scale 
The mean MPSS score at baseline for both groups was 23. The MPSS scores are largely 
similar between the groups at the different time points, indicating they experienced similar 
withdrawal symptoms. At 4 weeks, 3 months and 6 months both groups demonstrated similar 
reductions in the MPSS score. Figure 3.28 presents the MPSS scores by randomisation group 
at five time points.  
 
 
 
Figure 3.28 MPSS by randomisation group at baseline, quit date, 4 weeks, 3 months and 
6 months. 
Boxplot representing five-number summary: minimum value that is no greater than 1.5 times 
the IQR (lower whisker), 25th percentile (bottom of box), median (dark line in middle), 75th 
percentile (top of box) and maximum value that is no greater than 1.5 times IQR (upper 
whisker). Mild outliers (open circles) are values between 1.5 and 3 times the IQR. Extreme 
outliers (asterisks) are values more than 3 times the IQR.   
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Expired air carbon monoxide measure 
The intervention group presented with a higher baseline eCO reading compared to the control 
group (23 ppm versus 18 ppm). The eCO reduced in both groups during the study. The 
control group had a 6 ppm reduction in eCO over the 6 months of the study, with the largest 
reduction occurring between 4 weeks and 3 months. The intervention group had a 12 ppm 
reduction in eCO over the 6 months of the study, with this all occurring by the 4-week time 
point and being maintained. Figure 3.29 presents the eCO by randomisation group at five time 
points. 
 
 
Figure 3.29 eCO by randomisation group at baseline, quit date, 4 weeks, 3 months and 6 
months. 
Boxplot representing five-number summary: minimum value that is no greater than 1.5 times 
the IQR (lower whisker), 25th percentile (bottom of box), median (dark line in middle), 75th 
percentile (top of box) and maximum value that is no greater than 1.5 times IQR (upper 
whisker). Mild outliers (open circles) are values between 1.5 and 3 times the IQR. Extreme 
outliers (asterisks) are values more than 3 times the IQR.   
  
200 
 
Salivary cotinine and anabasine analysis 
The salivary cotinine concentration was slightly higher in the intervention group at baseline 
(343 ng/ml versus 303 ng/ml). The intervention group had a reduction in salivary cotinine 
concentration at both the 4-week and 6-month time points (64 ng/ml and 62 ng/ml 
respectfully), indicating they had reduced their nicotine intake (from any source; tobacco, 
NRT or e-cigarettes). The control group had a small increase in salivary cotinine 
concentration at 4 weeks (12 ng/ml), followed by a reduction at 6 months (37 ng/ml), 
indicating they had reduced their nicotine intake by the end of the study. Figure 3.30 presents 
the salivary cotinine concentrations by randomisation group at four time points.  
The salivary anabasine concentration was similar between the groups at baseline, 1.1 ng/ml in 
the control group and 1.2 ng/ml in the intervention group. The intervention group had a 
reduction in salivary anabasine concentration of 0.4 ng/ml at both the 4-week and 6-month 
time point, indicating a reduction in tobacco smoking. The control group showed no change in 
salivary anabasine concentration at 4 weeks and an increase of 0.5 ng/ml at 6 months, 
indicating an increase in tobacco smoking. This appears to be in contrast to the previously 
detailed reduction of nicotine. Possible explanations include that there was no real difference 
(no statistical testing has been performed), this was the effect of an extreme outlier in the 
control group at 6 months (see Figure 3.31) or that there was a complex change in smoking 
behaviour i.e. increased exposure to tobacco metabolites could have occurred from 
compensatory smoking when participants reduced the number of cigarettes they smoked (self-
reported cigarettes per day reduced from a mean of 17 to 9 throughout the study). Figure 3.31 
presents the salivary anabasine concentrations by randomisation group at four time points.  
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Figure 3.30 Salivary cotinine concentration by randomisation group at baseline, quit 
date, 4 weeks and 6 months. 
Boxplot representing five-number summary: minimum value that is no greater than 1.5 times 
the IQR (lower whisker), 25th percentile (bottom of box), median (dark line in middle), 75th 
percentile (top of box) and maximum value that is no greater than 1.5 times IQR (upper 
whisker). Mild outliers (open circles) are values between 1.5 and 3 times the IQR. Extreme 
outliers (asterisks) are values more than 3 times the IQR.   
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Figure 3.31 Salivary anabasine concentration by randomisation group at baseline, quit 
date, 4 weeks and 6 months. 
Boxplot representing five-number summary: minimum value that is no greater than 1.5 times 
the IQR (lower whisker), 25th percentile (bottom of box), median (dark line in middle), 75th 
percentile (top of box) and maximum value that is no greater than 1.5 times IQR (upper 
whisker). Mild outliers (open circles) are values between 1.5 and 3 times the IQR. Extreme 
outliers (asterisks) are values more than 3 times the IQR.   
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Self-reported number of cigarettes (any type) per day 
At baseline, the number of cigarettes smoked per day was 17 in both groups, based on 
participants’ self-reporting. The number of cigarettes smoked throughout the study decreased 
in both groups. The intervention group had an initial rapid decrease at the quit date which was 
largely maintained throughout the study period. The control group had a more gradual 
reduction throughout the study and by 6 months both groups had comparable levels. Figure 
3.32 presents the self-reported number of cigarettes per day, for all participants, at five time 
points.  
When limiting the analysis to those still smoking, similar patterns were seen, with both groups 
reporting 11 cigarettes/day at 6 months. Figure 3.33 presents the self-reported number of 
cigarettes per day, for those still smoking, at five time points.  
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Figure 3.32 Self-reported number of cigarettes per day for all participants (any type). 
Boxplot representing five-number summary: minimum value that is no greater than 1.5 times 
the IQR (lower whisker), 25th percentile (bottom of box), median (dark line in middle), 75th 
percentile (top of box) and maximum value that is no greater than 1.5 times IQR (upper 
whisker). Mild outliers (open circles) are values between 1.5 and 3 times the IQR. Extreme 
outliers (asterisks) are values more than 3 times the IQR.   
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Figure 3.33 Self-reported number of cigarettes per day for those still smoking (any 
type). 
Boxplot representing five-number summary: minimum value that is no greater than 1.5 times 
the IQR (lower whisker), 25th percentile (bottom of box), median (dark line in middle), 75th 
percentile (top of box) and maximum value that is no greater than 1.5 times IQR (upper 
whisker). Mild outliers (open circles) are values between 1.5 and 3 times the IQR. Extreme 
outliers (asterisks) are values more than 3 times the IQR.   
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Smoking abstinence 
Smoking abstinence was assessed by several different methods in this study. These comprised 
self-reporting and biochemical validation with eCO and salivary analysis. Six different 
measures of smoking abstinence, of increasing strictness, are presented in Table 3.37. Across 
all the measures there were more quitters in the intervention group at all time points. The 
number of quitters reduced with the increasing strictness of the smoking abstinence measure 
i.e. overall there were 12 self-reported quitters at 6 months but this reduced to 8 following 
application of the RS6-eCO and 5 following application of the RS6-S. Generally there was 
good agreement between the two biochemical assessments of tobacco intake (eCO and 
salivary analysis). Across the three follow-up visits at where both eCO and saliva were 
collected (quit date, 4 weeks and 6 months) there was agreement on 26 self-reported quit 
statuses and disagreement on 9. All the disagreements involved the salivary analysis being 
more strict and classifying the participant as a smoker, when the eCO analysis had not. This is 
likely to be due to the longer half-life of the salivary biomarkers and hence the increased 
sensitivity of the salivary analysis to detect previous smoking within 3-5 days compared to 
12-24 hours for eCO.  
Using RS6-eCO, there were two quitters in the control group giving a cessation rate of 5% 
[95% CI: 1%-17%] and six in the intervention group giving a cessation rate of 15% [95% CI: 
7%-29%]. Non-attenders are counted as smokers as per the Russel Standard (West et al., 
2005b). Both the RS6-eCO quitters in the control group reported using an e-cigarette as part 
of their quit attempt. One of these participants used an e-cigarette for the whole duration of 
the study whilst the other used it for the first part of the study, stopping after the 4-week visit.  
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Figure 3.34 Smoking abstinence measures at 6 months by randomisation group. 
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3.5.15 Data completeness 
Overall excellent data completeness was achieved across the outcome measures used in this 
study for those followed up. Most measures achieved 100% completeness at all time points as 
detailed in Table 3.40. There were a small number of instances where data could not be 
collected for clinical reasons (e.g. not enough healing time had elapsed following treatment) 
and due to incomplete questionnaire completion (two instances). All of the OHQoL-UK 
questionnaires were complete with no missing items (these were self-completed in clinic with 
a research dental nurse checking for completeness). All of the FTND questionnaires were 
partially or fully completed with 1% of baseline questionnaires having one missing item. All 
of the MPSS questionnaires were partially or fully completed with 1% of baseline 
questionnaires having 5 missing items, 4% of visit 2 questionnaires having one missing item, 
2% of visit 6 questionnaires having one item missing and 2% of visit 6 questionnaires having 
two items missing. No patterns were present with regards to the missing items.   
In total, 281 saliva samples were collected. Three saliva samples, from three participants, had 
an insufficient volume for laboratory analysis. One saliva sample could only have partial 
laboratory analysis (SC and not SA) due to an insufficient volume. All of these were collected 
at the start of the study, all within the first ten saliva samples collected, indicating there may 
have been a procedural error.    
One participant declined for his samples (saliva, GCF or subgingival plaque) to be transferred 
outside of the European Economic Area (EEA), specifically requesting his samples were not 
processed in the USA (the subgingival plaque samples were originally planned to be 
processed in the USA but this was later revised to a UK-based laboratory).   
PPD data were carried forwards between visit 5 and 6 for four participants on five teeth. The 
mean (SD) of the carried forwards PPD data was 4.5 mm (1.6). Table 3.39 provides details of 
the carried forwards data by randomisation group.   
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 Control group 
n=3 
Intervention group 
n=2 
Total 
n=5 
Mean (SD) PPD 
(mm) of data carried 
forwards between 
visit 5 and 6 
4.8 (1.8) 
 
4.1 (1.3) 
 
4.5 (1.6) 
 
 
Table 3.39 Summary of PPD data carried forwards between visit 5 (3 months) and visit 
6 (6 months).
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Data element  
Visit  Consented 
for 
procedure 
Completed 
procedure/ 
data collected 
Data 
completeness 
Comment 
Pocket Probing Depths Baseline 80 80 100% 1030- Data not collected from three teeth. 
The indices were being taken alongside 
the patient’s treatment under local 
anaesthetic due to anxiety. They failed to 
attend part way through these sessions 
hence the data incompleteness.  
Visit 5 64 61 95% 1040, 1048, 1058- Oral health indices not 
collected on three participants at visit 5. 
This is because their periodontal 
treatment had extended beyond the 
original 2 visits or had been delayed, 
meaning not enough healing time has 
elapsed following the treatment to collect 
the indices. Smoking outcome data was 
still collected.    
Visit 6  58 58 100%  
Gingival Index  Baseline 80 80 100% See comments in PPD comments above 
Visit 5 64 61 95% See comments in PPD comments above 
Visit 6  58 58 100%  
Plaque Index Baseline 80 80 100% See comments in PPD comments above 
Visit 5 64 61 95% See comments in PPD comments above 
Visit 6  58 58 100%  
Bleeding on Probing Baseline 80 80 100% See comments in PPD comments above 
Visit 5 64 61 95% See comments in PPD comments above 
Visit 6  58 58 100%  
 
 
Baseline 80 80 100% See comments in PPD comments above 
Visit 5 64 61 95% See comments in PPD comments above 
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Data element  
Visit  Consented 
for 
procedure 
Completed 
procedure/ 
data collected 
Data 
completeness 
Comment 
Clinical Attachment Loss Visit 6  58 58 100%  
Clinical Oral Dryness Score Baseline 80 80 100%  
Visit 5 64 61 95% See comments in PPD comments above 
Visit 6  58 58 100%  
Expired air Carbon 
Monoxide 
Baseline 80 80 100%  
Visit 2 76 75 99% Carbon monoxide machine failure (1046) 
Visit 4 67 66 99% Carbon monoxide machine failure (1006) 
Visit 5 64 64 100%  
Visit 6  58 58 100%  
Saliva sample Baseline 80 80 100%  
Visit 2 76 76 100%  
Visit 4 67 67 100%  
Visit 5 64 64 100%  
Visit 6  58 58 100%  
Subgingival plaque sample Baseline 80 80 100%  
Visit 2 76 76 100%  
Visit 5 64 61 95% See comments in PPD comments above 
Visit 6  58 58 100%  
Gingival crevicular fluid 
sample 
Baseline 80 80 100%  
Visit 5 64 61 95% See comments in PPD comments above 
Visit 6  58 58 100%  
Fagerstrom Test for 
Nicotine Dependence 
(6 items) 
Baseline 80 80 100%  
Visit 2 76 76 100%  
Visit 4 67 67 100%  
Visit 5 64 64 100%  
Visit 6  58 58 100%  
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Data element  
Visit  Consented 
for 
procedure 
Completed 
procedure/ 
data collected 
Data 
completeness 
Comment 
Mood and Physical 
Symptoms Scale 
(12 items in three 
subsections with 7,2,3 
questions) 
Baseline 80 80 100% Participant 1021 missed 5 items from this 
questionnaire so has been classed as 
missing in data analysis.  
Visit 2 76 76 100%  
Visit 4 67 67 100%  
Visit 5 64 64 100%  
Visit 6  58 57 99% Participant 1071 missed two items from 
this questionnaire. Following the ‘rule of 
halves’ it was not possible in impute 
means, as more than half of the 
subsection was missing, and the whole 
questionnaire was classed as missing.   
Oral Health Quality of Life 
Questionnaire 
(16 items) 
Baseline 80 80 100%  
Visit 6  58 58 100%  
 
Table 3.40 Data completeness.
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3.5.16 Definitive study sample size calculation 
One of the objectives of this pilot trial was to collect estimates of the variables and parameters 
required to inform a definitive study sample size calculation.  
There are two important outcomes of the e-cigarette intervention under investigation: smoking 
abstinence rates and periodontal health. Therefore, I propose that the future definitive study 
should have co-primary outcomes and be powered accordingly.  
For the smoking abstinence outcome measure, I propose to use Russell Standard 6-month 
sustained abstinence, defined as self-report of smoking no more than five cigarettes in the 
previous 6 months and not smoking in the previous week, verified by an eCO reading below 
10 ppm. A control group rate of smoking abstinence at 6 months of 7% was used based on 
previous research (Carr and Ebbert, 2012) and in keeping with the rate seen in this pilot study 
(5%, 95% CI: 1%-17%). Minimally clinically important differences (MCIDs) have previously 
been reported in the range of 6% to 10% (West et al., 2010; Bullen et al., 2013; Caponnetto et 
al., 2013; Stapleton et al., 2013; Lindson-Hawley et al., 2014; Hajek et al., 2015c; Sarkar et 
al., 2017), with 10% being used most recently by e-cigarette studies (Bullen et al., 2013; 
Caponnetto et al., 2013; Stapleton et al.; Hajek et al., 2015c).  
In keeping with the Russell Standard (West et al., 2005b), and recent studies (Tappin et al., 
2012; Hajek et al., 2015c), sample sizes are not required to be inflated to allow for attrition, as 
those who are lost to follow-up are included in the analysis as smokers. However, this 
approach has recently been challenged (Jackson et al., 2014), with recommendations that 
sensitivity analysis also be completed (with inflation for attrition) around the assumption that 
lost to follow-up are counted as smokers. Table 3.41 presents four scenarios in which either 
an 8% or 10% MCID has been used, with or without inflation for attrition. Scenario 4 is 
unlikely to be practicable.  
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Scenario MCID Inflate for 
attrition? 
Total 
consented and 
randomised 
participants 
Total potential participants 
needed to be approached 
1 10 No 466 804 
2 10 Yes 640 1104 
3 8 No 674 1162 
4 8 Yes 924 1594 
 
Table 3.41 Sample size scenarios 
 
Scenario 3 has been used in this sample size calculation; in order to detect an 8% difference in 
6-month smoking abstinence rates between intervention arms, with a control group rate of 7% 
(90% power, 5% significance level, two-sided test) 337 participants will be required per arm, 
674 in total (Dobson and Gebski, 1986). Given any randomised participants who are lost to 
follow-up will be included in the ITT analysis of smoking abstinence as smokers at 6 months, 
this sample size has not been adjusted for attrition. However, the consent rate amongst those 
eligible in the pilot trial was 67%, (95% CI: 58%-75%). Given that the definitive study will be 
conducted in multiple centres and the pilot trial was conducted in a single centre (and as part 
of a doctoral fellowship), it would be prudent to use the lower bound of this 95% CI and on 
this basis, the future definitive study would need to approach 1162 potentially eligible patients 
in order to consent and randomise 674.          
For the periodontal health outcome measure there are several potential outcome measures that 
could be used. Whole mouth mean PPD is often used, despite not being the best method to 
assess clinical significance (Addy and Newcombe, 2005). This calculation uses a MCID of 
0.25 mm in line with previous research (Preshaw et al., 2004). Pooled standard deviations of 
the change from baseline to 6 months for the outcome measures assessed in the pilot trial are 
presented in Table 3.42. For PPD the pooled standard deviation was 0.56mm. Therefore, to 
detect a difference between intervention arms in the mean change from baseline in PPD of 
0.25 mm (pooled standard deviation of 0.56 mm, 90% power, 5% significance level, two-
sided test) 107 participants will be required per arm, 214 in total (Julious, 2010).     
Assessing the proportion of healthy or diseased sites may be a more relevant measure of 
clinical significance. A PPD of 4 mm is often used as a threshold as pockets ≤4 mm are 
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manageable by the clinician and patient, and pockets ≥5 mm have a poorer long-term 
prognosis (Lang and Tonetti, 2003; Matuliene et al., 2008). Proportionally large differences 
between groups, of 25-50%, are probably required for clinical significance (Addy and 
Newcombe, 2005). The pooled standard deviation of the change in the percentage of diseased 
sites (PPD ≥5 mm) from the pilot trial was 13.5%, and the observed mean reduction from 
baseline in the control group was 19.0% (which is in line with other studies (Preshaw et al., 
2013)). To detect a relative 25% difference in the mean reduction in the percentage of 
diseased sites, 19% versus 23.75% (pooled standard deviation 13.5%, 90% power, 5% 
significance level, two-sided test) 171 participants will be required per arm, 342 in total.   
Both of the sample sizes calculated for these periodontal outcome measures (mean PPD and 
percentage of diseased sites) are less than the sample size calculated for smoking abstinence 
(n=674 in total).  
Taking into account the participant retention rate observed in the pilot trial (73%, 95% CI: 
62%-81%), PDD data at 6 months would be expected to be available for approximately 492 
participants. Using the same standard deviations as in the PDD sample size calculations 
above, it can be calculated that, a 0.16 mm difference between intervention arms in the mean 
change in PPD and a 21% relative difference in percentage of diseases sites would be 
detectable with PDD data on 246 participants per arm.      
The sample size calculations were performed using the proc power twosamplemeans and 
twosamplefreq procedures in SAS version 9.4 of the SAS System for Windows 7, copyright © 
2012 SAS Institute Inc. 
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Parameter Pooled standard deviation 
3 month change in mean PPD 0.51 
6 month change in mean PPD 0.55 
3 month change in mean PPD [mm] of those sites with a baseline PPD ≥5 mm 0.65 
6 month change in mean PPD [mm] of those sites with a baseline PPD ≥5 mm 0.65 
3 month change in mean PPD [mm] of those sites with a baseline PPD ≥6 mm 1.00 
6 month change in mean PPD [mm] of those sites with a baseline PPD ≥6 mm 0.96 
3 month change in mean PPD [mm] of those sites with a baseline PPD ≥7 mm 1.20 
6 month change in mean PPD [mm] of those sites with a baseline PPD ≥7 mm 1.36 
3 month change in mean PPD [mm] of those sites with a baseline PPD ≤4 mm 0.30 
6 month change in mean PPD [mm] of those sites with a baseline PPD ≤4 mm 0.35 
3 month change in percentage of sites with PPD ≥5 mm     13.96 
6 month change in percentage of sites with PPD ≥5 mm     13.51 
3 month change in percentage of sites with PPD >6 mm     7.70 
6 month change in percentage of sites with PPD >6 mm     7.46 
3 month change in mean MGI 0.35 
6 month change in mean MGI 0.50 
3 month change in mean PI 0.45 
6 month change in mean PI 0.45 
3 month change in meal CAL 0.70 
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Parameter Pooled standard deviation 
6 month change in mean CAL 0.81 
3 month change in % BOP score 12.67 
6 month change in % BOP score 13.55 
3 month change in CODS  1.80 
6 month change in CODS  1.46 
3 month change in PESA [mm2]  383.04 
6 month change in PESA [mm2]  396.23 
3 month change in PISA [mm2] 468.09 
6 month change in PISA [mm2] 461.00 
6 month change in OHQoL-UK  14.29 
 
Table 3.42 Pooled standard deviations for periodontal outcome measures.
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3.5.15 Feasibility outcomes 
There were a number of feasibility trial objectives assessed in this study. The outcomes of 
these are presented in Table 3.43.   
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Trial objective Outcome 
To estimate the eligibility rates among our patient 
population.  
 
Could only be assessed for periodontal new patient clinic recruitment source: 29 
eligible participants were identified from 391 patients giving a 7.4% eligibility rate 
[95% CI: 5.2%-10.5%]. 
(Unable to make any estimates beyond this.) 
 
To assess patients’ willingness to enter the trial. 
 
80 participants were consented from 119 potentially eligible patients (67%).  
To estimate the recruitment rate; can 80 eligible 
patients be recruited in a 12-month period?   
Unable to recruit within 12 months but successfully completed within 15 months. 
Average recruitment rate was 5.3/month.  
  
To ascertain the retention rate of the participants for 
6-month follow-up data. 
 
58 participants completed the study (reaching the 6-month follow-up visit) giving a 
retention rate of 73% [95% CI: 62%-81%].  
To ascertain the randomised group contamination 
rates (i.e. the extent of cross-over between the two 
arms of the trial). 
 
20% [95% CI: 11%-35%] of those in control group reported using an e-cigarette at 
some point in the study. One participant (3%) reported using an e-cigarette at all 
follow-up time points.   
To test a weekly smoking status data collection 
method.  
Generally poorly completed by participants with only 46% of participants 
completing it more than half of the time.   
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Trial objective Outcome 
  
To compare descriptively novel and traditional 
periodontal outcome measures. (Novel: PISA, 
PESA. Traditional: PPDs.)  
 
See section 3.5.12. The traditional and novel periodontal outcome measures gave 
comparable results (not surprising).  
To estimate the standard deviation of the 
periodontal outcome measures to input to the 
sample size calculation for future definitive trials. 
 
See section 3.5.16  and Table 3.42. 
To test the collection of subgingival plaque for 
microbiome analysis.   
 
Successfully collected 100% of samples at baseline and 6 months, and 95% of 
samples at 3 months (of those who attended these visits).  
To test the collection of GCF for inflammatory 
biomarker analysis.  
 
Successfully collected 100% of samples at baseline and 6 months, and 95% of 
samples at 3 months (of those who attended these visits). 
To ascertain participant compliance when provided 
with an e-cigarette.  
 
- 39 (98%, 95% CI: 87%-100% ) participants accepted the intervention. 
- 36 (90%, 95% CI: 77%-96%) participants using at quit date.  
- 31 (78%, 95% CI: 63%-88%) participants using at 4 weeks. 
- 28 (70%,95% CI: 53%-83%) participants using at 3 months. 
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Trial objective Outcome 
- 21 (53%, 95% CI: 38%-67%) participants using at 6 months. 
 
To describe tobacco smoking and e-cigarette usage.  
 
See section 3.5.14 smoking outcome measures for a detailed description of these 
data.  
 
To ascertain participant behaviour regarding the use 
of the e-cigarette: straight nicotine replacement or 
nicotine cessation device? 
 
10-18% of participants chose to use non-recommended brands of e-liquids at the 
different follow up points. These participants made up the vast majority of the 
quitters in the intervention group. 
Further exploration of e-cigarette perceptions in chapter 5.   
 
To complete a Qualitative Process Evaluation to 
establish the views of participants on the provision 
of e-cigarettes and to finalise the exact 
characteristics of an e-cigarette intervention for the 
future definitive study for this patient group. 
See chapter 5.  
 
Table 3.43 Feasibility outcomes.
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3.6 Discussion 
3.6.1 Main findings 
Recruitment, interventions and retention to the study 
The study achieved its target of recruiting 80 patients who were smokers, suffering from 
periodontitis, who had recently attended a dentist. Patients were recruited from a variety of 
sources including primary and secondary care environments. The vast majority of the patients 
identified to the research team by recruiting sources were found to be eligible, probably due to 
the broad nature of the eligibility criteria and diligent work of those identifying. However, 
approximately a third of the patients identified did not go on to participate in the study for a 
variety of personal reasons and by failing to attend baseline appointments. PICs had a 
particularly low conversion rate with less than half of identified patients going onto 
participate in the study, while the DEC had a two-thirds conversion rate, and the periodontal 
new patient clinic had an 83% conversion rate.  
The smoking cessation interventions were well accepted by the participants. Only one 
participant in the intervention group declined to accept the e-cigarette starter kit. Adherence to 
the e-cigarette intervention was good with the majority (90%) of the participants in the control 
group using the e-cigarette at the quit date, 78% at 4 weeks, and 53% at 6 months. There was 
a moderate level of e-cigarette use by the control group despite participants being asked to 
refrain from e-cigarette use. Participants in the intervention group who deviated from 
recommendations and used non-recommended brands of e-liquid, appeared to achieve higher 
quit rates (although statistical testing was not completed).     
The periodontal treatment was successfully delivered to all participants, usually using the 
FMD approach over two visits. However, in a small number of participants (3), due to clinical 
need or patient anxiety, the treatment was delivered in a quadrant-wise approach (over 3 or 4 
visits). For three participants we were unable to collect oral health indices at the 3-month visit 
as there had been insufficient healing time period following the completion of the treatment 
(smoking outcome data was collected, however).     
Participant retention to the study was moderate with 73% of the participants completing the 
study; rates of retention were the same for the control and intervention groups. Each visit had 
a designated study window and compliance with these was mixed. At the 4-week time point, 
11% of participants attended outwith the study period (16% FTA); the corresponding value at 
the 6-month time point was 9% (28% FTA). The vast majority of the participants who did not 
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finish the study failed to attend a visit and were then uncontactable, despite having multiple 
contact methods.     
Acceptability and feasibility 
The study interventions and procedures were completed with little complication. High rates of 
data completeness were achieved for all of the questionnaires and outcome measures assessed 
in the clinic. The biological samples (saliva, GCF and subgingival plaque) were collected 
without problems from all participants (where collection was possible i.e. not from the three 
participants who did not have enough healing time at the 3-month visit, following their 
periodontal therapy). However, the weekly smoking questionnaire had poor completion rates 
with only 30% of participants completing it at least 80% of the time, meaning no valid data 
could be derived from these.  
Of those patients who failed to complete the study, most dropped out after the completion of 
the active periodontal therapy, prior to the review visits (4 weeks, 3 months and 6 months). 
This could have been because some participants placed little value in the review visits after 
receiving the active periodontal therapy; future trial designs could consider appropriately 
positioned incentives to reduce participant attrition (Brueton et al., 2014). It is also possible 
that the burden of visits contributed to the participant attrition rate with participants having to 
attend six visits over six months. This number of visits is normal for patients undergoing a 
course of periodontal treatment (with review), but may have been too intense for those 
participants who were irregular dental attenders previously (i.e. those recruited from DEC and 
some PIC sites). This is supported by the differential retention rates observed between 
recruitment sources with PIC and DEC participants having considerably lower retention rates, 
53% and 66% respectively.  Future trial designs should consider whether the number and 
duration of the study visits can be reduced, and the setting of the research study changed, in 
order to minimise participant attrition.   
Outcome measures 
Descriptive statistics could be produced for the nine oral health outcome measures and five 
smoking outcome measures, as planned. The microbiological and inflammatory biomarker 
analysis were exploratory and for the purposes of the pilot trial analysis focused on the ability 
to collect the samples rather than the laboratory findings and meaning thereof.  
Statistical significance testing was not conducted, in keeping with the pilot design of the trial, 
which was not powered to measure efficacy/effectiveness or to carry out hypothesis testing. 
However, point estimates with 95% confidence intervals have been presented for the outcome 
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measures. Overall, the oral health outcome measures showed improvement during the study, 
with broadly similar changes in both groups. For example: the mean PPD reduced by 0.7 mm 
(95% CI: 0.5-0.9) in the control group and by 0.8 mm (95% CI: 0.6-1.0) in the intervention 
group; the percentage of sites with severe disease (PPD ≥5 mm) reduced by 19% (95% CI: 
14-24) in the control group and 22% (16-27) in the intervention group; and the patient 
reported oral health quality of life (OHQoL-UK) improved by 9 units (95% CI: 0-16) in both 
groups. There was no evidence of difference between the traditional and novel periodontal 
outcome measures.  
The smoking outcome measures also showed improvement during the study. There appeared 
to be greater improvements in the intervention group, although this needs confirming in an 
appropriately powered definitive trial. For example, eCO reduced by 6 ppm (95% CI: 1-10) in 
the control group and 12 ppm (95% CI: 8-16) in the intervention group. A range of smoking 
abstinence measures were used; the RS6-eCO was 5% in the control group and 15% in the 
intervention group.      
Key parameters for a future trial 
A future trial would likely have co-primary outcome measures: a measure of smoking 
abstinence and one of periodontal health. The outcome measure estimates derived in this pilot 
trial can be used to inform sample size calculations for future definitive trials. The design of a 
future definitive trial should consider methods to address the e-cigarette use by the control 
group e.g. utilising a wait list control design, although this may have implications for the 
control group cessation rate.  
A summary of the key findings for this pilot trial is presented in Table 3.44, which is based on 
methodological issues for feasibility studies as identified by Shanyinde et al. (2011).  
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Methodological issues Findings Evidence 
1. Did the feasibility study 
allow a sample size calculation 
for the definitve study?  
Retention rates estimated.  
 
 
Variability of outcome measures 
estimated.  
 
Sample size calculation for definitive 
trial was conducted.  
Target of 80 achieved at a rate of 5.3 participants/month. A 
retention rate of 73% was achieved at 6 months.  
 
See Table 3.34, Table 3.35, Table 3.36, Table 3.37 and Table 
3.38. 
 
Number of potential participants needing to be identified: 1162 
Number needing to be randomised: 674 
2. What factors influenced 
eligibility and what proportion 
of those approached were 
eligible?  
A small number of those identified to 
the research team were ineligible. This 
because they had started using an e-
cigarette or stopped smoking.  
5 out of 119 potentially eligible participants were ineligible.  
 
For those attending the periodontal new patient clinic the main 
reason for ineligibility was being a non-smoker.  
 
We are not able to comment beyond this from the data collected 
in the study.   
3. Was recruitment 
successful?  
Yes, the required number of 
participants were recruited over 15 
months.  
Initially recruitment was slow. Once PICs and DEC started 
contributing the recruitment rate improved.  
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Methodological issues Findings Evidence 
4. Did eligible participants 
consent?  
Approximately a third of potentially 
eligible participants progressed to 
enter the study. The main reasons for 
not progressing were work or personal 
commitments, disinterest and failing to 
attend visits.   
80 out of 114 eligible participants progressed to consenting and 
entering the study.  
5. Were participants 
successfully randomised and did 
randomisation yield equality in 
groups?  
Worked well.  40 participants were randomised to each group. A good balance 
of the majority of demographic variables was achieved. 
However, those in the control group appeared to have more 
severe periodontal disease and this may be need to be a 
stratification variable in the future definitive trial.   
6. Were blinding procedures 
adequate?  
This worked well.  As planned, the oral health outcome assessor was blinded.  
7. Did participants adhere to 
the intervention?  
The intervention group adhered well to 
the e-cigarette intervention.  
 
Several participants in the control 
group contravened instructions not to 
use an e-cigarette.   
90% of the intervention group were using the e-cigarette at the 
quit date.  
 
20% [95% CI: 11%-35%] of the control group used an e-
cigarette at some point in the study.  
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Methodological issues Findings Evidence 
8. Was the intervention 
acceptable to the participants?  
The intervention was acceptable to the 
participants.  
39 of 40 participants accepted the e-cigarette starter kit.  
11 (28%, 95% CI: 16%-43%) participants chose to use non-
recommended e-liquids.  
Over half [53%, 95% CI: 38%-67%] of the participants in the 
control group confirmed using the e-cigarette for the 6 months 
of the study.  
The participants interviewed provided positive feedback on the 
e-cigarette intervention (see chapter 5).  
9. Was it possible to 
calculate intervention costs and 
duration?  
Not formally assessed within this pilot 
trial but estimated costs provided.  
E-cigarette starter kit cost: £38.97 (eTank starter kit = £14.40, 
additional e-liquid = £3.60, spare battery = £9.99, spare tank = 
£4.99, UK plug = £5.99). These costs are those incurred by the 
pilot trial and correct as of July 2016.  
Healthcare professional costs: Approximately a 10 minute 
tutorial was delivered with the e-cigarette starter kit. If a dentist 
delivered the tutorial this would cost £6.80 compared to £2.10 
for a dental nurse (T Homer, personal communication, 6 
August 2018).  
Total cost: £45.77 (dentist delivery) 
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Methodological issues Findings Evidence 
10.  Were outcome 
assessments completed?  
There was good completion of 
outcome assessments in clinic.  
The weekly smoking questionanire 
was poorly completed by the 
participants.  
See section 3.5.15.  
 
See section 3.5.7 and Table 3.24. 
11. Were outcome measured 
those that were the most 
appropriate outcomes?  
The outcome measures allowed 
assessment of periodontal health and 
smoking behaviour.  
The traditional and novel measures of oral health allowed 
detailed assessment of oral health and oral health related quality 
of life.  
The smoking outcome measures allowed assessment of 
smoking reduction and abstinence.  
12. Was retention to the study 
good?  
Retention was acceptable.  Retention was similar to that predicted (73% versus 75%).  
13. Were the logistics of 
running a multicentre trial 
assessed?  
Not assessed within the pilot trial.  - 
14.  Did all components of the 
protocol work together?  
No problems were identified.  There were no difficulties in following the protocol in order to 
recruit, randomise and deliver interventions to the participants.  
Table 3.44 Summary of findings against methodological issues for feasibility studies. 
*The methodological issues in this table are based on those discussed by Shanyinde et al. (2011).  
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3.6.2 Relationship to previous research 
Participant recruitment and retention 
Previous research in this field has rarely provided in-depth descriptions of participant 
recruitment. There are only two comparable prospective studies (Preshaw et al., 2005; Rosa et 
al., 2011), as identified in a systematic review (Chambrone et al., 2013). Rosa et al. (2011) 
screened 201 patients attending a smoking cessation clinic over a two-year period, finding 93 
(46%) to be eligible, who were subsequently recruited to the study. Preshaw et al. (2005) 
recruited 49 patients from the clinics of a dental hospital, in a similar method to that used in 
the current study, but did not report the number of screened patients.  
The 27% 6-month attrition rate of the current study is in keeping with these studies. Rosa et 
al. (2011) reported a 32% 6-month attrition rate and the study by Preshaw et al. (2005) 
reported a 41%  twelve-month attrition rate [as reported in Nasry et al. (2006), 6-month data 
not reported].   
Eligibility criteria 
The current study had several medical conditions as exclusion criteria or as areas requiring 
further discussions. The information leaflet for the product we used in this study specified it 
not being suitable for pregnant or breastfeeding women, those who should avoid using 
tobacco or nicotine products for medical reasons and those with unstable heart conditions, 
severe hypertension or diabetes. However, as the product was regulated under the TPD and 
not as a medicinal product, we took a precautionary approach and applied those conditions 
detailed in the summary of product characteristics for the e-Voke (an e-cigarette that obtained 
a medicinal licence in 2015, but was never made commercially available) (Medicines and 
Healthcare products Regulatory Agency, 2015) and other forms of NRT e.g. Nicorette 15mg 
Inhaler (Medicines and Healthcare products Regulatory Agency, 2011). These ‘special 
warnings and precautions’, are more comprehensive but broadly similar to the instructions on 
the TPD product, and are based upon those developed for traditional NRT. They are included 
either because nicotine can affect the condition (e.g. nicotine can exacerbate oesophagitis, 
gastritis or peptic ulcers) or the condition can affect the clearance of nicotine, increasing 
adverse effects (e.g. severe renal impairment).  
Other research has used less stringent eligibility criteria regarding medical conditions. For 
example, Hajek et al. (2015c) only excluded pregnant or breastfeeding patients; Bullen et al. 
(2013) excluded pregnant or breastfeeding patients, those who had a heart attack, stroke, or 
severe angina in the previous two weeks, and those with poorly controlled medical disorders; 
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and Caponnetto et al. (2013) excluded those with symptomatic cardiovascular disease, 
symptomatic respiratory disease, regular psychotropic medication use, current or past history 
of alcohol abuse, pregnancy or breastfeeding. The eligibility criteria (medical conditions) used 
in the current study, although stricter than previous research, did not appear to adversely 
affect eligibility rates (based on the limited data we have from the periodontal new patient 
clinic in which only one out of 391 patients was ineligible on medical grounds) and similar 
criteria could be used in future studies.     
The minimum number of teeth required to be eligible for this study was reduced from 20 to 
16 part way through the study (after seven months’ recruitment). We found that, due to the 
severe nature of periodontal disease in some smokers, many of the potential participants had 
suffered from tooth loss and had less than 20 teeth. We reviewed the reason for using 20 teeth 
as a cut off and found this to be arbitrary. Comparing to previous research, Rosa et al. (2011) 
required 10 teeth whilst Preshaw et al. (2005) did not specify. We decided to revise our lower 
limit to 16 teeth which represents half of the dentition of a normal adult, giving a fair 
representation of the disease profile and enough teeth for the periodontal measures to be 
useful and for samples to be collected. Data were not available on the number of potential 
participants who were rejected on the original criteria (20 teeth). However, following the 
amendment, 11 participants (out of approximately 69 identified potentially eligible 
participants, 16%) had 16-19 teeth at baseline, showing the benefit in this eligibility criteria 
modification to the study recruitment.          
Periodontal disease classification is worthy of further discussion given the recent changes 
(Caton et al., 2018). Principally, the new classification system removes the terms chronic and 
aggressive, instead using a model based on staging and grading. There are four stages of 
severity and complexity of management, with extent being assessed as localised, generalised, 
or molar-incisor distribution. There are three grades for risk of progression/anticipated 
treatment response: slow, moderate and rapid. The field of periodontology is currently 
transitioning between the two systems and the current advice from the British Society of 
Periodontology (BSP) is ‘for the time being it is recommended that clinicians continue to use 
the existing classification system’ (The British Society of Periodontology, 2018). The 
periodontal disease eligibility criteria used in the pilot RCT anticipated recruiting individuals 
with chronic periodontitis but used a criterion based on having at least eight sites with a PPD 
≥5 mm. A future study would be able to use the same criterion within the new classification 
system. Based on this our participants would be diagnosed as having periodontitis with stage 
III or IV and grade C (smokers of  ≥10 cigarettes/day are classified as high risk) under the 
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new classification system (Tonetti et al., 2018). A future definitive study would need to align 
with the classification system being used at the time.               
Response to SCA intervention 
The control group in the current study received SCA as part of usual care, achieving a 5% quit 
rate at both 4 weeks and 6 months (RS6-eCO). This is similar to the rates discussed in a 
Cochrane systematic review of brief advice interventions delivered by physicians, which 
concluded that the brief advice intervention could increase 6-month quit rates to 5% from the 
3% unassisted rate (Stead et al., 2013a). Another Cochrane systematic review focusing on 
smoking cessation within the dental setting concluded that quit rates could be increased to 7% 
(Carr and Ebbert, 2012).  
The studies by Preshaw et al. (2005) and Rosa et al. (2011) reported particularly high 6-
month quit rates, 29% and 33% respectively [Nasry et al. (2006) reported the 6-month quit 
rates for the study by Preshaw et al. (2005)]. These rates are considerably higher than that of 
the current study and there are two likely reasons for this discrepancy. Firstly, the 
interventions were more intensive than the current study. Preshaw et al. (2005) provided SCA 
but participants also had access to NRT and Zyban from the dental clinic. Rosa et al. (2011) 
also provided an intensive intervention which included four weekly 1-hour lectures, 
psychologist-assisted cognitive behavioural therapy, NRT or Zyban depending on clinical 
need and further smoking cessation counselling using motivational interviewing techniques at 
the four dental follow-up visits. Secondly, both studies only included smokers willing to quit, 
with Rosa et al. (2011) recruiting patients already choosing to attend a smoking cessation 
service and Preshaw et al. (2005) excluded ‘contented smokers’ who wished to continue 
smoking. The current study utilised a more pragmatic approach, including all smokers 
regardless of their intention to quit, therefore getting a real-world quit rate realistic to that 
achieved by these interventions in regular general dental practice.   
Acceptability of e-cigarette intervention 
Of the forty participants who were offered the e-cigarette starter kit in the current study, only 
one declined, giving a 98% (95% CI: 87%-100%) acceptance rate (this participant also 
declined any referral to the stop smoking services and did not make a quit attempt during the 
study period). This acceptance rate is in keeping with other RCTs (Bullen et al., 2013; 
Caponnetto et al., 2013; Adriaens et al., 2014) who imply a 100% acceptance rate, although 
not explicitly stating this within their papers. A real-world e-cigarette acceptance rate is likely 
to be lower with one example reporting a 69% e-cigarette acceptance rate when smokers 
attended a stop-smoking service in London (Hajek et al., 2015a). In a clinical trial scenario, a 
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high acceptability rate might be expected, with participants completing a thorough informed 
consent process prior to randomisation and any individuals not wanting to use an e-cigarette 
being less likely to engage with the study. Within clinical trials this unavoidable selection bias 
limits the external validity of results. However, in the current study, we tried to limit this by 
informing potential participants that the e-cigarette intervention simply involved having the 
offer of an e-cigarette starter kit, which they could decline and continue with usual care (SCA 
and option of referral to the stop smoking services). 
Participants were advised to use the same brand of e-liquid as provided in the e-cigarette 
starter kit, as per manufacturer’s instructions. The manufacturer’s instruction manual states 
that only their brand of e-liquids should be used in the device and that vapour quality and 
satisfaction may vary if used other than recommended. Perhaps unsurprisingly, with the wide 
availability of e-liquids, 11 (28%) of the participants reported using a non-recommended 
brands of e-liquids during the study period. These participants made up the vast majority of 
the quitters in the intervention group, 83% of RS6-eCO and 75% of RS6-S. This suggests that 
these participants were more engaged with the intervention and experimenting with different 
products was an important aspect of the intervention, leading to success in quitting smoking.    
Response to e-cigarette intervention 
The recent Cochrane systematic review on e-cigarettes (Hartmann-Boyce et al., 2016) 
included two studies which reported biochemically validated quit rates at four weeks of 23% 
and 14%, and at six months of 7.3% and 10-12% (depending on e-cigarette set up) (Bullen et 
al., 2013; Caponnetto et al., 2013). The intervention group in the current study, who received 
the e-cigarette starter kit, achieved similar if not higher biochemically validated (eCO) quit 
rates of 23% and 20% at four weeks and six months respectively (15% and 10% when 
applying the strict RS6-eCO and RS6-S respectively). Participant intention to quit varied 
considerably between the studies: Bullen et al. (2013) who only included those ‘wanting to 
quit’, Caponnetto et al. (2013) including only those ‘not intending to quit’ and the current 
study which did not have an intention to quit selection criterion. The higher quit rates seen in 
the current study could be due to changes over the five years since the original studies (Bullen 
et al., 2013; Caponnetto et al., 2013) including product improvements and increased social 
acceptability of e-cigarettes.  
It was interesting to note that both of the RS6-eCO quitters in the control group used a self-
purchased e-cigarette (against instructions) as part of their quit attempt.  
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Control group contamination 
The current study had moderate contamination of the control group with 20% (95% CI: 11%-
35%) of participants in the control group using an e-cigarette at some point in the study. The 
studies by Bullen et al. (2013) and Caponnetto et al. (2013) did not report on this, which has 
likely become more of an issue with the widespread availability and popularity of e-cigarettes 
in recent years. For example, Bullen et al. (2013) conducted their study in New Zealand 
between 2011 and 2013 where nicotine-containing e-cigarettes were illegal and population 
prevalence rates of use were low. Other studies (Caponnetto et al., 2013; Adriaens et al., 
2014) utilised designs that did not have a non-e-cigarette control group. For example, 
Caponnetto et al. (2013) provided all participants with an e-cigarette but varied the nicotine 
content of the e-liquid, while Adriaens et al. (2014) used a wait list control design where 
participants in the control group were provided with an e-cigarette after two months.   
The current study used a commitment form, similar to other studies (Hajek et al., 2015c), in 
an attempt to minimise the use of non-allocated cessation products.  
The moderate e-cigarette use by the control group in the current study illustrates a challenge 
for future research in this field. In studies where participants are allocated to non-e-cigarette 
options it is likely there is going to be considerable contamination, given the widespread 
popularity and availability of e-cigarettes. Completely inhibiting e-cigarette use by 
participants in the control group poses ethical dilemmas. For example, a participant may try 
the allocated (non-e-cigarette) intervention and be unsuccessful, but then decide they want to 
quit using an e-cigarette, and it would be unethical for researchers to stand in the way of a quit 
attempt. The relatively high reporting of non-compliance in the control group in this study is 
likely to be due to an open approach by researchers who encouraged honesty without 
consequences. Additionally participants were aware that salivary analysis was being 
undertaken, potentially increasing honesty in reporting smoking status.    
Response to periodontal therapy  
Conventional non-surgical periodontal therapy was provided in this study and mean PPD 
reductions of 0.7-0.8 mm were observed. This magnitude of reduction is in keeping with 
existing research (Heasman et al., 2006). Studies with at least three months follow-up have 
shown a range of mean PPD reductions in smokers: 0.2 mm (Rosa et al., 2011), 0.33 mm 
(Grossi et al., 1997), 0.5 mm (Preshaw et al., 2005), 0.65 mm (Pucher et al., 1997), 1.02 mm 
(Ryder et al., 1999), 1.23 mm (Palmer et al., 1999), 1.35 mm (Tomasi and Wennstrom, 2004), 
1.6 mm (Jin et al., 2000) and 1.9 mm (Renvert et al., 1998). Although it is hard to directly 
compare studies, due to differences in interventions and designs, it is clear that the clinical 
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response to the periodontal therapy delivered in the current study was broadly similar to that 
previously reported in the literature.   
Periodontal response to e-cigarette use 
The current study, being a pilot trial, was not powered to show a difference in outcome 
measures. However, the periodontal response to the non-surgical periodontal therapy 
appeared to be broadly similar, if not slightly better in the e-cigarette intervention group. As 
previously discussed (see section 1.4.6), there is an absence of definitive research on the 
clinical periodontal effects of e-cigarette use. However, there are a number of non-randomised 
clinical pilot studies (Franco et al., 2016; Reuther et al., 2016; Tatullo et al., 2016; Wadia et 
al., 2016; Javed et al., 2017a; Al‐Aali et al., 2018) which all indicate improvement in oral 
health when tobacco smokers switched to vaping e-cigarettes, in keeping with the findings of 
the current study. A definitive study, powered to undertake this analysis is required and has 
recently been called for in a large national review (Stratton et al., 2018).   
The pilot study by Wadia et al. (2016) concluded that there was a significant increase in BOP 
at 2 weeks when smokers switched to vaping. As previously discussed, this study (Wadia et 
al., 2016) has several flaws: inappropriate statistical testing for a pilot study, flawed power 
calculation, no control group and inappropriate interpretation (it is well documented that 
smokers have a short term increase in BOP when they quit, potentially accounting for the 
results of the study by Wadia et al. (2016)). Nevertheless, the results from the current study 
showed similar percentage BOP reductions in both groups indicating there was not a major 
clinically significant detrimental effect of the e-cigarette on BOP.     
Participant weekly smoking questionnaire completion rates 
The current study asked participants to complete a weekly smoking questionnaire, enquiring 
about their smoking habits over the previous seven days. The majority of participants (85%) 
opted for our default option which was a SMS text message with a link to the online survey. 
A small number (12%) requested the link sent via email, with 4% completing a paper version 
of the questionnaire. Although most participants (85%) completed at least one questionnaire 
entry, more regular completion rates were poor. Only 30% of participants completed the 
questionnaire at least 80% of the time, increasing to 41% for those 59 participants who 
completed the study. Completion peaked at quit date, dropped in the first 4 weeks, plateauing 
for the remainder of the study (see Figure 3.7). Completion rates were slightly lower in the 
control group.     
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The benefit of this data collection technique is the reduction in recall bias by collecting 
contemporaneous data. Participant diaries have often been used in research, often utilising a 
paper and pen format. However, as technology has developed, different mediums have been 
used to collect the data (Jones and Woolley, 2014). The range of weekly smoking 
questionnaire formats available in the current study allowed participants’ preferences to be 
accommodated. The poor completion rates of the weekly smoking questionnaire by our 
participants was disappointing and worse than that reported by similar studies (Aigner et al., 
2016). Possible explanations for this include that this was one of several data collection 
methods in the study, rather than the only method used in some other studies which achieved 
higher completion rates.  
The findings of the current study therefore highlight that this research data collection 
technique has poor completion rates in the study population and should be avoided in future 
research without considerable redesign e.g. use of incentives or less frequent questionnaires 
(once every 4 weeks).   
Interestingly a number of the participants felt the weekly smoking questionnaire was acting as 
an intervention in itself. Below is an illustrative quote from one of the TDF interviews.  
 
It’s [the weekly survey] made me aware, that, even though that you’re not 
there, you’re still there, in the background… Just lurking, you know, that 
you’ve still got the, like the, the long reach, support that you know, I’ve still 
got that connection, with the study.  And you’re not getting forgotten about.  
What you’re doing, matters, because you want these, statistics… it does 
make you sit down and evaluate it and look at it at the wider picture if you 
like. (Female, 52 years, 15 cigs/day) 
 
Adverse events 
The current study reported no SAEs and 56 AEs which were mainly associated with the 
sequelae of severe periodontal disease e.g. toothache, dentine hypersensitivity, tooth loss and 
abscesses. Thirty-five percent of participants in the control group and 53% of participants in 
the intervention group reported an adverse event. This is in keeping with previous e-cigarette 
RCTs with Bullen et al. (2013) reporting approximately 45% of participants reporting an AE.  
Direct comparison with previous periodontal research is difficult as adverse events have 
rarely been reported. For example, Rosa et al. (2011) and (Preshaw et al., 2005) did not report 
adverse events in their papers. The Cochrane systematic review on e-cigarettes (Hartmann-
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Boyce et al., 2016) found that the most frequently reported AEs were mouth and throat 
irritation. This is in keeping with the current study, which also reported that a number of 
participants, exclusively in the intervention group, reported mouth ulceration or soreness of 
the intra-oral soft tissues. The number of these AEs was small (5 events in 5 participants) but 
the increased number occurring in the intervention group could be related to the e-cigarette 
intervention (other forms of orally-administered NRT have been associated with soreness and 
ulceration) or could be the result of the higher quit rate in the intervention group (smoking 
cessation is associated with soreness and ulceration).   
3.6.3 Strengths and limitations 
Strengths 
A strength of the current study is the broad and complementary nature of the mixed research 
methods utilised. The pilot trial focused on quantitative data collection with regards to 
smoking and periodontal/oral health whereas the broader feasibility study also utilised 
qualitative research methods (participant interviews) in order to gain a deeper understanding 
of the interventions and research processes (see chapters 4 and 5).  
The feasibility study was well designed and complied with reporting guidelines. The  
CONSORT checklist for pilot and feasibility studies (Eldridge et al., 2016) has been used, 
complying with 35 of 35 relevant checklist items which compares favourably to the previous 
research in this field which achieved scores of 5/28 to 12/29 (see section 3.2). Similarly, the 
interventions provided in this study were reported in detail using the TiDieR checklist, 
enhancing transparency and reproducibility.  
As discussed earlier (see section 3.2), previous studies investigating oral health and e-
cigarettes were generally poorly designed and hence this study is the first properly conducted 
pilot trial in this field. The findings from this study will allow for a well-designed and 
efficient definitive study in order to answer the research question. 
Limitations 
The contamination rate of the control group (using e-cigarettes, when asked not to) was an 
important finding of the current study. On the one hand, this is a limitation as it makes the 
interpretation of the results challenging, but on the other, it is an important feasibility outcome 
that will shape the design of a future definitive study.  
The current study was conducted in a single specialist dental clinical research facility within a 
secondary care environment, where the chief investigator and principal investigator were 
based. This allowed for dedicated experienced research teams to conduct high quality research 
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but applicability to primary care may be reduced compared to a study conducted in a primary 
care environment. Future studies should consider this in their design. 
The control group in the current study appeared to have more severe periodontal disease at 
baseline than the intervention group. Ideally, the groups should have balanced disease profiles 
and hence a future definitive study should stratify for periodontal disease severity.   
This study used several measures of smoking abstinence, including the Russell Standard 
(West et al., 2005b). The Russel Standard has six criteria of which this study fully complied 
with five. The sixth specifies that follow-up data should be collected blind to smokers’ 
allocation, which was not completely possible in the current study. Periodontal/oral health 
outcome measures were collected by a blinded outcome assessor but the smoking outcome 
measures were collected by non-blinded members of the research team. This was mainly for 
practical reasons and resource limitations of a doctoral fellowship project. The reason West et 
al. (2005b) include this criterion is to avoid differential efforts being devoted to contacting 
subjects in different treatment groups and they recommend follow-up rates should be reported 
by group. The current study reported detailed follow-up rates by group and the findings show 
that equal numbers of participants (29 in each group) completed the study. Table 3.20 
presents key parameters by randomisation group for those who were lost to follow-up 
compared to those who completed the study. Those participants lost to follow-up appeared to 
have higher eCO and FTND readings and more severe periodontal diseases, although 
probably not statistically significant. It is noteworthy that in the study by Bullen et al. (2013) 
the research assistants (and project co-ordinator) were not blinded. Caponnetto et al. (2013) 
did manage to achieve blinding as the e-cigarettes provided looked identical, with the 
pharmacy conducting randomisation and preparation.            
A challenge with all e-cigarette research is the rapidly moving pace of the field, particularly 
with regards to product development and population use. It is common for e-cigarette devices 
used in research studies to become obsolete or discontinued throughout the duration of the 
study. In the current study we used a second generation tank design, the Vype eTank, which 
was still on the market at the close of the study (Waitrose, 2018), although not on the 
manufacturer’s website (Vype, 2018). However, over the two years from choosing the product 
to the close of the study there has been considerable product development and this device is 
now largely superseded, for example, by the eTank Pro in the Vype product range. The rapid 
changes in popularity and usage of e-cigarettes also potentially makes the applicability of the 
findings challenging. For example, the eligibility criteria of the current study required 
participants not to have used an e-cigarette regularly within the last month. With ever 
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increasing uptake of e-cigarettes by smokers, this could potentially lead to decreases in the 
eligibility rates observed in the current study. However, the rapid rise in e-cigarette popularity 
appears to have plateaued over the last few years, indicating that the findings are likely to still 
be applicable. Nonetheless, in order for the findings of the current study to remain of optimum 
relevance, it is important that the definitive study is instigated rapidly.     
3.6.4 Implications for future research 
Recruitment 
Participant recruitment to a future definitive study should utilise findings from the current 
study. A recruitment rate of five participants per month can be expected for a dental research 
centre such as the one used in this study. In order to achieve sufficient participant numbers it 
is likely that a future study would need to utilise a multi-centre and/or primary care approach. 
Future studies should be aware of the differences between recruitment sources with regards to 
the proportion of potential participants fully entering the study e.g. less than half of potential 
participants identified from primary care (PICs) converted to fully entering the study. 
However, higher rates might have been achieved if the study visits were carried out in 
primary care e.g. by a research team (research dental nurse and hygienist) visiting the practice 
on a regular session. 
Eligibility criteria should follow the current pilot study by requiring 16 teeth (rather than 20) 
and not including willingness to quit in the criteria.      
Study design 
Future research should utilise a pragmatic study design, similar to the current study, which 
allowed inclusion of a broad range of participants and has wide applicability of the findings to 
general dental practice. The randomisation process should include stratification on periodontal 
disease severity in order to achieve balance between the groups.  
Future research should consider appropriate designs to reduce or account for e-cigarette use 
by the non-e-cigarette control group. One option may be to utilise a staggered approach (i.e. a 
wait list control design) where all participants are offered an e-cigarette but at different time 
points, some at the start of the study and some after six months, in a similar approach to 
Adriaens et al. (2014) (participants were given e-cigarette at baseline or after eight weeks). 
Participants in the non-e-cigarette control group may be more likely to refrain from e-cigarette 
use if they know they are going to be provided one in the (near) future. This design would be 
good to address the research question about the potential effects of e-cigarettes on smokers’ 
periodontal health. This is because the group not initially using the e-cigarette would likely 
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achieve a low quit rate, achieving a good comparison. However, this design would be 
suboptimal for comparing the efficacy of the interventions on smoking cessation outcome as 
the usual care intervention would likely be affected by this staggered design with some 
participants choosing to delay their quit attempt until they get the e-cigarette (in six months 
time).  
Another option is to not have a non-e-cigarette group, instead both groups are provided with 
an e-cigarette, either with or without nicotine, in a similar design to previous studies 
(Caponnetto et al., 2013). Again this design option has limitations, as it assesses the effect of 
nicotine in the e-cigarettes rather than the whole intervention (e.g. hand-to-mouth, vapour 
production, flavours) which limits its relevance and external validity. A pragmatic trial design 
could also be used, similar to the current study, evaluating the effect of offering an e-cigarette 
(rather the effect of using an e-cigarette). Framing the question in this way minimises the 
impact of e-cigarette use in the control group.    
In the current study, participants were aware that the study was investigating e-cigarettes and 
some may have felt disappointed when they were allocated to the non-e-cigarette control 
group and therefore purchased their own e-cigarettes. It would be possible to redesign the 
participant information to include less focus on e-cigarettes, making it more broadly about 
smoking cessation, and possibly reducing the e-cigarette use by the control group. A clustered 
design approach in which a whole research centre or dental practice is allocated to the non-e-
cigarette or e-cigarette group may further assist with this, although this would require a larger 
sample size (due to intra-centre correlation) and may not be acceptable to some centres.    
The e-cigarette intervention delivered in this study was well received and future research 
could utilise a similar approach whereby participants are provided with a starter kit and 
expected to source their own supplies after the initial period. It is important to have a range of 
flavour choices, tobacco and non-tobacco.   
Future studies should consider design features to enhance participant retention. In the current 
study, the most frequent time point for participants to drop out was during the review period, 
after completion of the active periodontal therapy. Future studies should consider incentives 
to enhance retention through these review visits. A recent Cochrane systematic review 
investigated strategies to improve retention in randomised trials, and although several trials 
investigated this in the context of questionnaire responses, very few evaluated ways to 
improve participant retention in a study (Brueton et al., 2014). Monetary incentives were 
shown to be effective in increasing questionnaire responses and other strategies needed 
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further evaluation. Only one study investigated the effect on participant retention and found 
no difference when participants were provided with a certificate of appreciation and/or a lapel 
pins (Bowen et al., 2000).  
Consideration should also be given to reducing the burden of the study by reducing the 
number and frequency of the study visits. For example, follow up periodontal data could be 
collected at the 6-month visit rather than at both 3-month and 6-month visits. In the current 
study, the 3-month periodontal data could not be collected on all participants due to the 
proximity of their periodontal therapy completion. Furthermore, the 6-month time point 
corresponds with the time points for the smoking outcome measures (e.g. Russell Standards), 
unlike the 3-month time point. The periodontal outcome measures in the pilot trial had similar 
responses at both 3 months and 6 months, indicating little information would be lost by 
removing the 3-month visit or at least by reducing the data collection at this visit. In a future 
study design, it would be important to see the participant at the 3-month time point to provide 
SPT but the collection of research data is not necessary.    
Outcome measures 
Future studies should minimise the number of outcome measures collected in order to reduce 
participant burden. The current study had 16 outcome measures and these could be reduced in 
a future definitive study. A future study would likely have co-primary outcome measures: a 
measure of smoking abstinence and one of periodontal health. For the smoking outcome 
measures it would be important to collect self-reported use, eCO and possibly SC/SA in order 
to establish smoking abstinence. The FTND is a useful baseline measure of nicotine 
dependence, which could also be repeated at six months. The MPSS assesses withdrawal 
symptoms which is not directly relevant to this study and hence this assessment could be 
removed from the future definitive study. For the oral health outcome measures there should 
be no change to those collected in this study. The majority of the indices collected are 
required as part of usual care (PPD, MGI, PI, CAL, BOP) or derived from these measures 
(PISA, PESA). The CODS is an important measure to continue in a definitive study due to the 
potential drying effect of e-cigarette vapour. The OHQoL-UK questionnaire is an important 
patient reported outcome which should be continued in a future definitive study. 
A set of core outcome measures for periodontal studies is under development using the Core 
Outcome Measures in Effectiveness Trials (COMET) methodology (Glenny et al., 2012; 
Lamont et al., 2017). The results are not yet published but email correspondence has 
identified that five core outcomes will be recommended: probing depths, quantified levels of 
gingivitis, quantified levels of plaque, quality of life and tooth loss (T Lamont, personal 
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communication, 21 August 2018). All of these were collected in the pilot trial and should also 
be collected a future definitive study.  
The collection of subgingival plaque and GCF for microbiological and inflammatory 
biomarker analysis should be reviewed in the design of a future definitive study, potentially 
being removed. This will depend on the findings from the analysis of these samples from the 
current study and the aims of the definitive study.    
Sample size 
A future definitive study should base its sample size calculation on the findings of the current 
study. It is proposed that the definitive study should have co-primary outcomes as there are 
two important outcomes under investigation: smoking abstinence rates and periodontal health. 
A sample size calculation based upon the outcome of smoking abstinence, requires 337 
participants per arm which is also large enough to cover the periodontal health outcome 
measures (e.g. PPD or percentage of diseased sites [PPD ≥5 mm]). The participant attrition 
rate and eligibility rates seen in the pilot trial can be taken into account to provide estimates 
for the definitive study design.   
3.7 Conclusions 
It was feasible to provide an e-cigarette intervention for smoking cessation, for patients with 
periodontitis, within the dental setting. The data suggested that the intervention may improve 
smoking quit rates and may have minimal positive effects on periodontal health at 6 months. 
The findings of this study will inform the design and sample size of a future definitive study.  
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Chapter 4 Perceived influences on smoking behaviour and perceptions of 
dentist-delivered smoking cessation advice: A qualitative interview 
study.  
___________________________________________________________________________ 
4.1 Abstract 
Background 
Smoking cessation advice (SCA) from the dental team is an important aspect of patient care. 
Previous research has focused on dental professionals’ perceptions of providing SCA and has 
identified facilitators and barriers to providing SCA. However, there has been a limited 
amount of research focusing on patients’ perceptions of receiving SCA in the dental context. 
This study aimed to explore the views of patients with periodontitis receiving dentist-
delivered SCA.    
Methods 
Theory-based, one-to-one, semi-structured interviews were conducted with a purposive 
sample of 28 adults who smoked tobacco and had recently received SCA as part of a course of 
dentist-delivered periodontal therapy. Participants were sampled to reflect a range of ages and 
smoking behaviours. The interview was based on the 12 domains within the Theoretical 
Domain Framework (TDF) to explore perceived influences on smoking behaviour. Interviews 
also elicited participants’ views on dentist-delivered SCA. Interview transcripts were analysed 
thematically. 
Results 
In regards to perceived influences on smoking behaviour, a broad and complex range of 
themes emerged, covering all 12 of the TDF domains. Seven more prominent TDF domains 
(main themes in brackets) emerged: (1) social influences (family and friends, social 
pressures); (2) social/professional role and identity (identity - secret smoking); (3) knowledge 
(experiences/perceptions of stop smoking medications); (4) environmental context and 
resources (social, home and workplace environment, resources for smoking, resentment 
towards authority); (5) emotions (stress management, pleasure of smoking and fear of 
quitting); (6) nature of the behaviour (habitual nature, link to other behaviours, smell); (7) 
beliefs about consequences (health).  
With regards to views on dentist-delivered SCA, five main themes emerged: (1) opportunistic 
nature; (2) personal context and tangible prompts; (3) positive context of cessation attempt; 
(4) lack of previous support; and (5) differences by comparison with doctor-led SCA.  
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Conclusions 
From the perspective of the patient, dentist-delivered SCA was supported and positively 
received. Future research should focus on intervention optimisation based on the themes 
identified.       
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4.2 Introduction 
The provision of SCA is an important aspect of patient care. Dental professionals in the UK 
are advised, in several guidance documents, to provide SCA to all their patients who smoke 
(National Centre for Smoking Cessation and Training, 2012c; The National Institute for 
Health and Care Excellence, 2018). There are variations in how SCA can be delivered as 
previously discussed in chapter 1 (see section 1.3.2 and Table 1.1). A recent Cochrane 
systematic review and meta-analysis identified a number of relevant studies and concluded 
that SCA delivered in the dental setting can be an effective intervention (Carr and Ebbert, 
2012).   
A number of cross-sectional surveys have investigated patients’ perceptions of SCA delivered 
by dental professionals. The surveys generally report a positive attitude to dentist-delivered 
SCA, with increasing positive attitudes over time. Earlier studies reported lower rates of 
patient acceptance of SCA, with a US study (Campbell et al., 1999) reporting that 58.5% of 
dental patients believed dental offices should deliver SCA. Similarly, a large Australian 
survey found 61% of patients agreed that they would expect their dentist to discuss smoking 
with their patients (Rikard-Bell et al., 2003). This survey (Rikard-Bell et al., 2003) questioned 
the effectiveness of non-medical clinicians in providing SCA, on the basis that patients 
reported low confidence in their dentist’s ability to assist them in quitting with less than a 
third reporting to make a quit attempt if advised to by their dentist. The authors called for 
more research into the acceptability and effectiveness of SCA, and suggested that dentists 
would be justified in resisting calls to provide SCA to their smoking patients due to the 
questionable efficacy (Rikard-Bell et al., 2003). More recent surveys have found ‘very 
positive’ attitudes towards dentist-delivered SCA with percentages over 80% reported when 
similar questions were asked of dental patient populations in Ireland and India (Terrades et 
al., 2009; Sood et al., 2014). Terrades et al. (2009) also discussed the potential usefulness of 
highlighting the visible effects of smoking (e.g. tooth staining) but this was not investigated 
within their study.  
These cross-sectional surveys are limited by their design in providing any detail or depth of 
understanding regarding patients’ perceptions. A reasonable body of qualitative evidence 
exists for dental professionals’ perceptions of, and barriers to, providing SCA in the dental 
setting (Lala et al., 2017). However, there are no published qualitative studies investigating 
patients’ perceptions of dentist-delivered SCA. Within medical settings some limited 
qualitative evidence does exists of patients’ perceptions of SCA. For example, Butler et al. 
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(1998) conducted in-depth qualitative interviews with patients attending general medical 
practices in South Wales. This study controversially concluded that not all smokers should be 
provided with SCA and that doctors should tailor their approach to the type of patient using a 
patient-centred approach (i.e. focusing efforts on individuals showing interest in quitting). 
This was widely criticised at the time with subsequent correspondence advising that doctors 
continue to deliver evidence-based, brief interventions (e.g. the 4A’s approach) to all smokers 
regardless of doctors’ assessment of patient willingness to quit (Liu and Tang, 1998; Solberg 
and Kottle, 1998). They (Liu and Tang, 1998; Solberg and Kottle, 1998) also highlighted that 
physicians should avoid emphasising the ‘advise’ components of these interventions, as they 
can be seen as unhelpful prolonged attempts to convince and warn. The findings from the 
study conducted by Butler et al. (1998) may not be entirely relevant to the dental setting given 
the large differences in the clinical setting and patient experience. Additionally, the modern 
relevance of this study is questionable given that it was conducted over two decades ago with 
considerable societal changes since then and a greater range of smoking cessation 
interventions now available. 
Qualitative research interviews can be conducted in a variety of techniques: un-structured, 
semi-structured and in-depth (DiCicco‐Bloom and Crabtree, 2006). The Theory Domain 
Framework (TDF) provides an effective structure for semi-structured interviews on behaviour 
change (Michie et al., 2005; Cane et al., 2012). Basing interviews on the TDF ensures all 
theory-based predictors of behaviour and behaviour change are covered. The TDF was 
developed by an expert consensus group who reduced 40 theories of behaviour, with 128 
theoretical constructs, to 12 domains. The TDF provides a framework for ascertaining 
influences on behaviour and mapping to existing theory.      
In summary, evidence from quantitative studies indicates a positive attitude to dentist-
delivered SCA but there is an absence of any qualitative research providing depth of 
understanding. The aim of this study was to explore patient perceptions on dentist-delivered 
SCA using theory-based, semi-structured interviews in order to inform future intervention 
development and optimisation.  
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4.3 Method 
4.3.1 Design 
One-to-one semi-structured interviews were conducted using a pre-specified interview 
schedule based upon the TDF (Michie et al., 2005; Cane et al., 2012). The TDF consists of 12 
domains which represent broad explanations for behaviour and behaviour change 
hypothesised by current theory. The 12 domains comprise: ‘beliefs about capabilities’, 
‘knowledge’, ‘social influences’, ‘environmental context and resources’, ‘motivation and 
goals’, ‘behavioural regulation’, ‘memory, attention and decision processes’, ‘emotions’, 
‘social or professional role/identity’ and ‘skills’. Using the TDF ensures comprehensiveness 
and ability to connect data to specific relevant theories.   
4.3.2 Participants 
A purposive sample of twenty-eight adults was recruited from a larger group of eighty 
participants taking part in a two-armed feasibility RCT (described in chapter 3). Potential 
participants were approached face-to-face at their baseline study visit. All those who were 
approached to participate in the interviews accepted the invitation. The detailed eligibility 
criteria have been previously described in chapter 3 (see section 3.4.2) but briefly include 
adults smokers, not currently using an e-cigarette, with severe chronic periodontal disease. 
The purposive sample were selected to reflect a range of ages, gender, smoking behaviour 
(number of cigarettes/day), nicotine dependence (FTND), eCO measurements and RCT group 
(control/intervention).  
4.3.3 Interview protocol 
A interview schedule (see Appendix S) was developed based upon the 12 domains within the 
TDF (Michie et al., 2005), ensuring broad coverage of the theories of behaviour change 
within the interview. The schedule was designed to explore perceived influences on smoking 
behaviour, views on dentist-delivered SCA, views on e-cigarettes (chapter 5) and feasibility 
aspects of the research process (chapter 5). ‘Smoking’ was explicitly defined at the start of 
each interview, differentiating it from e-cigarettes and vaping. Participants were initially 
asked to confirm the details of their current and previous smoking behaviour, including 
previous quit attempts. Open questions were asked in each of the theoretical domains in order 
to elicit responses about smoking behaviour. The interview protocol was developed 
collaboratively within the research team. During a TDF training workshop, delivered by 
experienced researchers in this field, the interview protocol was piloted on workshop 
participants and refined. Further piloting was conducted within the research team.   
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4.3.4 Interview procedure 
Participants were interviewed in person within a research dental surgery at the Newcastle 
(Newcastle upon Tyne, UK) DCRF. An initial interview was conducted shortly after the SCA 
intervention (usually at visit 3 of the feasibility RCT) with a follow-up interview 
approximately six months later (usually at visit 6 of the feasibility RCT). The initial 
interviews were conducted between September 2016 and January 2018 with follow-up 
interviews between February 2017 and June 2018. The interviews were conducted by myself, 
Richard Holliday, a male research dentist conducting a PhD. No other staff members were 
present for the interviews. The researcher had appropriate training having completed a 
Masters in Clinical Research (general qualitative research training) and a training workshop 
(interviewing skills and conducting theory domain interviews). The researcher also had day-
to-day support from an experienced health psychologist with experience of using interviews 
of this design. There was no relationship between the researcher and participants prior to 
study commencement. The researcher was providing dental care, including SCA, for the 
participants as part of the pilot RCT. As with all qualitative research there was potential for 
researcher bias and a reflexivity statement is provided in chapter 6 (see section 6.4.1). There 
were no conflicts of interests and the interview schedule included a statement reassuring 
participants that there are no right or wrong answers, answers would not influence future care 
and that the participant was the expert from which the research team was trying to learn. 
Participants were aware of the aims of the research study as detailed in the participant 
information sheet (see Appendix G); primarily to investigate if e-cigarettes can help smokers 
(who have periodontitis) stop smoking. The study was approved by a NHS Research Ethics 
Committee (REC reference: 16/NE/0219). All participants provided informed written consent 
(see Appendix H) for participation in the feasibility RCT which included the possibility of 
being invited for interview. A £10 gift voucher was provided after completing each interview.   
4.3.5 Analysis 
Interviews were audio-recorded, anonymised and transcribed verbatim by a professional 
transcriber (David Anderson of Fairway Business Services). Field notes were taken if 
required. Although the TDF provided the structure for the interview schedule, the domains 
were not used as an explicit framework for the analysis. Instead interview transcripts were 
analysed thematically by the researcher using the domains as an initial framework but with 
expansion possible after an initial review of transcript content. Coding was completed using 
Nvivo software (QSR International Pty Ltd. Version 11, Edition: Pro, 2015). The reliability of 
the coding was checked by a second researcher (Dr Suzanne McDonald). Data saturation was 
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assessed and confirmed using standard recommendations (Francis et al., 2010). Interview 
transcripts were not returned to participants for comment/correction, although the second 
interview gave an opportunity for participants to reflect on themes identified from the first 
interview. This study adhered to the consolidated criteria for reporting qualitative research 
(COREQ) and a completed COREQ checklist is included (see Appendix T) (Tong et al., 
2007).  
4.4 Results  
4.4.1 Demographic data 
Twenty-eight participants (12 male) completed baseline interviews, which were conducted 
shortly after SCA intervention delivery (6 to 48 days after intervention [mean: 25 days]). Six 
participants were lost to follow up and 21 participants completed a follow-up interview. Equal 
numbers of participants were recruited from each RCT group (control/intervention). Further 
demographic characteristics of the sample are displayed in Table 4.1.  
Interview participants were aged 25-60 years (mean age: 45 years). Participants were heavy 
smokers, all smoking at least 10 cigarettes per day (median number of cigarettes per day: 15; 
mean eCO: 21 ppm), with a moderate level of nicotine dependence (mean FTND: 5). The 
interview participants represented a wide range of employment statuses with almost equal 
numbers in professional, intermediate and routine/manual/unemployed categories. The 
baseline interviews lasted between 10 and 52 minutes (mean length: 25 minutes).            
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 Not interviewed 
(n=56) 
 Interviewed 
(n=28) 
   All 
participants 
(n=28) 
Randomised groups 
Control 
(n=14) 
Intervention 
(n=14) 
Gender [n (%)] 
   Male 
   Female 
 
27 (52%) 
25 (48%) 
  
12 (43%) 
16 (57%) 
 
7 (50%) 
7 (50%) 
 
5 (36%) 
9 (64%) 
Age (years) 
Min  
Median (LQ-UQ) 
Mean (SD) 
Max 
 
 
19 
43 (38-50) 
44 (11) 
71 
  
25 
45 (36-56) 
45 (11) 
60 
 
25 
47 (37-57) 
49 (11) 
57 
 
27 
45 (35-53) 
44 (10) 
60 
Ethnicity [n (%)] 
White (British, Irish, other White) 
Asian or Asian British (Indian, Pakistani, Bangladeshi, other 
Asian) 
 
 
47 (90) 
5 (10) 
  
28 (100) 
0 
 
14 (100) 
0 
 
14 (100) 
0 
Age started smoking (years) 
Min  
Median (LQ-UQ) 
Mean (SD) 
Max 
 
 
 
10 
16 (15-17) 
16 (3) 
24 
  
12 
15 (14-16) 
16 (3) 
29 
 
12 
15 (14-16) 
15 (2) 
20 
 
12 
15 (14-16) 
16 (4) 
29 
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 Not interviewed 
(n=56) 
 Interviewed 
(n=28) 
   All 
participants 
(n=28) 
Randomised groups 
Control 
(n=14) 
Intervention 
(n=14) 
No. cigarettes per day 
Min  
Median (LQ-UQ) 
Mean (SD) 
Max 
 
 
10 
15 (11-20) 
17 (6) 
30 
  
10 
15 (15-24) 
19 (8) 
40 
 
10 
15 (14-30) 
19 (8) 
30 
 
10 
15 (14-21) 
18 (8) 
40 
FTND 
Min  
Median (LQ-UQ) 
Mean (SD) 
Max 
 
 
1 
5 (3-6) 
5 (2) 
9 
  
1 
5 (3-8) 
5 (2) 
9 
 
1 
5 (3-8) 
5 (3) 
9 
 
2 
5 (4-6) 
5 (2) 
9 
eCO (ppm) 
Min  
Median (LQ-UQ) 
Mean (SD) 
Max 
 
 
 
 
 
 
2 
20 (12-28) 
21 (12) 
55 
 
  
1 
20 (11-28) 
21 (11) 
49 
 
1 
20 (11-27) 
20 (12) 
49 
 
8 
22 (13-28) 
21 (10) 
40 
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 Not interviewed 
(n=56) 
 Interviewed 
(n=28) 
   All 
participants 
(n=28) 
Randomised groups 
Control 
(n=14) 
Intervention 
(n=14) 
Employment status [n (%)] 
Working in a routine or manual occupation 
Working in an intermediate occupation 
Working in a managerial or professional occupation 
Unemployed/not working for a year or more 
Full time student 
Retired 
Sick/Disabled/Unable to return to work 
Home carer (unpaid) 
None of these  
 
15 (29%) 
13 (25%) 
9 (17%) 
6 (12%) 
1 (2%) 
5 (10%) 
2 (4%) 
1 (2%) 
0 
  
6 (21%) 
9 (32%) 
9 (32%) 
2 (7%) 
0 
0 
1 (4%) 
1 (4%) 
0 
 
3 (21%) 
4 (29%) 
4 (29%) 
1 (7%) 
0 
0 
1 (4%) 
1 (4%) 
0 
 
3 (21%) 
5 (36%) 
5 (36%) 
1 (8%) 
0 
0 
0 
0 
0 
 
Table 4.1 Demographic data of interviewed participants with comparison by intervention group and against those not interviewed.
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4.4.2 Overview of themes 
Smokers with periodontitis, attending the dentist for a course of periodontal therapy, have a 
broad and complex range of influences affecting their smoking behaviour and views about 
quit attempts. The following results section is organised into two broad areas: (1) views on 
influences on smoking behaviour and (2) views on dentist-delivered SCA.  
Regarding influences on smoking behaviour, the interview data were coded within all 12 TDF 
domains, although seven of the domains were more prominent. These TDF domains (main 
themes in brackets) were: (1) social influences (family and friends, social pressures); (2) 
social/professional role and identity (identity - secret smoking); (3) knowledge 
(experiences/perceptions of stop smoking medications); (4) environmental context and 
resources (social, home and workplace environment, resources for smoking, resentment 
towards authority); (5) emotions (stress management, pleasure of smoking and fear of 
quitting); (6) nature of the behaviour (habitual nature, link to other behaviours, smell); (7) 
beliefs about consequences (health).  
When specifically considering the dentist-delivered SCA five main themes emerged: (1) 
opportunistic nature; (2) personal context and tangible prompts; (3) positive context of quit 
attempt; (4) lack of previous support; and (5) differences by comparison with doctor-led SCA. 
Figure 4.1 details all the themes and sub-themes.  
The following sections described the seven TDF domains and related themes regarding 
smoking behaviour followed by the five themes relating to dentist-delivered SCA. Direct 
quotes are provided and individual participant characteristics (gender, age, average number of 
cigarettes per day) are shown in brackets following each quote. Supplementary participant 
quotes are provided in Appendix U.  
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Social influences 
Social/professional 
role and identify  
Knowledge 
Environmental 
context and 
resources 
Nature of the 
behaviour 
Emotions 
Beliefs about 
consequences 
Family & friends Social pressure 
Identity- secret smoking 
Experiences/perceptions of 
stop smoking medication 
Influence of social, home and 
workplace environments 
Cost of 
smoking 
Resentment towards authority 
Stress management Pleasure of smoking 
Smoking dependence 
Link to others’ behaviours 
Smell 
Health 
Main themes Significant sub-themes 
Behavioural 
regulation 
Motivation & goals 
Beliefs about 
capabilities 
Skills 
Less significant themes 
Differences by comparison with 
doctor-led SCA 
Lack of previous support 
Positive context of quit attempt 
Personal context and tangible prompts 
Opportunistic nature 
Dentist-delivered SCA themes 
Figure 4.1 Coding tree 
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4.4.3 Theory-based influences on smoking behaviour   
 
Social influences 
The influence of family members and friends 
A persistent theme that emerged from that data was that participants felt their smoking 
behaviour or quit attempt were strongly influenced by social factors. Often this was at an 
inter-personal level with participants perceiving that family members or friends influenced 
their smoking behaviour or quit attempts. 
 
Supportive [family]. Very much so… my other half [wife], she’s an ex-
smoker… her view is, “If you want to smoke, it’s up to you. I don’t mind, 
but if by not smoking, you’re going to be around longer, then I’d rather you 
were around longer.” That’s her, quite grounded view of it. (Male, 56 years, 
20 cigs/day) 
 
This quote illustrates the supportive influence (social support) of a close family member on a 
quit attempt. The pressure exerted by the family member is indirect and not overpowering, 
perhaps due to her status as an ex-smoker. The participant appears to respect her view by 
referring to it as ‘grounded’.  
Other family members can also offer support, particularly young family members. The study 
participants were usually at least middle-aged and many reported that their children or 
grandchildren had a positive influence on their quit attempt.   
 
…me (my) son’s just so positive, he doesn’t smoke and we’re (I’m) getting 
the proper Mam (mum) pep talk. So that’s really good. (Female, 58 years, 
15 cigs/day)    
 
Younger family members are more likely to be non-smokers, as the above quote illustrates, 
and were often encouraging their older relatives (study participants) to quit smoking. Social 
acquaintances and friends also imparted influence.  
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Really encouraging [friends]. So much, to the fact that, I think I told you, I 
was away this weekend, been across to Spain, and me pal’s [friend] done 
exactly the same [quit smoking with e-cigarette]. (Male, 58 years, 15 
cigs/day) 
 
This quote illustrates the positive influence (on quitting) of a friend and demonstrates an 
example of collaborative behaviour. However, when participants had friends who were 
smokers they often found this to be a negative influence (on quitting).  
 
…I have avoided people who smoke. Because a lot of me [my] friends do 
smoke so I haven’t been visiting them. ‘Cos I thought the temptation’s still 
early days at the moment. (Female, 45 years, 10 cigs/day)  
 
In the early stages of a quit attempt participants often tried to avoid temptation, especially 
from friends, as illustrated in this quote. Participants reported avoiding situations or 
individuals that they perceived to have a negative influence on their quit attempt.    
 
Social pressure 
Beyond personal social influences, participants also perceived a strong influence of wider 
societal factors on their smoking behaviour. They had a strong sense that as smokers they 
were part of a minority.  
 
There’s not a lot of people around me [that smoke], I don’t think I even 
have any family that smoke anymore… Everyone has, who did smoke, 
which isn’t many, has stopped (Male, 38 years, 10 cigs/day) 
 
It’s not as noticeable as what it used to be [smoking]. It’s gone down 
dramatically, the smoking. (Female, 57 years, 20 cigs/day) 
 
These quotes demonstrate that participants had an awareness that smoking prevalence had 
steadily declined. This social comparison was both within their personal social circles (first 
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quote) and also at a wider population level (second quote). Beyond the sense that they were 
part of a minority they also felt strong negative societal pressures against smoking.  
 
There’s no doubt that in the current climate where smoking isn’t socially 
acceptable, that it’s not a question of being forced to go outside to have a 
cigarette, because you’d feel very uncomfortable having a cigarette in 
somewhere with everybody else. (Male, 56 years, 20 cigs/day) 
 
Participants reported being aware of injunctive norms (smoking was not welcome or socially 
acceptable), as illustrated in the above quote. In this case, the participant talks about feeling 
uncomfortable and this affecting his smoking behaviour. Similarly, other participants spoke of 
feeling ‘embarrassed’ to smoke in public. The age of the participant, in this case, is also 
important, as smoking was socially acceptable and a social norm for a large proportion of his 
life. In other cases this feeling went beyond feeling uncomfortable.  
 
It was different when you could smoke in pubs and it’s not a social thing 
now I don’t think it is… But now it’s something that I don’t want it to be 
[smoker]. (Male, 38 years, 10 cigs/day) 
 
The societal pressures felt by this participant make them want to disassociate from being a 
smoker. The environmental context of the ‘pub’ is influential to many participants and this is 
explored in a later in this section. Participants often felt there was a poor physical image 
associated with a person smoking.  
 
I think is looks horrible. I think it looks awful when you see somebody 
walking down the street with a tab in their mouth. (Female, 49 years, 20 
cigs/day) 
 
 
As in this quote, participants often considered that smoking had a negative impact on 
appearance and was ‘unattractive’. Some participants reflected that this influenced their own 
perceptions and potentially their smoking behaviour.  
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…because society’s changed, I think smoking now is not as acceptable 
anywhere, as it used [to be], I mean at one time you could have a cigarette 
in a restaurant, you can’t now, it’s not acc-, it’s just not acceptable. So, and 
I want to be accepted. I don’t want to be the one that’s not accepted. I don’t 
want to be the one that’s not cool anymore. You know what I mean? I want 
to like, be cool. (Female, 52 years, 15 cigs/day) 
 
This quote highlights many of the themes identified within this section. Societal changes are 
noted by the participant, leading to a perception that smoking is not acceptable or ‘cool’ 
(injunctive norms) and a desire to quit smoking in order to conform to societal norms.   
 
Social/professional role and identity  
Identity - secret smoking 
Following on from the previous domain/theme (social influences/social pressure) some of the 
interview participants reported trying to hide their smoking behaviour and identified 
themselves as ‘secret smokers’.  
…there’s quite a few of my friends, don’t know I smoke… I would go and 
sneak and have a cigarette somewhere… I don’t know for me it was sort of 
a hidden type of thing, it was, as I say, I wouldn’t go out and smoke, 
especially like at work. I don’t think anybody at work knows I do smoke. 
(Female, 47 years, 10 cigs/day) 
 
This quote highlights a participant who is trying to hide her smoking behaviour, identifying it 
as hidden or secret. This is particularly notable in public environments such as the workplace. 
This influence of the workplace is explored later in this section. For other participants, 
smoking was an important aspect of their identity.  
 
I like, old motorbikes, I like old unusual cars, I like old strong beers and 
stuff. It’s almost as though, puffing on a roll up is, almost part of that… it’s 
[smoking] become more of a hobby, one of my life choices is through 
motorcycling. 30 odd years I’ve ridden old Harley Davidsons everywhere.  
(Male, 56 years, 20 cigs/day) 
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This quote illustrates that smoking still has perceived value or is consistent with identity or 
behaviour in some groups in society. The participant felt smoking (rolled tobacco) was an 
important aspect of group identity (motorcycling culture) and this affected his smoking 
behaviour, making him less likely to make a quit attempt.  
 
Knowledge  
Experiences/perceptions of stop smoking medications 
It was clear that many of the interview participants had made several previous quit attempts. 
They had extensive experience of using smoking cessation medications and/or services. 
Perceptions towards stop smoking medications were largely negative.  
 
And I’ve tried the patches… I stopped smoking for five weeks, but I was on 
the patches for four weeks of that. [Interviewer: OK. And how did you find 
them?] Terrible. Absolutely terrible. (Female, 58 years, 15 cigs/day) 
 
This quote illustrates negative perceptions towards nicotine patches based upon the 
participant’s personal experiences. Others developed opinions on stop smoking medications 
using feedback from other people.  
 
Well, apparently, the tablets are supposed to be quite good, but again 
they’re, and they’re supposed to give you, a lot of bad side effects I think... 
like dreams and sort of, so I was like, oh, not, something that I didn’t want 
to ever try. (Female, 35 years, 10 cigs/day)   
 
[talking about Champix] I don’t know how I feel about, almost 
brainwashing yourself… Yes, you’re tricking your taste, but it’s your mind 
that needs to be behind it. ‘Cos you’re still going to have the urge for the 
cigarette... and it’s almost like you’re fighting each other. Your mind’s 
fighting your physical addiction. (Female, 37 years, 30 cigs/day) 
 
Perceived side effects of stop smoking medications were mentioned by some participants, as 
in this case. Interviewees often cited side effects as a reason to justify not using the 
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medications in a quit attempt. Some participants felt uncomfortable with the lack of control 
and perceived ‘brainwashing’ traits of some of these medications. However, not all 
participants had negative experiences and perceptions.   
 
Well, the Champix one, that really really works. But, it just made me, an 
emotional wreck. I mean, normally things that I could deal with, I mean 
there was one lady, was moaning about there wasn’t enough jam in her 
doughnut, and I was sort of like, “Well, I didn’t make the bloody 
doughnut”… I just found I wasn’t able to tolerate things. So I just, but I 
think I probably would consider it again… Because it really does work.  
You like, put a cigarette in your mouth and you’re like, “I just don’t want 
it”.  It’s quite clever… Me Mum’s done marvellous on it. (Female, 49 years, 
15 cigs/day)  
 
In this quote, although the participant experienced some negative side effects from the 
medication these appear to be outweighed by the positive effects experienced by the 
participant and her mother.    
 
Environmental context and resources  
The influence of social, home, and workplace environments 
Participants reported that different environments had an influence on their smoking 
behaviour.  
 
…the clubhouse at the caravan. Yeah, there are sort of several areas where 
you can go and have a cigarette and there’s always someone saying “Are 
you going to come out and have a cigarette?” (Female, 47 years, 15 
cigs/day) 
 
Social environments, especially those involving alcohol were often one of the hardest for 
participants to refrain from smoking in, as illustrated in the above quote. The link with 
alcohol is powerful and explored later in this section. The effect of smoke-free legislation was 
mentioned by several participants.   
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I mean certainly nowadays when, if you happen to be down the pub and you 
want to have a cigarette, you have to go outside... so, I suppose that time 
that you spend outside, you could spend it inside, socially interacting, 
although the converse is also true, ‘cos a lot of my friends like to stand 
outside anyway so... (Male, 47 years, 15 cigs/day) 
 
…it’s all gone [social aspects of smoking] because the pubs have all 
stopped it [allowing smoking inside] so you feel like a pariah stood outside 
smoking (Male, 59 years, 30 cigs/day) 
 
These quotes demonstrate how smoke-free legislation has changed behaviour in pubs in the 
UK, with differing experiences between the two participants. In the first quote the participant 
feels they have to smoke to be part of the social group that stands outside. Conversely, in the 
second quote the participant feels alienation and stigmatisation by having to stand outside. In 
some cases the social environment can also extend into the home environment.   
 
…‘cos people come [to the house] and they all smoke… So I’m going to 
ban it after Christmas from me [my] house. [laughs]… I need a smokers’ 
hut for me [my] back garden. (Female, 43 years, 20 cigs/day) 
 
In this case the interviewee’s friends were smoking in her house. She was aware of how this 
was negatively impacting her quit attempt and she was planning to challenge this in the near 
future. The influence of the workplace environment was perceived to be strong and to exert a 
negative impact on quitting attempts or success.  
 
When I’m at work I smoke quite a bit… So, that has been tough. (Female, 
31 years, 30 cigs/day) 
 
The workplace can be a tough environment during a quit attempt, as in the above quote, with 
people often finding it a setting in which they smoke a lot. For others, the challenge of this 
environment was the availability of tobacco from colleagues or as a coping mechanism for 
stress. The social interactions associated with smoking in the workplace also place pressures 
on a quit attempt.  
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…there’s a few smokers and you get to find out the gossip. Or who’s 
twisting [complaining] about who. (Female, 40 years, 25 cigs/day) 
 
Similarly to the earlier participant who feared missing out on social interactions in the 
smokers-area outside of the pub, this participant describes a comparable situation in the 
workplace. Another participant felt that the smokers’ area was an important decision-making 
space. 
   
I say tongue-in-cheek really, we always laugh at work because… More 
decisions are made and you find out far more there [outside smoking area].  
I’ll sit in a meeting for hours, and we’ll argue and debate, [then we’ll] go 
out for a cigarette, someone will be there, ‘So, we’re going to do this, this 
and this...’, ‘Yeah.’  (Male, 56 years, 20 cigs/day) 
 
This office-based worker suggests that the outside smoking area is important for work-based 
relations both in terms of finding out information and making decisions. The participant 
introduces the comment by suggesting it might not be totally true (tongue-in-cheek) but then 
states that it is often acknowledged by co-workers which implies there is some reality to the 
statement. However, the negative influence of the workplace was not consistent and some 
reported that it had a positive influence on their smoking behaviour.  
 
Yeah. Work is quite formal so, I wouldn’t even dream of smoking at work.  
Even, staff parties or whatever... (Female, 47 years, 10 cigs/day) 
 
Only a small number of participants reported reduced smoking in the workplace. It was 
usually those with more professional or managerial roles and, as illustrated in the quote 
above, this was usually due to the perceived negative image associated with smoking.   
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Cost of smoking 
Another prominent theme in interviews was the cost of purchasing tobacco products. 
Smoking was described as expensive, and participants drew comparisons with other goods or 
services that money could be spent on instead.  
 
Ridiculous amounts [spent on cigarettes]. That’s the crazy thing. I’ll see, I 
don’t know, make-up, for example, I’ll look for what’s on offer.  It’s like a 
tenner, I’ll be like [cautious], however I have no qualms what-so-ever in 
handing over £20 for 40 cigarettes. And that is crazy. Like, over a month 
it’s like 200 odd pounds. So that is a significant amount, that’s like what, 
half of a mortgage payment? If not, slightly more? But for some reason you 
don’t think about anything about handing it over. (Female, 37 years, 30 
cigs/day) 
 
These participants, as illustrated in the above quote, were very aware of the significant 
proportion of their income they were spending on tobacco smoking. However, other 
interviewees felt unaffected by the financial costs of smoking.  
 
It’s never been an issue… I’m not boasting, but... It’s never been an issue 
with me… I would imagine it will be with quite a lot of people because it 
can be a bloody expensive exercise. (Male, 58 years, 15 cigs/day) 
 
…it’s not expensive what I buy, buy cheap pouch tobacco, 50 grams I only 
pay £9 for it, which is cheap but, it lasts me two weeks you know. (Male, 27 
years, 15 cigs/day) 
 
These quotes illustrate that participants felt unaffected by the financial cost of smoking either 
due to their sufficient income (first quote) or, more often, due to access to cheap tobacco 
(second quote).   
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Resentment towards authority 
A theme strongly voiced in a small number of interviews was resentment towards authority 
regarding smoking behaviour. This was usually targeted toward tobacco control polices and 
often focused around cost and taxes.      
 ...the government shouldn’t sell cigarettes, full stop. And then, they would 
save fortunes in dental healthcare and they would save fortunes in 
healthcare. ‘Cos they wouldn’t have all of this [these] problems. [I] Don’t 
know why they don’t just stop selling them, I mean they’re making them so 
bad for you, why sell them in the first place? ‘Cos they make too much 
money off them, that’s why… But I mean, you think about even the 
country, I mean, how much money the governm- [government], the NHS 
would save, with smoking-related diseases. Absolute millions.  (Female, 52 
years, 15 cigs/day) 
 
This participant gives a broad account of the reasons why smoking is bad for the healthcare 
system but cynically feels the government continues to allow the sales of cigarettes for 
financial reasons. The participant’s use of language in reference to the government is 
noteworthy. They seem to imply that the government is the manufacturer of cigarettes and 
that they make them harmful on purpose, showing a deep resentment towards them.      
 
Emotions  
Stress management 
Participants perceived a wide range of emotional influences on their smoking behaviour. 
Many associated increased smoking with stress and perceived stress as a barrier for 
unsuccessful quit attempts.  
 
…it’s only really if there’s like a stressful sort of situation going on and I 
think at the moment I’m in a good place at work that I haven’t really had 
that much stress, lately, so that’s probably why I’m in a better, frame of 
mind to sort of think about you know, stopping altogether. (Male, 45 years, 
15 cigs/day)     
 
This example highlights how participants linked smoking as a coping mechanism for stress. In 
this case, they felt the recent reduction in stress was beneficial for their quit attempt. Similarly 
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to stress, other participants cited major ‘life events’ as influencing factors on their smoking 
behaviour.  
 
...three or four year ago, me mam [mother] died. So the first thing I done 
[did] was went and, went, after I’d come from the hospital...’cos we were 
there when she died, went straight to the shop, bought a lighter, bought a 
packet of cigarettes, so... (Female, 49 years, 15 cigs/day) 
 
Several different types of ‘life events’ were cited as major influences on smoking behaviour 
or reasons for previous relapse such as relationship issues, moving house or bereavement, as 
in this case. These life events were usually negative or stressful events but one participant also 
had a positive ‘life event’ negatively impacting on their quit attempt.  
 
Yeah, got it [new job], yeah, I was happy about that, found out last night… 
I ended up having a cigarette because of it like (Male, 27 years, 15 cigs/day) 
 
This participant celebrated getting a new job by having a cigarette, despite a recent period of 
abstinence. He used the cigarette as a reward following finding out the good news.  
 
Pleasure of smoking 
The pleasurable aspects of smoking emerged as a prominent theme in some interviews.  
 
But, it’s a funny thing because, I don’t mind smoking, I just know the 
damage it’s doing to us [me]. You know like, I’ve never not enjoyed 
[smoking] (Female, 58 years, 15 cigs/days) 
 
This participant has an internal struggle; she is well aware of the harms and negative aspects 
of smoking but enjoyed it and found it pleasurable.  
 
Fear of quitting 
A small number of participants articulated a ‘fear’ of stopping smoking. 
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I think it’s a fear, of hearing everybody going through such a horrific time, 
never fully getting over it, thinking oh, you hear about people 15, 20 years 
later, saying, “Oh, do you know, I could just do with a cigarette”. And it’s 
almost like torturing yourself, you’re wanting something so much, but you 
can’t have it. (Female, 37 years, 30 cigs/day)   
 
In this quote, the participant is articulating a fear associated with a quit attempt. She describes 
nicotine withdrawal symptoms and craving for a cigarette.  
 
Nature of the behaviour  
Smoking dependence 
The addictive and habitual nature of smoking was a major theme that emerged from the 
interview data.  
 
But, when you say how many do you smoke in a day, I don’t actually stop, I 
wake up during the night [to smoke]... yeah, and I think, I’m not entirely 
sure, but it’s a habit born out of addiction. But I’ve been doing that for 
years. I’m a lot better now than what I used to be... for example, last night, I 
went to bed at about half ten, and I was up just after midnight. Then I got up 
at three, and then I was up at about half four. But I literally, I go back to 
sleep straight away… It’s almost like the urge to smoke is so subconscious I 
can’t fully settle, it’s strange… I don’t know, I actually think it’s a habit 
now. (Female, 37 years, 30 cigs/days) 
 
This participant is demonstrating powerful nicotine dependence, having to break her sleep 
every two hours for a cigarette. Beyond the pharmacological dependence the participant feels 
her behaviour has now developed into a habit or routine.  
 
Link to other behaviours 
The participants’ smoking behaviour was often linked to other behaviours/habits such as 
drinking coffee, tea or alcohol.    
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I’ll have a coffee and a tab [cigarette], a coffee and a cigarette. A cup and a 
tab [cigarette]. (Female, 58 years, 15 cigs/day) 
  
In this quote the participant is revealing how intimately her smoking behaviour is linked to 
coffee drinking. It was very common for participants to describe the intimate relationship 
between smoking and drinking coffee or tea, almost as if they are the same behaviour. There 
was also a strong link to alcohol.  
I don’t want to go out drinking anytime soon, ‘cos I think that’s the biggest 
pitfall for it. (Male, 27 years, 15 cigs/day) 
 
As in this case, many participants were aware of social situations involving alcohol as being 
high risk for relapse during a quit attempt. Many tried to avoid these situations in the early 
stages of a quit attempt.  
 
Smell 
The smell associated with smoking emerged as a strong theme from the data. Many 
participants were acutely aware of the smells associated with smoking and presented strong 
views on this.  
 
I think the smell as well… You know, the amount of, sort of deodorant and 
the amount of perfume, the amount of, mints and mouthwash that I was 
using because actually I didn’t like the smell of it, or the way it made my 
clothes and myself smell.  So I think that’s an advantage that I’ve seen 
already [of quitting], that I don’t, you know, I’m not using as much 
mouthwash or anything. (Female, 47 years, 10 cigs/day) 
 
This quote illustrates the awareness and self-consciousness of some participants about their 
smoking habit. This participant had developed a routine to mask the smell and was using the 
reduction in this as positive reinforcement during the current quit attempt.  
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Beliefs about consequences  
Health 
The majority of the participants had perceptions about the consequences of their smoking 
behaviour, with most of this centred on health concerns.  
 
And health wise, probably health wise is the main thing really. I’ve got a 
fear, and probably getting to the age now, the fear’s going to kick in a bit 
more… I’ve got a fear of dying… Terrible fear. (Male, 60 years, 15 
cigs/day) 
 
Many participant were very concerned about the health damage caused by smoking, as in this 
quote. However, there were a wide spectrum of views with others less concerned.  
  
…I look at how old I am, you see, and sometimes I say to myself, “I ain’t 
bothered if I live another 10 years. I really couldn’t give a toss”. And that’s 
the thing in the head. You see. Doesn’t bother us, because there’s something 
better on the other side you know. (Male, 59 years, 30 cigs/day) 
 
This participant articulates a view of having few concerns about their health, perhaps due to 
their beliefs. This viewpoint was unique amongst the participants interviewed. Some 
participants articulated health concerns in relation to quitting smoking.  
 
I’m just sort of like thinking… you know like smoking and stopping 
smoking is just like opening a Pandora’s box. Do you know what I mean? 
(Female, 58 years, 15 cigs/day) 
 
This participant was worried about the unknown and about making changes to a long-standing 
routine. Others spoke about behavioural changes such as ‘not being a very nice person’ or 
about weight concerns, particularly the fear of weight gain following quitting.   
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4.4.4 Dentist-delivered smoking cessation advice findings  
The following section presents findings with regards to the dentist-delivered SCA. Five 
themes are described with illustrating quotes.  
Opportunistic nature 
The opportunistic nature of the dentist-delivered SCA developed as a theme from the data. 
Several participants commented on the SCA being unexpected at the dental visit.  
 
Just coming in here, like last week, as somebody just offering you an olive 
branch, that hope, to think, whereas before I was just going on, and “I’ll get 
round to it [quitting] one day”. (Female, 58 years, 15 cigs/day) 
 
This quote illustrates the opportunistic nature of the SCA and how it was viewed positively by 
the participant as an ‘olive branch’. The SCA was often linked to the discussions about 
periodontitis, which also appeared to strongly impact several participants.  
 
And so it’s sort of been like a slap in the face sort of thing, like, “Oh wow, I 
didn’t realise it was doing that much damage”. (Female, 29 years, 10 
cigs/day) 
 
Connecting the SCA to the periodontitis appeared to have had a powerful effect for several 
participants, as in this case. Others described similar reactions using phrases such as ‘it hit me 
like a brick’. Several participants reflected on the dentist-delivered SCA being a significant 
moment in their journey to quitting.    
 
I was going to, I had planned on stopping anyway because of, moving house 
and wanting to stop, but I think sort of the gum disease, sort of, that was the 
final sort of, made the final decision. (Female, 47 years, 10 cigs/day) 
  
As in many cases, this participant had existing intentions to quit smoking but the dentist-
delivered SCA appears to be a major influencing factor along this journey.   
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Personal context and tangible prompts 
Oral health considerations were commonly referred to as reasons for quitting with  
participants being very concerned about appearance and tooth loss. All the participants in this 
study had periodontitis and they often referred to the consequences of periodontitis as a 
motivation for their quit attempt.  
 
I had it in me [my] head, once I’d found out, about me [my] bones and me 
[my] gums and that, that I wanted to stop… It’s given us that extra push 
really. (Male, 36 years, 15 cigs/day) 
 
As in the previous section, this quote illustrates the perceived influence of dental 
considerations on the participants’ quit attempt. The personal context of adverse effects 
seemed to be an important consideration.   
 
I know, the problems I’ve had with my front teeth. And that appears to be 
linked to smoking, because I started smoking again when issues started to 
happen and I think my personal appearance and my personal, sort of, feeling 
towards my teeth are more important and that’s why I needed to stop 
smoking as well… I know, on some packets of cigarettes, there’s some 
photographs and, it still doesn’t put you off, but I think when it happens to 
you, then it’s personal (Female, 47 years, 10 cigs/day) 
 
In this quote, the participant chiefly talks about their aesthetic concerns related to the 
periodontitis and how this is having a strong personal effect on her, much more so than the 
health warning images she has seen on cigarette packets. Several of the participants referred 
to a form of visual prompt that influenced them.  
 
...so, when I seen how bad the back of my teeth are, I don’t know how I 
didn’t notice that but, when I did notice that, [laughs] that was a click... 
(Male, 27 years, 15 cigs/day) 
I thought me teeth looked disgusting on that X-Ray… ‘cos they were 
coming out of the bone weren’t they? (Female, 57 years, 20 cigs/day) 
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These quotes illustrate that the visual appearance of their teeth (e.g. tooth staining, drifting, 
tooth loss) or the x-ray appearance were influential aspects of the dentist-delivered SCA.     
 
Positive context of quit attempt 
In this study, the SCA was delivered as part of a course of periodontal therapy. Several of the 
participants focused their quit attempt on positive aspects associated with reducing the 
ongoing damage to their periodontal health or with the outcomes of the periodontal therapy 
e.g. improved outcomes.  
 
I know I’m having treatment but at the end of the treatment as long as I’m 
not smoking, there is going to be lots of improvement. Rather than carry on 
smoking and having the treatment it’s... it’s sort of outweighing itself really, 
there’s not much point. (Female, 45 years, 10 cigs/day) 
 
This participant is framing her quit attempt in a positive context alongside their periodontal 
treatment. Likewise, some participants reflected on the positive early outcomes of their 
periodontal therapy.  
 
I’m really pleased with, the outcome of that cleaning of my teeth and I 
really don’t want to, spoil it… Yeah, I’m really so pleased, they feel, lovely.  
Mm-hmm. (Female, 49 years, 20 cigs/day) 
 
This quote highlights how the early outcomes of periodontal therapy, such as cleaner teeth, 
were noted by participants and used as a motivation to quit or remain abstinent from smoking.   
  
Lack of previous support 
There were also some negative perceptions about previous dental care in relation to smoking 
cessation particularly around a lack of previous advice. 
 
 …my normal dentist never ever told me it was that [smoking was a risk 
factor for periodontitis]. It was just some infection I got… I never, I mean, 
yes, I knew it probably would cause some kind of damage to my gums at 
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some point, but, because I’ve never been told that, it’s never kind of, stuck 
there. I mean, if I had been told that years ago, when I first started, then 
probably it would have been a lot easier for me to say, “Well, I’m going to 
try”… But like I say, if the dentist had told me it was due to the smoking in 
the first place… I could have quit the smoking by now. (Male, 60 years, 15 
cigs/day) 
 
This participant felt that previous dentists had not provided sufficient information on smoking 
and periodontal health. There is an aspect of blame presented, with the participant feeling he 
would have quit smoking by now if he had been told sooner.  
 
Different to doctor-delivered SCA 
The dentist-delivered SCA was received positively by the participants. Many participants felt 
the dental context of the SCA was different to SCA they had received previously in other 
settings.  
 
…it’s like, it’s, coming from a nurse or a doctor who tells you that your 
lungs is all… you can’t see it, so you just think, “Oh, maybe’s not me, I’ll 
be alright”, but when you can physically see it, and you can see how it’s 
affected me gums… and affected me teeth and the receding of me gums and 
the bone… I can’t see inside me body, but I can see me teeth… I can see the 
difference that you’s [you] are doing, and I can feel the difference that you’s 
[you] are doing (Female, 52 years, 15 cigs/day) 
 
This participant felt the dentist-delivered SCA was more powerful because she could 
physically see the damage caused by smoking, unlike the potential damage on her lungs. This 
participant also identified the personal context and tangible nature of condition as being 
important, as discussed earlier in this section. The nature of the professional interaction was 
also noted by some participants.  
   
...I would say you’ve [dentist] had much more impact on me, than even, the 
doctor… I think because, I can’t hide me gums from you… you go to the 
doctor with an illness, whatever it might... and then it’s brought up in 
conversation but it’s only for a few minutes. Yes, he’s done his job because 
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he’s telling you, you know like, you should stop smoking (Female, 58 years, 
15 cigs/day) 
 
This participants felt SCA from a general medical doctor was sometimes a routine ‘tick box’ 
exercise. However, when delivered by the dentist, the SCA was perceived to carry more 
influence for many of the previously mentioned themes: personal context and tangible 
prompts, and positive context.  However, dentist-delivered SCA did not have a positive effect 
on everyone with one participant reporting little impact.    
 
To tell you the truth it didn’t make that much effect, ‘cos I was already 
aware that I shouldn’t be doing it in the first place. (Male, 44 years, 30 
cigs/day) 
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4.5 Discussion 
4.5.1 Summary of main findings 
The main findings from interviews related to two broad topics: smoking behaviour and 
dentist-delivered SCA. In terms of smoking behaviour, this was perceived to be affected by a 
broad and complex range of influences. Social influences had an important role at both the 
personal level (family and friends) and at a wider level (social pressure). Some participants 
were strongly affected by social role and identity and reported being secret smokers. Previous 
experiences of smoking cessation medications and services were extensive and often negative. 
Likewise, although a wide range of environmental factors influenced participants, the 
workplace was particularly strong and often perceived to be a negative influence on quitting 
attempts or success. Although resources for smoking were sometimes a major consideration 
(e.g. high cost), many participants felt unaffected by this partly due to sufficient income or 
access to cheap tobacco. Emotional influences were impactful including stress, ‘life events’ 
and fear. Participants were mindful of the addictive and habitual nature of smoking as well as 
the health consequences, although a small number felt they would be immune or didn’t care.    
In terms of dentist-delivered SCA, the opportunistic nature of this intervention was important 
for several of the participants. Putting the advice in a personal context, with tangible prompts, 
was a powerful motivator for quitting. Framing the advice and subsequent quit attempt in a 
personal context was seen as useful. Generally the dentist-delivered SCA was received 
positively, often being compared superiorly to medical doctor-delivered SCA.   
 
4.5.2 Relationship to previous research 
Influences on smoking behaviour  
Smoking behaviour has many components including initiation, maintenance, cessation and 
relapse. Since our sample primarily comprised relatively long-term smokers, often with 
previous experience of quit attempts, the behavioural components of interest are maintenance, 
cessation and relapse. 
Unsurprisingly, our study found that social influences were a strongly perceived influence on 
smoking behaviour. At a personal level, participants perceived influence from family and 
friends, usually in a positive context in respect of quit attempts. This is in keeping with the 
existing literature that has shown the strong influence of the social environment. The majority 
of the literature has focused on smoking initiation in adolescents or young adults with strong 
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influences of parents, siblings and peers (Daly et al., 1993; Tyas and Pederson, 1998). Social 
factors also have important influence on the continuation of smoking (smoking maintenance) 
with quit attempts more likely if there is a partner who objects to smoking (West et al., 2001) 
or for those who live in a home with a smoking ban (Li et al., 2011). Conversely, the presence 
of other smokers, in the form of friends (Richmond et al., 1993) or romantic partners (Murray 
et al., 1995), often decreases quit success. Interventions that exploit these social influences by 
involving ‘significant others’ have unfortunately shown equivocal results (May and West, 
2000; Park et al., 2002) and smoking cessation guidelines do not explicitly advocate these at 
present (Shahab, 2012).   
A social factor that was perceived strongly by our participants was the positive influence of 
younger family members, who were encouraging them to quit smoking. The mean age of our 
interview participants was 45 years, making it likely that they would have children, 
nieces/nephews or grandchildren who are teenagers or young adults. There are likely to be 
significant generational differences with regards to the experience of and attitudes towards 
smoking. Smoking prevalence rates are now very low in these young age groups with rates as 
low as 7% being reported for 15 year-olds in England (NHS Digital, 2017). The younger 
generation will have also experienced very different cultural influences and norms regarding 
smoking e.g. the smoking ban in public places. There is a notable lack of scientific literature 
exploring this phenomenon. Although not directly comparable, a recent study found that if 
parents, who had recently quit smoking, engaged in anti-smoking socialization of their 
children they lowered their own odds of relapse (Jackson et al., 2016). A study conducted by 
the Department of Health in 2011 surveyed 1000 children in England about their view on 
parental smoking (Department of Health, 2011). They demonstrated the strong anti-smoking 
stance of the ‘new smokefree generation of kids’ who labelled smoking as ‘stupid’ and said 
they would never try a cigarette. The strength of the feeling was confirmed by the fact that 
many said they would give up all their Christmas presents or pocket money to get their 
parents to quit. Almost a third of respondents admitted hiding their parent’s cigarettes to help 
them to quit. Future research should confirm the finding of the present study regarding the 
influence of younger family members on middle-aged quitters and explore the potential to 
utilise this in behavioural interventions. 
These cultural changes have also undoubtedly contributed to the negative societal pressures 
perceived in the current study. These included a feeling of being in the minority, 
stigmatisation of smoking/smokers and participants hiding their smoking (secret smokers). 
These influences emerged particularly strongly, in keeping with the existing evidence that 
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perceptions of what ought to be done by other people (injunctive norms) rather than 
perceptions of what is done by other people (descriptive norms) had greater influence on 
motivation to quit (van den Putte et al., 2005).  
The concept of a smoking stigma is extensively discussed in the literature (Stuber et al., 2008; 
Scheffels, 2009; Tombor et al., 2015; Castaldelli-Maia et al., 2016) and was a powerful 
influence on the participants, with several trying to avoid stigma by being ‘secret smokers’. 
This has been described recently by Thirlway (2018). Stigma can reduce smoking but can also 
contribute towards negative consequences such as loss of self-esteem, defensiveness and 
resolve to continue smoking (Evans-Polce et al., 2015). On lung cancer, for example, public 
health campaigns have inadvertently increased stigma towards those diagnosed with lung 
cancer and this has potentially led to deleterious downstream psychological and/or medical 
outcomes (Riley et al., 2017).  
Stigma is also an important concept in periodontitis sufferers. The current study, as well as 
existing literature (O'Dowd et al., 2010), has identified that periodontitis sufferers are likely to 
suffer from a range of negative emotions, not directly related to their smoking habit, including 
stigma, shame, embarrassment and regret about their oral health. Smokers with periodontitis, 
therefore, potentially suffer from a toxic combination of influences from both smoking and 
periodontitis and behavioural interventions should be sensitive to this.  
Thirlway (2018) provided a convincing argument for smoking stigma operating as a proxy for 
class stigma. She argues that smoking is being rejected by the middle-class not only because 
of the health harms but because it has become associated with lower classes; class stigma and 
smoking stigma have thus become mutually reinforcing. She introduces the Bourdieuian 
concept of ‘cleft habitus’ where an individual does not feel ‘at home’ in their class position. 
The two examples she provides are the upwardly mobile smoker or the middle-class smoker 
who is engaged in work/leisure pursuits which have their roots in working-class culture. A 
pertinent example of the later, from within the current study, involves a professional male 
who was heavily involved in a working-class culture (motorcycling) and perceiving this as an 
important influence on his smoking behaviour.   
Negative perceptions towards stop smoking medication are a well-recognised barrier towards 
uptake (Foulds et al., 2009). A range of explanations include concerns regarding the safety of 
nicotine (in the form of NRT), as well as concerns over the side effects, safety and efficacy of 
the medications (Etter and Perneger, 2001; Bansal et al., 2004; Hammond et al., 2004; Roddy 
et al., 2006b). In the current study the participants expressed the strongest concerns regarding 
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the possible side effects of the medications, referring to their own personal experiences or 
those of others around them.        
The significance of workplace policies and practices on smoking behaviour has been well 
established, both in terms of prevalence rates (Farkas et al., 2000) as well as differential 
cessation success rates when exposed to different work environmental factors (Albertsen et 
al., 2004). Consequently, workplace based interventions have been developed with several 
potential advantages (peer-group support, targeting those unlikely to access primary care 
alone and not using personal time) (Cahill and Lancaster, 2014). Thus, it is unsurprising that 
the current study also identified workplace factors as a significant perceived influence on 
smoking behaviour. Some particularly useful insights included the perceived importance of 
the smoking social interaction, with participants concerned about missing out on both 
important business decisions and ‘gossip’.     
Governments around the world have used fundamental principles of economics to reduce 
smoking rates by making it expensive through taxation (Chaloupka, 1999). The evidence 
generally concludes that increasing prices reduces socio-economic inequalities by hitting the 
poorest hardest (Giskes et al., 2007; Amos et al., 2011; Chaloupka et al., 2011). The 
relationship however is not simple due to the addictive nature of the product and presence of 
‘illicit tobacco’. In the current study, the participants roughly separated into two groups: those 
for whom the financial cost of smoking was significant and those who reported little 
perceived influence. In the UK, the issue of ‘illicit’ tobacco is well established (Action on 
Smoking and Health, 2017b) and many of our interview participants openly admitted to 
accessing tobacco via different routes including smuggling (‘cheap whites’) or bootlegging 
(legally purchased abroad and transported to another country with a higher tax rate, in 
amounts beyond those reasonable for personal use).  
In keeping with the literature, this study found a strong and complex relationship to emotions. 
Macnaughton et al. (2012) discuss the deep reliance smokers had on their cigarettes, referring 
to them as ‘friends’ or ‘companions’ and this was apparent in our study with several 
participants turning to them during important life events. Perhaps unsurprisingly the 
‘pleasure’ of smoking is perceived by smokers as a major reason for continued smoking (Ho, 
1989) and indeed enjoying smoking is linked to fewer quit attempts (West et al., 2001). This 
‘pleasure’ will be related to the psychoactive effects of nicotine (Benowitz, 2009) but also the 
complex physiological associations with smoking. Given the public health messages and 
cultural changes over recent decades, there can be a perception, by some, that continued 
smoking can be almost solely explained pharmacologically as a nicotine addiction. However, 
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our study reinforces the powerful influence of ‘pleasure’ and this should be acknowledged 
and utilised by policy makers and when designing interventions.  
Dentist-delivered SCA 
In the current study, participants had positive perceptions about the dentist-delivered SCA, 
which was in keeping with recent patient surveys (Terrades et al., 2009; Sood et al., 2014). 
The opportunistic nature of the intervention seemed to carry certain influence, reinforcing 
existing guidance to HCPs (The National Institute for Health and Care Excellence, 2018). In 
the particular context of this study, the participants were also receiving a course of periodontal 
therapy and several participants were shocked by the severity of their periodontal disease; in 
some cases this appeared to have a synergistic effect with their existing knowledge about 
smoking harms.  
The personal context of the oral health harms appeared particularly important e.g. tooth loss, 
mobility or staining. NICE guidance on behaviour change (The National Institute for Health 
and Care Excellence, 2007) highlights a number of concepts for behaviour change based upon 
the psychological literature and indeed includes ‘personal relevance (emphasising the 
personal salience of health behaviours)’. Another concept they (NICE) identify is ‘positive 
attitude (promoting positive feelings towards the outcomes of behaviour change)’ which was 
another theme identified from the current study. This was perceived particularly powerfully 
when participants had seen early improvements from their periodontal therapy.    
Elsewhere in medicine, the diagnosis of a significant (smoking-related) disease has been 
associated with an increased quit rate and an ideal time (a ‘teachable moment’) for SCA 
interventions (Bassett et al., 2012). The current study would indicate that a smoker with 
periodontitis who attends the dentist for a course of periodontal therapy would be in an ideal 
position to receive a SCA intervention. The concept of a ‘teachable moment’ is described as 
‘a particular set of circumstances which leads individuals to alter their health behaviour 
positively’ (Lawson and Flocke, 2009). Lawson and Flocke (2009) reviewed the literature on 
teachable moments, finding they were used across a variety of disciplines but were poorly 
developed both conceptually and operationally. They identified 81 articles, of which only one 
was in the dental setting (Stevens et al., 1995) indicating the potential underutilisation within 
this field and an area of future research.   
As well as a general resentment towards authority (e.g. governments) the current study found 
negative perceptions towards previous dental care and a lack of previous advice. The existing 
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literature is absent in this field and this should be an area of future research. Future 
interventions should also consider this in their design.  
Finally, with our participants being long-term smokers, many had received previous SCA 
from other HCPs. Many perceived the dentist-delivered SCA to be different to that from 
medical doctors. The aspects explored in this section (opportunistic, personal and positive) 
contributed toward the perception that the dentist-delivered SCA (in the particular context of 
the study) was more impactful than SCA delivered during a doctor’s visit which might have a 
perception of ‘routine’ and a ‘tick box’ exercise.     
4.5.3 Strengths and limitations 
This study is the first qualitative research study to investigate patient perceptions of receiving 
SCA in the dental setting. The study utilised the TDF, a comprehensive theoretical framework 
covering all potential hypotheses for behaviour and behaviour change and allowing findings 
to be matched to theory. The TDF has been used extensively in a wide range of applications, 
being cited in over 800 peer-reviewed publications (Atkins et al., 2017). As this was a 
qualitative study, the views expressed are unlikely to be representative of all smokers with 
periodontal disease. That said, as participants were recruited from a sample taking part in a 
clinical feasibility study, characteristics of participants were broadly representative of the 
condition in question (smokers with periodontal disease). For example, the age distribution 
was typical of those presenting with periodontal disease and smoking measures indicated a 
moderate nicotine dependence.    
However, some limitations of the research are acknowledged. The interviews were conducted 
within the clinical setting for logistical reasons. The participants were part of a larger clinical 
study which involved six clinical visits (over approximately six months) and, in order to 
minimise participant burden and increase compliance, the interviews were scheduled to run 
prior to an existing study visit, within the dental surgery. This had the potential to influence 
the participants’ responses and in order to minimise any effect the immediate environment 
was considered. Participants were seated on a sofa, away from the dental chair, and offered a 
hot drink in order to help them feel at ease. Another consideration was that the interviews 
were conducted by the research dentist (a limitation of a PhD research project) and again this 
may have influenced the participants’ responses. In an attempt to minimise any influence of 
this, the participants were reassured at the start of the interview that there were no right or 
wrong answers and that their care would not be affected in anyway by their responses. A 
previous study compared interviews by general medical practitioners and a social scientist and 
found no differences in how frank the participants were, with similar proportions of critical 
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accounts about health services (Butler et al., 1998). Nonetheless, the qualitative results should 
be interpreted with this consideration and future research confirm results where required.  
4.5.4 Implications for future research and practice  
The findings of this study offer a detailed understanding of the potential influences on 
smoking behaviour of smokers with periodontitis attending the dentist. There are a broad and 
complex range of potential influences which have largely been explored in previous research. 
The theory-based domains most relevant to this patient group were: social influences, 
social/professional role and identity, knowledge, environmental context and resources, 
emotions, nature of the behaviour and beliefs about consequences. Novel themes that were 
identified comprised: influence of young family members, resentment towards 
authority/previous lack of support and the potential for the initiation of periodontal therapy to 
be a teachable moment. Dentist-delivered SCA was well accepted by participants and the 
important aspects of this were the opportunistic nature, personal context, use of tangible 
prompts and positive context of the quit attempt. Two novel themes developed around a lack 
of previous support (from dentists) and comparison of SCA from medical doctors.  
Future research should focus on further exploring the novel themes identified to establish their 
importance in other populations with similar and different disease profiles. Future 
intervention development should consider the theory-based domains and themes identified as 
important during their design.    
4.6 Conclusions 
Smokers with periodontitis have a wide range of influences on their smoking behaviour. 
These largely cover well established themes identified from previous qualitative studies with 
smokers recruited in clinical settings. Additional concepts were: the influence of younger 
family members and resentment towards authority/previous lack of support. Dentist-delivered 
SCA was perceived positively with important aspects being the opportunistic nature, personal 
context, use of tangible prompts and positive context (of the quit attempt). The findings of 
this study could be used to inform future intervention development and optimisation.  
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Chapter 5  E-cigarettes for smoking cessation within healthcare settings: 
patients’ perceptions and research feasibility. A qualitative interview 
study.  
___________________________________________________________________________ 
5.1  Abstract 
Background 
Healthcare professionals (HCPs) have a professional duty to offer smoking cessation advice 
(SCA) to their patients who smoke. Most e-cigarette users initiate use independently without 
advice from a HCP. However, there is likely to be an increasing role for HCPs in supporting 
patients to stop smoking with e-cigarettes. The aim of this study was to explore the 
perceptions of individuals attending a healthcare setting towards e-cigarettes, and the 
acceptability and feasibility of providing e-cigarettes within this setting.         
Methods 
Theory-based, one-to-one, semi-structured interviews were conducted with a purposive 
sample of 28 adult smokers with periodontitis who were part of a feasibility randomised 
controlled trial (n=80). They were randomised (1:1) to receive either usual care (SCA) or 
usual care plus the offer of an e-cigarette starter kit. Participants were sampled to reflect a 
range of ages and smoking behaviours. The interview was based on the 12 domains within the 
TDF to explore perceptions of theory-based influences on smoking behaviour. Interviews also 
elicited participants’ views on dentist-delivered SCA (+/- e-cigarette) and the research 
process. Interview transcripts were analysed thematically. 
Results 
Several themes emerged regarding perceptions of e-cigarettes: influence of other e-cigarette 
users; previous e-cigarette experience; concerns about addiction to e-cigarettes/nicotine; 
health considerations; and social acceptability. For those who had been offered the e-cigarette 
starter kit, the main additional themes that emerged included: benefit of behavioural 
similarities to traditional cigarette smoking (hand-to-mouth, vapour, habit); and influence of 
flavours. E-liquid flavour choice was dichotomous: for or against tobacco flavours. 
Conclusions 
Smokers positively perceived the provision of an e-cigarette for smoking cessation within the 
dental healthcare setting. A wide range of positive and negative perceived influences were 
identified which could inform future approaches and interventions.  
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5.2 Background 
E-cigarettes have been around for just over a decade, hence the public’s perceptions are still 
developing and the focus of much attention. In 2010, there was low awareness of e-cigarettes 
with almost no smokers using e-cigarettes in quit attempts in England (West et al., 2018). 
However, by 2014, e-cigarettes were the most common quitting aid, and were used in around 
a third of quit attempts, which continues to be the case in 2018 (West et al., 2018). 
Perceptions towards the relative health harms have also changed. In the UK in 2013, only 7% 
of people surveyed believed e-cigarettes were more or equally harmful as compared to 
smoking conventional cigarettes but this had increased to 26% in 2017 (Action on Smoking 
and Health, 2017a). This is unrelated to awareness which has remained high (Brown et al., 
2014b; Action on Smoking and Health, 2017a). US data have shown similar trends with a 
tripling (x 3.1) of those perceiving e-cigarettes to be more or equally harmful than 
conventional cigarettes between 2012 and 2015 (Majeed et al., 2017). Recent research has 
identified that many people are concerned about addiction and the addictiveness of e-
cigarettes (Thirlway, 2016; Lucherini et al., 2017; McNeill et al., 2018). McNeill and 
colleagues (2018) called for the ‘widespread misperceptions’ about the relative risks of 
nicotine and tobacco to be ‘addressed and corrected’.  
Research studies on e-cigarettes are still relatively novel and face a unique set of challenges. 
The first clinical studies on e-cigarettes, which investigated acute effects such as craving and 
nicotine delivery, commenced in 2008 and were subsequently published in 2010 (Bullen et 
al., 2010; Eissenberg, 2010; Vansickel et al., 2010). Since then, a large amount of research 
has been conducted or is in the process of being conducted. Indeed, the recent Cochrane  
systematic review of e-cigarettes for smoking cessation (Hartmann-Boyce et al., 2016)  
identified 24 completed studies and 27 ongoing studies. There are many practical issues in 
conducting clinical research on a novel and varied product such as e-cigarettes e.g. device 
choice and flavour/strength options. Some research studies have chosen to limit heterogeneity 
by restricting participants to specific devices, e-liquid flavours and strengths while others 
have taken a more pragmatic design.  
In summary, smokers’ perceptions of e-cigarettes are diverse and dynamic. E-cigarette-based 
interventions within the healthcare and research settings are currently non-optimised. The aim 
of this study was to explore the perceptions of individuals attending a healthcare setting 
towards e-cigarettes and the acceptability and feasibility of providing e-cigarettes within this 
setting.     
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5.3 Methods 
A detailed description of the methods is provided in the previous chapter (see chapter 4). 
Briefly, theory-based, one-to-one, semi-structured interviews were conducted with a 
purposive sample of twenty-eight participants, fourteen of whom had received the e-cigarette 
intervention and the remainder of whom had received the control condition (dentist-delivered 
SCA). Both interventions are described in detail in chapter 3 (see section 3.4.5 and 3.4.6). 
Briefly, the e-cigarette intervention involved the provision of an e-cigarette starter kit (second 
generation device, choice of four flavours and four nicotine strengths, see Table 3.2) with 
participants expected to source and purchase their own supplies after the initial period (2-3 
weeks). Participants were sampled to reflect a range of ages and smoking behaviours. The 
interview schedule (see Appendix S) was developed based upon the 12 domains within the 
TDF (Michie et al., 2005), ensuring broad coverage of the theories of behaviour change 
within the interview. The schedule was designed to explore perceived influences on smoking 
behaviour (chapter 4), views on dentist-delivered SCA (chapter 4), views on e-cigarettes 
(chapter 5) and feasibility aspects of the research process (chapter 5). A reflexivity statement 
is provided (see section 6.4.1). This study adhered to the COREQ criteria and a completed 
COREQ checklist is include (see Appendix T) (Tong et al., 2007). 
5.4 Results 
5.4.1 Demographic data 
As described in chapter 4, twenty-eight participants completed baseline interviews shortly 
after intervention delivery (6 to 48 days after intervention [mean: 25 days]). General views on 
e-cigarettes were explored with all twenty-eight participants. A more detailed exploration of 
acceptability issues was conducted for the fourteen participants who had been provided with 
an e-cigarette starter kit. These fourteen participants were aged 27-60 years (mean age: 44 
years). Participants were heavy smokers, all smoking at least 10 cigarettes per day (median 
number of cigarettes per day: 15; mean eCO: 21ppm) with a moderate level of nicotine 
dependence (mean FTND: 5). In terms of employment, an almost equal numbers of 
participants were in professional, intermediate and routine/manual/unemployed categories. 
There were nine females and five males. Demographic characteristics of the sample are 
summarised in Table 4.1.    
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5.4.2 Overview of themes 
For perceived influences on smoking behaviour, a broad range of themes emerged, covering 
all 12 of the TDF domains, as presented in chapter 4. Smokers with periodontitis had a range 
of experiences and perceptions regarding e-cigarettes. Five over-arching themes emerged 
from the data: influence of other e-cigarette users; previous e-cigarette experience; concerns 
about addiction to e-cigarette/nicotine; health considerations; and social acceptability of e-
cigarettes. When considering those who had been offered the e-cigarette starter kit, three 
additional themes emerged, comprising the benefit of behavioural similarities with smoking 
(hand-to-mouth, vapour, habit); the influence of e-cigarette flavours; and technical issues.  
Direct quotes are provided and individual participant characteristics (gender, age, average 
number of cigarettes per day) are shown in brackets following each quote. Supplementary 
participant quotes are provided in Appendix V.  
 
5.4.3 Influence of other e-cigarette users  
Many of the participants reported knowing existing users of e-cigarettes. These e-cigarette 
users almost always acted as a positive influence towards vaping through their conversations 
or actions. 
 
…a lot of people I know, they seem, quite positive about it [vaping], and I 
haven’t had any sort of negative, feedback or anything from it so.  I think 
they kind of like think, “Well it’s, probably a lot better than a lot of the, 
junk and stuff that’s actually in a normal cigarette. (Male, 45 years, 15 
cigs/day)    
 
In this case, the participant knew many e-cigarette users and he perceived them to be positive 
about vaping. He compared vaping to conventional smoking and felt that the e-cigarette users 
he knew thought it would be ‘a lot better’. Other participants reported similarly positive 
impressions by observations of people around them.   
 
A lot of the girls at work, have been really successful on the e-cigarettes… 
about six or seven of the girls at work have stopped smoking with the e-
cigarettes... and they’re supportive as well, the girls at work are dead 
supportive as well.  (Female, 52 years, 15 cigs/day) 
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This participant had experienced many of her workplace friends successfully quitting smoking 
by using the e-cigarette. The workplace has been previously identified as an important 
influence of smoking behaviour, as discussed in chapter 4 (see section 4.4.3). At the time of 
the interview this participant had quit smoking using an e-cigarette (provided in the study). 
The support of her vaping friends appeared to be an important influence on her continued use 
of the e-cigarette. Other participants were aware of the positive views of e-cigarette users but 
still sceptical themselves.     
 
a lot of people say, “Well it’s a lot better than smoking”… the amount of 
people using them now it’s ridiculous, when you actually look around in 
like a smoking area outside where I work, it is quite crazy how, it’s kind of 
weird, so a lot of people must have a positive views of them as well you 
know. (Male, 27 years, 15 cigs/day) 
 
This participant had noted the large number of e-cigarette users in his environment and 
presumed they had positive views on e-cigarettes. However, his choice of language (e.g. 
ridiculous and weird) suggests he is unconvinced himself and uncomfortable with the number 
of e-cigarette users.  
 
 
5.4.4 Previous e-cigarette experience  
The eligibility criteria for the current study required participants to have not used an e-
cigarette regularly, within the 30 days prior to enrolment. However, many had previous 
personal experience of e-cigarettes from an earlier time period. Over two-thirds (68%) 
reported prior use of an e-cigarette, of whom around a third (37%) had previously used an e-
cigarette on a daily basis. This previous experience varied considerably from having used 
multiple devices in successful quit attempts (prior to relapse) to having a few puffs on friend’s 
devices. Overall, however, these participants’ previous experience of e-cigarettes was 
predominantly negative.   
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I did [previously use an e-cigarette], but it was when they first came out and 
it used to just leak all over the place in me [my] pocket, and the one that 
I’ve got off you is just brilliant because it doesn’t leak.  And that’s why I 
gave up on, that [previously].” (Female, 52 years, 15 cigs/day) 
 
As in this case, the negative previous experience was sometimes due to technical or practical 
issues. This participant found the previous device leaked and that caused her to stop using it. 
In other cases, the negative experiences were related to the sensations experienced by the 
participant.      
 
Well I’ve only tried one, nearly took the back of me [my] throat out, so I 
just, [laughs]… didn’t bother. Cos I think I just had it on the wrong 
setting… Yeah. I couldn’t stop [coughing], I thought I was going to 
choke… It was horrible. (Female, 57 years, 20 cigs/day) 
 
… it tasted really funny, you could taste like the, it sounds weird but you 
could actually taste like electricity in your mouth which was very weird. 
(Female, 45 years, 10 cigs/day) 
 
These quotes illustrate typical examples of previous negative e-cigarette experiences 
described by participants. In the first quote the participant experienced an unpleasant 
sensation in her throat followed by a cough which she described as ‘horrible’. The second 
quote is more related to an unpleasant taste or sensation in the participant’s mouth. In other 
cases, participants went to the effort of sourcing and purchasing e-cigarettes but were put off 
using them for other reasons other than a negative experience of actually trying it.    
 
I’ve bought two different types [of e-cigarette], I bought the ones with the 
batteries and I’ve bought the liquid ones… But I’ve been frightened to use 
them… I just didn’t have the confidence to use them, because you know 
when you see them on the television... and then there’s sort of like, the 
scare, things... (Female, 58 years, 15 cigs/day) 
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Concerns about the safety and health harms of e-cigarettes, as reported in the media, are cited 
by this participant to be reasons for her not using the e-cigarette she purchased. This is 
explored in subsequent sections (see section 5.4.5 and 5.4.6) 
 
5.4.5 Concerns about addiction to e-cigarette/nicotine 
Many participants reported concerns about addiction to either e-cigarettes or nicotine. Some 
expressed this as worries about becoming over-reliant on the e-cigarette with several 
participants describing a negative image of a ‘vaper’ with an e-cigarette constantly in their 
mouth.  
 
…me [my] brother in law, he’s really addicted to his... the vapour pen, and 
me [my] wife says, she doesn’t want me addicted to that… He packed in 
[smoking] before and just had nothing, but he’s packed in this time, and his 
vapour pen’s never out of his mouth… I don’t want to be like, walking like 
around and like having just a vapour pen in my mouth all the time you 
know what I mean… I’ll wean myself off this... (Male, 40 years, 30 
cigs/day) 
 
In this quote, the participant describes a family member who he feels had become over-reliant 
on an e-cigarette. The participant has anxieties about his own use, based upon these concerns, 
and planned to reduce his e-cigarette use. Some of the participants disliked the idea of still 
being ‘addicted’ to something following switching (from tobacco cigarettes to e-cigarettes). 
 
I know people who have tried e-cigarettes... and they’re ridiculous, they just 
smoke them [the] same as what they did, and they become addicted to them.  
So it’s like, to me, it feels like they’re just replacing one addiction for 
another... (Female, 49 years, 15 cigs/day) 
 
This quote illustrates concerns about simply replacing one perceived addiction with another 
(e-cigarettes replacing tobacco cigarettes). Worries about a lack of control with e-cigarettes 
compared to tobacco cigarettes were also voiced.  
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...when I’m smoking [tobacco] cigarettes I know exactly what I’m getting.  
If I move to a vaper [e-cigarette], I don’t really know how much, how much 
of a hit I’m getting… [If I used tobacco cigarettes] I think it would be easier 
for me to do it [cut down], to measure what I’m having you know. And less, 
and less, and less. (Male, 44 years, 30 cigs/day) 
 
Participants were comfortable with their tobacco smoking routine, often having done this for 
multiple decades. They voiced worries about the lack of control when moving to e-cigarettes, 
finding ‘dosing’ difficult to measure. In this case, the participant used this as a reason for 
continuing to use tobacco cigarettes as they felt they had more control for cutting down.  
 
 
5.4.6 Health considerations 
The possible health implications of using e-cigarettes were regularly discussed by participants 
who expressed a range of opinions. Some participants believed the e-cigarettes to be less 
harmful to their health than tobacco cigarettes.   
 
…it’s [vaping’s] like as if I’m having a cigarette but it’s not doing as much 
harm. (Male, 40 years, 30 cigs/day) 
 
 
I feel better for it [switching to e-cigarettes]. I really do. I don’t feel like I 
smell… me [my] mouth’s a lot healthier, I’m not wheezing, I’m not 
coughing, on a morning, it’s, I just feel in myself, a lot healthier for packing 
in real cigarettes and going on to the e-cigarette. It’s a massive difference. 
(Female, 52 years, 15 cigs/day) 
 
These quotes illustrate that some participants held the opinion that e-cigarettes were less 
harmful than tobacco cigarettes. In the first quote, this appears to be an opinion based on 
general knowledge whereas in the second quote, the view is based on, or reinforced by, 
personal experience of improved health after switching to e-cigarettes from tobacco 
cigarettes. Other participants, and their relatives, had negative views of the health harms from 
e-cigarettes, often citing media stories.  
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I did go on the e-cigarettes for a while… But then me Mam [mum], [fell] 
seriously ill, and I’ve actually been looking up this week about it and I 
think... from what they described, apart from the tumour she had Popcorn 
lung…Which is part of the e-cigarette… or so they think. (Female, 47 years, 
15 cigs/day) 
 
In this example, the participant had a family bereavement of a relative who was a life-long 
smoker and recent e-cigarette user. The participant has conducted her own research and cites 
popcorn lung as a health harm from e-cigarettes. Another participant also specifically 
mentioned popcorn lung in this context.   
 
5.4.7 Social acceptability 
The participants expressed a range of perceptions about the social acceptability of e-
cigarettes. Some of the participants felt they were socially acceptable with lots of other people 
using e-cigarettes around them.  
  
I think at the moment they are [socially acceptable]. I think they’ve almost 
become a bit of a fashion trend.  A bit trendy at the moment. (Male, 56 
years, 20 cigs/day) 
 
Although this participant feels e-cigarettes are socially acceptable, they suggest this might be 
transient and just a short lived trend. Many participants were comfortable using the e-cigarette 
around family, friends and in public.   
 
…I don’t feel out of place when I’m using it, I don’t feel uncomfortable 
using it, walking through town or wherever I feel I need it you know. (Male, 
27 years, 15 cigs/day) 
 
Others went further and felt the e-cigarette was accepted by smoking culture.  
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Yeah, very acceptable because a lot of people… go outside to smoke a 
cigarette but a lot of people go outside to smoke their e-cig as well… So it’s 
just a case of just general people just standing outside, and I think because 
you see the smoke, you don’t actually think of it as an e-cig, you just think, 
yeah, you’re just fitting in. (Female, 45 years, 10 cigs/day) 
 
This quote illustrates how a smoker has switched to e-cigarettes and feels their social 
interactions are unchanged. Many participants describe choosing to continue going outside 
when vaping as if they were still smoking.  
 
...I’ve just slotted it [e-cigarette] in exactly what I would normally do. So, 
even if it is raining, and sometimes I think, “What are you doing stood 
outside having a cigarette on a morning, when it’s raining?” Like, “How 
stupid are you?” I’ve still done it, this morning, I just thought, “No, just go 
out, and just do it, doesn’t matter if you’re going to get wet”, because really, 
I could have it [e-cigarettes] in the house, but I don’t want to start that. 
(Female, 35 years, 10 cigs/day) 
 
In this case, the participant is choosing to restrict her use of the e-cigarette to outside areas, 
even in her home environment. She talks about not wanting to get into a habit of using the e-
cigarette inside her house. Other participants chose to use their e-cigarette outside to continue 
social interactions.  
 
…when I go out socialising, me [my] friends go out for a cigarette, a lot of 
places you can’t do the e-cig inside, so I’ve been going out with them but 
just using that, and it’s psychologically [psychological], I’m still smoking 
with them but obviously not smoking [tobacco] cigarettes. (Female, 45 
years, 10 cigs/day) 
 
It was important to a number of participants to be able to continue their social routine when 
switching to e-cigarettes and hence they often chose to self-enforce smoking restrictions on 
their e-cigarette use. Others describe regulations forcing them to go outside in some 
environments.  
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[At work] Yeah well I still have to go outside with that [e-cigarette]. 
(Female, 60 years, 15 cigs/day) 
 
Several participants perceived negative perceptions towards e-cigarettes and vapers. Some 
experienced negative comments personally, while others perceived negative attitudes more 
widely.       
 
I suppose it’s as frowned upon as a cigarette because, people aren’t told 
how... what’s in an e-cigarette. And what’s coming out of an e-cigarette.  
It’s certainly, I’m sure, 90% or 95% of people, if you stood next to them 
with an e-cigarette [they] would shy away as they would with a normal 
cigarette... When I’m out socially I wouldn’t use it. (Male, 58 years, 15 
cigs/day) 
 
 
In this case, the participant describes the negative perceptions towards e-cigarettes they 
perceived by the general public and how it means they wouldn’t use an e-cigarette when out 
socially. Other participants were uncomfortable about how vaping looked.   
 
I think if you see someone with a, e-cig, you just know that they used to be 
a smoker, it just doesn’t look attractive. I’ll be honest but I don’t think 
either [e-cigarettes or tobacco cigarettes], look attractive… I think they’re 
awful. (Female, 35 years, 10 cigs/day) 
 
…some of the girls at work, ee, honest to God they’ve got these, chambers, 
they’re like... I’m like, “Oh my God, do you really need that? (Female, 52 
years, 15 cigs/day) 
 
In the first quote, the participant feels vaping, due to it’s similarly to tobacco smoking, is 
unattractive. The second quote focuses on the more complex devices of which a number of 
participants had negative opinions. One participant was particularly insightful about the 
changing social norms as the prevalence of e-cigarettes in the population increases. They felt 
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embarrassment using e-cigarettes in previous quit attempts but this was reduced in the current 
quit attempt due to more widespread use.  
 
…when I stopped the last time, for the three months, with it [e-cigarette], 
there wasn’t as many people using them... and I did feel, quite embarrassed, 
going out and using them… But now, there’s such an influx of people 
actually using them [e-cigarettes] it is quite strange, if you’re walking round 
with a cigarette now rather than the e-cigarette. (Female, 47 years, 15 
cigs/day) 
 
 
5.4.8 Benefit of behavioural similarities 
Many of the participants reflected that the e-cigarette provided a more fulfilling experience 
than simply supplying nicotine. Its similarity to tobacco smoking was perceived to be highly 
beneficial in terms of helping participants to quit.   
 
It has helped, because, I don’t know whether you can appreciate this.  It’s 
like having a pen in your hand. You need something to do with your hands. 
(Male, 58 years, 15 cigs/day) 
 
The most commonly mentioned feature was the tactile sensation of holding something in their 
hands or the ‘hand-to-mouth’ action, as illustrated in the above quote. Other sensations such 
as vapour production or the ‘throat hit’ were important for several of the participants. 
 
…and that’s where I find it good with the e-cigarette because it replaces 
that.  And you can see the smoke blowing out, you get the throat hit, and 
it’s, it’s exactly, a replacement and it’s, aye, I’ve really, found it [quitting 
tobacco cigarettes] quite, easy, in a way. (Female, 52 years, 15 cigs/day) 
 
The closeness of the actions and sensations of vaping compared to tobacco smoking were 
important for this participant and reportedly led to an easy quit attempt. The quote below 
illustrates the strength of feeling and deep consideration some participants had on this topic.    
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…you know the e-cigarettes, the good ones you can get now, I find I can get 
a good inhale and blow a lot of smoke out and that’s the type of sensation I 
like the most. I mean, if I sucked something in, and didn’t blow anything 
out, it doesn’t seem as though I had a cigarette.  You see?... But although 
when I get the actual, feel this vapour or whatever it is, it’s that which is 
probably the psychological thing. You see because, just supposing they 
made a wonder tablet, and I took that tablet, mmm, made us feel like I 
didn’t feel like a smoker, in my head and that would still say, “I want a 
[breath in/out] this bit”, although this wonder tablet stopped that craving for 
the nicotine shall we say. I believe so, really do.  Especially with being 
smoking for 40 years. It’s that sensation. (Male, 59 years, 30 cigs/day) 
 
The behavioural similarities to tobacco smoking were vitally important attributes of the e-
cigarette for many of our participants, especially those who have been tobacco smoking for 
most of their life, as in the above quote.  
 
 
5.4.9 Perceptions of the e-cigarette starter kit  
Of the forty participants who were offered an e-cigarette starter kit as part of the feasibility 
RCT, thirty-nine accepted it (14 of these completed interviews as part of the current study). 
One participant declined the kit on the grounds that they did not intend to change their 
smoking behaviour. Generally, participants reported that they found the e-cigarette starter kit 
acceptable.  
 
I thought that [the e-cigarette starter kit] was amazing. You know the 
quality of the e-cigarette that you’ve given me and the liquids and you’ve 
given me the, you know, the tutorial about how to use the e-cigarette. 
(Female, 47 years, 10 cigs/day) 
 
Furthermore, participants felt the quantity of supplies were sufficient.  
 
And it does give you a few weeks to get into the routine of it… And I really 
don’t see why, the NHS, whatever [or whoever], should have to pay after 
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that… And when you think about it, the amount of money that that is, 
considering a packet of cigarettes, and how long it lasts, ‘cos they [e-
cigarettes] do last a long time... (Female, 47 years, 15 cigs/day) 
 
The starter kit was designed to last for 2-3 weeks to give the participants a reasonable trial 
period and allow them to source their own supplies. The participant in this quote reflects that 
it lasted long enough for them to get into the routine of using it. She also felt that morally the 
NHS (or other healthcare provider) shouldn’t need to supply any more than this and that the 
costs of supplies were relatively minimal. Participants reported finding it straightforward to 
source their own supplies either at pharmacists, corner shops or online.  
  
I think, using it for a week you’re going to decide whether it’s going to be 
the right tool for you to stop smoking or not, so, I think two bottles is fair… 
Yeah, they’re all about aren’t they [e-liquids]. You’re right, they sell ‘em in 
Boots [pharmacists], they sell ‘em in McColl’s [newsagents], they sell ‘em, 
everywhere you want to go... (Male, 27 years, 15 cigs/day) 
 
Participants were provided with two batteries and a number reflected on the usefulness of this.  
 
It’s [using the e-cigarette] all about organisation. It’s like I’ve got one 
battery on charge and I’m using the other one. You know, so when I’ve 
finished that one, that one can go straight on. So you haven’t got that time 
that you haven’t got an E-Cigarette, that would be the time that you would 
pick up a [tobacco] cigarette. (Female, 52 years, 15 cigs/day) 
 
This participant also felt the provision of two batteries was essential in preventing relapse to 
tobacco smoking by ensuring that the e-cigarette was always charged when she needed to use 
it.   
 
5.4.10 Influence of flavour 
Participants were provided with a choice of four e-liquid flavours: tobacco, mint, cherry and 
unflavoured. As part of the trial, they were asked to select two bottles of e-liquid, provided 
without cost. The most common choice combinations were ‘Tobacco & Mint’, ‘Mint alone’, 
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‘Mint and Cherry’ and ‘Tobacco alone’. Less than half chose a tobacco flavour within their 
selection. Participants had the choice of four nicotine concentrations (0, 6, 12, 18 mg/ml). The 
most common choice of nicotine concentration was 18 mg/ml. Full details of the e-liquid 
choices are presented in chapter 3 (see section 3.4.6 and Table 3.2).   
Participants had relatively dichotomous views on flavour preference. The first group held 
strong preferences against tobacco flavours, believing this might be too similar to tobacco 
smoking.  
 
I don’t know, ‘cos I feel like if you’re going to quit [tobacco smoking] you 
might as well not have cigarette flavour because it’s defeating the point, to 
me anyway. So and I love cherry flavoured stuff so, cherry and minty [is 
what I used]. (Female, 31 years, 30 cigs/day) 
 
This quote illustrates a participant who preferred the non-tobacco flavours and felt using a 
tobacco flavored e-cigarette would undermine the quit attempt. As in this case, several 
participants had a preference for mint flavours.  
 
I think just with the mint… it’s a fresh, it’s nice and fresh, on your breath, 
and that. It’s just, it’s a pleasant taste. (Female, 52 years, 15 cigs/day) 
 
Mint or menthol flavours were seen as refreshing and spoken about positively by a number of 
participants. The second group held the view that the e-liquid flavour should be similar to 
their smoking experience so chose the tobacco flavour.  
I think I chose the tobacco [flavour e-liquid] because I was a little bit 
frightened that, it would have been too much of a leap from going from no 
cigarettes to pure mint… But to be honest, the thought now, of going back 
to tobacco [e-liquid], after using the mint [e-liquid], I didn’t want to go back 
to the tobacco [e-liquid], I didn’t want to use the tobacco one, I just want 
the mint one ‘cos I feel as though it’s like, fresh… And I didn’t, I don’t 
want that stale taste in me [my] mouth again. (Female, 52 years, 15 
cigs/day) 
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Trying to maintain the similarity to tobacco smoking by using tobacco flavoured e-liquid was 
seen as important by this participant. They then transitioned to mint flavour after using the e-
cigarette for a while and subsequently felt that they would be unlikely to go back to the 
tobacco flavour.  
 
I went for the normal mixture like the tobacco one and the menthol one as 
well… I quite like the idea of mirroring the flavours. I think some of these, 
you know, oh, sweet bubble gum, is ridiculous, because if I want bubble 
gum, I go and buy bubble gum… I think it should be a, similar flavour, shall 
we say. (Male, 56 years, 20 cigs/day) 
 
Again this quote illustrates the importance some participants placed on ‘mirroring’ the 
flavours they were familiar with when tobacco smoking, which also included menthol 
cigarettes in this case. This participant spoke about the tobacco and menthol flavours as 
‘normal’ and reflected that the wider range of fruity/sweet flavours were ‘ridiculous’ which 
was a common theme in several interviews. However, this was not universal, with some 
participants keen to try all flavours (this has previously been illustrated in section 3.5.9, Table 
3.28 and Table 3.30). Conversely, one participant was keen to avoid any flavour and chose the 
unflavoured e-liquid.  
 
…‘cos I want to get away from... the tobacco taste. But with the fruit one, 
like I say, me [my] chest [harsh on chest].  But then I wanted something 
sweet afterwards… So that’s defeated the object for me. ‘Cos I don’t want 
to put loads more weight on, so I think, you know, if I don’t want anything 
sweet... (Female, 40 years, 25 cigs/day) 
 
This participant cited several reasons for her choice of the unflavoured e-liquid. She wanted to 
avoid the tobacco taste, to break away from smoking. She had a previous unpleasant 
experience of the fruit flavours, which she had perceived to be harsh on her chest and made 
her want to eat something sweet after use, causing concerns about weight gain.   
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5.4.11 Technical issues 
A small number of our participants reported technical issues with the e-cigarettes provided in 
the study.  
 
I took my e-cigarette to work on Saturday... and for some reason the damn 
thing’ll not work… I don’t know if it’s broken... because, when you inhale 
it… You’re supposed to press the button, wait until it, thingies… But then 
you’re getting, your lips is getting covered in oil. (Female, 60 years, 15 
cigs/day) 
 
This participant experienced problems with one of the tanks provided as part of the starter kit, 
having e-liquid leak onto her lips. This was an isolated incident but did highlight that 
operating the device was not always straightforward for all participants, including those who 
had never used an e-cigarette prior to agreeing to join the study.  
Assistance with operating devices was sometimes obtained from family or friends if technical 
issues arose.  
 
My son’s 22 and he was, he’s been very helpful, as in, you know, showing 
me what to do with the e-cigarette and making sure it was charged and that 
I’ve got enough liquid, and how to put the liquid in, just reminding me 
again how to do it… I’d arranged everything around… [going] to the 
caravan, to enable me to quit.  I had got up that morning, thought “Right, 
OK, this is the day I’m going to do it”, and then tried to use the E-Cigarette, 
[but it] didn’t work… and I hadn’t took [taken] the battery charger with 
me… Or the charging USB.  So then, I rang my son, he said. “Don’t worry, 
when you come back, just do it when you come back”. Anyway, when I 
went back, he tried it and said you haven’t clicked it five times before it sort 
of starts and I was like, “Oh, right, OK”, and he said, “Well, start 
tomorrow”. Which I did do, yeah. (Female, 47 years, 10 cigs/day) 
 
The quote highlights the importance of the participant’s son in helping her overcome initial 
issues with using the e-cigarette. Despite being provided with instructions on operating the 
device by the researcher, a number of participants struggled with the automatic safety lock 
which requires the button to be pressed 3 times in close succession to deactivate.   
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5.5 Discussion 
5.5.1 Principal findings 
Interviews with study participants found that a number of factors could influence both 
positive and negative attitudes towards e-cigarettes. In terms of positive attitudes these were: 
interactions with existing users (vapers); health benefits; a perception that vaping was seen as 
socially acceptable; and the social and sensory similarities to tobacco smoking. More negative 
attitudes were influenced by: personal previous e-cigarette experiences; concerns about 
addiction; health concerns relating to possible risks of using e-cigarettes; and lack of social 
acceptability. Interviews also explored the acceptability of the intervention (e-cigarette starter 
kit). Overall it was perceived to be acceptable with participants, and they were happy to 
source and purchase their own supplies of e-liquid after the initial period. Interviewees 
differed in their choice and experience of using different e-liquid flavours, and there were 
some instances of technical difficulties in using the device, particularly initially.  
5.5.2 Relationship to previous research 
Overall perception of e-cigarettes 
The findings of this qualitative research are largely in keeping with the existing literature in 
terms of smokers’ perceptions and experiences of e-cigarettes.  
Some participants in this study had negative previous experiences of e-cigarettes, as some 
other recent studies have found (Wackowski et al., 2016). Most smokers in the UK who try e-
cigarettes do not go on to use them regularly, often because of concerns about risks, lack of 
understanding about how to use them or the importance of finding the right device, nicotine 
strength and flavour (McNeill et al., 2018). It is likely that at least some of our participants’ 
experiences would have been with early products, often of poor quality and now superseded 
by better products. Naïve users are more likely to use first-generation devices, which have 
been shown to have poor blood nicotine delivery and further contributed to the unrewarding 
experience (Bullen et al., 2013; Hajek et al., 2017; Ruther et al., 2017). Similarly, there is a 
steep learning curve for users, with naïve users demonstrating lower blood nicotine levels 
than experienced users, suggesting the vaping technique needs some practice (Farsalinos et 
al., 2015; Hajek et al., 2015b).  
Another possible explanation for the poor previous e-cigarette experiences is a feature of our 
study design and eligibility criteria. Those individuals who had a good e-cigarette experience 
are more likely to have become regular users (with or without tobacco cigarettes) (Wackowski 
et al., 2016) and therefore have been ineligible for this research study. Therefore, by design, 
298 
 
our participants were more likely to have had suboptimal previous e-cigarette experiences. 
The participants in the current study were similar to the majority (>80%) of tobacco smokers 
who are not currently using e-cigarettes (Action on Smoking and Health, 2017a). Over 40% 
of all current smokers have never tried e-cigarettes (McNeill et al., 2018).   
A complementary theme that developed was the concern about addiction to the e-cigarette 
and/or nicotine, with participants worried about substituting one addiction for another. As 
previously discussed (see section 1.4.7), there were widespread misperceptions around 
nicotine addiction and health risks, which appeared to have contributed to smokers having 
significant concerns about becoming addicted to e-cigarettes. A recent survey in the UK 
found that concerns about addiction were the most frequent reason for smokers not trying e-
cigarettes (Action on Smoking and Health, 2017a). There is relatively little evidence on 
perceptions of the addictiveness of e-cigarettes (McNeill et al., 2018) although one survey 
reported that approximately half the participants (adult smokers, ex-smokers or e-cigarette 
users) thought e-cigarettes were more or equally addictive than tobacco cigarettes (McNeill et 
al., 2018). In addition, a qualitative study with young adults in Scotland found that they 
viewed vaping as more addictive than smoking (Lucherini et al., 2017). These young smokers 
felt in control of their smoking habit but perceived some vapers to be uncontrolled, constantly 
using their e-cigarettes. They voiced similar concerns to those seen in this study about simply 
replacing one addiction with another and were concerned about their ability to quit vaping. 
The demographics of our samples were very different (age and setting), yet this theme was 
remarkably similar with almost identical quotes from participants. These issues may be 
applicable to a wide range of smokers and indeed studies with adults have identified similar 
findings (Vijayaraghavan et al., 2017; Gentry et al., 2018).        
Unsurprisingly, given the well-known health harms of tobacco smoking, health considerations 
of e-cigarettes were a strong theme highlighted by our participants. Some participants 
perceived e-cigarettes to be less harmful than tobacco, either based on their own experience of 
switching or on their pre-existing views. Glasser et al. (2017) conducted a systematic review 
and identified a large number of studies (n=188) reporting consumers’ perceptions of e-
cigarettes. A major reason for use was due to the perception that e-cigarettes were less 
harmful/less toxic than tobacco cigarettes.   
In the current study, others held concerns about the health harms of e-cigarettes which, on at 
least one occasion, stopped e-cigarette use. This is in keeping with recent surveys which 
reported that less than half of adults report the accurate perception that e-cigarettes are less 
harmful than tobacco cigarettes (Action on Smoking and Health, 2017a; Majeed et al., 2017; 
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West et al., 2018). The proportion stating that e-cigarettes are less harmful than cigarettes are 
lowest among current smokers who had never used an e-cigarette (33%) and highest (90%) in 
ex-smokers who had used/tried an e-cigarette (Action on Smoking and Health, 2017a). This 
difference, based on e-cigarette experience, was also demonstrated by our participants. They 
experienced positive attitudes towards e-cigarettes from existing users and also perceived 
them to have been effective in helping people to quit tobacco smoking.        
Overall, our participants perceived e-cigarettes to be socially acceptable with participants 
comfortable using them in a wide range of situations. A recent Royal College of Physicians 
(RCP) report discussed the potential importance of the ‘cultural acceptability’ of e-cigarettes 
(Royal College of Physicians, 2016). For example, social identity as a smoker can be 
maintained by vapers sharing smoking breaks and being accepted by other smokers. 
Additionally, vaping is non-medicalised, unlike NRT, and does not imply rejection of 
smoking or a commitment to quitting. This particular perspective was not identified in the 
findings from this study, which is, likely because the study was conducted in a medical 
setting, with the e-cigarette being provided by a clinician.       
The sensory similarities between vaping and tobacco smoking were identified by our 
participants as being particularly important. As previously discussed (see section 1.1.2), 
smoking addiction is not simply related to the pharmacological effects of nicotine but also to 
the complex range of stimuli and behaviours associated with nicotine delivery (Rose et al., 
2000; Royal College of Physicians, 2016). The hand-to-mouth action, vapour production and 
‘throat hit’ were perceived as advantageous elements of e-cigarette use. One of our 
participants expressed this when he imagined a ‘wonder tablet’ stopping the cravings but not 
being able to replace the sensation of breathing in/out smoke, something he has done for 40 
years.  
Perceptions of the e-cigarette starter kit  
Overall, the participants provided with the e-cigarette starter kit perceived this positively. 
There were a small number of technical issues experienced by some of the participants. 
Thirlway (2016) reported that older women in particular found e-cigarettes too much trouble, 
quickly becoming impatient with product unreliability. In the current study, although numbers 
were low, there were several older female participants who reported technical difficulties. 
Young family members played a role in supporting the participants, complementary to the 
‘social influence and identity’ theme described in chapter 3. Participants felt they were 
provided with an appropriate amount of e-liquid and generally reported few issues in sourcing 
their own supplies. The provision of two batteries was reported to be useful; however, given 
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the rapid pace of product development, and battery technology, this may be largely irrelevant 
for future products and studies. As e-cigarettes and other novel nicotine products continue to 
evolve and users become more heterogeneous, new and flexible ways of conducting research 
studies will be required e.g. users might be allowed to experiment with different products 
(trial and error) (Robson and McNeill, 2017).   
Flavour 
With regards to e-liquid choice, the participants were guided in respect of nicotine strength 
based upon the amount they smoked at baseline. Given that they were usually moderate to 
heavy smokers it is unsurprising that most chose the highest nicotine concentration (18 
mg/ml). No guidance was provided however for flavour choice, which was varied (although 
limited to four flavours in this study). Our findings have important implications for future 
clinical studies as well as wider regulations. Participants expressed relatively dichotomous 
views, holding strong preferences either against or in favour of tobacco flavours. Those 
against tobacco flavours wanted their e-cigarette experience to be different to that of tobacco 
smoking, choosing mint or cherry flavours in this study. Conversely those in favour of 
tobacco flavours wanted the familiarity to tobacco smoking. The e-liquid flavour choices of 
participants in the current study and the opinions they expressed in the interviews are in 
keeping with flavour preferences observed in the wider population. In the UK overall, the 
most recent national survey data suggests that the most popular groups of flavours among 
current e-cigarette users are fruit (29%), tobacco (27%) and menthol/mint (25%) (Action on 
Smoking and Health, 2017a). Very few current users chose to use no flavours (3%)(Action on 
Smoking and Health, 2017a), which is in keeping with the current study (1%).     
5.5.3 Strengths and limitations 
The general strengths and limitations of this research have been previously discussed in 
chapter 4 (see section 4.5.3). The current study is one of the first pieces of qualitative research 
to investigate perceptions towards e-cigarettes of patients in a dental healthcare setting. This 
is an important population demographic to understand as they are potentially susceptible to 
influence from dental professionals. This study also investigated feasibility issues around e-
cigarette research and the findings will have use in future study design. The main limitation of 
this work is that researcher was the same person who provided the intervention, and this may 
have influenced responses. Efforts were made to minimize this effect as previously discussed 
in chapter 4 (see section 4.5.3). Future research should aim to have any qualitative interviews 
conducted by a separate researcher.       
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5.5.4 Implications for future research and practice  
The findings of this study offer a detailed understanding of perceptions towards e-cigarettes of 
individuals accessing health services, particularly in the dental health setting. Future smoking 
cessation interventions which use e-cigarettes should consider and, where appropriate, be 
informed by the identified positive and negative influencing factors. The negative influencing 
factors offer greatest potential for improving an intervention, by removing barriers. Negative 
previous personal experiences of e-cigarettes can be a barrier to use and can be addressed by 
appropriate training and support or the provision of a simple easy-to-use but effective device. 
Health concerns and concerns about addiction and dosing were also powerful barriers to use 
and could be addressed within future interventions e.g. by education. Within the healthcare 
setting, the prescription of an e-cigarette as part of a smoking cessation intervention would 
help address these barriers, as recently recommended in a government report (House of 
Commons, 2018). Smokers would have more confidence in a product provided by a 
healthcare professional, overcoming their previous negative experiences. Likewise, the fact a 
healthcare professional has deemed it appropriate to provide an e-cigarette would help reduce 
health concerns and improve confidence. The e-cigarette starter kit provided in this study was 
highly acceptable to participants and future interventions (research or non-research) should 
consider utilizing a similar design. A small number of participants (older females) would have 
benefited from additional support regarding technical issues and future interventions should 
consider this in their design. An important finding was about flavour choice with dichotomous 
views for and against tobacco flavours. Interventions and research studies which limit 
participants to one flavour (usually tobacco) are potentially not using this intervention to its 
full potential. Ideally participants should have range of choices and these findings support 
recommendations in the UK (for example from PHE) to research funders to consider moving 
from studies which have high internal validity to those that have higher generalisability 
(McNeill et al., 2018).  
5.6 Conclusions 
Smokers accessing dental health services had pre-existing views on e-cigarettes based upon a 
wide range of influences, and these views may reflect those of patients in other healthcare 
settings. Understanding these influences could allow e-cigarette interventions in the 
healthcare setting to be suitably designed and optimised. Smokers positively perceived the 
provision of an e-cigarette for smoking cessation within the dental healthcare setting. The 
model of providing an e-cigarette starter kit and requiring users to source their own supplies 
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after an initial period was deemed acceptable. When designing future interventions, patient 
choice would be important to consider, including offering a range of flavour options.  
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Chapter 6 General Discussion 
___________________________________________________________________________ 
6.1 Background 
Tobacco smoking causes significant morbidity and mortality worldwide. The oral health 
effects are important and include oral cancer and periodontitis. Many strategies have been 
proposed and implemented in order to reduce smoking prevalence at both a population and 
individual level. Advice from health care professionals, such as dental professionals, plays an 
important role in supporting smokers to quit, although research is lacking on the patients’ 
perspective of such advice. E-cigarette use is now common in many populations, often being 
used for smoking reduction or cessation and sometimes as a longer-term replacement. It is 
important to understand the role of e-cigarettes as a smoking cessation aid within the dental 
setting but also to consider any implications for oral health.      
The aim of the PhD research was to explore the behavioural and biological changes when 
smokers with periodontitis were provided with an e-cigarette. This chapter discusses how the 
PhD research contributes to the existing evidence base and considers its strengths and 
limitations. The implications of the research findings are discussed along with 
recommendations for future research.  
 
6.2 Main findings  
A series of mixed methods studies were conducted to explore the behavioural and biological 
impacts of e-cigarettes within the dental setting. Firstly, a systematic review was conducted to 
clarify the evidence with regards to the effects of nicotine on oral cells in vitro. Secondly, a 
feasibility study explored the delivery of an e-cigarette within the dental setting by conducting 
a pilot RCT with process evaluation.   
6.2.1 Systematic review on in vitro effects of nicotine 
The systematic review identified a large number of studies investigating the in vitro effect of 
nicotine on oral cells. There was high heterogeneity and the studies were often of 
poor/moderate quality. Cell viability was the most studied variable and the results indicated 
that, at physiological concentrations (i.e. GCF and salivary concentrations of nicotine seen in 
tobacco smokers, NRT users, e-cigarette users and non-users), nicotine was not cytotoxic to 
periodontal cells in vitro (salivary levels in smokeless tobacco users was high enough to 
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achieve cytotoxicity). Nicotine may have effects on other cell functions although evidence 
was contradictory.  
These findings support the supposition that nicotine is not the damaging agent in tobacco 
smoke. Hence, nicotine’s use in the form of NRT or e-cigarettes should not be discouraged 
based on the premise that there is evidence that nicotine is cytotoxic to oral cells.  
6.2.2 Pilot trial 
The pilot RCT successfully recruited 80 smokers with periodontitis of whom, 58 completed 
the study, giving a 73% retention rate. The e-cigarette intervention was well received with 
90% using it at the quit date and over half using it for the duration of the study. Several 
participants chose to diverge from the recommended brand of e-liquid and an interesting 
observation is that these individuals made up almost all of the quitters in the intervention 
group. One in five participants in the control group used an e-cigarette, against instructions, 
an important variable to consider when designing future research.  
Outcome measures were successfully completed in clinic but a weekly smoking questionnaire 
had poor completion rates. Smoking outcome measures demonstrated harm reduction 
(reduction from baseline to 6 months of eCO) of 6 ppm [95% CI: 1-10] and 12 ppm [95% CI: 
8-16] in the intervention and control groups respectively; rates of abstinence (carbon 
monoxide verified continuous abstinence for 6 months) for the two groups were 5% [95% CI: 
1%-17%] and 15% [95% CI: 7%-29%]. The oral health outcome measures demonstrated 
slight improvement in the intervention group compared to the control group.   
Modifications to the study design were proposed, such as: not collecting research data at the 
3-month review visit, introducing an incentive for attendance at post-treatment follow-up 
visits, not using a weekly questionnaire, consolidating the number of outcome measures 
collected, considering a wait list control design and conducting part of the research in a 
primary care setting. 
 
6.2.3 Qualitative interviews 
A broad and complex range of factors were perceived to influence smoking behaviour in 
individuals with periodontitis, including: social influences, social/professional role and 
identity, knowledge, environmental context and resources, emotions, nature of the behaviour 
and beliefs about consequences. Dentist-delivered SCA was positively perceived and several 
important aspects were perceived by patients, comprising: opportunistic nature, personal 
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context and tangible prompts, positive context of cessation attempt, lack of previous support 
and differences by comparison with doctor-led SCA.     
6.3 Relationship to previous research 
Each chapter has individually considered how the findings relate to previous research. 
However, it is important to compare the methods used in the PhD research to the existing 
evidence base.  
The feasibility study with embedded pilot RCT provided a detailed understanding of the 
viability of delivering and studying the intervention in question, with several important 
implications for the future definitive study. The design and reporting of the study has 
followed recommendations such as the CONSORT checklist for pilot and feasibility studies 
(Eldridge et al., 2016); Robson and McNeill (2017) and TiDieR checklist for reporting 
interventions (Hoffmann et al., 2014). Lancaster et al. (2004) previously reviewed the 
medical literature and concluded that pilot trials were often poorly conducted and 
inadequately reported. Although a systematic review of the dental literature has not been 
undertaken, it is clear that very few, if any, dental feasibility or pilot studies follow these 
principles and standards. In chapter 3, I presented an evaluation of the dental pilot studies 
investigating e-cigarettes and oral health, concluding that they were poorly reported and had 
several fundamental weaknesses. We recently wrote a letter to a journal editor (Holliday et 
al., 2018) highlighting concerns about a so-called pilot study published in their journal (Javed 
et al., 2017a) and called more broadly for journals to ensure pilot studies comply with 
minimum reporting standards.  
In chapter 3 (see section 3.2) I discuss the limitations of the pilot study by Wadia et al. (2016) 
in which they inappropriately concluded that there was a statistically significant increase in 
gingival inflammation when smokers switched to vaping. However, an increase in gingival 
inflammation when smokers quit is a well-established clinical observation and can likely 
account for the findings of this study, particularly given the lack of a control group. Indeed, 
there is an inverse interpretation of the results; that e-cigarette use had no effect upon the 
normal rapid recovery of the inflammatory response following smoking cessation. The results 
from the pilot trial conducted during this PhD, although not suitably powered for statistical 
testing, do not support the conclusion of Wadia et al. (2016). Unfortunately, a recent national 
review (Stratton et al., 2018) has included this study (Wadia et al., 2016), and without 
disease-specific expertise on their review panel to interpret the results, they have concluded 
that e-cigarette aerosols can ‘induce gingival inflammation in the oral cavity’. A separate 
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national review (Byrne et al., 2018) has repeated these conclusions, reinforcing and 
disseminating them further. This example highlights the responsibility on researchers and 
journal editors to ensure their studies follow the highest standards of design and reporting 
[e.g. CONSORT extension for pilot and feasibility trials (Eldridge et al., 2016)] in order to 
ensure research rigour and minimise potential for misinformation. Generally, there is a need 
to raise awareness of pilot and feasibility study methodology and reporting within dental 
research and improve standards. Concerning the specific topic of e-cigarettes and oral health, 
the current study represents the first properly conducted pilot trial in the field. The findings 
from this study will allow for a well-designed and efficient definitive study in order to answer 
the research question.  
When designing a trial it is important to consider the impact on applicability of every design 
decision. The PRagmatic Explanatory Continuum Indicator Summary 2 tool (PRECIS-2) 
allows trialists to ensure their study design is consistent with the intended purpose by scoring 
10 aspects of the study design (Loudon et al., 2015). The tool produces a useful illustration, 
the PRECIS-2 wheel, which demonstrates to trialists if their trial design will support the 
overall aim. It also identifies consistency between domains (the smoothness of the wheel) 
with regards to explanatory or pragmatic approaches.  
The pilot RCT in this PhD was designed to be at the pragmatic end of the explanatory-
pragmatic spectrum (Schwartz and Lellouch, 1967; Thorpe et al., 2009; Loudon et al., 2015) 
but formal testing using the PRECIS-2 wheel was only completed retrospectively. Figure 6.1 
presents the PRECIS-2 wheel for this study and Table 6.1 provides the explanation and 
rationale for each score. Overall, the trial was rather pragmatic, scoring the highest possible 
pragmatic scores in several domains. However, several domains were identified as less 
pragmatic, specifically: the setting, flexibility of delivery and participant follow-up. A future 
definitive study which aimed to have a pragmatic approach should aim to review these areas 
to improve consistency (and improve the smoothness of the wheel). For example, the setting 
for a future definitive study could be conducted in both secondary and primary care 
environments in keeping with the intended environments of the intervention in usual care. 
Additionally, the delivery of the intervention could be more flexible, perhaps delivered by a 
dental nurse with little additional training on the topic and with little instruction.          
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Figure 6.1 The PRECIS-2 wheel for the pilot RCT.  
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PRECIS-2 domain Rationale for score 
Eligibility The study had pragmatic eligibility criteria, very similar to those in usual care. There was no 'willingness to quit' criterion, 
similar to the universal approach of smoking cessation interventions taken in usual care. The criteria for age were broad, 
only having a lower cut off (18 years of age) in keeping with the legal age restrictions around e-cigarettes in the UK. The 
medical exclusion criteria were in keeping with the instructions provided with NRT and e-cigarettes. Our study included a 
lower smoking threshold (≥10 factory-made cigarettes/day or 7g [0.25 oz) loose tobacco/day or 14 hand-rolled 
cigarettes/day) which is not present in usual care (all smokers are provided smoking cessation interventions regardless of 
their smoking amount). We also excluded smokers who had used a e-cigarette for more than two days in the last 30 days, 
which may not represent usual care when these smokers would be included. A score of 4 was awarded as eligibility was 
very similar but not identical to usual care.  
 
Recruitment We recruited through usual care environments in an opportunistic manner. Participants were only recruited after they 
presented to a dental clinic on their own behalf without any overt recruitment effort. We recruited from a range of 
primary care and secondary care dental clinics. A score of 5 was awarded as we recruited from a diverse range of usual 
care appointments.  
 
Setting A hub-and-spoke design was utilised with participants being identified in a number of environments but the research 
study being conducted in a secondary care dental setting. The single centre design limits the generalisability of the results 
and is more explanatory (although a single centre design was appropriate for a pilot study, with the resource constraints 
associated with a PhD). The results of the study will be applicable to secondary care (where the study was conducted) but 
also to primary care and future studies should have a primary care component to ensure applicability of the results. A 
score of 3 was awarded due to the single centre secondary care setting. 
 
Organisation Identical organisation to usual care with same staff. The e-cigarette intervention delivered in this trial was relatively 
pragmatic. A simple starter kit was provided designed to replicate what might be available on prescription in the future. 
Staff required some limited additional training and delivered a short tutorial to participants on the e-cigarette which 
largely followed the instruction manual. A score of 4 was awarded as the organisation was very similar, but not identical 
to usual care.  
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PRECIS-2 domain Rationale for score 
 
Flexibility (delivery) Protocol driven- The interventions and co-interventions delivered followed a detailed protocol. Adherence and 
compliance- Interventions were audio-recorded to check for compliance but no measures were in place to improve 
compliance. A score of 2 was awarded as there was a rather explanatory approach to intervention delivery.  
 
Flexibility 
(adherence) 
There was full flexibility in how participants engaged with the intervention. There were no special measures to enforce 
engagement or compliance. Participants were instructed to continue using the same brand of e-liquid (as recommended in 
the manufacturer’s instructions), although there were no consequences for violating this. A score of 5 was awarded as a 
highly pragmatic approach was taken to intervention adherence. 
 
Follow-up The number of follow-up visits was as would be as expected in usual care. However, the duration of these visits was 
longer than in usual care due to the collection of research data (some would be part of usual care but some is beyond 
what would be collected in usual care). Participants were also contacted if they failed to keep trial appointments (in order 
to improve retention) but this would be over and above that conducted in usual care. A score of 3 was awarded as the 
study had both explanatory and pragmatic aspects to participants follow-up.  
 
Primary outcome The primary outcome was smoking abstinence which is of obvious importance to participants and commissioners of care. 
This outcome was measured by self-reporting and with expired air carbon monoxide readings, the same as usual care. A 
score of 5 was awarded due to the highly pragmatic approach. N.B. This was a pilot trial and hence the study objectives 
were to do with assessing the viability of delivering and evaluating the intervention. The primary outcomes for the 
definitive study would likely be smoking abstinence and periodontal health.  
 
Primary analysis An intention-to-treat analysis with all available data. A score of 5 was awarded due to the highly pragmatic approach. 
 
Table 6.1 Rationale for PRECIS-2 domain scores.
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When specifically considering the e-cigarette intervention, previous clinical studies have 
taken a range of approaches. Many studies, especially earlier studies or those measuring 
specific biological outcomes, often chose to follow a traditional tightly controlled design with 
regards to the e-cigarette intervention. They have provided the e-cigarette device (Bullen et 
al., 2013; Caponnetto et al., 2013; Adriaens et al., 2014), sometimes with spare batteries 
(Bullen et al., 2013) and a substantial e-liquid supply: 2 months (Adriaens et al., 2014), 12 
weeks (Caponnetto et al., 2013), or 13 weeks (Bullen et al., 2013). There was often little 
flexibility concerning intervention adherence with participants having no choice of e-liquid 
strength and/or flavour (Bullen et al., 2013; Caponnetto et al., 2013; Adriaens et al., 2014). A 
choice of e-liquid flavours is rare in research studies, with most only providing tobacco 
flavour (Caponnetto et al., 2013; Adriaens et al., 2014) or unflavoured (Fraser et al., 2015). 
Some studies offered a choice between tobacco and menthol (Lopez et al., 2016; Beebe, 
2017).  
The recent Cochrane systematic review (Hartmann-Boyce et al., 2016) acknowledged the 
challenges of making a ‘blanket assessment of cessation efficacy’ due to the large variation in 
the e-cigarette intervention. Robson and McNeill (2017) argue that strict eligibility criteria 
and requiring fidelity to an intervention (e.g. type, dose, duration and frequency) is discordant 
with what happens in real life. Hence, research studies have started to shift towards the 
pragmatic end of the explanatory-pragmatic spectrum when considering the e-cigarette 
intervention. For example, Hajek et al. (2015c) provided an e-cigarette starter kit, with a 2-
week supply of e-liquid (18 mg/ml, tobacco flavour) and expected participants to source their 
own e-liquid beyond this. The current study chose a similar approach, although being even 
more pragmatic by providing a choice of four e-liquid flavour and strength options. Other 
studies have taken an even more pragmatic approach, allowing some elements of trial and 
error by participants when selecting the e-cigarette (Bauld et al., 2018) as recommended by 
McNeill et al. (2018).  
The outcome measures with regard to smoking cessation and periodontal health used in this 
study, and proposed for the future study, fit with the core outcome sets recommended by the 
COMET initiative (T Lamont, personal communication, 21 August 2018) (West et al., 2005a; 
Glenny et al., 2012).  
6.4 Strengths and limitations 
The specific strengths and limitations of my research have been discussed in each chapter. 
However, this section will acknowledge the main strengths and limitations of the research as a 
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whole. A major strength is that the research has been conducted in a rigorous manner 
following the relevant standards for each methodology. The systematic review followed the 
PRISMA statement and checklist; the pilot RCT followed the CONSORT extension for pilot 
and feasibility studies, with interventions being described using the TiDieR checklist; and the 
qualitative interviews employed the TDF framework and followed the COREQ checklist. The 
mixed-methods approach combining the quantitative pilot trial with qualitative interviews has 
allowed us to gain different and more insightful perspectives on the findings. A good example 
of this is the e-liquid flavour choices observed in the pilot trial being enriched by the 
participants’ perspectives arising in the interviews.  
This study was the first qualitative research study to investigate patient perceptions of 
receiving SCA in the dental setting and the theory-based findings will be important influences 
to consider when designing interventions.      
A strength of the research was to approach the feasibility study with the widest perspective 
considering all the possible aspects of a future definitive trial. Specifically, the work 
conducted around identifying, negotiating and helping form solutions for the regulatory 
barriers that existed for e-cigarette research was fundamentally important.    
A particular strength of this project was the multi-disciplinary nature of the supervisory team. 
Although I have led the research, the specialist input and advice from a range of disciplinary 
experts has added huge value to this project, directing me to relevant literature and 
challenging my and each other’s thinking.  
There are some important limitations of the research presented in this PhD that should be 
acknowledged. The systematic review limited its scope to nicotine (excluding cotinine) and to 
four domains in order to keep the review focused and manageable. The pilot RCT had 
challenges with control group contamination, moderate to high participant attrition rates, and 
differential baseline disease severity between groups. The qualitative interviews had some 
limitations concerning the setting of the interviews.      
6.4.1 Reflexivity (positionality) statement 
Reflexivity is an important component of qualitative research and is the process of reflecting 
on how the researcher could influence the research conduct and findings. This is particularly 
important on the topic of this thesis (e-cigarettes) as it is still an emerging topic, on which 
strong and divergent views are held. 
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For this study I was the main researcher, a 32-year-old white male from a middle class 
background. I have been educated to degree level and live in the north-east of England. I have 
conducted a range of research projects on the topic of oral health (particularly periodontal 
diseases) with the aspiration of improving the health of patients and the wider public. On the 
subject matter of tobacco, I am a never-smoker but have experienced first-hand the extensive 
health harms that can result from use. My clinical work involves treating patients with severe 
periodontal disease and oral cancer, both of which have tobacco smoking as a major risk 
factor. My research aspirations are to help develop or optimize interventions to help smokers 
quit/reduce and limit their health harms. Regarding e-cigarettes, I first became interested in 
the subject matter in 2013 after treating a patient using a device. Since then I have taken a 
close interest and I am currently conducting several research projects on the topic (including 
this PhD). My opinion is that conversations based around whether e-cigarettes are ‘good or 
bad’ are overly simplistic. There are many variables to consider but for the subjects of this 
study (adult smokers, often with several failed quit attempts), the use of e-cigarettes as a quit 
aid or longer term substitute appears to be a sensible and potentially effective approach. I am 
open-minded to the developing evidence base and would describe my current position as 
‘cautiously positive’. For the duration of this study (2016-2018) my opinions have remained 
stable. My opinions are in keeping with the majority of the experts and organizations in this 
field, although I am aware that there are a wide range of viewpoints globally. I have concerns 
about the lack of oral health research conducted so far and would like to see oral health 
considerations play a more prominent role in this field. I feel passionately about research 
rigour and have generally been disappointed by the quality of the research so far published on 
the topic of oral health and e-cigarettes. I have no financial conflicts of interest and am funded 
by a NIHR fellowship. I have never received funding from a tobacco or e-cigarette 
manufacturer. 
6.5 Implications for future research 
The primary outcome from the feasibility study is the conclusion that a future definitive study 
(in the form of a pragmatic RCT with economic evaluation and qualitative process evaluation) 
would be viable and worthwhile. The pilot RCT identified many aspects of study design that 
will help deliver an optimum definitive study (as detailed in chapter 3). Some of the most 
significant findings are now considered.  
Regarding recruitment, a rate of five participants per month can be expected for a dental 
research centre. When utilising a hub-and-spoke design (i.e. several locations identifying 
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potential participants and one hub location conducting the research) there were lower rates of 
engagement and retention from those participants coming from primary care. Future research 
designs may consider conducting the research in several locations, including primary care. 
Including a primary care aspect to the research design will also increase applicability and 
make the design more pragmatic.  
The pilot RCT observed considerable e-cigarette use by the non-e-cigarette control group and 
a definitive study should consider study designs to reduce or account for this. For example, a 
wait list control design may be useful, although will likely have implications for the control 
group abstinence rate.  
The e-cigarette intervention, in the form of a starter kit, delivered in this study worked well 
and represents a highly pragmatic approach i.e. it resembles what might be available on 
prescription in the future or what a patient might buy over the counter when initiating use 
after advice from a dental professional. The importance of having a range of flavours was 
highlighted, both tobacco and non-tobacco options. Our findings also suggest that 
experimenting with different products, brands and flavours was an important aspect of the 
intervention. In the pilot RCT, these ‘experimenters’ made up all but one of the quitters. 
Future trials should allow participants to source their own products following provision with 
the starter kit.  
The weekly smoking questionnaire was poorly completed in the pilot RCT and should not be 
used in future research without modifications. Incentives should be considered to maximise 
participant retention following completion of the periodontal treatment.   
A sample size calculation based upon co-primary outcomes, smoking abstinence rates (RS6-
eCO) and periodontal health (PPD or percentage of sites with PPD ≥5 mm), requires 674 
participants. Once participant attrition and eligibility rates are accounted for, 1162 potentially 
eligible participants will need to be approached. A multi-centre RCT including both primary 
and secondary care locations would be a suitable study design to achieve these participant 
numbers.   
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6.6 Overall conclusions 
Nicotine is likely not to be the harmful component of tobacco smoke on oral health. Patients 
perceive dentist-delivered smoking cessation interventions positively. E-cigarettes may 
represent an effective option for smoking cessation within the dental setting and a future 
definitive study should evaluate this. This study should be designed upon the findings of the 
pilot RCT presented in this thesis.  
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Chapter 7 Appendices 
___________________________________________________________________________ 
Appendix A Supplementary Figure S1- PRISMA Checklist  
Section/topic  # Checklist item  
Reported in 
section No.  
TITLE   
Title  1 Identify the report as a systematic review, 
meta-analysis, or both.  
Chapter 2 
(Identified as a 
systematic review) 
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as 
applicable: background; objectives; data 
sources; study eligibility criteria, participants, 
and interventions; study appraisal and 
synthesis methods; results; limitations; 
conclusions and implications of key findings; 
systematic review registration number.  
2.1 
 
 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the 
context of what is already known.  
2.2 
Objectives  4 Provide an explicit statement of questions 
being addressed with reference to 
participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
2.3 and Table 2.1  
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and 
where it can be accessed (e.g., Web 
address), and, if available, provide 
registration information including registration 
number.  
2.7 
Eligibility 
criteria  
6 Specify study characteristics (e.g., PICOS, 
length of follow-up) and report characteristics 
(e.g., years considered, language, publication 
status) used as criteria for eligibility, giving 
rationale.  
2.3  
Information 
sources  
7 Describe all information sources (e.g., 
databases with dates of coverage, contact 
with study authors to identify additional 
studies) in the search and date last searched.  
2.3  
Search  8 Present full electronic search strategy for at 
least one database, including any limits used, 
such that it could be repeated.  
2.3.2 
Study selection  9 State the process for selecting studies (i.e., 
screening, eligibility, included in systematic 
review, and, if applicable, included in the 
meta-analysis).  
2.3.3 and Figure 
2.1 
Data collection 
process  
10 Describe method of data extraction from 
reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining 
and confirming data from investigators.  
2.3.3  
Data items  11 List and define all variables for which data 
were sought (e.g., PICOS, funding sources) 
2.3 
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Section/topic  # Checklist item  
Reported in 
section No.  
and any assumptions and simplifications 
made.  
Risk of bias in 
individual 
studies  
12 Describe methods used for assessing risk of 
bias of individual studies (including 
specification of whether this was done at the 
study or outcome level), and how this 
information is to be used in any data 
synthesis.  
2.3.4 
Summary 
measures  
13 State the principal summary measures (e.g., 
risk ratio, difference in means).  
NA 
Synthesis of 
results  
14 Describe the methods of handling data and 
combining results of studies, if done, 
including measures of consistency (e.g., I2) 
for each meta-analysis.  
2.3 
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Appendix B Supplementary Table S1: Reasons for exclusion of reviewed full-text studies  
Study Reason for exclusion Further details 
Almasri et al. (2007) Non-relevant outcome assessed Measured cytokine expressions rather than production or secretion 
Al-Qattan & Soory 
(2012) 
Non-relevant cell types & assays Periosteal fibroblast, osteoblast; metabolic activity & DHT yields 
Argentin & Cichetti 
(2006) 
Non-relevant outcome assessed Mechanisms of nicotine-induced genotoxicity (nitric oxide; caspase-1) 
Austin et al. (2001) Non-relevant outcome assessed (indirect) Indirect assessment of HGF adhesion (integrin β1 expression) 
Chang et al. (2003a) Non-relevant outcome assessed Mechanisms of nicotine-induced genotoxicity (c-fos; thiols) 
Chang et al. (2003b) Non-relevant outcome assessed Mechanisms of nicotine-induced cytotoxicity (COX-2 expression) 
Chang et al. (2005) Non-relevant outcome assessed; nicotine not a variable Mechanisms of nicotine-induced cytotoxicity (heme oxygenase-1) 
Cogo et al. (2009) Non-relevant cell types Human epithelial cell (KB, cervical adenocarcenoma) bacterial colonisation 
Fang & Svoboda (2005) Non-relevant outcome assessed HGF differentiation into myofibroblasts 
Gao et al. (2014) Non-relevant outcome assessed; nicotine not a variable HGEC genotoxicity; nicotine is control vs. smokeless tobacco 
Giannopoulou et al. 
(2001) 
Non-relevant outcome assessed (indirect) Effect of nicotine-exposed HGEC on HGF proliferation & collagen production 
Hanes et al. (1991) Non-relevant outcome assessed Binding, uptake & release of nicotine by HGF 
Ito et al. (2013) Non-relevant cell types & outcomes assessed Ca9-22, HSC3 cell (oral squamous cell carcinoma) expression of LDL receptor 
Jeong et al. (2009) Nicotine not an isolated variable Nicotine always varied alongside LPS 
Katz et al. (2005) Non-relevant outcome assessed; nicotine not a variable RAGE upregulation in HGF exposed to nornicotine 
Katz et al. (2007) Non-relevant outcome assessed; nicotine not a variable RAGE upregulation in HGEC exposed to nornicotine 
Kirschneck et al. (2015) Non-relevant outcome assessed (indirect) Indirect assessment of cytokine production (mRNA for IL-6 & COX-2) 
Leonardi et al. (1999) Non-relevant outcome assessed Immunocytochemical expression of α2 integrin by GF 
Martinez et al. (2005) Non-relevant cell types Rat fibroblast viability 
Peacock et al. (1993) Non-relevant outcome assessed (indirect) Effect of nicotine-exposed HGEC on HGF viability/attachment 
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HGEC= Human gingival epithelial cell, HGF= Human gingival fibroblast, HPDLC= Human periodontal ligament cell. 
References 
Al-Qattan, T., & Soory, M. (2012). Anabolic Actions of the Regenerative Agent Enamel Matrix Derivative (EMD) in Oral Periosteal Fibroblasts and 
MG 63 Osteoblasts, Modulation by Nicotine and Glutathione in a Redox Environment. Journal of Functional Biomaterials, 3, 143-162.  
Almasri, A., Wisithphrom, K., Windsor, L. J., & Olson, B. (2007). Nicotine and lipopolysaccharide affect cytokine expression from gingival 
fibroblasts. Journal of Periodontology, 78, 533-541.  
Argentin, G., & Cicchetti, R. (2006). Evidence for the role of nitric oxide in antiapoptotic and genotoxic effect of nicotine on human gingival 
fibroblasts. Apoptosis, 11, 1887-1897.  
Austin, G. W., Cuenin, M. F., Hokett, S. D., Peacock, M. E., Sutherland, D. E., Erbland, J. F., & Billman, M. A. (2001). Effect of nicotine on fibroblast 
beta 1 integrin expression and distribution in vitro. Journal of Periodontology, 72, 438-444.  
Chang, Y. C., Hsieh, Y. S., Lii, C. K., Huang, F. M., Tai, K. W., & Chou, M. Y. (2003). Induction of c-fos expression by nicotine in human 
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stimulated with nicotine. Journal of Periodontal Research, 40, 252-257.  
Pi et al. (2010) Non-relevant outcome assessed Mechanisms of nicotine-induced genotoxicity (COX-2 expression, nitric oxide synthase 
induction) 
Sadaoka et al. (2013) Non-relevant outcome assessed Chromogranin A production in HPDLC exposed to nicotine 
Snyder et al. (2002) Non-relevant outcome assessed (indirect) Indirect assessment of HGF adhesion (integrin β1 expression) 
Soory & Suchak (2003) Non-relevant outcome assessed Nicotine modulating HGF metabolism of testosterone to DHT 
Tinti & Soory (2012) Non-relevant outcome assessed Mechanisms of oxidative effect of nicotine on HGF (DHT yields) 
Tinti & Soory (2013) Non-relevant outcome assessed; nicotine not an isolated 
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Mechanisms of oxidative effect on HGF; nicotine always varied alongside H2O2 
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Appendix C Supplementary Table S2: Characteristics of included studies: cell type, cell origin, investigations, quality assessment according to 
modified CONSORT checklist, funding source(s) and location of first author. 
Study Cell types 
investigated 
Cell Origin  Investigations completed Quality 
assessment 
score 
Funding source First 
author 
location 
Primary 
cells or 
cell line?  
Location or 
origin?  
Smoker?  Age (years)?  Cell viability Cell 
attachment/ 
adhesion 
Cell 
proliferation 
Cytokine 
production 
   
Alpar et al. (1998) HPDLC + 
HGF 
Primary Attached gingiva 
and molar root 
ligament 
 
Smokers & 
non-smokers 
 
Not specified  X  X  6 No 
details 
provided 
Germany 
Argentin & Cicchetti 
(2004) 
HGF Cell line  Coriell Cell 
Repository, 
AG09429;  
apparently 
healthy Caucasian 
female 
 
Not specified 25  X 
 
 X  8 Ministry of 
Education, 
University & 
Research (MIUR) 
grant 
 
Italy 
Chang et al. (2001) HPDLC Primary  Orthodontic 
premolar 
extractions, 
healthy 
individuals 
 
Not specified  Not specified  X    8 Chung Shang 
Medical and 
Dental College  
Taiwan 
Chang et al. (2002) HPDLC Primary Orthodontic 
premolar 
extractions, 
Not specified  Not specified  X  X  8 Chung Shang 
Medical and 
Dental College 
Taiwan 
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Study Cell types 
investigated 
Cell Origin  Investigations completed Quality 
assessment 
score 
Funding source First 
author 
location 
Primary 
cells or 
cell line?  
Location or 
origin?  
Smoker?  Age (years)?  Cell viability Cell 
attachment/ 
adhesion 
Cell 
proliferation 
Cytokine 
production 
   
healthy 
individuals 
 
Checchi et al. (1999) HGF 
 
Primary Periodontal 
surgery 
Smokers & 
non-smokers 
16 - 25 and 
40 - 65 
 X  X  9 Consiglio 
Nazionale delle 
Ricerche (National 
Research Council, 
Italy) 
 
Italy 
Ciapetti et al. (1999) HGF Primary  Periodontal 
surgery 
Smokers & 
non-smokers 
 
16 - 65  X  X  8 No details 
provided  
Italy 
Desjardins & Grenier 
(2012) 
HGF + 
HOEC 
Primary 
(HGF)/ 
Cell line 
(HOEC) 
HOEC: 
transformed 
(immortalised) 
GMSM-K from 
University of 
North Carolina.  
HGF: gingival 
biopsy from 
Caucasian male, 
“normal” health 
status, HGF-1, 
American Type 
Not specified 28 (original 
source of 
HGF) 
 X   X 8 Fondation de 
l’Ordre des 
Dentistes du 
Québec; Canadian 
Institutes of Health 
Research 
Canada 
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Study Cell types 
investigated 
Cell Origin  Investigations completed Quality 
assessment 
score 
Funding source First 
author 
location 
Primary 
cells or 
cell line?  
Location or 
origin?  
Smoker?  Age (years)?  Cell viability Cell 
attachment/ 
adhesion 
Cell 
proliferation 
Cytokine 
production 
   
Culture Company 
(ATCC).  
 
Dinos et al. (2015) HGF Primary  Gingival biopsy, 
healthy 
individuals, no 
local 
inflammation 
 
Non-smokers Not specified  X  X*  8 No details 
provided 
USA 
Esfahrood et al. (2015) HGF Cell line Pasteur Institute 
of Iran, C-165 – 
further details 
unavailable 
 
Not specified Not specified  X X   9 “None declared” Iran 
Fang & Svoboda (2005) HGF Primary  Crown 
lengthening 
surgery, healthy 
individuals 
Non-smokers Not specified    X*  9 Baylor Oral Health 
Foundation; 
National Institutes 
of Health; Tobacco 
Endowment Fund, 
Texas A&M 
University 
 
USA 
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Study Cell types 
investigated 
Cell Origin  Investigations completed Quality 
assessment 
score 
Funding source First 
author 
location 
Primary 
cells or 
cell line?  
Location or 
origin?  
Smoker?  Age (years)?  Cell viability Cell 
attachment/ 
adhesion 
Cell 
proliferation 
Cytokine 
production 
   
Gao et al. (2013) HGEC Primary Healthy gingival 
tissues, healthy 
individuals 
Not specified Not specified  X 
 
   7 University of 
Louisville; RJ 
Reynolds Tobacco 
 
USA 
Giannopoulou et al. 
(1999) 
HPDLC Primary  Orthodontic 
premolar 
extractions; 
Caucasian males 
 
Not specified Not specified   X X  6 P. Baehni provided 
equipment 
Switzerlan
d 
Ho & Chang (2006) HGF Primary  Crown 
lengthening 
surgery, healthy 
individuals, no 
local 
inflammation 
 
Not specified Not specified  X    8 No details 
provided 
China 
James et al. (1999) HPDLC 
 
Primary  Orthodontic 
premolar 
extractions 
Not specified Not specified   X   8 Oral & Dental 
Research Trust; 
Nuffield Health 
Foundation 
 
UK 
Johnson & Organ (1997) HGEC Primary  Crown 
lengthening 
surgery, 4 female; 
Non-smokers 41 (mean)  X  X X 9 NIDR grant USA 
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Study Cell types 
investigated 
Cell Origin  Investigations completed Quality 
assessment 
score 
Funding source First 
author 
location 
Primary 
cells or 
cell line?  
Location or 
origin?  
Smoker?  Age (years)?  Cell viability Cell 
attachment/ 
adhesion 
Cell 
proliferation 
Cytokine 
production 
   
3 male, no signs 
of periodontitis, 
no systemic 
conditions 
requiring NSAIDs 
or antibiotics in 
previous 3 
months 
 
Johnson et al. (2010) HGEC Primary  Crown 
lengthening 
surgery, healthy 
individuals, no 
systemic 
conditions 
requiring NSAIDs 
or antibiotics in 
previous 3 
months 
 
Non-smokers < 50  X   X 8 National Institute 
of Dental and 
Craniofacial 
Research USA. 
(R29DEO10153; 
RO1DE13334) 
 
USA 
Kang et al. (2011) HGF Cell line ATCC, HGF-1, 
gingivial biopsy 
from Caucasian 
Not specified 28 (original 
source of 
HGF) 
 
 X    8 “None” South 
Korea 
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Study Cell types 
investigated 
Cell Origin  Investigations completed Quality 
assessment 
score 
Funding source First 
author 
location 
Primary 
cells or 
cell line?  
Location or 
origin?  
Smoker?  Age (years)?  Cell viability Cell 
attachment/ 
adhesion 
Cell 
proliferation 
Cytokine 
production 
   
male, “normal” 
health status 
 
Kashiwagi et al. (2012) HGEC Primary  Periodontal 
surgery, healthy 
individuals 
Non-smokers 45 (mean)  X   X 9 Japan Society for 
the Promotion of 
Science  
 
Japan 
Kim et al. (2012) HPDLC Cell line Transformed 
(immortalised) 
PDL cell line 
from Hiroshima 
University, Japan 
Not specified Not specified  X   X 8 Korea Healthcare 
Technology R&D 
Project, Ministry 
for Health, Welfare 
& Family Affairs, 
Korea. (A100093) 
 
South 
Korea 
Lee et al. (2005) HGEC Cell line Transformed 
(immortalised) 
HGEC line from 
Kagoshima 
University, Japan 
 
Not specified Not specified  X  X  8 Wonkwang 
University 
South 
Korea 
Lee et al. (2008) HGEC Cell line Transformed 
(immortalised) 
HGEC line from 
Not specified Not specified  X    8 Wonkwang 
University 
South 
Korea 
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Study Cell types 
investigated 
Cell Origin  Investigations completed Quality 
assessment 
score 
Funding source First 
author 
location 
Primary 
cells or 
cell line?  
Location or 
origin?  
Smoker?  Age (years)?  Cell viability Cell 
attachment/ 
adhesion 
Cell 
proliferation 
Cytokine 
production 
   
Kagoshima 
University, Japan 
 
Lee et al. (2009) HPDLC Cell line Transformed 
(immortalised) 
HPDLC cell line 
from Wongkwang 
University, Japan 
 
Not specified Not specified  X    8 Korea Research 
Foundation 
South 
Korea 
Lee et al. (2013) HPDLC Primary  Orthodontic 
premolar 
extractions 
Not specified Not specified  X    7 Kyung Hee 
University grant 
 
South 
Korea 
Mahanonda et al. (2009) HGEC 
 
Primary  Crown 
lengthening 
surgery, healthy 
periodontium 
from lifetime 
non-smokers with 
no history of 
periodontitis 
 
Non-smokers Not specified  X   X 9 Thai Health Grant, 
Chulalongkorn 
University Fund, 
Thai Government 
Research Budget 
 
Thailand 
Nakao et al. (2009) HGF Primary  Gingival biopsy 
of healthy 
interdental papilla 
Not specified Not specified  X   X 9 Japan Society for 
the Promotion of 
Science  
Japan 
329 
 
Study Cell types 
investigated 
Cell Origin  Investigations completed Quality 
assessment 
score 
Funding source First 
author 
location 
Primary 
cells or 
cell line?  
Location or 
origin?  
Smoker?  Age (years)?  Cell viability Cell 
attachment/ 
adhesion 
Cell 
proliferation 
Cytokine 
production 
   
prior to 
orthodontic 
premolar 
extraction 
 
Nakata et al. (2013) HGEC 
 
Cell line Cell Research 
Corp, Singapore, 
hOMK107 – from 
Caucasian female 
Not specified 52 (original 
source of 
HGEC) 
 
 X    9 Ministry of 
Education, Culture, 
Sports, Science 
and Technology of 
Japan  
Japan 
Olson et al. (2005) HPDLC Cell line Originated from 
periodontally and 
systematically 
healthy subjects 
 
Not specified Not specified    X X 8 No details 
provided  
USA 
Park et al. (2013) HGF 
 
 
Cell line Transformed 
(immortalised) 
HGF line 
originated from 
interdental papilla 
gingival tissue 
adjacent to sound 
premolar & 
permanent molar 
Not specified Not specified  X    9 Korea Healthcare 
Technology R&D 
Project of Ministry 
for Health, Welfare 
and Family 
Affairs, Korea; 
National Research 
Foundation of 
Korea.   
South 
Korea 
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Study Cell types 
investigated 
Cell Origin  Investigations completed Quality 
assessment 
score 
Funding source First 
author 
location 
Primary 
cells or 
cell line?  
Location or 
origin?  
Smoker?  Age (years)?  Cell viability Cell 
attachment/ 
adhesion 
Cell 
proliferation 
Cytokine 
production 
   
teeth in healthy 
subjects 
 
 
San Miguel et al. (2010) HGF + 
HPDLC 
Primary  Gingival tissues 
and extracted 
teeth (“because of 
clinical 
necessity”), 
healthy 
individuals  
Non-smokers Not specified  X    9 Texas A & M 
Research 
Foundation grant 
480191; 
PerioSciences LLC 
assisted obtaining 
grant support. 
 
USA 
San Miguel et al. (2012) HGF + 
HPDLC 
Primary  Premolar 
extractions 
(ligament cells, 
adjacent healthy 
gingiva or 
interdental 
papilla), healthy 
individuals 
 
Non-smokers Not specified  X  X  9 PerioSciences LLC USA 
Silva et al. (2012) HGF Primary   Retromolar 
gingiva harvested 
during third molar 
extraction,  
Non-smoker Not specified  X    9 Chilean Fund for 
Science and 
Technology 
(1090142) 
Chile 
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Study Cell types 
investigated 
Cell Origin  Investigations completed Quality 
assessment 
score 
Funding source First 
author 
location 
Primary 
cells or 
cell line?  
Location or 
origin?  
Smoker?  Age (years)?  Cell viability Cell 
attachment/ 
adhesion 
Cell 
proliferation 
Cytokine 
production 
   
healthy female 
individual, no 
history of 
inflammation at 
site, no relevant 
medical or drug 
history in 
previous 6 
months  
 
Tanur et al. (2000) HGF Not 
specified 
Frozen cells from 
Eisenhower Army 
Medical Centre, 
Augusta, Georgia  
 
Not specified Not specified   X   7 Texas A&M 
University, Baylor 
College of 
Dentistry 
USA 
Takeuchi et al. (2010) HGF + 
HPDLC 
Primary   Gingiva harvested 
during impacted 
third molar 
extraction, 
ligament from 
lower premolar 
orthodontic 
extractions, 
“Normal” tissues 
Not specified 23 - 34  X    9 Ministry of 
Education, 
Science, and 
Culture, Japan 
(20592437, 
19109008, 
19592142) 
Japan 
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Study Cell types 
investigated 
Cell Origin  Investigations completed Quality 
assessment 
score 
Funding source First 
author 
location 
Primary 
cells or 
cell line?  
Location or 
origin?  
Smoker?  Age (years)?  Cell viability Cell 
attachment/ 
adhesion 
Cell 
proliferation 
Cytokine 
production 
   
from male and 
female donors 
 
Takeuchi-Igarashi et al. 
(2014) 
HGF + 
HPDLC 
Primary   Gingiva harvested 
during impacted 
third molar 
extraction, 
ligament from 
lower premolar 
orthodontic 
extractions, 
“Normal” tissues 
from male and 
female donors 
 
Not specified 23 - 34     X 9 Ministry of 
Education, 
Science, and 
Culture, Japan 
(20592437)  
Japan 
Tipton & Dabbous 
(1995) 
HGF Primary Non-inflamed 
gingival tissues, 
healthy individual 
 
Not specified Not specified  X  X X 9 University of 
Tennessee College 
of Dentistry 
USA 
Wendell and Stein 
(2001) 
HGF 
 
Primary  Periodontal 
surgery in cases 
of chronic 
periodontitis, 
male and female, 
Not specified 35 - 65  X   X 
 
8 National Institute 
of Dental and 
Craniofacial 
Research 
USA 
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Study Cell types 
investigated 
Cell Origin  Investigations completed Quality 
assessment 
score 
Funding source First 
author 
location 
Primary 
cells or 
cell line?  
Location or 
origin?  
Smoker?  Age (years)?  Cell viability Cell 
attachment/ 
adhesion 
Cell 
proliferation 
Cytokine 
production 
   
no antibiotics or 
anti-inflammatory 
medication 6 
weeks prior to 
harvesting 
 
(DE07258, 
DE11519) 
Wu et al. (2013) HPDLC Primary  Orthodontic 
premolar 
extractions 
Not specified “young 
patients”  
    X 9 National Natural 
Science 
Foundation of 
China (30973315, 
81170964) 
 
China 
Wu et al. (2014) HPDLC Primary  Orthodontic 
premolar 
extractions 
Not specified “child 
patients” 
    x 9 Laboratory of 
Endodontics of the 
Fourth Military 
Medical 
University; 
National Natural 
Science 
Foundation of 
China (81170964). 
 
China 
 Zhou et al. (2007) HGF Primary Crown 
lengthening 
Non-smokers Not specified  x   x 8 No details 
provided   
USA 
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Study Cell types 
investigated 
Cell Origin  Investigations completed Quality 
assessment 
score 
Funding source First 
author 
location 
Primary 
cells or 
cell line?  
Location or 
origin?  
Smoker?  Age (years)?  Cell viability Cell 
attachment/ 
adhesion 
Cell 
proliferation 
Cytokine 
production 
   
surgery, clinically 
healthy 
HGEC= Human gingival epithelial cell, HPDLC= Human periodontal ligament cell, HGF= Human gingival fibroblast, HOEC= Human oral epithelial cell, HGEC= Human gingival epithelial cell.  
*Studies investigated cell proliferation indirectly using wound repopulation.  
Wording in quotation marks indicates direct quote from source data.  
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Appendix D Supplementary Table S3: Quality assessment of included studies based on a modified CONSORT checklist. 
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Alpar et al. (1998) ✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✕ ✓ ✕ ✕ ✕ 6 
Argentin & 
Cicchetti (2004) 
✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✕ ✓ ✕ 8 
Chang et al. 
(2001) 
✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✕ ✓ ✕ 8 
Chang et al. 
(2002) 
✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✕ ✓ ✕ 8 
Checchi et al. 
(1999) 
✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✓ ✓ ✕ 9 
Ciapetti et al. 
(1999) 
✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✓ ✕ ✕ 8 
Desjardins & 
Grenier (2012) 
✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✕ ✓ ✕ 8 
Dinos et al. 
(2015) 
✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✓ ✕ ✕ 8 
Esfahrood et al. 
(2015) 
✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✓ ✓ ✕ 9 
Fang & Svoboda 
(2005) 
✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✓ ✓ ✕ 9 
Gao et al. (2013) ✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✕ ✕ ✓ ✕ 7 
Giannopoulou et 
al. (1999) 
✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✓ ✕ 6 
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Ho & Chang 
(2006) 
✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✓ ✕ ✕ 8 
James et al. 
(1999) 
✓ ✓ ✓ ✕ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✓ ✓ ✕ 8 
Johnson & Organ 
(1997) 
✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✓ ✓ ✕ 9 
Johnson et al. 
(2010) 
✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✕ ✓ ✕ 8 
Kang et al. (2011) ✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✕ ✓ ✕ 8 
Kashiwagi et al. 
(2012) 
✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✓ ✓ ✕ 9 
Kim et al. (2012) ✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✕ ✓ ✕ 8 
Lee et al. (2005) ✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✓ ✕ 8 
Lee et al. (2008) ✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✕ ✓ ✕ 8 
Lee et al. (2009) ✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✕ ✓ ✕ 8 
Lee et al. (2013) ✕ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✕ ✓ ✕ 7 
Mahanonda et al. 
(2009) 
✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✓ ✓ ✕ 9 
Nakao et al. 
(2009) 
✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✓ ✓ ✕ 9 
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Nakata et al. 
(2013) 
✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✓ ✓ ✕ 9 
Olson et al. 
(2005) 
✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✓ ✕ ✕ 8 
Park et al. (2013) ✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✓ ✓ ✕ 9 
San Miguel et al. 
(2010) 
✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✓ ✓ ✕ 9 
San Miguel et al. 
(2012) 
✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✓ ✓ ✕ 9 
Silva et al. (2012) ✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✓ ✓ ✕ 9 
Tanur et al. 
(2000) 
✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✕ ✕ ✓ ✕ 7 
Takeuchi et al. 
(2010) 
✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✓ ✓ ✕ 9 
Takeuchi-Igarashi 
et al. (2014) 
✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✓ ✓ ✕ 9 
Tipton & Dabbous 
(1995) 
✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✓ ✓ ✕ 9 
Wendell and Stein 
(2001) 
✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✕ ✓ ✕ 8 
Wu et al. (2013) ✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✓ ✓ ✕ 9 
Wu et al. (2014) ✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✓ ✓ ✕ 9 
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 Zhou et al. 
(2007) 
✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✓ ✕ ✕ 8 
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Appendix E Supplementary Table S4: Principal findings of studies which investigated cell viability, cell attachment or adhesion, cell 
proliferation or wound repopulation. 
Study Cell types investigated Assay used? Principal finding  
Cell viability  
 
   
Alpar et al. (1998) HPDLC + HGF Fluorescent dyes and trypan blue exclusion test Reversible effects with 1.9-10.3 mM (24 h, vacuolation, impaired membrane integrity, no p value presented, 
both HPDLC & HGF) 
Irreversible toxicity with 10.3-15.5 mM (≥24 h, no p value presented) 
ED50
 = 15.19-15.56 mM depending on cell type and assay (24 h)  
 
Argentin & Cicchetti (2004) HGF Trypan blue exclusion test Reduction with 10 μM (24 h, p<0.01, >25% reduction); approx. 60% reduction with 1 mM (24 h, p<0.001) 
 
Chang et al. (2001) HPDLC MTT No effect observed with 5 mM (4 h) 
At 5-20 mM cytotoxicity observed in concentration- and time-dependent manner (6, 24 h; no p value 
presented)  
 
Chang et al. (2002) HPDLC MTT Reduced viability with 5, 10, 15 mM (24 h, p<0.05); reduction >70% with 20, 25 mM (24 h, p<0.001) 
 
Checchi et al. (1999) 
 
 
HGF 
 
 
Neutral red uptake assay 
 
 
Reduced viability with 3.7 mM* (48 h, p<0.05), no effect seen at 24 h  
Stimulatory effect with 370 μM* (24 & 48 h) for cells from ≥40 y (p<0.05, NS at 48 h for smokers) 
 
Ciapetti et al. (1999) HGF Neutral red uptake assay No effect of 37 μM* (24, 48 h; p<0.05) 
Stimulatory effect with 370 μM* (24 & 48 h, non-smokers only, p<0.05)  
Reduced viability with 3.7 mM* (24 h, non-smokers only, p<0.05, approx.10% reduction); smokers and non-
smokers reduced by approx. 40% at 48 h (p<0.05)  
 
Desjardins & Grenier (2012) HGF + HOEC 
 
MTT Reduced viability with 310-920 µM* (24 h, p<0.005, both HGF & HOEC)  
Dinos et al. (2015) HGF Microscopic observation Cytotoxicity observed with 4 mM nicotine (4 d, no statistical testing presented)  
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Study Cell types investigated Assay used? Principal finding  
 
Esfahrood et al. (2015) HGF MTT No effect of 1 nM – 0.1 mM (24 h) 
Reduced viability with 1 mM – 20 mM (24 h, p<0.05) 
 
Gao et al. (2013) HGEC SRB 
 
 
No significant difference with 6.2 μM-2.8 mM* (48 h) 
Stimulatory effect of 460 µM* (5 h, no p value presented, approx. 50% increase) 
EC-50 not reached with <2.8 mM* (24 h) 
 
Ho & Chang (2006) HGF Lactate dehydrogenase leakage 
 
Reduced viability with 5, 10, 15, 20 mM (24 h, p<0.05, approx. 30/45/65/90% reduction respectively) 
Johnson & Organ (1997) HGEC MTS No effect with 100 nM, 10 µM or 1 mM (4 & 24 & 48 h) 
 
Johnson et al. (2010) HGEC MTS No effect with 100 nM & 1 mM (24 h, no data shown) 
 
Kang et al. (2011) HGF 
 
MTT Reduced viability with 1, 5, 10, 20 mM (24 h, p<0.05, approx. 30/50/80/90% reduction respectively)  
 
Kashiwagi et al. (2012) HGEC “Preliminary experiments” No effect of 10 nM – 1 mM (24 h)  
 
Kim et al. (2012) HPDLC MTT Reduced viability with 10 mM (24 h, p<0.05, approx. 45% reduction) 
No effect with 1, 5 mM (24 h, p<0.05) 
 
Lee et al. (2005) HGEC MTT Reduced viability with 6, 60, 300, 600 μM (24-120 h, p<0.05, approx. 30/50/55/75% reduction respectively at 
24 h) 
IC50= 300 µM (24 h) 
 
Lee et al. (2008) HGEC MTT Reduced viability with 5 mM (8 h, p<0.05, approx. 40% reduction), 20 mM (4 h, p<0.05, approx. 45% 
reduction) 
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Study Cell types investigated Assay used? Principal finding  
Lee et al. (2009) HPDLC MTT Reduced viability with 10, 15 mM (24 h, p<0.05, approx. 20/60% reduction respectively); 10mM showed 
effects after 9 h (p<0.05) 
 
Lee et al. (2013) HPDLC MTT Reduced viability with 10 mM (12 h, p<0.05, approx. 25% reduction); reduced viability with 5, 10 mM (24 h, 
p<0.05, approx. 20/40% reduction respectively); reduced viability with 5, 10 mM (48 & 72 h, p<0.05, approx. 
40/60% reduction respectively); no effect with 2mM (12, 24, 48, 72 h) 
 
Mahanonda et al. (2009) HGEC 
 
MTT and trypan blue exclusion  No effect with 0.1, 0.3, 1mM (24 h) 
Nakao et al. (2009) HGF “Preliminary experiments” No effect up to 10 mM (no duration provided [24 h implied])  
 
Nakata et al. (2013) HGEC 
 
MTT No effect with 1 µM & 1 mM (24 h) 
Park et al. (2013) HGF 
 
MTT No significant effect of 5 mM nicotine (24 h)  
San Miguel et al. (2010) HGF + HPDLC MTS Reduced viability with 6, 8, 10 mM (10 h, no p value presented, approx. 40-50% reduction, both HGF & 
HPDLC) 
 
San Miguel et al. (2012) HGF + HPDLC MTS HGF: Reduced viability 6 & 8 mM (30 m, p<0.05, approx. 40% reduction) 
HPDLC: Reduced viability with 6 & 8 mM (60 m, p<0.05, approx. 20-25% reduction) 
 
Silva et al. (2012) HGF MTS No effect with 150 nM* - 200 μM* (24, 48, 72 h; p<0.05) 
 
Takeuchi et al. (2010) HGF + HPDLC Trypan blue exclusion test Stimulatory effect with 620 nM* (12-48 h, p<0.05, both HGF & HPDLC) 
Reduced viability with 6.2 & 62μM* (12-48 h, p<0.05, approx.40-50%/ 90-100% reduction respectively, both 
HGF & HPDLC) 
  
Tipton & Dabbous (1995) HGF Microscopic observations during “Preliminary 
experiments”. 
Reduced viability with >5 mM* (24 h, no duration or p value stated) 
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Study Cell types investigated Assay used? Principal finding  
Wendell and Stein (2001) HGF 
 
Trypan blue exclusion test No effect with 1 nM, 1 µM, 1 mM (12-48h) 
 Zhou et al. (2007) HGF MTT No effect with 1.54 mM* (72 h) 
    
Cell attachment or adhesion    
    
Esfahrood et al. (2015) HGF MTT  Reduced adhesion with 1 nM, 1 µM, 1 mM, 5 mM (24 h, p<0.05, root surface) 
 
Giannopoulou et al. (1999) HPDLC Cell count  Reduced attachment with 150 nM* (6 h, no p values presented, plastic culture plates, dose dependant inhibition 
0.6-15.4 µM*) 
 
James et al. (1999) HPDLC 
 
MTT  Reduced attachment with 31 mM* (24 h, p<0.05, plastic culture plates, greater effect for cells from lower 
passages) 
 
Tanur et al. (2000) HGF 
 
Cell count Root surface: Reduced cell attachment with 150, 310, 620 nM* (4 w, p<0.05) 
Glass surface: Reduced cell attachment with 310, 620 nM* (4 w, p<0.05) 
Cell proliferation    
    
Alpar et al. (1998) 
 
HPDLC + HGF Cell count using trypan blue, SRB, DNA content 
 
Reduced proliferation with >3.9 mM and complete arrest of proliferation with >31 mM (24 h, both cell types, 
no p value presented)  
 
Argentin & Cicchetti (2004) 
 
HGF Cell count using Neubauer Chamber and trypan blue  
 
No effect with 1 μM (24, 36, 48,72 h) 
 
Chang et al. (2002) 
 
HPDLC Thymidine incorporation Reduced proliferation with 25, 50, 100, 200 μM (96 h, p<0.05, approx. 20/50/70/85% reduction respectively) 
Complete arrest of proliferation with 400 μM (96 h, p<0.001) 
 
Checchi et al. (1999) 
 
HGF Flow cytometry using Hoechst 33342 Reduced proliferation with 3.7 mM* (24 h, p<0.05, no effect on cells from smokers aged >40 y)  
No effect with 37μM* or 370 μM* (24 h, p<0.05) 
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Study Cell types investigated Assay used? Principal finding  
Ciapetti et al. (1999) 
 
HGF Hoechst DNA quantitation Reduced proliferation with 3.7 mM* (48 h, p<0.05) 
No effect with 37 μM*, 370 μM*(24, 48 h, p<0.05) or 3.7 mM* (24 h, p<0.05) 
 
Giannopoulou et al. (1999) 
 
HPDLC Thymidine incorporation 
 
Reduced proliferation with 0.6, 1.5, 3, 6, 12 μM* (24-48 h, no p value presented, approx. 25/40/50/80/90% 
reduction respectively) 
No effect with 30, 150 nM* (24-48 h) 
 
Johnson & Organ (1997) 
 
HGEC Acid Phosphatase assay  No effect with 100 nM, 10 μM or 1 mM (4-48 h) 
Lee et al. (2005) 
 
HGEC Flow cytometry + Western Blot for cell-cycle 
regulatory protein 
Implied decrease in cell proliferation, with more cells in G0 or G1 phase and fewer in S phase of the cell cycle 
Increase in p21 and decrease in p53 expression with 6, 60, 300 μM 
 
Olson et al. (2005) 
 
HPDLC Cell count using Coulter counter Increase in proliferation of cells when exposed to 2.3 mM (24 h, p<0.05) 
Reduction in proliferation of cells when exposed to 9.2mM (24 h, p<0.05) 
 
San Miguel et al. (2012) 
 
HGF + HPDLC Bromodeoxyuridine assay HGF: Reduced proliferation with 6, 8 mM (30 m, p<0.05, approx. 20% reduction) 
HPDLC: No effect with 6, 8 mM (30 m) 
 
Tipton & Dabbous (1995) 
 
HGF Thymidine incorporation Reduced proliferation with 62 μM* or 0.2, 0.3, 0.5, 0.6, 1.5, 3.1 or 4.6mM* (24 h, p<0.05) 
Wound repopulation (or rate of artificial wound closure)   
    
Dinos et al. (2015) HGF Photomicrography No effect with 1, 2, 4 mM (24, 48 h; p<0.05)  
Reduced wound repopulation with 4mM (96 h, p<0.05) 
Reduced wound repopulation with 1, 2, 4 mM (144 h, p≤0.001) 
 
Fang & Svoboda (2005) HGF Photomicrography Reduced wound closure rates with 0.5 μM (12, 24, 36 h; p<0.05) 
HGEC= Human gingival epithelial cell, HPDLC= Human periodontal ligament cell, HGF= Human gingival fibroblast, HOEC= Human oral epithelial cell, HGEC= Human gingival epithelial cell, h= hour(s), d= day(s).   
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Appendix F Supplementary Table S5: Principal findings of studies which investigated inflammatory mediator production. 
Study Cell types 
investigated 
Inflammatory 
mediator assessed 
Principal finding 
Desjardins & Grenier (2012) HGF + HOEC 
 
 
CCL5, IL-6, IL-8 
 
HOEC: increase of CCL5 with 300 nM* (24 h, p≤0.005, no effect on IL-6 + IL-8) 
HGF: no effect on CCL5, IL-6, Il-8 with 300 nM* (24 h, data not shown)  
 
Johnson & Organ (1997) HGEC PGE2, IL-1α, IL-1β  No effect on PGE2 with 100 nM, 10 µM, 1 mM (4-48 h)  
Increased IL-1α in cell lysate with 1mM (24, 48 h; p=0.0061, no effect seen in cell culture supernatant)  
No effect on IL-1β in cell lysate with 1mM (4, 24, 48 h; p<0.01)  
 
Johnson et al. (2010) HGEC IL-1α, IL-8 Increase in IL-1α with 1 mM (24h, p<0.0018, no effect with 0.1 µM)  
No effect on IL-8 at 100 nM, 1 mM (24 h) 
 
Kashiwagi et al. (2012) HGEC  
 
IL-8 Increased production with 1 mM  (24 h, p<0.01, HGEC stimulated with IL-1β) 
 
Kim et al. (2012) HPDLC MMP-2, MMP-9, 
PGE2 
Increased PGE2 with 5, 10 mM (24 h, p<0.05)  
Increased MMP-2 + MMP-9 with 1, 5, 10 mM (24 h, no p value presented)  
 
Mahanonda et al. (2009) HGEC  
 
IL-8 Increased IL-8 with 0.3, 1 mM (24 h, p<0.05, HGEC stimulated with P.gingivalis LPS + TNF-α)  
Nakao et al. (2009) HGF PGE2 Increased PGE2 with 1-10 mM (6 h, no p value presented) 
 
Olson et al. (2005) HPDLC IL-6 Increased IL-6 with 1.5, 2.3 mM* (24 h, p<0.05)  
Decreased IL-6 with 9.24 mM* (24 h, p<0.05)   
 
Takeuchi-Igarashi et al. (2014) HGF + HPDLC TGF-β1, MMP-1, 
TIMP-1 
HGF: increased in TGF-β1 in cell culture supernatant with 6.2 nM* (12, 24 h; p<0.05, no effect seen in cell lysate); increase in MMP-1 in cell lysate with 6.2 
nM* (24, 48 h, not statistically significant); increase in TIMP-1 with 6.2 nM* (12, 24, 48 h; p<0.05).  
  
HPDLC: increased TGF-β1 in cell lysate with 6.2 nM* (12 h, p<0.01); ); increase in MMP-1 in cell lysate (24, 48 h; not statistically significant); increase in 
TIMP-1 with 6.2 nM* (12, 24, 48 h; p<0.05). 
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Study Cell types 
investigated 
Inflammatory 
mediator assessed 
Principal finding 
 
Tipton & Dabbous (1995) HGF Collagenase activity  Increased collagenase activity with 1.5, 3.1, 4.6 mM* (144 h, p<0.008)  
 
Wendell and Stein (2001) HGF IL-6 & IL-8 
 
Increase in IL-6 with 1 nM, 1 µM, 1 mM (48 h, p=0.018/0.003/0.024 respectively); 1nM induced the greatest response at 24 h (p=0.02) 
Increase in IL-8 with 1 nM (24 h, p<0.02, no effect at 48 hrs)  
 
Wu et al. (2013) HPDLC IL-1β   Increase in secretion with 10µM (72 h, p<0.01) 
 
Wu et al. (2014) HPDLC IL-1β + IL-8 Increased secretion of IL- 1β + IL-8 with nicotine 10μM (24 h, p<0.01)  
 
Zhou et al. (2007) HGF MMP-1, MMP-2, 
MMP-3, MMP-14, 
TIMP-1, TIMP-2 
No effect on MMP-1 and MMP-2 with 1.5 mM* (48 h)  
Increased prevalence in membrane extracts of MMP-14 (43 kDa) and MMP-2 (68kDa) with 1.5 mM* (48 h, no p value presented)  
Slightly reduced levels of TIMP-1 in nicotine-treated cells (1.54 mM, 48  h, no p values presented); TIMP-2 appeared to be redistributed to cell membranes by 
nicotine exposure  
HGEC= Human gingival epithelial cell, HPDLC= Human periodontal ligament cell, HGF= Human gingival fibroblast, HOEC= Human oral epithelial cell, HGEC= Human gingival epithelial cell, h= hour(s), d= day(s), MMP= 
Matrix Metalloproteinase, TIMP= Tissue Inhibitors of Metalloproteinases.    
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Appendix G CONSORT checklist for pilot and feasibility trials 
 
Section/Topic 
Item 
No Checklist item 
Reported 
in section 
No. 
Title and abstract 
 1a Identification as a pilot or feasibility randomised trial in the title 3.1 
1b Structured summary of pilot trial design, methods, results, and conclusions (for specific 
guidance see CONSORT abstract extension for pilot trials) 
3.1 
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale for future definitive trial, and reasons for 
randomised pilot trial 
3.2 
2b Specific objectives or research questions for pilot trial 3.3.1, 3.3.2 
Methods 
Trial design 3a Description of pilot trial design (such as parallel, factorial) including allocation ratio 3.4.1 
3b Important changes to methods after pilot trial commencement (such as eligibility criteria), 
with reasons 
3.4.17, 
Table 3.12 
Participants 4a Eligibility criteria for participants 3.4.2 
4b Settings and locations where the data were collected 3.4.2 
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Section/Topic 
Item 
No Checklist item 
Reported 
in section 
No. 
 4c How participants were identified and consented 3.4.3 
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and 
when they were actually administered 
3.4.5, 3.4.6, 
3.4.7 
Outcomes 6a Completely defined prespecified assessments or measurements to address each pilot trial 
objective specified in 2b, including how and when they were assessed 
3.4.12, 
3.4.15 
6b Any changes to pilot trial assessments or measurements after the pilot trial commenced, 
with reasons 
3.4.17 
 6c If applicable, prespecified criteria used to judge whether, or how, to proceed with future 
definitive trial 
NA 
Sample size 7a Rationale for numbers in the pilot trial 3.4.4 
7b When applicable, explanation of any interim analyses and stopping guidelines NA 
Randomisation:    
Sequence  
generation 
8a Method used to generate the random allocation sequence 3.4.9 
8b Type of randomisation(s); details of any restriction (such as blocking and block size) 3.4.9 
Allocation 9 Mechanism used to implement the random allocation sequence (such as sequentially 
numbered containers), describing any steps taken to conceal the sequence until 
interventions were assigned 
3.4.11 
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Section/Topic 
Item 
No Checklist item 
Reported 
in section 
No. 
concealment 
mechanism 
Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who 
assigned participants to interventions 
3.4.9 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care 
providers, those assessing outcomes) and how 
3.4.11 
11b If relevant, description of the similarity of interventions NA 
Statistical methods 12 Methods used to address each pilot trial objective whether qualitative or quantitative 3.4.21 
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were approached and/or assessed for 
eligibility, randomly assigned, received intended treatment, and were assessed for each 
objective 
3.5.2, Table 
3.13, Figure 
3.5, Table 
3.14, Table 
3.40 
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Section/Topic 
Item 
No Checklist item 
Reported 
in section 
No. 
13b For each group, losses and exclusions after randomisation, together with reasons 3.5.4, Table 
3.15, Table 
3.16 
Recruitment 14a Dates defining the periods of recruitment and follow-up 3.5.2 
14b Why the pilot trial ended or was stopped NA 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group 3.5.5, Table 
3.17, Table 
3.18, Table 
3.19  
Numbers analysed 16 For each objective, number of participants (denominator) included in each analysis. If 
relevant, these numbers should be by randomised group 
3.5 
Outcomes and 
estimation 
17 For each objective, results including expressions of uncertainty (such as 95% confidence 
interval) for any 
estimates. If relevant, these results should be by randomised group 
3.5.12, 
3.5.14 
Ancillary analyses 18 Results of any other analyses performed that could be used to inform the future definitive 
trial 
Chapter 4 & 
5 
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Section/Topic 
Item 
No Checklist item 
Reported 
in section 
No. 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT 
for harms) 
3.5.6 
 19a If relevant, other important unintended consequences NA 
Discussion 
Limitations 20 Pilot trial limitations, addressing sources of potential bias and remaining uncertainty about 
feasibility 
3.6.3 
Generalisability 21 Generalisability (applicability) of pilot trial methods and findings to future definitive trial and 
other studies 
3.6.2 
Interpretation 22 Interpretation consistent with pilot trial objectives and findings, balancing potential benefits 
and harms, and considering other relevant evidence 
3.6.2 
 22a Implications for progression from pilot to future definitive trial, including any proposed 
amendments 
3.6.4 
Other information 
 
Registration 23 Registration number for pilot trial and name of trial registry 3.4.18 
Protocol 24 Where the pilot trial protocol can be accessed, if available 3.4.18 
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders 3.4.18 
 26 Ethical approval or approval by research review committee, confirmed with reference 
number 
3.4.17 
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Appendix H Participant Information Sheet (PIS) 
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Appendix I PIC proforma 
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Appendix J E-cigarette users guide 
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Appendix K E-cigarette intervention discussion guide 
1 ‘You have been allocated to receive an e-cigarette as part of this study’   
2 ‘We want you to ‘switch’ to e-cigarettes’ 
3 ‘You are still free to use any of the other ways to stop you want to use on 
top of this’ 
4 Provide E-cigarette starter kit including:  
- Vype eTank starter kit 
- Spare battery 
- Spare Clearomiser 
- UK plug 
 
5 Provide ‘E-cigarette user guide’ 
6 ‘We have produced this users guide.’  
7 Page 2- ‘This shows what you have included in the kit’ 2 batteries, 2 tanks, 
plug, usb charger, 2 bottles of e-liquid (we still need to select these)’ 
8 ‘Can you please check the seal on the kit and open it’ 
9 ‘You are allowed two bottles of e-liquid. Which ones do you want?’ 
10 Selection of e-liquids based on preference and nicotine concentration.  
11 ‘First I’m going to show you how to charge the batteries’ [Demonstration] 
12 ‘There are various colours of lights on the battery and charger’ ‘This is what 
they mean’ [use page 5 of users guide] 
13 ‘Next I’m going to show you how to put e-liquid into the device’ [use page 4 
of the users guide] 
14 Get participant to load liquid into device.  
15 ‘Finally I wanted to highlight a few items from the users guide’ 
16 ‘There is a manufacturers users guide at the back of the box that I 
recommend you read’  
17 ‘It’s really important you only use this charger’ 
18 ‘The date on the products is the date of manufacturer, not the expiry date. 
This can be a little confusing’ 
19 ‘We have provided you with two bottles of e-liquid which would last most 
people between 2-4 weeks. You will need buy your own e-liquid after these 
run out. We would like you to use only Vype e-liquids in this e-cigarette. The 
easiest place to buy these are the website which is detailed here [page 3]. 
There are also many shops which sell them and here are a few examples 
[page 3]. You are free to try any of their 9 flavours and any strength.    
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20 ‘you have one spare tank. These should last around 2-4 weeks. You will need 
to buy some more spare ones, which can be purchased here [page 3].’  
21 ‘we have also listed some top tips here [page 6- read list]’ 
22 ‘Do you have any questions?’ 
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Appendix L Informed Consent Form 
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Appendix M Participant commitment form 
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Appendix N FTND questionnaire 
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Appendix O MPSS questionnaire 
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Appendix P OHQoL-UK 
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Appendix Q TOC charter 
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Appendix R Study Protocol  
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Appendix S Interview schedule for TDF interview  
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Appendix T COREQ checklist 
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Appendix U Supplementary quotes 
Quote Participant details Domains Themes 
Yeah, especially my lass, she thinks it’s good [cutting down], she hates us 
smoking.  
 
Male, 35 years, 40 
cigs/day 
 
Social influences Influence of family 
members and friends 
My husband … he’s never ever smoked in his life.  Ever.  So, I’ve just spoken 
to him then, and he was like, “I’m really proud of you”, and I was like, “Thank 
you”. 
 
Female, 35 years, 
10 cigs/day 
 
Social influences Influence of family 
members and friends 
If I’m going to be a grandmother, you know, I don’t want to be a grandmother 
that’s got a fag hanging out of the side of her gob [mouth].  You know, I want, 
you know, I want to be able to have a little bit of money to spend on me 
grandchildren.  
 
Female, 52 years, 
15 cigs/day 
Social influences Influence of family 
members and friends 
...they [son and daughter] would love us to stop, they don’t smoke, they hate 
it.  Me [my] son’s always like, he was really enthusiastic about us coming 
here... 
 
Female, 49 years, 
15 cigs/day 
 
Social influences Influence of family 
members and friends 
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Quote Participant details Domains Themes 
And I never used to walk about, say Durham, smoking or anything like that.  I 
don’t know, it’s just our lass has always said it doesn’t look very, nice and so 
I’ve never done it really.  
Male, 36 years, 15 
cigs/day 
Social influences Social pressure 
    
I generally wouldn’t smoke, as in, in “public”, if you know what I mean Female, 47 years,10 
cigs/day 
Social influences Social pressure 
    
If I went out shopping, you know to the Metro, or something, I probably 
wouldn’t smoke as many because, I find it embarrassing…..I just don’t think it 
looks very attractive….. I think you just got used to going outside, yeah it was 
a bit of a pain... ...but you’d just end up accepting that.  You’re the leper and 
you have to go outside now. 
Female, 35 years, 
10 cigs/day 
Social influences Social pressure 
    
I don’t like walking down the street pushing a buggy having a cigarette you 
know what I mean?.... I don’t know, you kind of feel a bit of a leper, it’s 
already when you smoke it’s like, I don’t know.  No I just, don’t want to 
anymore like. 
Female, 31 years, 
30 cigs/day 
Social influences Social pressure 
    
435 
 
Quote Participant details Domains Themes 
…you feel like a pariah stood outside smoking. Male, 59 years, 30 
cigs/day 
Social influences Social pressure 
    
…because of the way I’m smoking, I am a secret smoker as well to some 
people. 
Male, 38 years, 10 
cigs/day 
Social/professional 
role and identity 
Identity- secret smoking 
    
I just never thought that was for me [stop smoking medications], really… just 
a couple of comments [from] people saying you have queer [strange] dreams 
and stuff like that, and side effects whatever 
Male, 36 years, 15 
cigs/day) 
Knowledge Experiences/perceptions 
of stop smoking 
medications 
    
Well I’m aware of the chewing gum, I wouldn’t fancy that….. I don’t like the 
idea of it.  In my mind is mouth cancer and all that sort of thing, you know, 
chewing baccy and that, I’m aware.  Probably doesn’t, but, you know, there is 
[are] other ways to do it so. 
Male, 44 years, 30 
cigs/day 
Knowledge Experiences/perceptions 
of stop smoking 
medications 
    
…[others] said it was amazing.  However, they did say the sleep, was horrific.  
You just feel constantly unsettled, and I don’t know whether I, does it, is it 
supposedly you just how you taste things and... And I don’t know how I feel 
about, almost brainwashing yourself.  
Female, 37 years, 
30 cigs/day 
Knowledge Experiences/perceptions 
of stop smoking 
medications 
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Quote Participant details Domains Themes 
    
I suffer from depression… Me doctor refused us [me] them, but me [my] Dad 
took them and he, turned into a real horrible man.  
Female, 40 years, 
25 cigs/day 
Knowledge Experiences/perceptions 
of stop smoking 
medications 
    
I work on, I do driveways and that so, it’s like, wherever you want to smoke 
sort of thing you know… Aye [yes], there’s no smoking restrictions at work, at 
all.  
Male, 35 years, 40 
cigs/day 
Environmental 
context and 
resources 
Influence of the 
workplace 
    
…‘Cos, my partner that I work with, he smokes.  And I’m finding that really 
difficult…. You know?  Especially when I’m having a really stressful night.  
Female, 49 years, 
20 cigs/day 
Environmental 
context and 
resources 
Influence of the 
workplace 
    
And then when I’m working it’s pretty stressful, you know, on the bridge of a 
ship or barges and stuff like that.  And I can be smoking one after the other 
really.  
Male, 59 years, 30 
cigs/day 
Environmental 
context and 
resources 
Influence of the 
workplace 
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Quote Participant details Domains Themes 
Big.  Big, cost… If I work, 12 hours a day, which is my normal working shift, 
then I would buy, 40 [cigarettes].  
Female, 60 years, 
15 cigs/day) 
Environmental 
context and 
resources 
Resources of smoking 
    
I don’t really pay that much… I’ve got friends that go to France every so often 
so I get them pretty cheap. 
Female, 43 years, 
20 cigs/day 
Environmental 
context and 
resources 
Resources of smoking 
    
I know a lot is made of the financial side of it.  I’m personally, it sounds silly, 
rolling tobacco is a lot cheaper than buying ready-made cigarettes… I go 
abroad on motorbikes several times a year, so I don’t pay a lot for my 
tobacco… And, I’m fortunate enough that I have a sufficient income that it’s 
not really an issue.  
Male, 56 years, 20 
cigs/day 
Environmental 
context and 
resources 
Resources of smoking 
    
If and when I’m working it’s really, well, some companies I work with you get 
it free.  Cigarettes.  And beer. But I don’t take the beer.  
Male, 59 years, 30 
cigs/day 
Environmental 
context and 
resources 
Resources of smoking 
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Quote Participant details Domains Themes 
So, I know the government saying like, “Pack in, pack in”, but they’re not 
making it easy for people. 
Male, 40 years, 30 
cigs/day 
Environmental 
context and 
resources 
Resentment towards 
authority 
    
...you get stressed, you smoke more.  Female, 43 years, 
20 cigs/day 
Emotions Stress management 
    
I suppose if you’re having a really bad day.  When everything goes wrong 
from the moment you get up, and you end up in a foul mood. [laughs] Then I 
tend to smoke a little bit more.  I’ll be more inclined to smoke, shall we say.   
Male, 56 years, 20 
cigs/day 
Emotions Stress management 
    
Oh, I’ve, well I’m in the middle of trying to sell me house and buy a new one, 
and that’s going pear shaped at the minute… Then I’ve had problems with a 
member of staff... so, quite, yeah, quite a lot of stuff going on... so 
unfortunately, I’m probably back on me 10 [cigarettes] a day again. 
Female, 47 years, 
15 cigs/day 
Emotions Stress management 
    
I’ve just gone through a difficult split.....so, that hasn’t helped at all.  Female, 58 years, 
15 cigs/day 
Emotions Stress management 
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Quote Participant details Domains Themes 
And like I say, when I went, I just had to go and buy some tobacco, and when 
I rolled a one up and smoked it, I felt great.  I mean I really, really did. 
Male, 59 years, 30 
cigs/day 
Emotions Pleasure of smoking 
    
I suppose, in a way for me the relaxation side of it…. You’re doing something, 
be it work as in work, or maybe stuff at home, decorating or whatever…. Or at 
the end of the day.  This evening, Friday, I always celebrate Friday.  So, I’ll 
get home this evening, put some music on, open a bottle of beer and have a 
cigarette.  And it’s part and parcel of that, if you know what I mean.  
Male, 56 years, 20 
cigs/day 
Emotions Pleasure of smoking 
    
… the thing is, I enjoy smoking when I’ve had a meal. Female, 38 years, 
10 cigs/day 
Emotions Pleasure of smoking 
    
You have a fear.  You know like a fear of stop smoking.  It’s, you know, like, I 
don’t know, like I’ll keep saying to myself, nothing’s going to happen to us if I 
stop smoking, do you know what I mean?  
Female, 58 years, 
15 cigs/day 
Emotions Fear of quitting 
    
… I do it out of habit…. I don’t actually think I need one. Female, 25 years, 
15 cigs/day 
Nature of the 
behaviour 
Habitual nature 
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Quote Participant details Domains Themes 
...I tend to smoke more, when I’m having a drink.  Which is typical I would 
guess. 
Male, 55 years, 15 
cigs/day 
Nature of the 
behaviour 
Link to other 
behaviours 
    
But that is in the situation of being in a pub when you’re drinking as well.  
That kind of, beer, cigarette thing. 
Male, 59 years, 30 
cigs/day 
Nature of the 
behaviour 
Link to other 
behaviours 
    
I don’t want to go out drinking anytime soon, ‘cos I think that’s the biggest 
pitfall for it. 
Male, 27 years, 15 
cigs/day 
Nature of the 
behaviour 
Link to other 
behaviours 
    
I know it sounds stupid but, for all that I enjoyed a cigarette....I don’t like the 
smell of it, I don’t.....I don’t actually like, the actual, smell and the taste that it 
gives you.....but I still, smoked...  
Female, 35 years, 
10 cigs/day 
Nature of the 
behaviour 
Smell 
    
I’m aware that I will be smelling of cigarettes, you know, I was very aware of 
it when I stopped smoking. It's not a pleasant smell, you know. 
Male, 40 years, 30 
cigs/day 
Nature of the 
behaviour 
Smell 
    
And there’s the risk of cancer. But, again, I think I’m on the, I’ve got this idea 
in me [my] head that I’m going to be an outlier as far as cancer, getting cancer 
goes because there’s, um, my grandparents smoked a ridiculous amount and 
Male, 55 years, 15 
cigs/day 
Beliefs about 
consequences 
Health 
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Quote Participant details Domains Themes 
they lived well into their 80s.  My Grandfather, used to smoke Capstan full 
strength, one after the other, he would smoke down to that, and then light the 
next one up, and his fingers were black, with nicotine... but that’s a false idea 
that, there’s no evidence for that. That’s just an idea I have. 
    
I might not be a very nice person… And I might put on weight… And that 
scares me. 
Female, 35 years, 
10 cigs/day 
Beliefs about 
consequences 
Health 
    
I don’t think about smoking affecting my teeth area so I don’t expect the 
dentist to be like “Right, this is what smoking’s doing, you need, help to cut 
down”... 
Female, 29 years, 
10 cigs/day 
 Dentist-delivered SCA: 
opportunistic nature 
    
… I think it kind of hit me a bit like, like a brick.  Female, 38 years, 
10 cigs/day 
 Dentist-delivered SCA: 
opportunistic nature 
    
You know, if I hadn’t had all of this carry on I would have just, continued…. 
But it’s really made us stop and think.  
Female, 49 years, 
20 cigs/day 
 Dentist-delivered SCA: 
opportunistic nature 
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Quote Participant details Domains Themes 
Where, you’ve actually, it’s almost, not took it out of my hands, but you’ve 
instigated it, by saying, “Look, I’m going to refer you to the group”.  They’ve 
been in touch, then I’ve been in touch, whereas, would I ever have got round 
to going… So it’s kind of set the ball rolling.  
Female, 37 years, 
30 cigs/day 
 Dentist-delivered SCA: 
opportunistic nature 
    
…that’s what scared me, because I think, your teeth are your personality aren’t 
they?  They’re everything about you. 
Male, 59 years, 30 
cigs/day 
 Dentist-delivered SCA: 
personal context and 
tangible prompts 
    
… it has made me think, “Crikey, right”, and because you have been willing to 
give me that sort of help and push then yeah, it’s, I think it’s a good thing sort 
of having your dentist say, “Look, this is what can, this is what’s happening” 
Male, 45 years, 15 
cigs/day 
 Dentist-delivered SCA: 
personal context and 
tangible prompts 
    
I didn’t think that me gums were as bad as what they were, and I have lost that 
much bone and that much gum, I was quite surprised, in fact I was horrified, 
‘cos I still think that I’ve got reasonably, nice teeth, on the whole, and I did 
look after me teeth... but I obviously, got the shock of me [my] life when you 
showed us how much of the gum and the bone that I had actually lost.  And 
Female, 52 years, 
15 cigs/day 
 Dentist-delivered SCA: 
personal context and 
tangible prompts 
443 
 
Quote Participant details Domains Themes 
that’s made us really, sit [up], because again, I can see it, you know what I 
mean?  And it’s not until it gets pointed out to you that it’s, oh God. Yeah.  
    
That was, yeah, that hit home.  Because like I was saying, you do think, “Oh, 
it’s not that bad”, however, when you see the evidence in front of ya [you] 
...and it is scary.  And you just think, “Oh my word”… so from the visual 
point of view and the talking through it, because as a smoker, you hear it all 
the time and it’s almost, like doesn’t, it’s water off a ducks back.  “Yeah, yeah, 
smoking’s bad, I get it”.  But when you see the evidence like that, and it kind 
of instigated me to do a bit more research myself... 
Female, 37 years, 
30 cigs/day 
 Dentist-delivered SCA: 
personal context and 
tangible prompts 
    
… when you showed us the X-Ray of me teeth, and everything, I thought, 
“Listen, I’m going to have to do something really”.  
Male, 40 years, 30 
cigs/day 
 Dentist-delivered SCA: 
personal context and 
tangible prompts 
    
… you see it [health warnings] on the cigarette packets and you think, “Is it 
scare tactics”, you just don’t know and like I say, I didn’t realise how bad, me 
[my] gums were until I’ve had all me [my] measurements done.  
Female, 40 years, 
25 cigs/day 
 Dentist-delivered SCA: 
personal context and 
tangible prompts 
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Quote Participant details Domains Themes 
…I am conscious of the problem, and the fact that something is being done.  
You know, you’re spending your time, your colleague’s spending your [their] 
time.  So, someone is helping you, something is being done to help a problem, 
it’s a positive side, if that makes sense. 
Male, 56 years, 20 
cigs/day 
 Dentist-delivered SCA: 
positive context of quit 
attempt 
    
It’s just knowing that it’s going to really help your gums a lot by stopping. Male, 36 years, 15 
cigs/day 
 Dentist-delivered SCA: 
positive context of quit 
attempt 
    
But, I think the possibility of seeing the damage that’s done, and the 
possibility, of it stopping in its tracks. 
Female, 37 years, 
30 cigs/day 
 Dentist-delivered SCA: 
positive context of quit 
attempt 
    
Now. I feel as though I’m giving myself, the best chance that I can possibly 
give myself, to reduce the... the impact of gum disease by stopping smoking 
now. 
Female, 52 years, 
15 cigs/day 
 Dentist-delivered SCA: 
positive context of quit 
attempt 
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Quote Participant details Domains Themes 
… it is the golden opportunity, you’re almost starting from scratch, you’re 
getting the best clean you’re ever going to get… And what an opportunity to 
waste, to be starting and with such good dental treatment, to then reverse all of 
that like with the smoking.  
Female, 37 years, 
30 cigs/day 
 Dentist-delivered SCA: 
positive context of quit 
attempt 
    
I think you’s [you’ve] have pushed us into it.  It’s like it’s always been there in 
the back of me [my] mind I need to do it, but like now, as I’m saying it’s like, 
getting them done and, having me [my] dental work done it’s boosted my self-
confidence, it’s made me feel better about myself, and it’s making me want to 
stop, so... 
Female, 31 years, 
30 cigs/day 
 Dentist-delivered SCA: 
positive context of quit 
attempt 
    
…I didn’t realise, I knew me teeth were really bad.  I knew they were really 
bad and that it was going to be kind of bad news, but I don’t think the other 
dentists have really addressed how bad it was with me. 
Female, 38 years, 
10 cigs/day 
 Dentist-delivered SCA: 
lack of previous support 
    
And where if I went to the doctors and it was like, “Do you smoke?” “Yeah”, I 
would come away and I wouldn’t think twice, but now with coming here, it 
does niggle in the back of me [my] mind…. All the time.  So I do think, from 
Female, 47 years, 
15 cigs/day 
 Dentist-delivered SCA: 
different to doctor-
delivered SCA 
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Quote Participant details Domains Themes 
getting advice here, I’ll be more inclined to stop then [than] definitely the 
doctors.  
    
I’ve listened more to you than what I would a doctor because a doctor you 
think “Oh, they just tell you this...”  you know, but I think, because a dentist 
tells you and yet you’re telling the person the impact it’s going to have, 
because you don’t, I mean me personally, I know I’ve seen it on cigarette 
packets, you get gum disease and you think, “Oh, yeah, haven’t had it yet, I’ve 
smoked all...”  But then obviously, over time you think, “I should have 
listened” but too late then.  So yeah, I do think a dentist has more impact than 
what a GP would have. 
Female, 45 years, 
10 cigs/day 
 Dentist-delivered SCA: 
different to doctor-
delivered SCA 
    
…it’s strange, because I’m diabetic I go for checks at my doctors and stuff. 
And they’ve sort of mentioned it, and I think because they’ve, I don’t know, 
maybe because whenever I’ve gone I’ve never been in the right mind-set to 
think, right yeah I’ll take their servi- [services], take up their services and help.  
And I’ve just sort of gone in and thought, “yeah, yeah, right, whatever”… but 
I think because I’ve been having the work here, and I know that you haven’t 
hold [held] me down and said, you know, “Right, OK, come on”. But I think 
Male, 45 years, 15 
cigs/day 
 Dentist-delivered SCA: 
different to doctor-
delivered SCA 
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Quote Participant details Domains Themes 
because… because your teeth are a lot of your, who you are as well, your 
whole sort of make up as well, it has made me think, “Crikey, right” 
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Appendix V Supplementary quotes: e-cigarettes 
Quote Participant details Themes 
…at least, I think it’s four of the lads, where I go to work, 
they, they all use them… one of the lads is down to three 
milligram or something like that in his, so, they must be 
working for him.  
Male, 35 years, 40 
cigs/day 
Influence of other e-cigarette 
users 
   
Plus I have, a friend of mine who is the same age as me, went to 
the same school and everything, [and] works offshore.  And he 
used to smoke roll up tobacco, just the same as me. And the next 
time I seen him, he was off the tobacco and he was on one of these 
electronic things [e-cigarette]. [He’s] Been on it, six month now 
and he’s finished with the tobacco altogether.  And he’s smoked 
more than me, more roll-ups… And I was talking to a Danish guy 
in Osbourne Road on, last Friday, he lives over here now, but he’s 
on an electric cigarette.  And, he swears by it, you know, and he’s 
give up the [tobacco] cigarettes totally, and he says, but he can’t 
give up the electronic one…  
 
Male, 59 years, 30 
cigs/day 
Influence of other e-cigarette 
users; concerns about addiction 
to e-cigarettes/nicotine 
   
And I found the cheaper ones, the early versions were 
really, bad for me, there’s no way I could use them, ‘cos 
I, cough, and cough, terrible.  But the newer ones, what 
Male, 59 years, 30 
cigs/day 
Previous e-cigarette experiences 
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Quote Participant details Themes 
I’ve had a try of, seem good, seem as though I could 
really get away with using one, you know, and I’m sure, 
for sure I would get off the cigarettes. I know that. I 
know.  
 
   
I’ve tried one but I didn’t feel like I got a big enough, 
like, puff off it. 
 
Female, 25 years, 15 
cigs/day 
Previous e-cigarette experiences 
And the other ones where you’ve got to press buttons and then 
after a while it gets a bit fiddley...’cos the refilling the liquid’s 
quite sticky and if you...And that’s a bit annoying ‘cos the battery 
runs out every now and again. (talking about non-study e-
cigarette) 
Male, 57 years, 10 
cigs/day  
Previous e-cigarette experiences; 
technical issues 
   
I’m not going to lie, it’s [e-cigarettes] not the best flavour...but, I 
don’t want it to taste nice, if that sounds...because I feel like if it 
tastes nice, I might use it more.  And I don’t...so I’ve waited, 
obviously I’ve got the nicotine one in and yeah, it’s probably not 
the best taste, but really, do you want to, a fag or a cigarette to 
taste really nice where you want to keep picking it up...don’t want 
that.  
Female, 35 years, 10 
cigs/day 
Concerns about addiction to e-
cigarette/nicotine 
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Quote Participant details Themes 
   
I think the one area, and I have a, almost a caution note, it’s the 
partner of one of the ladies I work with...who, quite a nervous 
person, and was a very very heavy smoker…40, 50 a day.  All his 
life, I mean really was.  About a year and a half ago… [he used an 
e-cigarette and] he actually has given up smoking.  And I think 
it’s tremendous, and within the group, tremendously.  But over the 
past year and a half, his reliance on the e-cigarette, is getting more 
and more and more…So, initially… a group of us went out for a 
meal, I went out for a cigarette, he’d come out with me and have a 
puff, yeah.  About three months ago, we went to a wedding 
reception, he had two e-cigarettes with him, in case the battery 
went wrong on one or ran out.  He was having secretive puffs on 
it, inside, and then coming out with me as well.  So it’s almost as 
though his addiction or habit, had turned.  
Male, 56 years, 20 
cigs/day 
Concerns about addiction to e-
cigarette/nicotine 
   
… the last time I had the e-cigarette it was like a learning curve as 
well, the one that used to leak.  ‘Cos really it was just 
permanently hanging out the side of me mouth, and it was like, 
I’m thinking like, my nicotine level must have gone flying up 
through the roof because I must have been taking more nicotine, 
than I would have been if I had’ve been smoking.  So that’s why 
I’ve decided, this time, when I’m going to do it, I’m going to 
Female, 52 years, 15 
cigs/day 
Previous e-cigarette experience; 
concerns about addiction to e-
cigarettes/nicotine  
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Quote Participant details Themes 
actually use me e-cigarette as if it was a cigarette, take a couple of 
puffs, and then put it down, ‘cos that’s, what you would do with a 
cigarette.  And then just leave it.  
   
To be honest I have more social side now...than what I did before.  
‘Cos when I was smoking, I was getting out of breath easy, and I 
was like me condition, I cannot walk that far and everything but, I, 
like I tend, like I can play with me grandchildren more and I’m not 
getting out of breath, and, it is a real kick home type of thing.  
Male, 40 years, 30 
cigs/day 
Health considerations 
   
He’s [husband] alright as long as I go outside. ‘Cos he’s like, you 
know, read reports that it hasn’t been, fully looked into, what the 
vape does to people around you.  I think there was something 
flying about Facebook the other day about popcorn lung or 
something so...he’s like, worried that I’m replacing one lung 
problem with another, but I said, “Well, it’s like everything, until 
everything’s been out a few years, you don’t know what’s going 
to happen”  
Female, 40 years, 25 
cigs/day 
Health considerations 
   
… if I give up the traditional cigarettes and just got on on a little 
electronic one, then I would see if I could stop that as well, you 
Male, 59 years, 30 
cigs/day 
Health considerations 
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Quote Participant details Themes 
know. ‘Cos they’re bound to be some kind of health issue with 
that as well.  
   
Ah, yeah. There’s quite a few people on my street use them…You 
see them all outside using it... They’re everywhere you go… Me 
Mam [mother] thinks it looks stupid but, it’s doing the job so. 
Female, 43 years, 20 
cigs/day 
Social acceptability 
   
I think me, it’s probably the e-cigarette is having something to do 
with my hands. Or having something in my hand which sort of 
replicates a cigarette.  
Male, 45 years, 15 
cigs/day 
Benefit of behavioural 
similarities 
   
I think it’s because I’ve got something to hold on to…So, I know 
it sounds stupid but, I’m getting that like I would get a cigarette. 
Female, 35 years, 10 
cigs/day 
Benefit of behavioural 
similarities 
   
…the patches and the little inhaler did worked but as I said, I find 
the e-cig because you’re actually seeing the smoke, so 
psychologically I think it does work better than, this little and plus 
this little plastic thing doesn’t look very good like...  
Female, 45 years, 10 
cigs/day 
Benefit of behavioural 
similarities 
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Quote Participant details Themes 
I think the e-cigarette’s really good…I think that’s really 
helped…Because it feels like you’re having a cigarette, but you’re 
not.  And it gives you the same sort of feeling. 
Female, 47 years, 10 
cigs/day 
Benefit of behavioural 
similarities 
   
Easier than I thought [quitting tobacco cigarettes].  It was a lot 
easier. I think it’s ‘cos you’re taking in smoke and you’re blowing 
it out so you feel like you’re having a tab…I don’t think I would 
have been able to do it without that…I think it’s just ‘cos you feel 
like you’re having a tab, ‘cos of the smoke…I think it’s, you need 
something in your hand.  
Female, 43 years, 20 
cigs/day 
Benefit of behavioural 
similarities 
   
…eventually you have to go your own way and it’s down to your 
own determination and what-not.  So, I think the amount that you 
gave us, and the kit that you gave us, was absolutely spot-on.  
Female, 52 years, 15 
cigs/day 
Perceptions of the e-cigarette 
starter kit 
   
… using it for a week you’re going to decide whether it’s going to 
be the right tool for you to stop smoking or not, so, I think two 
bottles is fair.  
Male, 27 years, 15 
cigs/day 
Perceptions of the e-cigarette 
starter kit 
   
I’ve had to buy some more liquid...I’m getting it from, ‘cos I 
wasn’t too keen on the minty one, it was very strong...so I’ve the 
Female, 31 years, 30 
cigs/day 
Perceptions of the e-cigarette 
starter kit 
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Quote Participant details Themes 
Lloyd’s chemist...opposite my doctor’s  has got, all the stuff in, 
the proper like, same as I’d got, so...  
   
I know there’s lots of shops sell that liquid as well including Boots 
[pharmacy], I was there yesterday.    
Female, 47 years, 10 
cigs/day 
Perceptions of the e-cigarette 
starter kit 
   
… I don’t live in Newcastle… so I’d ordered online, and it wasn’t 
until I went into Superdrug in Houghton, and they sell...They 
don’t have a massive selection...but they obviously sell the tops 
[tanks]...and you put the liquid in.  So that would be handy.  And 
they do like the starter packs and stuff like that. 
Female, 40 years, 25 
cigs/day 
Perceptions of the e-cigarette 
starter kit 
   
… but it has had its advantages having two batteries ‘cos I always 
make sure one’s on charge and I have it in the car as well so I can 
charge it in the car...Yeah, so I do think two batteries, if anyone’s 
going to stop it’s an advantage.  Because when one’s on charge 
you can use the other one obviously. 
Female, 45 years, 10 
cigs/day 
Perceptions of the e-cigarette 
starter kit 
   
I mean you got the extra battery as well, and I know from Karen at 
work. She’s got about six...all over the three years, ‘cos she 
always said, if she was at work and one ran out...it was like, “Well 
Female, 40 years, 25 
cigs/day 
Perceptions of the e-cigarette 
starter kit 
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Quote Participant details Themes 
what you’re going to do, what am I going to do?  What am I going 
to do?”  So she’s got like a few now, a couple in her work drawer, 
a couple at home...  
   
…I think I would just stick to like the fruity ones.  
Female, 60 years, 15 
cigs/day 
Influence of flavour 
   
[Asked if interested in tobacco flavoured e-liquids?] Not really, 
‘cos when I smoke, I divvent [don’t] really like the taste of it 
anyway, to tell you the truth…I just smoke ‘cos I need the 
nicotine sort of thing, so...the different flavours is actually better. 
Sort of thing, you know. 
Male, 35 years, 40 
cigs/day 
Influence of flavour 
   
I just thought, Mint [flavoured e-cigarette] would, [laughs] I 
don’t know whether it would refresh my breath or whatever, but 
I just thought Mint would be nice, yeah.  
Female, 47 years, 10 
cigs/day 
Influence of flavour 
   
[Interested in fruity flavours?] No, No, I tried them when me [my] 
son had it, and, I cannot. [laughs]…It’s just, they taste horrible 
really.  I don’t know why, but it’s just the taste of it, I cannot get 
Male, 40 years, 30 
cigs/day 
Influence of flavour 
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Quote Participant details Themes 
away with it…So I’d rather use the tobacco one and just come 
down off that...and then it’ll be alright.  
   
Tobacco flavour.  I’ve tried these strawberry and stuff like that and 
they do nothing for me.  
Male, 59 years, 30 
cigs/day 
Influence of flavour 
   
...and I’ve just been using the one flavour at the minute which was 
the Mint.  And yeah, I’ll probably look at getting that again ‘cos I 
found that nice, I’m not a big fan of Cherry but there wasn’t much 
[choice] so I think I’m going to stick with the mint… I’ve always 
smoked with menthol filters as well...and I actually find it quite 
close to what it was, to be honest with you, similarities to the 
taste.  
Male, 27 years, 15 
cigs/day 
Influence of flavour 
   
Blended tobacco, I’m still on that…Yeah. It’s like, when people 
pass you and they’re blowing out them fruity ones, I, it knocks 
you sick.  I don’t like the fruity ones.  
Female, 43 years, 20 
cigs/day 
Influence of flavour 
   
[What were the issues?] It was more getting it turned on…So I 
was like, “Right, I’ve got to press it 10 times”, so I was like, 
“Right”.  So then I was having a drag, then I felt embarrassed 
Female, 35 years, 10 
cigs/day 
Technical issues 
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Quote Participant details Themes 
having a... [laughs]…So then, it’d go off, so I couldn’t get, I 
couldn’t get a, an actual drag...so I was like, “Right, what am I 
actually doing?  I’m like, trying to get a drag on something that I 
can’t even work”,  So it just took me a little bit of time just to, I’ve 
got to turn it on 10 times...then you listen to like this gargly 
sound...and then obviously, you can use it…I’ve got it sussed.  
   
I must admit me son did say to us the other day, “Oh are you 
starting to use that [e-cigarette] again, that’s really good”… So I 
was thinking, ”Well, yeah”, and I think that did help because at 
the beginning of the week like I said, it give us a bit of a 
boost…So I really should have him, [laughs] constantly, behind, 
watching me, yeah. 
Female, 47 years, 15 
cigs/day 
Technical issues 
   
Obviously I’ve got like, me vapour pen…That’s really helped, 
really, really...I just borrowed it...me son had it, ah-huh.  And, he 
says, “Well you can lend it ‘til I get the money to get one”…I 
says, “Ah, nee bother”.  And it’s been absolutely great… 
(participant is using their own e-cigarette while in the control 
group) 
Male, 40 years, 30 
cigs/day 
Technical issues 
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